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ABSTRACT
The principal purpose of this study was to identify, develop and trial a new
warfarin education program to enhance warfarin knowledge, management and
compliance in a wider patient population, inclusive of the ‘high risk’ group. This
‘high risk’ group included patients who were elderly, had low literacy skills and
came from non-English speaking backgrounds.
Effective patient education is a central part of the practice of all health
professionals because it helps to ensure safe and effective warfarin management.
With recent increases in warfarin prescribing and warfarin-related adverse drug
events the need for an effective patient warfarin education program is more
apparent.
The study aims to improve currently available warfarin education programs
delivered to warfarin prescribed patients in a home-based setting. The new
program is conceptually based on five key elements: improved health
professional/patient communication and partnerships; improved warfarin
compliance; simple, easy-to-read warfarin information, improved continuity of care
between hospital and community settings; and improved patient follow-up.
Unfortunately, during the course of the study, many similar strategies and
interventions targeting these key elements were incorporated into the customary
program, as well as the new program, which may have impacted on the final
results of the study.
The study was conducted from February 2003 to February 2004, on consenting
patients who were prescribed warfarin and admitted to Illawarra Health’s The
Ambulatory Care Team (TACT). This prospective study included 50 intervention
patients receiving the new warfarin education program, and 52 control patients
receiving the customary warfarin education program offered to TACT patients.
Many of these patient participants also came from the ‘high risk’ group, which
included; the elderly, those with low literacy skills and those from non-English
speaking backgrounds.
The evaluation phase of the study involved comparing and contrasting the
effectiveness of the new warfarin education program against the customary
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warfarin education program, in terms of the patients’ warfarin knowledge,
management and compliance. The patients’ satisfaction with the information
received and their therapeutic outcomes (therapeutic INR scores, healthcare visits
and warfarin-related adverse drug events) were also compared and contrasted
between the two programs.
The findings of this study suggest that the new warfarin information booklet
(APPENDIX 12) was written in a better quality, easier-to-read format, than was the
Boots warfarin information booklet (2003). Overall, the trend in the results
suggested that the new warfarin education program more effectively educated
patients, including the ‘high risk’ patients, about their warfarin therapy, as
compared to the customary warfarin education program. The patients receiving the
new warfarin education program were more knowledgeable about their warfarin,
more confidently managed and complied with their warfarin therapy at home, and
achieved better therapeutic outcomes, than did patients who received the
customary warfarin education program. Interestingly, both the new and the
customary warfarin education programs used in this study appeared to be more
effective than other available warfarin education programs, achieving better
warfarin knowledge scores and therapeutic outcomes, with fewer warfarin-related
adverse drug events and healthcare visits.
The implications of this study are that by targeting the five key elements of an
effective warfarin education program we can help to improve warfarin knowledge,
management and compliance in many patients, including those from the ‘high risk’
group. Education based on the five key elements empowers patients to make
educated decisions about their warfarin therapy; which in turn help to optimise their
warfarin-related therapeutic outcomes and minimise warfarin-related adverse drug
events.
One of the major benefits of this research, is that the five key elements of an
effective patient education program, used in this new warfarin education program,
can be generically applied to other patient medication education programs.
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CHAPTER 1
INTRODUCTION

1.1 INTRODUCTION
Medication-related errors are the major cause of adverse events within the
healthcare system both in Australia and overseas, causing an estimated 10-20
percent of all medically related adverse events (Bates 1999; Dartnell, Anderson,
Chohan, Galbraith, Lyon, Nestor and Moulds 1996; Leape, Kabcenell, Berwick
and Roessner 1998). Australian research has shown that between 2 and 4
percent of all hospital admissions are due to adverse drug events, with an
estimated cost of at least $350 million per annum (Australian Council for Safety
and Quality in Health Care 2002; Roughead 1999; Runciman, Roughead,
Semple and Adams 2003). A large proportion of these adverse events could be
prevented by improving patient education and communication (Forster, Asmis,
Clark and Saied 2004; Wilson, Runciman, Gibberd, Harrison, Newby and
Hamilton 1995). The ‘Improving Medication Safety Workshop’ (Australian Council
for Safety and Quality in Health Care 2001) recommended a national approach to
reducing adverse drug events by targeting specific medications such as warfarin.
Inadequate patient education has been identified as a major cause of
adverse drug events involving warfarin in hospital and community settings
(Bhasale, Miller, Britt and Reid 1996). For ‘high risk’ groups which include the
elderly, those with low literacy skills and people from non-English speaking
backgrounds, the lack of literacy can be a major obstacle to effective healthcare,
communication and education (Doak, Doak, Friedell and Meade 1998). Written
patient medication information, including warfarin information, is often pitched at
a level beyond the comprehension of patients with low literacy skills, who, without
adequate education, face unnecessary health risks and possible hospitalisation
(Baker, Parker, Williams and Clark 1998; Baker 1997; Estrada, Barnes, MartinHryniewicz, Collins and Byrd 1999; Estrada, Hryniewicz, Barnes-Higgs, Collins
and Byrd 2000).
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This thesis reports the development, implementation and evaluation of a
new warfarin education program. The new program is founded on a conceptual
framework targeting five key elements:


health professional/patient communication and partnerships



warfarin compliance



simple, easy-to-read warfarin information



the continuity of care between hospital and community settings



patient follow-up.

The thesis contends that by incorporating strategies and interventions to target
and improve these five key elements, there will be an improvement in the
patients’ warfarin knowledge, management and compliance which will ultimately
lead to optimal therapeutic outcomes and minimal adverse drug events. Special
consideration in the development of the new program was given to the ‘high risk’
patient population, which include the elderly, those with low literacy skills and
those from non-English speaking background.
The following two chapters discuss the literary sources used to support
the need for a new warfarin education program, inclusive of simple, easy-to-read
warfarin information. They also provide the evidence for the five key elements,
which need to be targeted when producing an effective warfarin education
program.
The fourth chapter describes the conceptual framework used to develop
the new warfarin education program and the fifth chapter deals with the
methodology used to target the key elements. Processes used to develop the
new, simple and easy-to-read warfarin information booklet are described, as are
interventions and strategies to improve health professional/patient
communication and partnerships, warfarin compliance, continuity of care
between hospital and community settings and patient follow-up. Chapter five also
describes how evaluation questionnaires and outcome data were used to
compare and contrast the new warfarin education program against the customary
warfarin education program delivered to the patients admitted to Illawarra
Health’s The Ambulatory Care Team (TACT).
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The results of this research study and an analysis of the data collected for
the 102 patient participants during the evaluation phase are summarised in
Chapter 6. Information is provided about the improved readability, quality and
suitability of the new warfarin booklet (APPENDIX 12), as compared to the Boots
warfarin information booklet (2003) and other available written warfarin
information. Data regarding the patients’ warfarin knowledge, management and
compliance was evaluated to compare the effectiveness of the new program
against the customary warfarin education program delivered to The Ambulatory
Care Team (TACT) patients. The data was also used to compare the patients’
satisfaction with the information they received and their therapeutic outcomes
(i.e. therapeutic International Normalised Ratio (INR) scores and healthcare
visits) over the three month follow-up period between the two groups.
The final chapter provides an overview of the study with discussions about
the results, limitations, recommendations and implications for both current
practice in warfarin education and future research. Detailed description is
provided about the improved warfarin knowledge, management and compliance,
as well as improved satisfaction and therapeutic outcomes for the patients
receiving the new warfarin education program as compared to the customary
warfarin education program. Acknowledgement is made about the fact that many
similar strategies and interventions targeting the five key elements incorporated
into the new warfarin education program were also incorporated into the
customary warfarin education program. This certainly impacted on the final
results making them less significantly different than initially expected. However
based on the overall improvement in the warfarin education for all patients
receiving the new warfarin education program, including the ‘high risk’ group, it is
recommended that all home-based warfarin education programs adapt the new
program as a best practice model for an effective warfarin education program.
Based on the success of the results in this study, the final chapter concludes with
a recommendation that to be effective all patient medication education programs
need to target improving the following five key elements; health
professional/patient communication and partnerships; medication compliance;
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simple, easier-to-read medication information; continuity of care between hospital
and community settings; and patient follow-up.

1.2 ABOUT THIS STUDY
The focus of this research is the development and evaluation of a new
warfarin education program for a home-based ambulatory care service. The
objective of the new program was to improve warfarin knowledge, management
and compliance in a wider patient population, inclusive of the ‘high risk’ group.
The literature has identified inadequacies in current patient medication
education practices, especially with regard to warfarin, in both hospital and
community based settings. The researcher has witnessed first hand the impact of
these inadequacies both professionally and personally. Professionally, through
20 years of experience as a hospital and community pharmacist, and personally,
through her parents, who come from a non-English speaking background.
The patient populations who have the most problems with their
medications and knowing how to manage them include the elderly, those with
low literacy skills and those from non-English speaking backgrounds (Baker,
Parker, Williams, Pitkin, Parikh, Coates and Imara 1996; Forster, Asmis et al.
2004; Nadar, Begum, Kaur, Sandhu and Lip 2003). Unfortunately, with limited
time and resources during busy working schedules of health professionals who
treat them, these patients are often poorly educated resulting in an increased
incidence of poor therapeutic outcomes and adverse drug events (Australian
Council for Safety and Quality in Health Care 2002). This research is important
because it seeks to provide effective warfarin education to a patient population,
inclusive of this ‘high risk’ group, which will help to reduce the large incidence of
poor warfarin-related therapeutic outcomes and adverse drug events reported in
the literature (Halstead, Roughead, Rigby, Clark and Gallus 1999).
This thesis contends that the improved warfarin knowledge and
understanding acquired by patients from the new warfarin education program will
empower them to make confident, informed decisions about their warfarin
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management and compliance. The objective is to help optimise warfarin-related
therapeutic outcomes and minimise warfarin-related adverse drug events
(Australian Council for Safety and Quality in Health Care 2002).

1.3 OVERVIEW OF THE STUDY
The principal purpose of this study was to identify, develop and trial a new
warfarin education program to enhance warfarin knowledge, management and
compliance in a wider patient population. In order to achieve this several stages
were included in the study:
 The first stage of the study involved the development of a new warfarin
education program and a new warfarin information booklet, based on the
best evidence with regard to effective patient medication education
programs.
 The second stage of the study involved a 10-person ‘pilot test’ of the new
warfarin education program to ensure that the new booklet, education
session and evaluation questionnaires could be readily understood and
answered by the pilot sample typical of the study population.
 The third stage of the study involved a comparative analysis of the new
warfarin education program against the customary warfarin education
program delivered to patients admitted to Illawarra Health’s, The
Ambulatory Care Team (TACT). Comparing and contrasting the two
programs, immediately and three months after the initial warfarin
education session involved comparing the participating patients’ warfarin
knowledge, management and compliance, as well as their satisfaction with
the warfarin education programs. Outcome measures included: the
proportion of therapeutic International Normalised Ratio (INR) scores; the
number of general practitioner, emergency department and hospital visits;
and the number of warfarin-related adverse drug events.
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1.4 VALUE OF THIS RESEARCH
Warfarin is an oral anticoagulant which, until recently, has been mainly
prescribed for deep venous thrombosis, pulmonary embolus, prosthetic heart
valves, post hip surgery or to prevent the recurrence of myocardial infarction
(Ansell, Buttaro, Thomas, Knowlton and The Anticoagulation Guidelines Task
Force 1997; Gallus 1999). Recently, it has been found that warfarin dramatically
reduces the risk of embolic stroke in patients with atrial fibrillation (AF) and that
treatment benefits significantly outweigh the risks in these patients (Campbell,
Roberts, Eaton, Coghlan and Gallus 2001; Tillman, Charland and Witt 2000).
These new indications will increase the number of patients being prescribed
warfarin (Cruickshank, Ragg and Eddey 2001; The Newcastle Anticoagulation
Study Group 1998) and almost certainly increase the incidence of warfarinrelated adverse events, based on current educational practices (Gurwitz, Field,
Harrold, Rothschild, Debellis, Seger, Cadoret, Fish, Garber, Kelleher and Bates
2003; Halstead, Roughead et al. 1999).
Historically, patient warfarin education has been inadequate (Connor
1998) and the amount of information given possibly even overwhelming (Ansell,
Buttaro et al. 1997). A lack of patient education has been identified as a major
cause of poor warfarin-related therapeutic outcomes and adverse drug events in
both hospital and community settings (Bhasale, Miller et al. 1996; Halstead,
Roughead et al. 1999). It is timely therefore, to develop a more systematic
approach to the delivery of warfarin education, which addresses the needs of a
wider patient population, inclusive of elderly, low literacy and non-English
speaking background patients. Such a program should aim to improve warfarinrelated therapeutic outcomes and minimise adverse drug events by empowering
patients to successfully comply with and manage their warfarin therapy at home,
based on their improved warfarin knowledge and understanding.

6

1.5 THE SIGNIFICANCE OF THIS RESEARCH
Patient education is a central part of the practice of all health professionals
and is a very important way in which to ensure safe and effective warfarin
management. To date, warfarin education programs have been identified as
primarily unstructured and inadequate (Bhasale,Miller et al 1996; Ansell Buttaro
et al 1997; Connor 1998 and Halstead, Roughead et al 1999). This research
assesses whether the way in which the warfarin education program is structured,
the presentation of the written warfarin information and improved collaboration
between patients, carers and relevant health professionals will have an impact on
the effectiveness of the education program.
The new warfarin education program, which is delivered to patients in a
home-based setting, is based on a conceptual framework incorporating the five
key elements of an effective warfarin education program. The strategies and
interventions introduced in the new program also address the needs of the ‘high
risk’ patient population, in an attempt to ensure that they also benefit from the
program and achieve optimal therapeutic outcomes with minimum adverse drug
events.
One of the major benefits of this research is that the five key elements of
an effective patient education program used in this new warfarin education
program can also be generically applied to other patient medication education
programs in both hospital and community settings.
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CHAPTER 2
IDENTIFYING THE KEY ELEMENTS IN THE LITERATURE WHICH
CONTRIBUTE TO ADVERSE DRUG EVENTS, INCLUDING
WARFARIN-RELATED ADVERSE DRUG EVENTS

2.1 INTRODUCTION
In 1995, the use of medications in Australia was reported to be the most
common health-related action taken by people suffering from illness or injury
(ABS 1999). With that salient fact in mind, the purpose of this study was to
promote improved warfarin medication education in a wider patient population, to
help optimise therapeutic outcomes and minimise adverse drug events. The oral
anticoagulant, warfarin, is the focus of this study because its inappropriate use is
a large and unresolved problem (Halstead, Roughead et al. 1999). Warfarin also
has the potential of becoming an even bigger problem with recent increases in
prescribing for patients suffering from atrial fibrillation (Cruickshank, Ragg et al.
2001; Ezekowitz and Falk 2004).
This chapter commences with an introduction to patient education and its
potential impact on therapeutic outcomes and adverse drug events. Further it
reviews adverse drug events and their impact on healthcare costs by way of
hospital admissions and general practitioner encounters. Medication-related
adverse event terms are defined and the incidence of adverse drug events in
Australia, are discussed. Key factors which contribute to adverse drug events are
identified and include: poor health professional/patient communication and
partnerships; poor medication compliance; inappropriate written medicine
information; poor continuity of care between hospital and community settings;
and poor patient follow-up (Australian Council for Safety and Quality in Health
Care 2002; Roughead and Gilbert 2002). Consideration in this chapter is given to
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implementing strategies and interventions to target each of these key elements,
with a view to developing an effective warfarin education program.
The chapter concludes with an overview of the increasing problem of
warfarin-related adverse drug events (Campbell, Roberts et al. 2001; Hirri and
Green 2002), which may in part be due to the increase in warfarin prescribing
(Elliott, Woodward and Oborne 2002; Gallus, Baker, Chong, Ockelford and Street
2000; Peterson, Jackson and Bereznicki 2002), as well as inadequacies in the
currently available warfarin education programs (Connor 1998). This increasing
incidence of warfarin-related adverse drug events and warfarin knowledge
deficits in many patients (Cheah and Martens 2003; Nadar, Begum et al. 2003;
Tang, Lai, Lee, Wong, Cheng and Chan 2003) highlight the need for a new,
effective warfarin education program. Importantly, this new warfarin education
program should be designed to address the needs of the ‘high risk’ patient
population (the elderly, those with low literacy skills and those from non-English
speaking backgrounds) who are more likely to experience poor warfarin-related
outcomes (Estrada, Martin-Hryniewicz, Peek, Collins and Byrd 2004; Lambert
and Wynne 2003; Nadar, Begum et al. 2003). When used in conjunction with the
home healthcare delivery services (McGuire, Stowasser and Collins 1997), it is
envisaged that this new education program will help to improve warfarin-related
therapeutic outcomes and reduce the incidence of warfarin-related adverse drug
events.

2.2 RATIONALE FOR THE SEARCH STRATEGY
Serious limitations in available warfarin education programs became
increasingly apparent to the researcher through her 20 years’ experience as a
hospital and community pharmacist, and through her elderly migrant parents.
The researcher was also involved in developing and writing medication
information leaflets over many years, and attempted, unsuccessfully, to persuade
Boots Healthcare to rewrite its information booklet, ‘Warfarin: important
instructions for patients’ (2002, 2003) in a simpler, more accessible format. The
researcher then became interested in reviewing the home-based warfarin
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education program delivered to Illawarra Health’s The Ambulatory Care Team
(TACT) patients, including the development of a new simple, easy-to-read
information booklet, leading to the study presented in this thesis.
The literature reviewed for this study focused on available patient
medication information and in particular, warfarin information written in English.
They also focused on ways in which to educate patients effectively about their
medications, including improving their medication knowledge and understanding,
management and compliance.

2.2.1 The search strategy
A number of sources were used to search the literature about factors
possibly affecting patient medication education, medication compliance,
therapeutic outcomes and adverse drug events. Pubmed (1966-present),
CINAHL (1996-2004; 1966-present) and MEDLINE (1996-2004; 1966-present)
were among the most commonly used databases. Proquest 5000 (Health and
Medical), Expanded Academic Index (1980-Present), Australian Medical Index
(AMI), Synergy (1999-present), Science Direct, Embase and the Cochrane
Database of Systematic Reviews were also frequently accessed. The AUSTATS
database was used to search Australian Bureau of Statistics (ABS) information,
the Australian Institute of Health and Welfare (AIHW) website, the TGA website
and the Web of Science database (1975-present) provided useful citation
indices, which then could be further investigated. Finally, the First Search
database and other Australian University sites were accessed to scan for any
relevant theses, which may have been published about similar research studies.
Only materials published in the English language or translated into English were
accessed for the literature review.
The initial relevant search terms were quite broad and included: adverse
drug events; medication compliance and/or concordance; community based
patient compliance with drug therapy; medication self-management; patient
education and teaching; medication information; continuity-of-care; patient followup; evaluation of education programs; hospital-in-the-home programs;

10

literacy/culture/non-English speaking backgrounds; and medication. The search
was then narrowed down to: oral anticoagulants; warfarin (coumadin); warfarinrelated adverse drug events; warfarin compliance; warfarin education programs;
warfarin information; the evaluation of warfarin education programs; the effects of
literacy, culture and non-English speaking backgrounds on warfarin knowledge
and understanding. Warfarin, adverse drug events, medication compliance and
patient warfarin education programs proved to be the most useful terms for the
search strategy. Nevertheless, each of these terms introduced the researcher to
many articles that were subsequently excluded as they dealt with hospital
inpatient medication education programs, health behaviour change models and
medication self-management programs rather than the patients’ anticoagulation
management and education by a multidisciplinary team in their own home, which
became an important criterion for inclusion.
During the three year study, Medline and Cinahl alerts via
Autorun@ovid.com were also organised to scan for weekly updates on the
following search terms; ‘warfarin’, ‘medication compliance’, ’medication
education’, ‘communication barriers’ and ‘ethnic and cultural barriers’. As was
expected there was a great deal of duplication among these databases. Even
though over 200 sources were used in the literature review, there were very few
papers found which explored the key elements of an effective patient medication
education program, and in particular a patient warfarin education program. There
were many sources, which discussed the need to improve patient warfarin
knowledge and understanding as a means to optimise therapeutic outcomes and
minimise adverse drug events.
Inadequacies in acquiring sufficient information from the databases were
countered by accessing a variety of sources including books on the subject,
reports and government documents. These were obtained through library
catalogues, interlibrary loans, pertinent web sites and searching the
bibliographies and references listed in some of the accessed articles and
sources.
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2.3 THE IMPACT OF PATIENT EDUCATION ON THERAPEUTIC OUTCOMES
AND ADVERSE DRUG EVENTS

Patient education improves health outcomes by promoting healthy
behaviour and involving patients in their own health care decisions (JCAHO
1998). The process begins with the imparting of information, but it also includes
interpretation and integration of information to bring about attitudinal or
behavioural changes that benefit a person’s health status (Rankin and Duffy
Stallings 2000). Verbal communication, patient involvement, the readability of
written information and an evaluation of the learning outcomes have all been
identified as important issues to consider when providing patient education
(Webber 1990).
During recent times the notion of patient-centred care with patient
education as the central focus has been incorporated worldwide in strategies to
help achieve better therapeutic outcomes and reduce the incidence of adverse
drug events. Strategies which encourage patients to become active participants
in the decision making process about their care are the basis of the Joint
Commission on the Accreditation of Healthcare Organization (JCAHO) Standards
for Patient Education (JCAHO 1993) in the United States, the Medicines
Partnership Task Force (The Royal Pharmaceutical Society of Great Britain
1997) in the United Kingdom, and the recent ‘Consumer Engagement in Health
Care’ (Australian Government Department of Health and Ageing 2005) initiatives
supported by the Australian Government. Even though these initiatives are
becoming commonplace worldwide, there is very little evidence about their
impact reported in the literature, which often gives a largely one-sided view. The
common position is that if a medication and/or therapeutic regimen is not
followed as prescribed, then the problem must somehow be with the patient.
Neither the behaviour nor the attitude of the health professional, or the structure
of the education program, are taken into consideration when evaluating the
effectiveness of such initiatives. It is important therefore, to consider this point
when reading through the evidence available in the literature.
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There are very few data in the literature about the impact of patient
education alone on the medication related therapeutic outcomes and incidence of
adverse drug events. Typically patient education is discussed as one of several
interventions including counselling, familial support, follow-up, compliance aids
(Roter, Hall, Merisca, Nordstrom, Cretin and Svarstad 1998) used to promote
medication compliance, thereby improving therapeutic outcomes and reducing
adverse drug events.
A recent systematic review, found that interventions delivered by
pharmacists (e.g. medication education and counselling, written information,
medication review etc) directed toward hypertensive, hypercholesterolemic,
chronic heart failure, or diabetic patients improved therapeutic outcomes and
decreased the use and/or cost of health services, compared to patients not
receiving the interventions (Beney, Bero and Bond 2004). Pharmacist provided
videotapes, booklets, educational newsletters and follow-up have all been found
to improve medication compliance, especially amongst elderly patients (Poston,
Loh and Dunham 1998). There is also evidence in the literature that elderly
patients who received home based pharmacy counselling, medication review and
education services were more likely to be compliant with their medication than
were patients who only received a home visit (Lowe, Raynor, Purvis, Farrin and
Hudson 2000).
Esposito (1995) evaluated four educational programs to see which would
be more effective in increasing medication compliance amongst elderly patients.
He found that elderly patients were less likely to be compliant if they were
provided with (i) a medication fact sheet and a discharge summary sheet, or (ii) a
medication fact sheet with 30 minutes of verbal instruction on discharge from
hospital, as compared to the patients who received (iii) a medication schedule
written in large dark lettering, with a list of side effects and a dosage schedule, or
(iv) a medication schedule and 30 minutes of verbal instruction. Even though the
patient population was small in this study (n = 42) and hence the findings could
not be reported statistically. It is noteworthy that the patients given a medication
schedule, also known as a medication regimen, were more likely to be compliant
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with their medications and less likely to suffer from any adverse drug events.
These results support the earlier work of Ascione and Shimp (1984) who also
found that a reminder aid (e.g. written information, a medication reminder
calendar, or a medication reminder package) with verbal reinforcement improved
medication knowledge and compliance in 158 ambulatory cardiovascular
patients. These studies and a preponderance of information available in the
literature suggest that both written and verbal information given together,
compared to being given alone, help to improve the patients and/or carers
knowledge and satisfaction, resulting in better patient outcomes and fewer visits
to health care providers (Forster, Smith, Young, Knapp, House and Wright 2004;
Issacman, Purvis, Gyuro, Anderson and Smith 1992; Jenkins, Blank, Miller,
Turner and Stanwick 1996).
In summary, patient education has been found to improve therapeutic
outcomes and reduce the incidence of adverse drug events by promoting good
medication compliance. During recent times, worldwide organizations have taken
patient education one step further by encouraging patients to become active
participants in the decision making process. According to the evidence in the
literature successful patient medication interventions include: the provision of
medication information (verbal and written), medication counselling, medication
reviews and home based follow-up by all healthcare professionals and especially
the pharmacist.

2.4 ADVERSE EVENTS

2.4.1 Background
Adverse events are a major concern to the healthcare system, causing
significant personal burden and healthcare costs. Medication incidents are
recognised as a leading cause of adverse events both in Australia and
internationally (Forster, Murff, Peterson, Gandhi and Bates 2003; Kohn, Corrigan
and Donaldson 1999; Leape, Brennan, Laird, Lawthers, Localio, Barnes, Herbert,
Newhouse, Weiler and Hiatt 1991; Wilson, Runciman et al. 1995). Many of these
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adverse drug events are considered to be potentially preventable (Forster, Murff
et al. 2003; Wilson, Runciman et al. 1995) through effectively educating patients
about their medications and empowering them to make informed decisions about
their medication management and compliance (Australian Council for Safety and
Quality in Health Care 2002; Bhasale, Miller, Reid and Britt 1998; Mullen,
Simons-Morton, Ramirez, Frankowski, Green and Mains 1997).
Patient populations deemed to be at particularly ‘high risk’ of experiencing
adverse drug events include: the elderly (Forster, Asmis et al. 2004; Gurwitz,
Field et al. 2003); those with low literacy skills (Baker, Parker et al. 1996; Doak,
Doak et al. 1985; Feifer 2003); and patients from non-English speaking
backgrounds (Nadar, Begum et al. 2003; Shaw, Hemming, Hobson, Nieman and
Naismith 1977). Elderly patients (aged 65 years and over) are more likely to
experience adverse drug events because they generally take more medications
(Australian Council for Safety and Quality in Health Care 2002) and often suffer
from cognitive and/or physical limitations (Stewart and Caranasos 1989).
Patients with low literacy skills are more susceptible to adverse drug events
(Feifer 2003) because they know significantly less about their disease and how to
manage their medications (Williams, Baker, Parker and Nurss 1998). These
deficits in medication knowledge and understanding have also been found to
exist among the non-English speaking background (NESB) patients (Nadar,
Begum et al. 2003; Wilson, Racine, Tekieli and Williams 2003). An Australian
study found that a considerable proportion (35 percent) of their 257 NESB patient
participants had little or no understanding about their drug therapy (dose,
frequency and drug function) (Shaw, Hemming et al. 1977), which almost
certainly predisposed them to adverse drug events and poor compliance.
It is important, therefore, to examine what is known about adverse drug
events and how their incidence can be reduced or even potentially prevented by
way of improved patient medication education. It is also important to note that
interventions and strategies which target improved patient medication education,
should always consider the needs of the ‘high risk’ patient population.
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2.4.2. Definitions
Due to the varying use of terms in the literature and throughout this
chapter, specific definitions of medication related adverse events are listed
below. The terms ‘adverse event’, ‘medication incident’, ‘adverse drug event’,
‘adverse drug reaction’ and ‘medication error’ are all used to describe medication
related problems (Australian Council for Safety and Quality in Health Care 2002).
 An Adverse Event (AE) is an incident in which harm resulted to a person
receiving healthcare (Australian Council for Safety and Quality in Health
Care 2001).
 Medication incidents are problems which occur in the prescription,
dispensing and administration of medicines (Australian Council for Safety
and Quality in Health Care 2002).
 An Adverse Drug Event (ADE) is a medication incident which leads to
patient harm (Australian Council for Safety and Quality in Health Care
2002).
 An Adverse Drug Reaction (ADR) is a side effect caused by a medication
on its own or in combination with other drugs (Australian Council for
Safety and Quality in Health Care 2002).
 A medication error is a failure in the (drug) treatment process that leads to,
or has the potential to, harm the patient (Ferner and Aronson 2000) and
includes an act of omission or commission (Australian Council for Safety
and Quality in Health Care 2001).
 Preventability of an adverse event is an error in management due to
failure to follow accepted practice at an individual or system level (Wilson,
Runciman et al. 1995)
 Potentially preventable includes the adverse events with a preventability
scale of 50 percent or more (Wilson, Runciman et al. 1995)
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2.4.3 Incidence of adverse drug events
Australian data indicate that adverse drug events make a significant
contribution to unplanned hospital admissions. The Australian national hospital
morbidity database shows that for a twelve month period from 1999 to 2000,
69,766 hospital separations were due to adverse drug events (Australian Council
for Safety and Quality in Health Care 2002; Runciman, Roughead et al. 2003).
Between 2 and 4 percent of all Australian hospital admissions have been
identified to be medication related (Australian Council for Safety and Quality in
Health Care 2002; Runciman, Roughead et al. 2003). This translates to 140,000
hospital admissions with an estimated cost in Australia of at least $350 million
dollars per annum, in the public hospital system alone (Australian Council for
Safety and Quality in Health Care 2002; Roughead 1999). The literature also
confirms that the elderly are more likely to be admitted to hospital because of
medication-related adverse drug events (Chan, Nicklason and Vial 2001; Hagan
and Cooper 1999). Twenty percent of patients aged 65 years and over
(Australian Council for Safety and Quality in Health Care 2002) and 30 percent of
patients aged 75 years and over (Chan, Nicklason et al. 2001) are believed to
experience unplanned medication-related hospital admissions.
Adverse drug events are not confined to hospital settings. They are also a
major problem in community settings as reported in the BEACH survey (Bettering
the Evaluation and Care of Health)(Runciman, Roughead et al. 2003). During
1999 - 2000, there were 4.1 adverse drug events recorded for every 1,000
general practice visits (Hargreaves 2001). The Australian incident-monitoring
study which collected reports from 673 general practitioners from 1996 - 1998
found that adverse drug events, were responsible for 1,556 (60 percent) of the
2,582 adverse events reported (Steven, Malpass, Moller, Runciman and Helps
1999). Analysis of 805 incident reports from another Australian general practice
study (October 1993 - June 1994) also found that adverse drug events (51
percent) were the most frequently reported adverse events, especially involving
patients aged 65 years and over (Bhasale, Miller et al. 1998). It could be argued
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that the data collected from these few general practice studies are not truly
representative of the incidence of adverse drug events Australia wide. They do,
however, provide a snapshot of the potential impact that adverse drug events
can have on general practice encounters and healthcare costs in the community
setting.
Although adverse drug events may be a common occurrence in both the
hospital and community settings, they should not be considered to be
unavoidable outcomes associated with medication use. Evidence in the literature
suggests that a large proportion of these adverse drug events are potentially
preventable (Gurwitz, Field et al. 2003; Rigby, Clark and Runciman 1999;
Roughead, Gilbert, Primrose and Sansom 1998). A Canadian prospective cohort
study of 400 patients discharged from hospital found that a majority of the 50
adverse drug events experienced by the 400 discharged patients could have
been prevented with improved patient education, communication, continuity of
care and patient follow-up (Forster, Murff et al. 2003). These claims are
consistent with other reports which also found that potentially preventable
adverse drug events could be reduced by improving patient medication education
and communication (Dartnell, Anderson et al. 1996; Forster, Asmis et al. 2004;
Forster, Clark, Menard, Dupuis and al 2004; Gandhi, Weingart, Borus, Seger,
Peterson, Burdick, Seger, Shu, Federico, Leape and Bates 2003; Roberts and
Stokes 1998). Similarly, an Australian study which reviewed the medical records
of over 14,000 admissions to 28 hospitals during 1992, suggested that 43
percent of the reported adverse drug events could have been potentially
prevented, identifying improved medication education and communication as
potential areas for improvement (Wilson, Runciman et al. 1995). From a
community perspective, an observational Australian study (October 1993 - June
1994) asserted that 322 (79 percent) of the 407 adverse drug events reported by
324 general practitioners could have been prevented by improving patient
education, patient and health professional communication, as well as the
continuity of care between hospital and community settings (Bhasale, Miller et al.
1998). Certainly each of these studies varied markedly in their estimate of how
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many adverse drug events were potentially preventable. Importantly however,
they all made the same claims that a significant proportion of the adverse drug
events could be potentially prevented by improved patient education,
patient/health professional communication and the continuity of care between
hospital and community settings. Clearly these are factors consistently
considered important in effective patient compliance to medication regimens.
In summary, it has been established that adverse drug events are leading
causes of adverse events both in Australia and overseas. They contribute to an
increase in healthcare costs by causing unplanned hospital admissions and
general practitioner encounters. There are studies reported in the literature,
which suggest that many of these adverse drug events could be potentially
prevented by improving patient education, patient/health professional
communication and the continuity of care between hospital and community
settings.

2.4.4 Key elements which contribute to adverse drug events

2.4.4.1 Introduction
Adverse drug events are a persistent and important problem of public
health in terms of morbidity, mortality and cost (Peyriere, Cassan, Floutard,
Riviere, Blayac, Hillaire-Buys, Quellec and Hansel 2003). Work in this area has
only been underway in Australia for approximately 10 years, with an emphasis on
medication safety and the reduction of adverse drug events in the past five years
(Australian Council for Safety and Quality in Health Care 2001). Following the
1999 report by the National Expert Advisory Group on Safety and Quality in
Australian Health Care, the Australian Council for Safety and Quality in Health
Care was established in January 2000 to prioritise medication safety in Australia
(Australian Council for Safety and Quality in Health Care 2002; Commonwealth
Department of Health and Aged Care 2000). One of the major strategies
identified by the council to minimise these potentially preventable adverse drug
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events was to improve patient medication knowledge and understanding by
effectively educating them about their medications (Australian Council for Safety
and Quality in Health Care 2002).
Key elements identified in the literature as contributing to adverse drug
events include: poor health professional/patient communication and partnerships;
poor medication compliance; inappropriate written medication information; poor
continuity of care between hospital and community settings; and poor patient
follow-up (Australian Council for Safety and Quality in Health Care 2001). In
order to help reduce the potentially preventable adverse drug events, it is
therefore important to target each of these key elements, as well as addressing
the needs of the ‘high risk’ patient population, in the development of patient
education programs.

2.4.4.2 Poor health professional/patient communication and partnerships
Poor health professional/patient communication and partnerships have
been identified by Bhasale, Miller et al (1998) and Elwyn, Edwards and Britten
(2003) as important factors which contribute to adverse drug events and poor
therapeutic outcomes. More recently Cox, Stevenson, Britten and Dunbar (2004)
identified that these factors result in patients having poor knowledge and
understanding of their medications, subsequently causing an inability to
appropriately manage them at home.
DiMatteo (1997) claimed that poor communication could result in as many
as half the number of all patients leaving their doctors’ offices not knowing what
they have been told or how to follow their therapeutic regimens. Patients
contributed to this poor communication through their unwillingness to ask
questions and/or challenge the health professional’s authority, being
overwhelmed with the information provided and misunderstanding medical
jargon. Becker and Maiman (1980) also found that patients often feel that they
are wasting the doctors’ valuable time and omit details which they deem
unimportant or are too embarrassed to mention.
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Ineffective patient/health professional partnerships are important as they
can precipitate adverse drug events because patients may not know enough
about their medications to manage them appropriately (Bhasale, Miller et al.
1998). Patients may feel unsupported in their attempts to become actively
involved and to ask questions about their medications and therapeutic regimens
(Cox, Stevenson et al. 2004; Elwyn, Edwards et al. 2003).
Patient populations most likely to experience poor therapeutic outcomes
and adverse drug events because of poor health professional/patient
communication and partnerships include the ‘high risk’ group. Elderly patients
(aged 65 years and over) have been found to have problems communicating and
forming partnerships with their health professionals (Stewart and Caranasos
1989). They typically take many medications and are overwhelmed with the
information received (Col, Fanale and Kronholm 1990; Ryan 1999). Reports in
the literature have identified that the proportion of people who use medications
increases with age, from 42 percent of those aged less than 15 years, to 86
percent of those aged 65 years and over (ABS 1999).
Patients with low literacy skills, which may include the elderly, also
experience poor health professional/patient communication and partnerships
because their health professionals are often unaware of their communication
problems which they seldom voluntarily admit and often try to conceal (Doak,
Doak et al. 1985). Similarly, the language, social and cultural barriers for nonEnglish speaking background (NESB) patients make it difficult for health
professionals to assess how effectively they have communicated with these
NESB patients (Davidhizar and Brownson 1999; Minas, Lambert, Kostov and
Boranga 1996).
Strategies to improve health professional/patient communication and
partnerships should also address the needs of each of these ‘high risk’ patient
groups. Two major elements of effective communication between the health
professional and the patient identified by DiMatteo (1997) are accurate
transmission of information to and from the health professional and the patient,
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as well as the health professionals’ emotional support and understanding of the
patient as a unique individual.
Reports in the literature have identified that communication improved
when health professionals offered patients encouragement, reinforcement of key
points by using repetition, reassurance and feedback (Clark, Gong, Schork,
Evans, Roloff, Hurwitz, Maiman and Mellins 1998; Estrada, Hryniewicz et al.
2000). A meta-analysis on the effectiveness of health education and health
promotion undertaken by Kok, van den Borne and Mullen (1997) concluded that
the effectiveness of health education is promoted by systematic planning and the
use of learning principles in the intervention, including relevance,
individualisation, feedback, rewards and facilitation. Providing environments
which encourage patients to listen, feel confident enough to ask questions and
participate in the decision making process have also been found to be important
ways in which to improve communication and partnerships (Elwyn, Edwards et
al. 2003; The Royal Pharmaceutical Society of Great Britain 1997). The
incorporation of such strategies into patient education programs are believed to
contribute to not only improved health professional/patient communication and
partnerships (Cox, Stevenson et al. 2004), but also improved therapeutic
outcomes (DiMatteo 1997; Elwyn, Edwards et al. 2003) and reduced incidence of
adverse drug events (Ascione and Shimp 1984; Esposito 1995).
A number of principles for improved health professional/patient
communication have been developed based on a large randomised control trial
involving 472 asthma patients, their parents and 69 paediatricians (Clark, Gong
et al. 1998). Positive outcomes from the trial were identified as successful
therapeutic outcomes of patients, improved parents’ knowledge about how to
manage their children’s asthma and a reduction in health care utilisation. The
investigators recommended that the following communication principles be
included in patient education programs.
 Attend to the patient (eye contact, sit closely with the patient slightly
leaning forward
 Elicit the patient’s underlying concerns about the condition
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 Construct reassuring messages that alleviate fears
 Address any immediate concerns that the family expresses
 Engage the patient in interactive conversation through use of open
ended questions, simple language, and analogies to teach
important concepts
 Tailor the treatment regimens by eliciting and addressing potential
problems in the timing, dose or side effects of the drugs
recommended
 Use appropriate non-verbal encouragement (pat on the shoulder,
nodding) and verbal praise when the patient reports using correct
disease managements strategies
 Elicit the patient’s immediate objective related to controlling the
disease and reach agreement with the family on a short term goal
 Review the long term plan for the patient’s treatment so the patient
knows what to expect over time, knows the situation under which
the physician will modify treatment, and knows the criteria for
judging the success of the treatment plan
 Help the patient plan in advance for decision making about chronic
condition (such as using diary information or guidelines for handling
potential problems and exploring contingencies in managing the
disease)
This is the only study that has approached the issue of health
professional/patient communication in such a systematic manner. Other studies
have identified some of these issues, for example DiMatteo (1997) identified that
the accurate transmission of information, emotional support and understanding
between the health professional and the patient were important in effective
communication, but none have drawn the issues together in such a
comprehensive fashion.
Extending the concept of communication, fostering and developing good
health professional/patient partnerships are also considered to be important in
medication education programs. Partnerships can empower patients to know and
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understand more about their medication, enabling them to make better educated
therapeutic decisions (Lorig, Sobel, Ritter, Laurent and Hobbs 2001; Mullen,
Simons-Morton et al. 1997). In a study of 952 patients with chronic disease, by
Lorig et al (1999), it was found that a structured self-management education
program improved health status and reduced hospitalisation rates over a 6month period. As compared with control group, the treatment group
demonstrated significant improvement in five of the health status variables (selfrated health, disability, social/role activities limitation, energy/fatigue, and health
distress; p< 0.02). The treatment group, as compared with the control group, also
had fewer hospitalisations (p<0.05) and spent, on average, 0.8 fewer nights in
the hospital (p = 0.01). The study concluded that these results were due to a
number of factors including the patients improved knowledge and understanding
about how to manage their medications and disease therapy at home, as well as
their improved communications with their physicians.
The importance of good patient/health professional partnerships in helping
to achieve optimal medication outcomes has only been recognised over the last
10 years with the promotion of the concept of patient concordance (Aslani and
Du Pasquier 2002; The Royal Pharmaceutical Society of Great Britain 1997).
Concordance describes the process whereby health professionals and patients
exchange their views on treatment and come to an agreement about the need (or
not) for a particular treatment (Elwyn, Edwards et al. 2003). In the United
Kingdom the role of the Medicines Partnership Task Force (1997) is to support
the national strategy through the promotion of concordance between the health
professionals and their patients. In the absence of any evaluation data
concerning the effectiveness of these collaborative strategies on the patients
medication related therapeutic outcomes and adverse drug events it is only
possible to speculate that such initiatives should produce positive effects.
Since poor communication and partnerships between health professionals
and their patients are believed to contribute to poor therapeutic outcomes and
adverse drug events (Elwyn, Edwards et al. 2003) it would seem reasonable to
suggest that patient education programs should incorporate strategies which
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target improved health professional/patient communication and partnerships.
Offering encouragement, reinforcement, reassurance and feedback (Clark, Gong
et al. 1998), as well as making patients feel confident to ask questions and be
part of the decision making process (The Royal Pharmaceutical Society of Great
Britain 1997) are amongst the factors reported in the literature to promote good
health professional/patient communication and partnerships. These factors need
to be considered in the development of patient medication education programs,
especially for the ‘high risk’ group of patients.

2.4.4.3 Poor medication compliance
Medication compliance is a key indicator of the success of patient
medication education programs. Current estimates of non compliance range from
20 to 70 percent for all medications (Barat, Andreasen and Damsgaard 2001;
Stewart and Caranasos 1989) and 50 to 65 percent for long-term medications
(Haynes, McKibbon and Kanani 1996), indicating there is much room for
improvement through patient medication education. Further, patient populations
most likely to encounter adverse drug events because of poor compliance, and
hence are high priorities for improved education initiatives, include the elderly
(Col, Fanale et al. 1990; Ryan 1999), those with low literacy skills (Feifer 2003)
and patients from non-English speaking backgrounds (Davidhizar and Brownson
1999).
Medication compliance, synonymous with medication adherence and
concordance, is defined as the extent to which patients follow the instructions
they are given for prescribed treatments. There are several methods which can
be used to measure compliance and these include pill counts, patients’ selfreport, pharmacy dispensing records, electronic monitoring systems, as well as
blood and urine assays. Some of the strengths and weaknesses of these
different methods are summarised in the following
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Compliance
Measurement
Pill count

Strengths

Weaknesses

- quick and easy
- the number of tablets can be
quickly inspected to see how many
have been taken from the pack

- cannot identify the number of days
missed
- patients can manipulate tablet
numbers
- can be time consuming if conducted
in a home setting
-patients may resent having their pills
counted

Self-reporting

- patients do their own reporting

- patient recall may be inaccurate
- patients may be reluctant to admit

- quick and easy
- - subjective measurement

‘noncompliance’
- patients may have a tendency to
over-report compliance
- researchers may allocate different
scores to self-reporting claims
- possible ‘Hawthorne effect’ because
patients are aware of being monitored
(Turner et al 2001)

Pharmacy
dispensing
records

- objective measure of compliance
- quick and easy
- can produce population based
analyses
- can generate reports from days to
years

- can be inaccurate if several
pharmacies are involved
- can prove to be timely and expensive
if several pharmacies are involved
- can lead to errors if patients stockpile
their medications

Electronic
monitoring
system (e.g.
Medication event
monitoring
system MEMS)

- provide a good record of the
number of times a patient
remembers to take their medication
- provide a good record of the
interval between doses

- expensive and cumbersome when the
electronic device does not fit the
prescription medication bottle
- can causes problems if the device
becomes faulty
- patients who are used to using
reminder dosing units (e.g. blister
packs, dosette boxes etc) cannot use
them with the electronic monitoring
device

Blood or urine
assays

- effective and accurate for
appropriate medications

- expensive and may not be routinely
available for many medications
- may be invasive
- some blood tests can be affected by
the timing of the last dose which can
cause misleading results

According to this summary it would be true to say that each compliance
measurement method is limited to some degree. These limitations have also
been highlighted in different reports which have found that self-reporting can
overestimate compliance (Haynes, McKibbon et al. 1996; Shalansky 2004), pill
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counts can underestimate compliance (Grymonpre, Didur, Montgomery and Sitar
1998), electronic monitoring devices are useless if they become faulty or lost
(Turner and Hecht 2001) and only complete pharmacy prescription data records
can be used to correctly estimate medication compliance (Grymonpre, Didur et
al. 1998).
There is no gold standard for measuring medication compliance, which is
why different researchers have used different methods over time. Earlier studies
typically used pill counts, whereas in recent times electronic monitoring devices
such as the Medication Event Monitoring System (MEMS) have replaced pill
counts as the reference standard (Farmer 1999). Reviewing the strengths and
weaknesses of the different compliance measurements listed above it could be
argued that no one single method is more reliable or superior to the other.
Perhaps the best way to deal with these shortcomings is to use at least two or
more of the most convenient and available compliance measurement methods,
which can be used to achieve the study’s goals. A good example of this, is a
recent study which compared the compliance of HIV protease inhibitors for 108
HIV infected adults over an 8 week period (Liu, Golin, Miller, Hays, Beck,
Sanandaji, Christian, Maldonado, Duran, Kaplan and Wenger 2001). The
researchers used a medication event monitoring system (MEMS), a pill count, a
self-report interview and a combination of all these results known as the
composite adherence score (CAS) to measure medication compliance which was
then compared to the HIV viral load in the blood. They found that the composite
score showed the strongest predictive relationship with the HIV viral load,
suggesting that a composite score of more than one compliance measurement
method is a more reliable way in which to predict medication compliance. In light
of this, it could be speculated that other studies which used two compliance
measurements such as self-reports and pill counts (Esposito 1995), as well as
pill count and electronic monitoring (Bansberg, Hecht, Charlebois, Chesney and
Moss 2001; Girvin, McDermott and Johnston 1999) more accurately predicted
medication compliance than did the studies which used only one medication
compliance measurement such as; self-reporting (Katon, Rutter, Ludman, Von

27

Korff, Lin, Simon, Bush, Walker and Unutzer 2001), pill counts (Haynes, Sackett,
Gibson, Taylor, Hackett, Roberts and Johnson 1976) and urine tests (Colcher
and Bass 1972).
The implications of the work to date are that at least two compliance
measures should be used when and if appropriate. In the absence of information
about the best way in which to measure warfarin compliance in a community
setting it could be argued that the two most appropriate methods include blood
assays known as the international normalised ratio blood tests, INR blood tests,
and self-reporting. The INR blood tests alone are not ideal because the tests can
be done at varying time intervals depending on how often they are ordered by the
health professionals thereby possibly distorting the overall results. The pill counts
would be difficult and time consuming to conduct in a community setting, the
electronic monitoring devices would need to be attached to each of the different
warfarin strengths which could also distort the results if certain strengths were
not always required during the research study, and pharmacy dispensing records
would not be ideal when and if participants were using multiple pharmacies. In
summary therefore, even though using the INR blood test and self-reporting are
not ideal, they are a step forward in the way warfarin compliance data can be
collected and evaluated.
Researchers have found that many factors can contribute to poor
medication compliance. These factors include poor knowledge and
understanding (Fineman and DeFelice 1992; Fitten, Coleman, Siembieda, Yu
and Ganzell 1995); cognitive and/or physical limitations such as failing eyesight
and hearing complications (Stewart and Caranasos 1989), misinterpretation of
instructions (Ruzicki, Bettesworth and Steele 1986); side effects (Ferguson,
Ziedins, West, Richardson and Michocki 1996), visiting numerous medical
practitioners, as well as having complex drug regimens which interfere with their
daily living (Pendleton 1992).
Reports in the literature have identified that these factors especially
contribute to poor medication compliance in the ‘high risk’ group (Ryan 1999;
Schlenk, Dunbar-Jacob and Engberg 2004). In a study of elderly patients, aged
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65 years and over, Col et al (1990) interviewed 315 patients admitted to hospital
and found that of the 89 patients admitted because of adverse drug events, 36
(11.4 percent) were due to non compliance. The authors identified that having
multiple medications, poor recall and seeing numerous physicians were amongst
the many contributing factors for non compliance. Similarly, patients with low
literacy skills may be non compliant because they cannot understand the
information provided to them by their health professionals (Feifer 2003; Mayeaux
Jr, Murphy, Arnold, Davis, Jackson and Sentell 1996; Roter, Rudd and Comings
1998). This may also be the case with non-English speaking background patients
(Ziguras, Klimidis, Lambert and Jackson 2001; Ziguras, Lambert, McKenzie and
Pennella 1998). Unfortunately, there is very limited evidence in the literature
about factors, which contribute to poor compliance in the non-English speaking
background patients. A major factor contributing to the poor representation of
studies with these populations in the literature is the subjects’ lack of the English
language, often used as ineligibility criterion for inclusion into studies. It may be
fair to assume, however, that they would also experience poor compliance based
on factors already discussed.
A recent systematic review of randomised trials of interventions to assist
patients follow prescriptions for medications (Haynes, Montague, Oliver,
McKibbon, Brouwers and Kanani 2001) identified that only 33 of the 1806
citations met the stringent criteria set by the reviewers. The criteria included that
(i) both compliance and treatment effects were measured, (ii) there was at least
80% follow-up of each group studied; and (iii) for long-term treatments, the
follow-up period was at least 6 months. The reviewers concluded that simplifying
the medication regimen could improve compliance and treatment outcomes for
both short and long term medications. However, to improve the compliance and
therapeutic outcomes of long term medications the interventions needed to be
more complex and include combinations of: more thorough patient education and
counselling; reminders; close follow-up; reinforcement; supervised selfmonitoring; family support and rewards for success. Surprisingly, given its
simplicity, they specified that the single most important intervention was recalling
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patients and making every effort to keep them in care. It is noteworthy that even
though there is evidence to support the positive influence of both social and
behavioural factors to improve compliance and therapeutic outcomes (Col,
Fanale et al. 1990), these were not targeted by any of the randomised control
trials evaluated in this review by Haynes et al (2001).
Similar results were also found in a meta-analysis (Roter, Hall et al. 1998)
which summarised the results of 153 studies published between 1977 to 1994
evaluating the effectiveness of interventions to improve patient compliance with
medical regimens. Inclusion criteria for the meta-analysis included: (i) an
intervention to influence or improve compliance; (ii) a control group and an
intervention group; (iii) compliance with a therapeutic recommendation; (iv) an
association with compliance and at least one intervention variable; (v) sample
size no less than 10 and (vi) a study published in English. This meta-analysis,
similar to the systematic review by Haynes, McDonald, Garg and Montague
(2002a), concluded that a mixed programmatic focus was much more effective at
improving medication compliance and therapeutic outcomes than was a single
programmatic focus. These mixed programmatic focus interventions included
patient education, familial support, heath professional/patient communication and
partnerships, as well as emotional support. Unfortunately, the effectiveness of
such mixed interventions, in patients with low literacy skills and from non-English
speaking backgrounds, have not been evaluated to date. It would be reasonable
to assume however, that such mixed focus interventions would also help to
promote medication compliance and therapeutic outcomes in these patient
populations.
Other interventions shown to improve medication compliance include the
use of compliance aids such as dosette boxes, reminders and blister packs
(Roter, Hall et al. 1998; Wong and Norman 1987). A review of the 52 medication
errors involving dosette boxes by Levings et al (1999) found that the problems
were associated with incorrectly filling the dosette box and/or incorrect use of the
dosette box. Even though this study concluded that more appropriate patient
selection and more care with filling the dosette boxes would minimise these
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adverse events, such compliance aids are not always the perfect solution to
compliance problems. Not only are they expensive but they are also
inappropriate for patients with significant cognitive impairment who cannot
remember when and if they took their last dose of medications. This may
subsequently result in patients either taking too many medications or not taking
enough and therefore contributing to poor compliance and possible adverse drug
events.
Stewart and Caranasos (1989) also have made recommendations to help
improve medication compliance, especially in the elderly patients. Their
recommendations include the following:
 Simple, clear instructions repeated periodically
 Written instructions
 Assessment of the cognitive function of the patient prior to the
education, and tailoring the education to their ability
 Development of a routine for taking medications
 Construction of a chart when multiple medications were used.

There is little doubt that improved medication compliance will help to
optimise therapeutic outcomes and minimise adverse drug events
(Haynes, McDonald et al. 2002a). Reports in the literature suggest that to
improve medication compliance a mixed programmatic intervention approach
rather than a single-focus intervention approach would be more successful for
both short and long term medications (Haynes, McDonald and Garg 2002b;
Roter, Hall et al. 1998). Since it is not possible at this stage to identify which
combination of factors would be most useful, patient medication education
programs should target the factors know to contribute to improved medication
compliance. These factors include patient education and counselling, reminders,
close follow-up, reinforcement, family support and where appropriate the use of
medication aids.

31

2.4.4.4 Inappropriate written medication information
It is difficult for patients to optimise their therapeutic outcomes and avoid
adverse drug events if they receive insufficient and inappropriate medication
information. This may result in errors in judgment, failure to recognise important
signs and symptoms of side effects, and possibly completely misunderstanding
therapeutic regimens and treatment plans (Bhasale, Miller et al. 1998).
Baker (1997) and Estrada, Hryniewicz et al (2000) have found that much
of the currently available written medication information cannot be read or
understood by a large proportion of the population. This is because it is written
between grade 9 and grade 14 levels, well beyond the comprehension of those
educated at or below a grade six level (Rolland 2000). It has also been identified
that written information often contains a lot of medical jargon and terminology
which cannot be read or understood by many patients, especially those with low
literacy skills (DiMatteo 1997; Murphy and Davis 1997). Written medication
information available in Australia, known as consumer medicine information
(CMI), has been found to include such complex terms (Baker 1997; Koo, Krass
and Aslani 2001).
Since 1995 it has been mandatory that all prescription medicines in
Australia be given to patients with the appropriate CMI, as outlined in the
Therapeutic Goods Regulations (1990). These CMIs are available as package
inserts, loose leaflets and in electronic format. The current legislation includes
regulations about the content and presentation of CMIs but these regulations are
not based on scientific evidence regarding how to communicate medicines
information effectively to consumers. It has been reported that patients find CMIs
difficult to read because of their font size, sheer volume of pages and their
common inclusion of medical jargon (Koo, Krass et al. 2001).
In an attempt to improve medication-related therapeutic outcomes, the
literature identifies the need to provide simple and easy-to-comprehend
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medication information (Esposito 1995). This information should be appropriate
for all patient populations, including the ‘high risk’ group. Poor literacy skills and
written patient medication information will be discussed in much greater detail in
the next chapter.

2.4.4.5 Poor continuity of care between hospital and community settings
Poor continuity of care between hospital and community settings has also
been recognised as an important contributor to adverse drug events (Australian
Council for Safety and Quality in Health Care 2002; Forster, Murff et al. 2003).
Recently the Australian Pharmaceutical Advisory Council (APAC) introduced the
‘Guidelines on the continuum of care of quality use of medicines between
hospital and community’ (Australian Pharmaceutical Advisory Council 1998) with
the aim to improve communication between both settings. Even though there are
no evaluation data available on the impact of adhering to these guidelines, based
on the fact that they were initially introduced to address the communication
problems between hospital and community settings it would be fair to suggest
that their effects would be positive. In other words, adherence to these guidelines
could help to optimise therapeutic outcomes and reduce adverse drug events by
promoting the timely transfer of information, not only to the patient and/or their
carer, but also to the patients’ health professionals working in the community
setting (Thornton, Simon and Mathew 1999).
Unlike typical hospital inpatient healthcare delivery services, Illawarra
Health’s The Ambulatory Care Team (TACT) is a multidisciplinary team, which
provides home healthcare delivery services to Illawarra residents aged 16 years
and over who would otherwise be hospitalised. TACT is similar to the
proliferating number of ‘Hospital in the Home’ (HITH) services available in
Australia since 1995 (Duke and Street 2003), which have provided home
healthcare delivery for medical conditions requiring anticoagulation management
and intravenous antibiotics. TACT differs to many other Australian HITH services
in that it provides a pharmacist to deliver home-based medication education
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which is a new and emerging philosophy in patient medication education (Mullan
1999; Stowasser 1999; Stowasser, Collins and Stowasser 2002).
In the absence of good continuity of care between hospital and
community-based settings (Balla and Jamieson 1994; Bolton, Mira, Kennedy and
Moses-Lahra 1998), TACT is well placed to promote the continuity of care by
incorporating the APAC guidelines (1998) into its everyday practice. There is an
implication that adhering to these guidelines will help to optimise therapeutic
outcomes and minimise adverse drug events.

2.4.4.6 Patient follow-up
Patient follow-up, including telephone follow-up, has been identified as an
important strategy to help optimise therapeutic outcomes and minimise adverse
drug events. Patient follow-up has the potential to improve health
professional/patient communication and partnerships, medication compliance,
medication information and the continuity of care because it directly impacts on
each of these factors (Haynes, McDonald et al. 2002a).
Evidence to support the positive influence of telephone follow-up on health
professional/patient communication and partnerships can be found in a study
conducted by an American telephone anticoagulation service, which managed
between 300 and 400 patients. Following a 12-month surveillance period, this
service found that its patients, all of whom received telephone follow-up, were
more proactive with their warfarin therapy and more likely to have therapeutic
blood tests results, than were patients who did not receive the follow-up service
(Waterman, Milligan, Banet, Gatchel and Gage 2001). Another study, which
involved 30 African American men with type 2 diabetes, also found that
telephone follow-up, accompanying a structured education program, contributed
to favourable diabetes health outcomes and improved patient/health professional
partnerships (Hendricks and Hendricks 2000). While these studies examine
actions of patients with different health problems, it appears that the importance
of patient follow-up is common to successfully managed community therapeutic
programs.
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A meta-analysis on the effectiveness of interventions to improve patient
compliance and education concluded that telephone follow-up was an integral
part of the essential mixed programmatic focus interventions (Roter, Hall et al.
1998). This meta-analysis included a study, which compared the effectiveness of
improving medication compliance in 82 patients for a 10 to 14 day course of
antibiotic therapy. The study found that the mean compliance for the telephone
follow-up patients who also received written and oral counselling was significantly
better than for the control patients who received neither telephone follow-up nor
counselling. Those in the former group achieved 85.4 percent mean compliance
while those in the latter just 76.6 percent mean compliance (Garnett, Davis,
McKenney and Steiner 1981). Similarly, another study within the same metaanalysis, observing 60 Non Insulin Dependent Diabetes Mellitus (NIDDM)
patients found that patients who received the follow-up intervention (by telephone
calls and home visits) were more compliant with their diabetes management plan
than were patients who received the standard educational program with no
follow-up intervention (Estey, Tan and Mann 1990). Regardless of the fact that
the medications were for both short and long-term use, the studies indicate that
patient follow-up, including telephone follow-up, helped to improve medication
compliance.
Regular follow-up in long-term self-management programs have been
found to enhance outcomes for asthmatic children (Gebert, Hummelink, Konning,
Staab, Schmidt, Szczepanski, Runde and Wahn 1998), as well as other chronic
disease states (Lorig 1996). A recent Australian study found that home-based
follow-up of patients discharged from hospital on warfarin therapy resulted in
significant reductions in the number of haemorrhagic complications (Jackson,
Peterson, Vial and Jupe 2004). An American study which evaluated the impact of
a 12-month follow-up telephone call service provided by a pharmacist to 221
patients discharged from a general hospital found that fewer patients from the
telephone call group returned to the emergency department within 30 days (10
percent phone call compared to 24 percent no phone call). This study found that
not only did the follow-up telephone service reduce the incidence of adverse drug
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events but it also increased patient satisfaction (Dudas, Bookwalter, Kerr and
Pantilat 2001).
Based on the evidence in the literature it can be concluded that follow-up
is an essential component for effective medication education. Patient follow-up,
including telephone follow-up, can be used to specifically target and reinforce
other factors such as; health professional/patient communication and
partnerships, medication compliance and management, patient education and
improved patient satisfaction, all of which help to optimise therapeutic outcomes
and minimise adverse drug events.

2.4.4.7 Summary
In order to optimise therapeutic outcomes and minimise adverse drug
events it is important to target key elements known to contribute to such events.
These key elements have been found to include improving health
professional/patient communication and partnerships, improving medication
compliance, providing simple, easy-to-read written medication information,
improving the continuity of care between hospital and community settings, and
offering patient follow-up. Effective medication education should not only target
these key elements, but should also address the needs of the ‘high risk’ patient
population.

2.5 WARFARIN

2.5.1 Introduction
The focus of the discussion will now turn to the oral anticoagulant warfarin.
Warfarin has been identified as a major medication causing adverse drug events,
both in Australia and overseas (Australian Council for Safety and Quality in
Health Care 2002; Forster, Murff et al. 2003; Hirri and Green 2002). To date,
warfarin-related adverse drug events have been identified as a large and
unresolved problem (Campbell, Roberts et al. 2001). This problem has the
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potential to grow and escalate with continually emerging research findings
demonstrating its benefits in patients with different disease states such as atrial
fibrillation (Ezekowitz and Falk 2004; Gallus, Baker et al. 2000; Peterson,
Jackson et al. 2002). Consistent with previous discussions of the ‘high risk’
patient population, those most likely to experience warfarin-related adverse drug
events include the elderly, those with low literacy skills (Estrada, MartinHryniewicz et al. 2004; Lambert and Wynne 2003; Tang, Lai et al. 2003) and
those from non-English speaking backgrounds (Nadar, Begum et al. 2003).
It could be argued that inadequate warfarin education programs (Connor
1998) and patient warfarin knowledge deficiencies (Cheah and Martens 2003;
Lambert and Wynne 2003; Nadar, Begum et al. 2003; Tang, Lai et al. 2003)
support the need for a new effective warfarin education program. This thesis
promotes the development and implementation of a new warfarin education
program, which acknowledges and averts the historical inadequacies, offering a
considered approach to effective patient education. This improved patient
education will in turn empower patients to make informed decisions about their
warfarin therapy, helping to optimise their therapeutic outcomes and minimise
adverse drug events (Ansell, Buttaro et al. 1997; Kagansky, Knobler, Rimon,
Ozer and Levy 2004).

2.5.2 Background
To understand why warfarin is being prescribed more frequently today, it
is essential to know its function. Warfarin, which is derived from clover (Catania
1994), works by limiting the availability of vitamin K, a necessary component in
the formation of coagulation factors II (prothrombin), VII, IX and X, and the
anticoagulant proteins C and S. Warfarin prevents new clots from forming and
existing clots from getting bigger (Catania 1994). The extent of the warfarininduced blood coagulation defect, expressed as an International Normalised
Ratio (INR), is the major determinant of treatment success or failure.
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To achieve safe and effective warfarin treatment, patients need to be
effectively educated about the most important considerations in managing their
warfarin therapy. These considerations include: indications for therapy; how and
when to take their warfarin; the importance of regular blood tests; target
International Normalised Ratio (INR) levels; possible warfarin-related side effects
and drug-to-drug interactions; and exercise, dietary and alcohol restrictions
required to optimise therapy (Gallus 1999).
Until recently the use of warfarin has been limited to the treatment of
venous thrombosis or pulmonary embolism, the prevention of systemic embolism
caused by prosthetic heart valves and the recurrence of embolic stroke (Gallus
1999). Less frequently, warfarin has been used to prevent systemic embolism in
refractory heart failure or when atrial fibrillation complicates cardiac valvular
stenosis or incompetence. There has also been limited usage of warfarin to
prevent venous thrombo-embolism after hip surgery, or to prevent a recurrence
of myocardial infarction (Gallus, Baker et al. 2000).
More recently, it has been found that warfarin dramatically reduces the
risk of embolic stroke in patients with atrial fibrillation (AF) and that treatment
benefits significantly outweigh the risks (Ansell, Buttaro et al. 1997; Gallus, Baker
et al. 2000). Despite these benefits in patients with atrial fibrillation, warfarin is
underused, especially in elderly patients (DeBray, Couturier and Siguret 2003;
Peterson, Jackson et al. 2002; Whittle, Wickenheiser and Venditti 1997),
primarily because physicians perceive the risk of poor compliance and a lack of
warfarin knowledge and understanding as being unacceptably high among these
patient populations (Man-Son-Hing and Laupacis 2003). With an increased
pressure to prescribe, however, and with the possibility of improving patient
warfarin education, this situation may change in the near future.

2.5.3 Incidence of warfarin-related adverse drug events
The literature identifies that warfarin is responsible for a high incidence of
adverse drug events (Australian Council for Safety and Quality in Health Care
2001; Forster, Murff et al. 2003; Runciman, Roughead et al. 2003). With recent
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increases in warfarin prescribing (Cruickshank, Ragg et al. 2001) and the
likelihood that prescribing will further increase for patients diagnosed with atrial
fibrillation (Gallus, Baker et al. 2000), warfarin-related adverse drug events will
almost certainly grow in magnitude.
Australian data support the evidence that warfarin-related adverse events
are a large and unresolved problem (AIHW 2003), causing an estimated cost of
$100 million per annum for hospitalisation alone in 1992 (Rigby, Clark et al.
1999). From 1999 to 2000, warfarin was associated with 5,080 adverse drug
events requiring admission to Australian hospitals, 7.3 percent of the total
adverse drug events (AIHW 2002). Data from the Australian Institute of Health
and Welfare (AIHW 2003), indicates that there has been a steady increase in the
number of warfarin-related hospital admissions over the past few years.
According to these data, hospital admissions with diagnosis code ICD-10-AM
T455 (anticoagulant poisoning) increased from 434 in 1998/99, to 449 in 1999/00
and then to 471 in 2000/01, an increase of 8.5 percent over the three year period
from 1998 to 2001. Similarly, hospital admissions for the external cause code
ICD-10-AM Y442 (anticoagulants primarily affecting blood constituents),
increased from 4,378 in 1998/99, to 5,080 in 1999/2000 and then to 5,228 in
2000/2001 (AIHW 2003), an increase of 19 percent over the three year period
from 1998 to 2001. Unfortunately, there are no data available about the incidence
of warfarin-related adverse drug events and the number of general practice
encounters over the past few years. However, based on the hospital data and the
evidence that patients can be successfully treated for warfarin induced bleeding
in an outpatient setting (Brigden, Kay, Le, Graydon and Mcleod 1998), as well as
the availability of guidelines to treat warfarin-related adverse events in both
community and hospital settings (Gallus, Baker et al. 2000) it could be assumed
that similar increases are being experienced in the community sector.
Data available from the Australian Therapeutic Goods Administration
(TGA) Adverse Drug Reactions Advisory Committee (ADRAC 2005) also indicate
that the reporting of suspected warfarin-related adverse drug events has
increased progressively over the past few years, from 47 reports in 1992, to 103
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reports in 1999 and then to 115 reports in 2004. Even though a significant portion
of these reports relate to the loss of anticoagulant control either because of
dose/compliance or interactions with other co-administered drugs and are not a
true indication of the total number of warfarin-related adverse drug events their
increase in number over the past few years supports the evidence that warfarinrelated adverse drug events are on the rise in Australia.
It could be argued that this steady increase in warfarin-related adverse
drug events could be attributed to the increase in warfarin prescribing (Arnsten,
Gelfand and Singer 1997; Elliott, Woodward et al. 2002; Peterson, Jackson et al.
2002), rising from 1.673 million warfarin prescriptions in 1999 (Commonwealth
Department of Health and Aged Care 2003) to 1.897 million warfarin
prescriptions in 2002 (Commonwealth Department of Health and Aged Care
2004). However, many other factors have been found to contribute to adverse
drug events. These factors include; poor health professional/patient
communication and partnerships (Bhasale, Miller et al. 1996), poor warfarin
compliance (Campbell, Roberts et al. 2001), poor and inappropriate written
warfarin information (Estrada, Hryniewicz et al. 2000; Estrada, Martin-Hryniewicz
et al. 2004), poor continuity of care between hospital and community settings
(Bramley-Moore, Dwyer, Perlman and Sucic 1996) and poor patient follow-up
(Pickette 2002). Importantly, warfarin-related adverse events are a major concern
for the ‘high risk’ patient population which include the elderly and those with low
literacy skills (Lambert and Wynne 2003; Tang, Lai et al. 2003), as well as the
non-English speaking background patients (Nadar, Begum et al. 2003).
In summary, the incidence of warfarin-related adverse drug events is on
the increase and will continue to rise with recent recommendations to prescribe
warfarin for diseases such as atrial fibrillation (Elliott, Woodward et al. 2002;
Peterson, Jackson et al. 2002). Strategies need to be put in place to improve
patient warfarin education (Hirri and Green 2002; Kagansky, Knobler et al. 2004)
by targeting the elements known to contribute to poor warfarin-related
therapeutic outcomes and adverse drug events.
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2.5.4 Inadequacies in currently available warfarin education programs
Effective patient education is paramount to the success of warfarin
therapy (Kagansky, Knobler et al. 2004; Pubentz, Calcagno and Teeters 1998;
Roche-Nagle, Chambers, Nanra, Bouchier-Hayes and Young 2003). Literature
spanning 20 years suggests that most warfarin education programs are based on
content, without demonstrating any structured framework, program design or
outcome evaluation (Wyness 1989). It appears that over the years, warfarin
education programs have evolved relying on the health professionals’ intuition,
convenience and habit as the use of warfarin has increased. The literature
suggests that many of these education programs are inadequate (Connor 1998),
presenting too much information and overwhelming patients (Ansell, Buttaro et
al. 1997).
There is almost no reporting of current available warfarin education
programs in the literature and as a consequence little evidence regarding
effectiveness of such programs. A review by Wyness (1989) some 15 years ago
provided evidence regarding 15 different warfarin education programs available
at the time. The major emphasis for each of the programs was content rather
than stating any education objectives or evaluation outcomes. The programs
mainly used written information sheets and/or booklets as teaching aids, with two
of the programs providing audiovisual videos. The points emphasized during the
education programs were based on the individual choice of the educator rather
than being based on any structural framework. The other important issue about
these warfarin education programs was that none of them were evaluated which
means that it is not possible to compare the effectiveness of the different
programs.
The primary warfarin-related focus in the literature today is on the
important warfarin information for health professionals (Deblinger 2000; GibbarClements, Shirrell, Dooley and Smiley 2000; Hirsh, Dalen, Deykin, Poller and
Bussey 1995). Evidence regarding the effectiveness of current warfarin
education programs is almost nonexistent. Interestingly however, for anyone with
access to a computer or the internet, there is a proliferation of information about
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warfarin. This electronically available information primarily is not based on any
systematic educational approach and is often devoid of scientific evidence.
Examples of these include the Clever Clog – anticoagulation education software
for use in the primary care setting, as well as the plethora of warfarin websites
available on the internet, some of which are listed here;
http://www.druginfornet.com/faq/faqcouma.htm;
http://www.nlm.nih.gov/medlineplus/druginfo/anticoagulantsystemic202050.html;
http://www.med.umich.edu/1libr/chheart/meds08.htm
http://clinical.caregroup.org/altmed/interactions/drugs/warfarin.htm
http://www.coumadin.com/consumer/INT_VitaminK1.asp
http://www.mims.hcn.net.au/ifmx-nsapi/mims-data/?MIva

Shortcomings in current warfarin education programs are borne out by
reports of deficiencies in patients’ warfarin knowledge, which can predispose
them to poor therapeutic control and adverse drug events (Lambert and Wynne
2003; Nadar, Begum et al. 2003; Wilson, Racine et al. 2003). Recent American
(Cheah and Martens 2003) and English (Taylor, Ramsay, Tan, Gabbay and
Cohen 1994) studies which evaluated patient warfarin knowledge, found that
overall most patients exhibited warfarin knowledge deficits, even after they had
received warfarin education. Cheah and Martens (2003) study of 50 hospital
inpatients, found that although 68 percent were satisfied with the education they
received, there was an overall warfarin knowledge deficit, with knowledge scores
ranging from 6.3 percent to 87.5 percent, out of a possible 100 percent (Mean,
46.9; Standard Deviation 20.9). Taylor et al (1994) evaluated the warfarin
knowledge scores for 70 outpatients using a different warfarin knowledge
questionnaire. They also found that overall warfarin knowledge was poor, with
only half the patients being able to identify adverse events associated with poor
anticoagulant control, a safe level of alcohol consumption and possible drug-todrug interactions with non-prescription drugs and warfarin therapy. Unfortunately,
because these studies did not use the same warfarin education programs or the
same questionnaire to analyse warfarin knowledge they cannot be directly
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compared. They do suggest however, that currently used warfarin education
programs are not effective in ensuring that the patients have adequate warfarin
knowledge and understanding to safely manage their warfarin therapy at home.
Many studies have confirmed that the patients most likely to experience
poor therapeutic outcomes and adverse drug events because of their warfarin
knowledge deficits are the elderly (Tang, Lai et al. 2003), those with low literacy
skills (Estrada, Martin-Hryniewicz et al. 2004) and patients from non-English
speaking backgrounds (Nadar, Begum et al. 2003). Tang et al (2003) conducted
a study in Hong Kong from January to March 1999 and found that overall
warfarin knowledge was poor in the 122 patients evaluated, especially amongst
the elderly and those with low literacy skills. Only 40 - 45 percent of the patients
knew the strengths of their warfarin tablets, the reason for taking their warfarin
and its effects on the body. The 60 patients who had read the written warfarin
information had a better warfarin knowledge than those who did not, and illiteracy
was noted as the main reason for not having read the written information. In this
study not only were the elderly patients and those with low literacy skills found to
have the poorest warfarin knowledge and understanding they were also found to
have poorer anticoagulant control. Similarly, a study by Estrada et al (2004)
found that of the 143 American patient participants over the age of 50, those with
poor literacy skills had poorer than average warfarin knowledge and
anticoagulant control. The study by Nadar et al (2003) on 180 non-English
speaking background (NESB) patients attending a United Kingdom
anticoagulation clinic, used different warfarin knowledge questionnaires to
evaluate their warfarin knowledge data, but interestingly they also found that on
average warfarin knowledge was poor with an average score of 5.5 (61.1
percent) out of a total score of 9 for the NESB and elderly patients. The results of
these studies highlight that current warfarin education programs do not effectively
educate patients, especially those at ‘high risk,’ about their warfarin therapy. This
predisposes patients to poor therapeutic outcomes and warfarin-related adverse
drug events. In addition, these studies also identify a limitation in the area of
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warfarin education research, as there appears to be a lack in common validated
instruments to determine the levels of warfarin knowledge and understanding.
There is also an absence of the descriptions and/or evaluations of
Australian based warfarin education programs in the literature. It must be
presumed therefore, that warfarin education in Australian hospital and community
settings is based on an ad hoc set of messages decided upon by the health
professionals. In the absence of consensus guidelines for warfarin education, the
health professionals themselves decide what information about warfarin they
should deliver to their patients. Concerns are mainly focused on the maintenance
of an appropriate International Normalised Ratio (INR). It is only when these
results are not within normal range that the health professionals question their
patients in an attempt to discover what it is that they may be doing to cause their
INR results to be outside therapeutic range.
As well as presenting the warfarin education on a seemingly ad hoc basis,
other idiosyncrasies regarding warfarin education exist. Rather than use the
warfarin consumer medicine information, CMI, many of the Australian health
professionals delivering warfarin education either develop and use their own
written patient warfarin information or alternatively use the Boots warfarin
information booklets (2002; 2003). Unfortunately, much of this information is
written at a level (Baker 1997; Estrada, Hryniewicz et al. 2000) beyond the
comprehension of many patients and hence inappropriate as a written
information resource.
Inadequacies in patient knowledge resulting from the currently available
warfarin education programs highlight the need for a new more systematic
approach to the delivery of warfarin education. Such a program should target the
key elements believed to contribute to poor therapeutic outcomes and adverse
drug events. During the development and implementation of this new program,
special consideration should be directed to the development and/or use of
validated instruments to determine if possible, the contribution of various
components of the program to improved medication outcomes.
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2.5.5 The impact of improved warfarin education of warfarin-related
therapeutic outcomes and adverse drug events
A well-organised structured education program should enable patients to
learn the necessary skills to achieve optimal therapeutic outcomes and minimise
adverse drug events. Kagansky et al (2004) reported a combined retrospective
and prospective cohort study on 323 patients, aged 80 years and older who were
discharged from hospital on an oral anticoagulant. After following up these
patients for approximately two to three years, the researchers found that the rate
of major bleeds was highest amongst the patients who received poor quality
warfarin education, which had been performed by the medical staff. The
education programs consisted of an explanation about the purposes of the oral
anticoagulant, the risk of complications and information about INR values. The
poor quality of such education was found to be the most significant risk factor
associated with bleeding complications in this elderly patient population. The
results of this study like many others (Arnsten, Gelfand et al. 1997; Nadar,
Begum et al. 2003; Roche-Nagle, Chambers et al. 2003) suggest that a good
quality warfarin education program could help to reduce the incidence of bleeding
complications associated with poor warfarin management.
Patients who have a poor understanding of the indications for warfarin use
and its potential adverse effects are more likely to be non compliant than are
those who receive warfarin education (Arnsten, Gelfand et al. 1997). Barcellona
et al (2002) found that the time spent within therapeutic range was improved for
patients who knew why they were taking their oral anticoagulant, as compared to
those who did not, significantly more so for the elderly patients aged 65 years
and over (89 percent versus 76 percent, p = 0.04). This study also found that
patients’ anticoagulation control could be improved by simply answering a
warfarin knowledge questionnaire.
Evidence exists that poor compliance with anticoagulant treatment occurs
in 10 – 26% of cases, especially among the elderly patients (Arnsten, Gelfand et
al. 1997). An audit of hospital admissions over a 3 month period found that poor

45

anticoagulant compliance was the major contributing factor causing overanticoagulation in 29 patients (Hirri and Green 2002). Similarly, Brigden et al
(1998) also found that along with drug-to-drug interactions, poor compliance was
a significant contributor to poor anticoagulation control in 65 patients admitted to
hospital.
Comprehensive patient education about warfarin should also target
improved patient education about drug-to-drug interactions with warfarin, which
has been found to be responsible for many warfarin-related adverse drug events
(Barcellona, Contu and Marongiu 2002; Brigden, Kay et al. 1998). Barcellona et
al (2002) found that patients who knew more about potential food and warfarin
interactions spent more time within therapeutic range than did those who did not.
Similarly, Wilson et al (2003) identified that more than half of the 65 African
American patients, aged 50 years and over in their study, could not read or
understand the culturally inappropriate written information given to them, and
were therefore more susceptible to warfarin related adverse drug events based
on possible drug-food interactions.
Thus patients’ knowledge abut warfarin is still generally poor, especially
for patients in the ‘high risk’ group (Cheah and Martens 2003; Lambert and
Wynne 2003; Nadar, Begum et al. 2003), highlighting the need for a more
effective warfarin education program. This new program would need to target the
many interventions found to help improve medication compliance (Haynes,
McDonald et al. 2002a; Roter, Hall et al. 1998), as well as the many other factors
believed to contribute to improved warfarin anticoagulation control. Such factors
include encouraging patients to be involved in the decision making process
(Dantas, Thompson, Manson, Tracy and Upshur 2004), promoting good health
professional communication and partnerships (Barcellona, Contu, Sorano and
Marongiu 2000), and providing easy-to-read culturally appropriate written
warfarin information (Estrada, Hryniewicz et al. 2000; Wilson, Racine et al. 2003).
Dantas et al 2004 conducted 21 face-to-face interviews with older patients and
found that even though satisfaction was high amongst all patients, those who
were more involved with the decision making process had a better warfarin
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knowledge and understanding than those who were not. Further evidence to
support the need to promote health professional/patient communication and
partnerships can be seen in the 96 percent response rate from the 264 patients
attending two Italian anticoagulation clinics, indicating that doctor-patient
relationships were very important to them (Barcellona, Contu et al. 2002). The
importance of easy-to-read culturally appropriate written warfarin information will
be further discussed in the next chapter.

2.5.6 Summary
Warfarin is one of the major medications causing adverse drug events,
both in Australia and overseas (Australian Council for Safety and Quality in
Health Care 2002; Forster, Murff et al. 2003). The incidence of warfarin-related
adverse drug events is on the rise with recent recommendations for increased
warfarin prescribing in atrial fibrillation (Cruickshank, Ragg et al. 2001).
Inadequacies in the currently available warfarin education programs (Connor
1998) and patient warfarin knowledge deficiencies (Cheah and Martens 2003;
Nadar, Begum et al. 2003; Tang, Lai et al. 2003), highlight the need for a new
patient warfarin education program to help improve the patients’ warfarin
knowledge and understanding (Hirri and Green 2002). This new warfarin patient
education program should target the key elements believed to contribute to poor
warfarin-related therapeutic outcomes and warfarin-related adverse drug events,
as well as the needs of the ‘high risk’ patient population.

2.6 CONCLUSION
This chapter has identified that many adverse drug events, including
warfarin-related adverse drug events, which are potentially preventable, have a
major impact on health, healthcare and healthcare costs, both in Australia and
overseas. Improved patient medication education has been recognised as an
important intervention, which can be used to help optimise therapeutic outcomes
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and reduce the potentially preventable adverse drug events. Recent and ongoing
increases in warfarin prescribing are likely to lead to a further increase in the
incidence of warfarin-related adverse drug events.
The literature has identified that current warfarin education programs are
not as effective as they should be, because many patients, and especially ‘high
risk’ patients, have deficits in their warfarin knowledge. This highlights the need
for a new more systematic approach to the delivery of warfarin education
targeting the key elements believed to contribute to poor therapeutic outcomes
and adverse drug events, while addressing the needs of ‘high risk’ patients. The
key elements which should be targeted include: improved health
professional/patient communication and partnerships; warfarin compliance;
simple, easy-to-read written warfarin information; continuity of care between
hospital and community settings; and patient follow-up.
The next chapter focuses on the problems associated with patients having
poor literacy skills and their inability to read and understand typically available
written medication information, including warfarin information. The chapter
recommends the use of a number of simple tests and instruments to assess and
ensure that written patient medication information can be read and understood by
a wider patient population, inclusive of those with low literacy skills. The chapter
also recommends a number of simple instruments, which can be used to ensure
that the patient medication education program is of a suitable, good quality
standard, which will satisfy the patients’ needs.
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CHAPTER 3
LOW LITERACY SKILLS, WRITTEN PATIENT MEDICATION
INFORMATION AND EVALUATION

3.1 INTRODUCTION

The previous chapter highlighted the need to target key elements which
contribute to adverse drug events, in order to improve patient medication
education, including patient warfarin education, and to help optimise therapeutic
outcomes. Several interventions which focus on these key elements were
discussed, with an emphasis on the need to accommodate the ‘high risk’ patient
population. This chapter focuses on problems associated with low literacy skills
and the readability of currently available written patient information, including
warfarin information. It also highlights the importance of evaluation, which is often
neglected in medication education programs.
Prior to developing and implementing any new patient medication
education programs, however, it is important to consider the problems associated
with patients having poor literacy skills. Unfortunately, poor literacy skills which
can contribute to poor patient knowledge and understanding (Davis, Crouch,
Wills, Miller and Abdehou 1990; Winslow 2001) can also aggravate the problems
associated with poor medication compliance, poor therapeutic outcomes (Horner,
Surratt and Juliusson 2000) and the increased incidence of adverse drug events
(Feifer 2003). Research indicates that much of the currently available written
patient medication information, used as an adjunct to verbal instruction, is written
at levels beyond the comprehension of many patients, and especially those with
low literacy skills (Koo, Krass and Aslani 2003; Mayeaux Jr, Murphy et al. 1996;
Rutledge and Donaldson 1998). This chapter considers some of the readability
tests, guidelines and evaluation instruments which can be used to ensure that
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written patient medication information can be read and understood by a wider
patient population, inclusive of those with low literacy skills.
Finally, the significance of evaluation cannot be overlooked and should be
identified as an important intervention for an effective patient medication
education program. Process, impact and outcome evaluation are invaluable ways
in which to ascertain the suitability and quality of an education program. The
patient’s satisfaction with the program is an important factor and assessing
whether or not it achieves its goals and objectives are important ways in which to
assess the success of the program.

3.2 LOW LITERACY SKILLS AND WRITTEN PATIENT MEDICATION
INFORMATION

3.2.1 The problem of low literacy in healthcare
Low literacy is a pervasive and under-recognised problem in healthcare,
both in Australia and overseas (Baker 1997; Mayeaux Jr, Murphy et al. 1996).
Low literacy skills have been found to contribute to increased healthcare costs,
adverse drug events, poor compliance (Feifer 2003) and an increase in hospital
admissions (Baker, Parker et al. 1998; Winslow 2001). For many patients, a lack
of literacy is a major obstacle to effective healthcare (Doak, Doak et al. 1998)
because they lack sufficient knowledge to effectively manage their medications
(Williams, Baker et al. 1998) and simply cannot read or understand the
commonly used written information (Council on Scientific Affairs 1999; Davis,
Michielutte, Askov, Williams and Weiss 1998; Roter, Rudd et al. 1998).
People with low literacy skills include not only the poorly educated but also
the elderly (aged 65 years and over) and immigrants who speak English as a
second language (Doak, Doak et al. 1996b). Based on data from the Australian
Bureau of Statistics (ABS), a large proportion of the Australian population has
low literacy skills. The 1996 Australian literacy survey identified that 20 percent of
Australians aged 15 to 65 years, and 41 to 46 percent aged 65 to 74 years, have
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very poor literacy skills (level 1) (Australian Bureau of Statistics 1996). Another
investigation has also found that of the 20 percent of Australians who are from
non-English speaking backgrounds (NESB), 2.5 percent speak little or no English
(McLennan 1998). These patient populations cannot read or comprehend the
typically available written medication information (Albright, Guzman, Acebo,
Paiva, Faulkner and Swanson 1996; Baker 1997; Davis, Michielutte et al. 1998).

3.2.2 Written patient medication information

3.2.2.1 Background
Written educational materials are convenient, economical and very useful
for providing medication information to patients and/or their carers (Bernier and
Yasko 1991; Clark, AbuSabha, von Eye and Achterberg 1999). Research has
identified that by adding simple and easy-to-read medication information to
verbal instruction there is an increase in patient knowledge, compliance and
satisfaction with therapeutic regimens (Baker, Roberts, Newcombe and Fox
1991; Roter, Hall et al. 1998). Evidence to support this is reported in a recent
Cochrane collaborative review of 33 randomised clinical trials which concluded
that combination strategies, including written medication information and
counselling, improve compliance and clinical outcomes for both short-term (less
than two weeks) and long-term treatments (Haynes, McDonald et al. 2002a).
Presently, the reading grade levels of written medication information,
including warfarin information, available in Australia and overseas have been
assessed to range from grade 9 to grade 14 (Baker 1997; Estrada, Hryniewicz et
al. 2000; Weiss 1997). These are considerably higher than the average reading
grade ability of many patients with low literacy skills, which is deemed to be
below a grade 6 readability level (Davis, Crouch et al. 1990; Rolland 2000).
Studies in America (Baker, Parker et al. 1998; Estrada, Martin-Hryniewicz et al.
2004; Gazmararian, Baker, Williams, Parker, Scott, Green, Fehrenbach, Ren and
Koplan 1999) and in Australia (Baker 1997) confirm that these patients have
difficulty reading currently available written medication information. The
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readability of 30 consumer product information (CPI) leaflets, currently known as
consumer medicine information (CMI), available in Australia (Baker 1997), using
the Flesch Reading Ease (FRE) formula (Flesch 1948) (APPENDIX One)
identified that only 40 percent or less of the patient population could read or
understand these leaflets. Koo et al (2001) also identified that in an Australian
study with 38 focus group participants over the age of 18, many of them were not
only dissatisfied with the font size and volume, but they were also dissatisfied
with the amount of medical jargon included in their CMI information.
Patients with low literacy skills are often too embarrassed to admit that
they cannot read or understand commonly used written patient information
(Mayeaux Jr, Murphy et al. 1996). They are more likely therefore to experience
poorer therapeutic outcomes and adverse drug events than are patients from the
general patient population (Baker, Parker et al. 1998; Consumers' Health Forum
of Australia 2000; Winslow 2001). Given that a sizeable proportion of the
Australian population has low literacy skills (Australian Bureau of Statistics 1996),
it has been recommended that written medication information should be available
at or below the average reading ability of an Australian, estimated to be grade 8
(Buchbinder, Hall, Grant, Mylvaganam and Patrick 2001). Indeed others like
Doak et al (1996) recommend that all written patient medication information
should be available at or below a grade 6 reading level, which arguably would be
more suitable for patients with low literacy skills. In some situations this may be
possible, unfortunately however because of medication names and related
terminology this may not always be possible.
Multiculturalism is identified as an important factor which affects the
comprehension of written patient medication information (Voelker 1995; Westby
1995; Wilson, Racine et al. 2003). This is especially true in Australia where much
of the information is almost exclusively written in English (Bajramovic and Tett
2000). Having the information translated into another language is not always an
easy solution because many non-English speaking patients are illiterate in their
native language, as well as in English. Ideally these patients need to be verbally
educated about their medications in their own languages with the assistance of
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an interpreter (Williamson, Stecchi, Allen and Coppens 1997). This would help to
reduce the communication barrier and improve medication education,
compliance and therapeutic outcomes for these non-English speaking
background patient populations (Lambert and Minas 1998; Minas, Lambert et al.
1996).
In summary, a large proportion of the Australian population has low
literacy skills and cannot read or understand the currently available written
patient medication information, including warfarin information. The time has come
to address this problem. All written patient medication information, including
warfarin information, should be presented in a simple and easy-to-read format,
written at or below a grade 8 to grade 6 reading level (Doak, Doak et al. 1996b).
The inclusion of these factors into written medication information would help to
ensure their readability and comprehension by a wider patient population,
inclusive of those with low literacy skills (Butow, Brindle, McConnell, Boakes and
Tattersall 1998).

3.2.2.2 Preparation of written patient medication information
A patient’s understanding and satisfaction with written information has
also been found to be influenced by factors such as format, colour, text, print size
and the use of illustrations (Clark, AbuSabha et al. 1999; Klug Redman 2001). It
is important, therefore, to address these factors which help to engage the interest
of most patient populations, including patients with low literacy skills (Koo, Krass
et al. 2003).
There are a number of tools and guidelines available to assist with
addressing factors such as format, colour, text, print size and illustrations. The
United Kingdom Department of Health recently produced the ‘Toolkit for
Producing Patient Information’ (2002) (APPENDIX 2) which is simple and easy to
use. Alternatively, the ‘Guidelines for Writing Patient Information’ (Doak, Doak et
al. 1996b) (APPENDIX 3) provide useful recommendations on how to ensure that
these factors are addressed for patients with low literacy skills. The impact of
both the ‘Toolkit for Producing Patient Information’ (2002) and the ‘Guidelines for
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Writing Patient Information’ (1996) on the quality and suitability of health
information have yet to be formally evaluated, however, they are functional,
practical and easy to use.
When preparing written information for distribution to patients from nonEnglish speaking backgrounds it is important to ensure that the information and
illustrations are culturally sensitive. Seeking the advice of cultural group
members and health professionals who are from these cultural groups during the
planning and development stage helps to ensure that the information is in fact
culturally-sensitive (Doak, Doak et al. 1996b). In most circumstances, when
money and time permits, written patient information should be translated from
English into the patients’ language, when and if required. This of course would
only benefit the non-English speaking background patients who are literate in
their native language (Williamson, Stecchi et al. 1997).
For the many health professionals who are involved in the preparation of
written patient medication information, it is important to acknowledge that the
patients’ understanding and satisfaction with the information can be influenced by
factors such as format, colour, text, print size and illustrations (Clark, AbuSabha
et al. 1999; Klug Redman 2001). Health professionals should therefore use
simple tools and guidelines such as the ‘Toolkit for Producing Patient Information’
(The United Kingdom Department of Health 2002) and the ‘Guidelines for Writing
Patient Information’ (Doak, Doak et al. 1996b) when preparing and developing
written patient information.

3.2.2.3 Assessing the readability of written patient medication information
The goal of written patient medication information is to increase patient
understanding and comprehension and to serve as resource material for the
patient and/or their carer. It is the responsibility of health professionals to ensure
that the available written medication information can be read and understood by
the majority of patients, including those with low literacy skills. There are two
methods which can be used to assess understanding and readability. The first
method involves assessing the patient’s health literacy level to ensure that s/he
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can understand the information. The second method involves assessing the
readability level of the written patient medication information.
A number of tests are available to assess patients’ health literacy levels.
These include simple word recognition tests such as the Wide Range
Achievement Test-Revised (WRAT-R) (Jastak and Wilkinson 1993), the Rapid
Estimate of Adult Literacy in Medicine (REALM)(Murphy, Davis, Long, Jackson
and Decker 1993) and the Slosson Oral Reading Test-Revised (SORT-R)
(Slosson 1990). For research purposes, the Test of Functional Health Literacy in
Adults (TOFHLA)(Nurrs, Parker, Williams and Baker 1995) is currently
considered the most useful health literacy comprehension test because it has
been found to have good content validity and it uses text from real healthcare
settings (Davis, Michielutte et al. 1998). Overall, these tests tend to be time
consuming to administer and busy health professionals might derive more benefit
from assessing the readability of the written patient medication information, as
opposed to assessing each patient’s health literacy level.
Readability formulae are designed to make quick and easy assessments
of readability and to estimate the reading grade level a patient requires to
understand written information. Some of the well-known formulae include SMOG
(McLauglin 1969) (APPENDIX 4), the Fry Readability Formula (FRY) (Fry 1968)
(APPENDIX 5) and the Flesch Reading Ease (FRE) formula (Flesch 1948)
(APPENDIX 1). Alternatively, there is the convenient and easy to use
computerised Flesch-Kincaid program available on Microsoft Office Word 2000.
Each of these readability formulae have a high correlation (Spadaro, Robinson
and Smith 1980) which means that they can all be readily used and interchanged
to assess the readability of written information. The major limitation for each of
these formulae, as far as written patient information is concerned, is that they are
not healthcare specific. Recently, an instrument called ‘The Readability
Assessment Instrument’ (RAIN) (Singh 1994) was developed to estimate the
readability and patient comprehension of written patient information.
Unfortunately to date, the validity and the ease with which this instrument can be
used is difficult to assess because its use has been limited to only one American
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study analysing the readability of seven different patient ‘phenytoin’ information
leaflets (Kirkpatrick and Mohler 1999).
In summary, there are two ways in which to assess whether or not written
medication information can be read and understood by patients. The first way,
which is considered more time consuming and less practical, is to assess the
individual patient’s health literacy levels by using tests such as: Wide Range
Achievement Test-Revised (WRAT-R) (Jastak and Wilkinson 1993); Rapid
Estimate of Adult Literacy in Medicine (REALM)(Murphy, Davis et al. 1993);
Slosson Oral Reading Test-Revised (SORT-R)(Slosson 1990); and the Test of
Functional Health Literacy in Adults (TOFLA)(Nurrs, Parker et al. 1995). The
second way is to assess the readability of the written medication information by
using readability formulae such as SMOG (McLauglin 1969), the Fry Readability
Formula (FRY) (Fry 1968), the Flesch Reading Ease (FRE) formula (Flesch
1948) and the computerised Flesch-Kincaid instrument on the Microsoft Office
Word 2000 program, keeping in mind that they are not healthcare specific. In
terms of convenience and efficiency, the latter is probably most suitable for busy
health professionals to ensure that the information they are providing can be read
and understood by the majority of their patients.

3.2.2.3.1 Assessing the readability of written warfarin information
Warfarin information available in Australia and internationally, has been
assessed as being written at a level beyond the comprehension of patients with
low literacy skills (Baker 1997; Estrada, Hryniewicz et al. 2000; Tang, Lai et al.
2003). An American study which used the Flesch-Kincaid Grade Level formula to
determine the readability of 50 brochures commonly used in anticoagulation
management units, found that all the brochures were written at levels beyond the
comprehension of patients with low literacy skills, educated at or below a grade 6
level. This study found that the mean readability level of the brochures was grade
10.7 (95 percent; CI 10.1 to 11.2). No brochures had a readability level of grade
6 or below; 12 percent (n=6) had readability scores at grade 7 to 8 levels; 74
percent (n=37) had readability scores at grade 9 to 12 levels; and 14 percent
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(n=7) were written at levels above grade 12 (Estrada, Hryniewicz et al. 2000).
Another study conducted in Hong Kong found that poor literacy skills were the
main reason for poor warfarin knowledge in 62 patients (50.8 percent) of the 122
patients studied. These patients were not able to read and understand the written
warfarin information provided to them (Tang, Lai et al. 2003). Finally, the most
recent American study conducted by Estrada et al (2004) found that 68 (47.6
percent) of the 143 patient participants over the age of 60 could not read healthrelated words written at or above grade 8 levels and were more likely to
experience poor anticoagulant control over a three month period. Similar studies
have not yet been conducted in Australia, nor have studies focused on patients’
use and/or satisfaction with their warfarin consumer medicine information (CMI)
or the commonly used Boots warfarin information booklets (2002, 2003). In the
absence of such data a computerised Microsoft Office Word 2000 Flesch-Kincaid
test was carried out on the commonly used Boots warfarin information booklet
(2002) which was found to be written at a grade 9.4 reading level and a grade 8.9
reading level for the more recent 2003 edition. Both booklets, therefore, which
are commonly used by Australian health professionals, are written at grade levels
well above the reading ability of patients with low literacy skills.
There appears to be an obvious lack of suitable written warfarin
information, especially for patients with low literacy skills, both in Australia and
overseas. This highlights the need to develop and produce a new warfarin
information booklet written at or below a grade 8 level (Buchbinder, Hall et al.
2001), or preferably even below a grade 6 level (Estrada, Hryniewicz et al. 2000).
Such a booklet should also adhere to recommended guidelines ensuring that it
appeals to the patients’ understanding and satisfaction based on factors such as
format, colour, text, print size and illustrations.

3.2.3 Summary
Written patient medication information is an efficient, relatively inexpensive
adjunct to verbal instruction. Unfortunately, currently available written medication
information, including warfarin information, is typically written at levels beyond
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the comprehension of many patients, especially those with low literacy skills
(Baker 1997; Estrada, Martin-Hryniewicz et al. 2004; Weiss 1997). Health
professionals who have the responsibility of preparing and providing written
patient medication information, including warfarin information, should
acknowledge that a large proportion of the population has low literacy skills and
should therefore ensure that the information is available at or below a grade 8
reading level (Buchbinder, Hall et al. 2001) or better still a grade 6 reading level
(Estrada, Hryniewicz et al. 2000). There are many simple readability tests such
as SMOG (McLauglin 1969), the Fry Readability Formula (FRY) (Fry 1968), the
Flesch Reading Ease (FRE) formula (Flesch 1948) and the computerised FleschKincaid instrument on the Microsoft Office Word 2000 program which can be
used to ensure that information is written at an appropriate level.

3.3. EVALUATION OF PATIENT EDUCATION PROGRAMS
Evaluation is an essential component of an effective patient education
program because it ensures that the program is suitable, effective and satisfies
the patient’s needs. Evaluation can be classified in three different ways. The first
is process evaluation, which measures the activities of the program, the quality of
the program and assesses whom the program is reaching. The second is impact
evaluation which measures the immediate effect of the program and the third is
outcome evaluation which measures the long-term effects of the program (Hawe,
Degeling and Hall 1990).
Process evaluation, which measures the activities of the program,
assesses the quality of the program and the suitability of the program to reach
target populations, can involve the use of readability, suitability, quality and
patient satisfaction instruments. Examples of some readability tests which have
already been discussed in this chapter, include the SMOG Formula (McLauglin
1969)(APPENDIX 4) and the Fry Readability Formula (Fry 1968)(APPENDIX 5).
Several instruments are available to assess the suitability and the quality of the
written patient information. One example of such an instrument is the ‘Suitability
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Assessment of Materials instrument’ (SAM) (Doak, Doak et al.
1996b)(APPENDIX 6). SAM is a useful validated tool, which evaluates the
content, literacy demands, graphics, layout and typography, as well as the
learning stimulation, motivation and cultural appropriateness of the written
information for patient populations, inclusive of the low literacy skilled
populations. A second instrument is the ‘Bernier Instructional Design Scale’
(BIDS)(Bernier 1996)(APPENDIX 7) which is a useful instrument for identifying
and measuring the presence (or absence) of instructional design and learning
principles within the written information. A third quick and easy-to-use instrument
is the ‘Checklist for print materials’(Bidford Maine Area Health Education Center
1996) (APPENDIX 8) which assesses the appropriateness of the written material
for patients. All of these instruments can be used to evaluate the quality and the
suitability of the written medication information, including warfarin information, for
both the general and low literacy skilled patient populations. The results of these
evaluations can also uncover deficiencies within the written medication
information which may need to be addressed to improve its suitability and quality.
An important arbiter of the quality of medication information is the extent to
which individuals perceive that the information has satisfied their needs (Horne,
Hankins and Jenkins 2001). Assessing patients’ satisfaction with the amount of
medication information provided is a prerequisite for developing partnerships in
the quality use of medicines and the optimisation of therapeutic outcomes (Cox,
Stevenson et al. 2004). It is important therefore to use tools such as the
‘Satisfaction with Information about Medicines Scale’ (SIMS)(Horne, Hankins et
al. 2001)(APPENDIX 20) which assesses the patients’ satisfaction and/or
dissatisfaction with the information they have received. Even though patient
dissatisfaction can be a disappointment to the health professional, it gives them a
chance to improve educational practices and hopefully remedy the situation.
Impact evaluation assesses whether or not the program has met its
objectives by evaluating patient knowledge and understanding, and their
adherence to recommended health behaviours such as medication management
and compliance. Changes in patients’ medication knowledge and understanding,
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as well as their medication management and compliance are measures of the
impact of the medication education programs, including warfarin education
programs. In the past, evaluation of warfarin education programs have been poor
(Wyness 1990), with recent studies identifying that even though patients received
warfarin education, they had deficits in their warfarin knowledge, often resulting
in poor warfarin management and compliance (Cheah and Martens 2003;
Lambert and Wynne 2003; Nadar, Begum et al. 2003; Tang, Lai et al. 2003). The
results of these recent studies highlight the need to evaluate the impact of
warfarin education programs on the patients’ warfarin knowledge and
understanding.
Finally, outcome evaluation assesses whether or not the program has met
its aims and objectives. Program outcome indicators need to translate into health
status measurements, which can include blood test results and healthcare
utilisation (for example; number of general practitioner, hospital and/or
emergency department visits). These are important indicators of the long-term
effectiveness of the education program and patients’ abilities to manage their
own medications (Lorig and associates 1996). These outcome evaluations would
be especially important for patients taking warfarin therapy, and in particular
those suffering from atrial fibrillation, a recently promoted indication for lifelong
warfarin therapy (Elliott, Woodward et al. 2002; Peterson, Jackson et al. 2002) .
Evaluation is therefore an important component of an effective patient
medication education program, including a warfarin education program, because
it assesses the quality and suitability of the program, patients’ satisfaction with
the program and the overall impact of the program in terms of patient knowledge
and understanding, medication management and compliance. Finally, outcome
evaluation measures the long-term effectiveness of the medication education
program. Evaluation not only ensures that the program appeals to the patients
and achieves its goals and objectives, but it also helps to identify possible
inadequacies within the program which may need to be addressed to improve its
quality and suitability.
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3.4 CONCLUSION
Effective warfarin education is invaluable for patients to be able to manage
their warfarin therapy and to make confident educated decisions about warfarin
management which may affect their anticoagulant control and health status
(Gibbar-Clements, Shirrell et al. 2000; Moore 1977). With recent increases in
warfarin prescribing (Elliott, Woodward et al. 2002) deficits in patient warfarin
knowledge (Cheah and Martens 2003; Nadar, Begum et al. 2003; Tang, Lai et al.
2003) and the rising incidence of warfarin-related adverse drug events (AIHW
2003), there is an obvious need to develop and implement a new and effective
patient warfarin education program.
This chapter has discussed the difficulties faced by patients with low
literacy skills in reading and understanding typically available written patient
information, including warfarin information. These difficulties can negatively
impact upon their therapeutic outcomes and in some cases lead to adverse drug
events. Written patient warfarin information should therefore be available at no
higher than a reading grade 8 level (Buchbinder, Hall et al. 2001), or preferably at
or below a grade 6 level (Estrada, Hryniewicz et al. 2000). This would ensure that
the warfarin information could be easily read and understood by a wider patient
population, inclusive of those with low literacy skills.
Since factors such as format, colour, text, print size and the use of
illustrations can impact upon a patient’s understanding and satisfaction with
written patient information (Clark, AbuSabha et al. 1999; Klug Redman 2001), it
is important to address each of these factors by adhering to simple guidelines
when developing and producing written patient medication information. Examples
of these guidelines include the ‘Toolkit for Producing Patient Information’ (The
United Kingdom Department of Health 2002) and the ‘Guidelines for Writing
Patient Information’ (Doak, Doak et al. 1996b). Adhering to these simple
guidelines helps to ensure that the written information engages the interest of
many patient populations, inclusive of those with low literacy skills (Koo, Krass et
al. 2003).
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This chapter has also discussed the importance of evaluation to ensure
that medication education programs, including those for warfarin, are of good
quality and are effective. Process, impact and outcome evaluation can be used to
assess the suitability of the program to reach target populations, its effectiveness
to improve patients’ medication knowledge, management and compliance and its
long-term effectiveness to achieve aims and objectives.
The next chapter will discuss in detail the conceptual framework used to
develop and design a new patient warfarin education program. The advantage of
using a conceptual framework is that it provides a blueprint to replicate
successful key interventions and strategies and offers a systematic process to
analyse success or failure of the program (Doak, Doak et al. 1996b). It is also
noted in the literature that educational programs most likely to succeed are those
developed and managed using structural frameworks (National Institutes of
Health 2001). One of the most significant aspects of this research study is that
even though there is a focus on developing an effective patient warfarin
education program, the conceptual framework can be generically applied to any
effective patient medication education program.
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CHAPTER 4
CONCEPTUAL FRAMEWORK FOR AN EFFECTIVE PATIENT
WARFARIN EDUCATION PROGRAM

4.1 INTRODUCTION
Historically, warfarin patient education programs have been inadequate
(Connor 1998), overwhelming (Ansell, Buttaro et al. 1997) and not properly
evaluated (Wyness 1989). Recent studies by Cheah et al (2003), Nadar et al
(2003) and Lambert et al (2003) have all found that patients, and especially those
from the ‘high risk’ group, have deficits in their warfarin knowledge after receiving
warfarin education. These studies and others published within recent years
(Barcellona, Contu et al. 2002; de Felipe Medina 2003; Roche-Nagle, Chambers
et al. 2003) highlight the need for more effective warfarin education programs to
reduce these warfarin knowledge deficits and to improve warfarin management
and compliance in a wider patient population, inclusive of the ‘high risk’ group.
The new warfarin education program developed and trialed for this study
was based on a conceptual framework which reflects ‘best evidence’ with regard
to patient medication education programs. The new program targeted the five
key elements identified in the literature which contribute to improved therapeutic
outcomes and reduced incidence of adverse drug events. These five key
elements were: improved health professional/patient communication and
partnerships; warfarin compliance; simple, easy-to-read written warfarin
information; continuity of care between hospital and community settings; and
patient follow-up.
A full evaluation of the new program, which will be discussed in the next
chapter, was also undertaken during the course of the study. During the
evaluation phase the new program was compared to and contrasted to the
customary warfarin education program delivered to The Ambulatory Care Team
(TACT) patients prescribed warfarin.
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This chapter outlines the conceptual underpinnings of these five key
elements and describes how they link to form the basis of an effective warfarin
education program. Importantly, using this conceptual framework to plan
interventions and strategies which target improved patient education provides a
blueprint to develop other much needed medication education programs.

4.2. Figure 1: Conceptual Framework For An Effective Warfarin
Education Program

Health professional/patient
communication & partnerships

Warfarin compliance

Simple, easy-to-read warfarin
information.

Effective
Warfarin
Education
Program

Continuity of care between hospital
and community settings

Patient follow-up
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4.3 INTERVENTIONS USED TO TARGET THE FIVE KEY ELEMENTS OF THE
CONCEPTUAL FRAMEWORK IN THE NEW WARFARIN EDUCATION
PROGRAM.

4.3.1 Health professional/patient communication and partnerships
Poor health professional/patient communication and partnerships have
been identified as major contributors to poor therapeutic outcomes and adverse
drug events (Bhasale, Miller et al. 1998; Cox, Stevenson et al. 2004; Elwyn,
Edwards et al. 2003). Interventions which target this key element are recognised
as important ways in which to improve patient knowledge and understanding and
to empower patients to make confident, educated decisions about their
medication management. The literature provides a range of strategies to help
improve health professional/patient communication and partnerships.
Health professionals should focus on promoting their roles as good
educators by developing good communication skills and collaborating more
effectively with their patients (Aslani and Du Pasquier 2002; Rankin and Duffy
Stallings 2000). Good communication and collaboration involves encouraging
their patients to become part of the education process by asking questions,
making comments and not being afraid to express their opinions (Dantas,
Thompson et al. 2004). Health professionals need to ensure their manner is
always encouraging, reinforcing, reassuring and approachable, especially when
accepting feedback (Clark, Gong et al. 1998; Kok, van den Borne et al. 1997).
They also need to seek the respect of their patients and in turn offer them
respect for their beliefs, assumptions and attitudes (The Royal Pharmaceutical
Society of Great Britain 1997). This study aimed to incorporate each of these
strategies into the new warfarin education program in an attempt to maximise
communication and collaborative interchange between the health professional
(who is also the researcher/pharmacist) and the patient.
The establishment of effective partnerships is reliant on learning
environments which encourage patients to listen, access information and to seek
reassurance about their knowledge and understanding (Australian Council for
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Safety and Quality in Health Care 2002). For the purposes of this study,
therefore, the initial warfarin education sessions were delivered to patient
participants in their own homes or at an alternate venue chosen by themselves.
Simple guidelines need to be adhered to by health professionals when
establishing good communication and partnerships with the ‘high risk’ patient
population. These simple guidelines, which were incorporated into the new
warfarin education program, include: using simple language; speaking slowly;
repeating and underlining key points; and not giving too many directives during
the education session (Doak, Doak et al. 1996b; Mayeaux Jr, Murphy et al.
1996). It is also important to urge carers and/or family members to attend the
education sessions (Doak, Doak et al. 1998) and ensure that interpreters are
made available for non-English speaking background patients (Williamson,
Stecchi et al. 1997).
In summary, interventions and strategies which promote good health
professional/patient communication and partnerships are essential components
of an effective warfarin education program because they help to optimise
therapeutic outcomes and minimise adverse drug events (Cox, Stevenson et al.
2004; Elwyn, Edwards et al. 2003). These interventions and strategies need to
target encouragement, reinforcement, reassurance and feedback (Clark, Gong et
al. 1998; Kok, van den Borne et al. 1997) in an environment which encourages
the patients, including those from the ‘high risk group’, to listen, access
information and seek reassurance about their knowledge and understanding
(Australian Council for Safety and Quality in Health Care 2002),

4.3.2 Warfarin compliance
Poor warfarin compliance is also a significant contributor to poor
anticoagulation control (Arnsten, Gelfand et al. 1997) and warfarin-related
adverse events (Brigden, Kay et al. 1998; Hirri and Green 2002). Knowing that
the ‘high risk’ patient population, including the elderly and those with low literacy
skills (Lambert and Wynne 2003; Tang, Lai et al. 2003), as well as the nonEnglish speaking background patients (Nadar, Begum et al. 2003) are most likely
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to experience poor warfarin-related therapeutic outcomes, it would be reasonable
to assume that this is significantly contributed to by poor warfarin compliance.
Targeting ways in which to improve warfarin compliance, especially in the ‘high
risk’ group, is therefore a key element of an effective warfarin education program.
According to the literature, however, improved medication compliance can
only be effectively achieved by including several interventions at the one time
(Haynes, McDonald et al. 2002a; McDonald, Garg and Haynes 2002; Roter, Hall
et al. 1998). These interventions include: educating the patients, carers and/or
family members about the importance of regular medication compliance;
explaining the implications of not complying with regular therapy; recommending
compliance aids when and if required; offering encouragement, reinforcement,
reassurance and follow-up; as well as undertaking medication reviews.
Good warfarin compliance can be encouraged by effectively educating the
patient, their carer and/or family member about warfarin therapy (Barcellona,
Contu et al. 2002). Several studies have highlighted the essential warfarin
information, which needs to be understood. This includes: how warfarin works;
the importance of taking warfarin appropriately and why regular monitoring is
necessary; appropriate dosing schedules; possible side effects and drug-to-drug
interactions; as well as possible necessary behaviour changes, for example;
exercise, dietary and alcohol restrictions (Gibbar-Clements, Shirrell et al. 2000;
Hirsh, Dalen et al. 1995). Carers and family members should always be urged to
attend warfarin education sessions to promote information recall and encourage
good patient warfarin compliance (Doak, Doak et al. 1996b).
Compliance aids such as blister packs, dosette boxes, medication alarms
and medication cards help to improve medication compliance for all patient
populations (Roter, Hall et al. 1998; Wong and Norman 1987), including the ‘high
risk’ patients (Levings, Szep et al. 1999). They have been found to be especially
useful for patients suffering from cognitive and/or physical limitations (poor eye
sight, hearing impairment) (Barat, Andreasen et al. 2001; Wong and Norman
1987). For the purpose of this study, even though all patients were informed
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about compliance aids, the ‘high risk’ patients were strongly encouraged to use
compliance aids.
Offering the patients encouragement, reinforcement, reassurance and
feedback promotes both good health professional/patient communication,
partnerships and good medication compliance (Kok, van den Borne et al. 1997).
These interventions in combination with patient follow-up, which will be discussed
later in this chapter, were all used in the new warfarin education program to help
promote warfarin compliance.
Patient medication reviews are an essential part of the practice of all
pharmacists because they can reduce inappropriate prescribing and adverse
drug events (Hanlon, Weinberger, Samsa, Schmader, Uttech, Lewis, Cowper,
Landsman, Cohen and Feussner 1996). They also help to improve medication
compliance in patients who suffer from any cognitive and/or physical limitations
(Stewart and Caranasos 1989), as well as those taking multiple medications,
including warfarin (Fulmer, Hollander-Feldman, Sook Kim, Carty, Beers, Molina
and Putnam 1999). Medication reviews not only help to simplify the medication
regimen for these patients but they also help to minimise possible drug-to-drug
interactions with warfarin (Becker and Maiman 1980; Haynes, McDonald et al.
2002a). For the purposes of this study, the researcher/TACT pharmacist
reviewed all the intervention patients’ medications, including their complementary
medications, to ensure that they were taken appropriately in an easy-to-follow
regimen. In the event of possible drug-to-drug interactions, the researcher/TACT
pharmacist collaborated with the patients’ healthcare providers to ensure that the
interacting drugs were ceased, changed or carefully monitored while taken in
combination with the warfarin therapy.
In summary, targeting interventions to improve medication compliance and
in this instance warfarin compliance is a key element of an effective education
program. Several interventions were included in the new warfarin education
program to help optimise warfarin compliance. These interventions included:
educating the patients, carers and/or family members about their warfarin
therapy; recommending compliance aids; offering encouragement,
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reinforcement, reassurance and follow-up; as well as undertaking medication
reviews. These interventions were especially important to help promote warfarin
compliance in the ‘high risk’ patient population.

4.3.3 Simple, easy-to-read warfarin information
Evidence suggests that patients who receive insufficient and inappropriate
medication information are more likely to experience poor therapeutic outcomes
and adverse drug events (Bhasale, Miller et al. 1998). Therefore, it is important to
provide simple and easy-to-read medication information (Esposito 1995; Houts,
Witmer, Egeth, Loscalzo and Zabora 2001) which is appropriate, readily available
and understood by all patients including those in the ‘high risk’ group (Doak,
Doak et al. 1996b).
There are many tools, instruments and guidelines available, which can be
used to ensure that warfarin information is written in a simple, easy-to-read
format with culturally sensitive illustrations. Readability tools such as the SMOG
test (McLauglin 1969)(APPENDIX 4), the Fry Readability Fry Readability Formula
(Fry 1968) (APPENDIX 5) and the computerized Flesch-Kincaid Instrument
available on the Microsoft Office Word 2000 program can be used to ensure that
the information is written at a suitable level. While, the ‘Toolkit for producing
patient information’ (The United Kingdom Department of Health
2002)(APPENDIX 2) and the ‘Guidelines for writing patient information’ (Doak,
Doak et al. 1996b) (APPENDIX 3), can be used to ensure that the information is
written in a simple, easy-to read format with attention to colour, text, print size
and graphics. Finally, the ‘Suitability Assessment of Materials” (SAM) instrument
(Doak, Doak et al. 1996b) (APPENDIX 6), the ‘Bernier Instructional Design Scale’
(BIDS)(Bernier 1996)(APPENDIX 7) and the ‘Checklist for print materials’
(Bidford Maine Area Health Education Center 1996) (APPENDIX 8) can all be
used to ensure the quality and the suitability of the written information, especially
for the ‘high risk’ patient population.
In the absence of available suitable written warfarin information (Estrada,
Hryniewicz et al. 2000) the researcher/TACT pharmacist used all of the tools,
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instruments and guidelines described above to develop the new warfarin
information booklet (APPENDIX 12). They were all deemed to be important
because of the evidence that patients’ use and satisfaction with written
information is dependent upon its readability, presentation and quality (Clark,
AbuSabha et al. 1999; Koo, Krass et al. 2003).
In summary, to improve warfarin-related therapeutic outcomes and
minimise adverse drug events, patients must be given sufficient and appropriate
written information. Good quality, simple, easy-to-read information, available in a
suitable format with culturally sensitive illustrations is therefore necessary to
effectively educate patients about their warfarin. Consequently, several tools,
instruments and guidelines were used in the development of the new warfarin
information booklet (APPENDIX 12) to ensure its readability, quality and
suitability for a wider patient population, inclusive of the ‘high risk’ group.

4.3.4 Continuity of care between hospital and community settings
Poor continuity of care between hospital and community settings has been
recognised as an important contributor to poor therapeutic outcomes and
adverse drug events (Bhasale 1998; Forster, Murff et al. 2003). The need to
focus on interventions which target the improvement of continuity of care with
regard to medication and medication information, has only become a priority in
Australia in the past few years. Many medication errors and adverse drug events
have arisen due to inadequacies in the transfer of relevant medication and
medication information between hospital and community settings (Clark, Graham
and Williamson 1999; Dartnell, Anderson et al. 1996). Misadventures occur
because patients, carers and community-based healthcare providers are often illinformed about medication changes which took place while the patients were
admitted to the healthcare services (Bhasale 1998) .
The recently prepared Australian Pharmaceutical Advisory Council
(APAC) ‘Guidelines on the continuum of care of quality use of medicines
between hospital and community’ (Australian Pharmaceutical Advisory Council
1998) (APPENDIX 9) provide useful strategies to improve this continuum of care
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between hospital and community settings for medication management, including
warfarin management. These APAC guidelines focus on the need to ensure that
an accurate medication history and review is carried out for each patient, that
patients are given medication and medication information in a timely manner and
that their nominated healthcare providers are informed about the new
medications and/or changes once patients have been discharged from the
healthcare service.
Improved continuity of care between hospital and community settings are
known to improve overall therapeutic outcomes and reduce adverse drug events
(Australian Council for Safety and Quality in Health Care 2002), which is why the
APAC ‘Guidelines on the continuum of care of quality use of medicines between
hospital and community’ (1998) were incorporated into the new warfarin
education program. All the patients’ medications were reviewed, warfarin
medication, information and education was delivered to the patients, their carers
and their general practitioners in a timely manner, upon admission and discharge
from Illawarra Health’s The Ambulatory Care Team (TACT).

4.3.5 Patient follow-up
Patient follow-up has also been shown to improve therapeutic outcomes
and reduce the incidence of adverse drug events (Dudas, Bookwalter et al.
2001). Patient follow-up can be achieved in several ways including: written
communication; face-to-face interviews; group sessions; and telephone followup. All of these patient follow-up methods are useful and effective because they
offer reassurance and reinforcement to the patients, encouraging them to be
proactive with their treatment regimens (Hendricks and Hendricks 2000;
Waterman, Milligan et al. 2001), while improving their satisfaction and reducing
the number of medication-related problems (Dudas, Bookwalter et al. 2001).
Patient follow-up is therefore an essential component of an effective
warfarin education program because not only does it have benefits of its own but
it also positively impacts upon some of the other key elements which include:
health professional/patient communication and partnerships; medication
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compliance; and the continuity of care (Haynes, McDonald et al. 2002a). Based
on limited time, resources and the fact that telephone follow-up appears to be
equally as effective as the other follow-up methods in improving health
professional/patient communication and partnerships (Hendricks and Hendricks
2000), medication compliance (Roter, Hall et al. 1998), patient education (Estey,
Tan et al. 1990) and medication self-management (Dudas, Bookwalter et al.
2001), it was concluded that telephone follow-up is a suitable way in which to
follow up patients and it was the method used in the study.

4.4 SUMMARY
In summary, having reviewed the literature, five key elements were
identified which need to be targeted when developing an effective medication
education program. These include: improved health professional/patient
communication and partnerships; medication compliance; simple, easy-to-read
medication information; the continuity of care between hospital and community
settings; and patient follow-up. As well as targeting these key elements it is also
necessary for effective programs to address the needs of the ‘high risk’ patient
population, which include the elderly, those with low literacy skills, and those
from non-English speaking backgrounds.
By introducing several interventions and strategies to target these five key
elements, it was intended that the new warfarin education program would
promote good health professional/patient communication and partnerships,
encourage optimal warfarin compliance and provide simple, easy-to-read written
warfarin information for the patients. Processes were also put in place for the
new program to achieve improved continuity of care between hospital and
community settings by adhering to the APAC guidelines (1998) and by providing
patient telephone follow-up.
This chapter has discussed the conceptual underpinnings of the five key
elements, which form the basis of an effective medication education program,
and in this instance a new warfarin education program. Strategies and
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interventions used to target these key elements in the new warfarin education
program, developed for this study, were also identified and described.
The next chapter will outline the methodology used to incorporate this
conceptual framework into the new warfarin education program, which will then
be compared to and contrasted with the customary warfarin education program
presented to patients prescribed warfarin, who are admitted to Illawarra Health’s
The Ambulatory Care Team (TACT).
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CHAPTER FIVE
METHODS

5.1. INTRODUCTION
The methods used in this study to develop, implement and evaluate the
new warfarin education program are described in depth throughout this chapter.
Initially, there is a description of the study design and how the five key elements
reflecting ‘best evidence’ are incorporated into the new program. The actual
program itself and the evaluation instruments used in the study are schematically
described in section 5.4, which then goes on to discuss the results of the pilot
study and the necessary ethical considerations. The chapter concludes with
information about how eligible patient participants were recruited, which
documentation they needed to complete and the questionnaires that were used
for evaluation purposes. A tabled summary of the methodological process and a
flowchart of the research study are also provided as an overview of the study
process and design.
It is important to note that for the purposes of this study, when referral is
made to the word ‘patient’ this also includes the primary ‘carer’ or ‘family
member’ who was responsible for managing and administering warfarin
medication, when patients did not do so themselves.

5.2 OVERVIEW OF THE STUDY
The purpose of the study was to develop and implement a new warfarin
education program, to help improve warfarin knowledge, compliance and
management in a wider patient population, inclusive of the ‘high risk’ patients.
This ‘high risk’ group of patients included the elderly, those with low literacy skills
and those from non-English speaking backgrounds. The study was conducted on
patients who were admitted to Illawarra Health’s The Ambulatory Care Team
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(TACT) and prescribed warfarin for either the first time, or after a period of no
less than 15 years. Even though TACT operates from within Wollongong
hospital, it is a community-based healthcare service, which visits, treats and
educates patients in their own homes.
The study was a prospective study involving all patients newly prescribed
warfarin and admitted to the Illawarra Health Ambulatory Care Team over a 12month period from February 2003 to February 2004. A prospective study was
considered reasonable because it looked forward in time and involved one group
being exposed and the other group not being exposed to the new warfarin
education program. Also, because outcome data such as warfarin knowledge
and understanding, satisfaction with the education program, medication
management and therapeutic data (e.g. warfarin levels) were to be collected after
the exposure to the education program. After consultation with Dr Pam Davy, a
statistician at the University of Wollongong, it was agreed that in order to detect a
difference in warfarin knowledge and understanding between the two groups, at
a power of 70% using the 5% level of significance, at least 100 participants - 50
control and 50 intervention - would be required for the study.
Power calculation is a statistical method used in the estimation of the
sample size needed to increase the likelihood of demonstrating genuine
differences within a study. A powerful study is very likely to find genuine
differences if any exist, and a weak study could easily miss them (Hassard
1991). To ensure that a difference is in fact genuine and not merely a random
occurrence, the level of significance or  level is usually set to 0.05 or less.
Generally speaking a power of 80% is the preferred level for a study thereby
providing a  level of 0.2. It is more appropriate to relax the  level rather than
the  level in a study because  errors (i.e. missing a genuinely better program or
treatment and hence continuing with an established reasonable program or
treatment), has less detrimental effects than  errors (i.e. switching from an
established effective program or treatment to a new relatively, unknown program
or treatment that is not actually any better)(Hassard 1991).
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In this study, a  level of 0.2 was assessed not to be practical because it
required a large sample size which could not be managed within the duration and
resources available for this PhD study. The  level was relaxed and a power of
70% was used in the calculation of sample size. The participants’ warfarin
knowledge was considered the most important variable because it was expected
to impact on the other variables being investigated (i.e. self-management,
medication-taking-measures, satisfaction with information, and health care
related outcome measures). The calculation was therefore based on this
variable, using a power of 70% and a 5% level of significance.
The main implication of the power calculation is that it would only be
expected to identify a statistically significant difference in the warfarin knowledge
variable for both groups within the time and resource constraints of this study. A
sample size of 100 with equal allocation to each arm was deemed adequate to
identify an improvement of one point for the mean warfarin knowledge
questionnaire scores attributable to the new warfarin education program
intervention. This calculation was based on a standard deviation of 4.5, a power
of 70%, a 5% significance level and a one sided test.
For the purposes of this study the group of patients receiving the new
warfarin education program are referred to as the intervention patients and the
group of patients receiving the customary warfarin education program are
referred to as the control patients. The new warfarin education program, was
conceptually based on the five key elements of an effective patient medication
education program, also included a newly developed warfarin information booklet
(APPENDIX 12). This new booklet was derived from a review of the literature and
written in a simple, easy-to-read format, whereas the customary warfarin
education program involved the TACT pharmacist reading through the Boots
warfarin information booklet (2003) with the patient in their own home.
Evaluation was incorporated into the study at three levels: process, impact
and outcome evaluation. This enabled the researcher/TACT pharmacist to
analyse and assess the suitability, quality and effectiveness of the new program
as compared to the customary program, in terms of the patients’ warfarin
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knowledge, compliance and management. The patients’ satisfaction with the
program and their long-term outcomes (therapeutic INR scores, as well as
general practitioner, hospital and emergency department visits) were also
compared and contrasted between the two programs. Unfortunately, customary
practice did not remain static during the study period due to the continuously
evolving professional practice of the TACT service. This is acknowledged as a
limiting factor of the research study and will be discussed in the final chapters of
this thesis.
The overall purpose of the study was to develop and implement a new
warfarin education program to help improve warfarin knowledge, compliance and
management in a wider patient population, inclusive of ‘high risk’ patients. The
conceptual framework of this new program, which incorporated five key elements
of an effective patient medication education program, can be readily used as a
blueprint for any other medication education program, in both community and
hospital settings.

5.3 THE PROCESS FOR THE DESIGN AND DEVELOPMENT OF THE NEW
WARFARIN EDUCATION PROGRAM AND THE NEW WARFARIN
INFORMATION BOOKLET

5.3.1 Introduction
The design of the research study involved several important components.
Firstly, the new warfarin education program incorporated interventions and
strategies to target the five key elements of an effective patient medication
education program which included: improved health professional/patient
communication and partnerships; warfarin compliance; simple, easy-to-read
warfarin information; the continuity of care between hospital and community
settings; and patient follow-up.
Secondly, evaluation was incorporated to compare and contrast the new
warfarin education program against the customary warfarin education program
delivered to TACT patients prescribed warfarin. Important components of the
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evaluation process included assessing the readability, suitability and quality of
the new written warfarin information booklet (APPENDIX 12) against the Boots
warfarin information booklet (2003). In addition, analysis of the patients’ warfarin
self-management, compliance, knowledge and understanding, as well as their
satisfaction with the warfarin education program, provided important data to
compare and contrast the two education programs.
Finally, reviewing the patients’ International Normalised Ratio (INR) blood
test results, the number of healthcare visits and side effects experienced, helped
to assess and compare the long-term effectiveness of both education programs.
These results provided data to compare the warfarin-related therapeutic
outcomes and adverse drug events for both programs over the three-month
period.
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The following diagram provides an overview of the methods used to
design, develop and evaluate the new warfarin education program, including the
new warfarin information booklet (APPENDIX 12).

Figure 2: Overview of the methods used to design, develop and evaluate
the new warfarin education program, including the new warfarin
information booklet (APPENDIX 12).
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The chapter will now discuss how the five key elements and evaluation
components were incorporated into the new warfarin education program design.
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5.3.2 Health professional/patient communication and partnerships
Several measures were incorporated into the new warfarin education
program design to promote good health professional/patient communication and
partnerships. The measures introduced by the health professional included:
offering the patient encouragement, reinforcement, reassurance and feedback;
delivering the initial education session in a home environment; urging carers
and/or family members to attend the education session; providing interpreters for
non-English speaking background patients; and always using simple and easyto-understand language
Encouragement was given to patients by asking lots of questions, inviting
them to make comments (Kok, van den Borne et al. 1997), and respecting their
opinions (The Royal Pharmaceutical Society of Great Britain 1997). Examples of
the questions asked to offer encouragement can be found in the ‘Transcript of
the new warfarin education session’ (APPENDIX 11). During the education
sessions, the patients were also urged to become active participants in their own
healthcare by recording their own INR results, warfarin doses and appointment
times in the new warfarin information booklet (APPENDIX 12).
Reinforcement was provided by using the new written warfarin information
booklet (APPENDIX 12), underlining the main points and referring to the
illustrations as visual aids (Doak, Doak and Lorig 1996a). The ‘Warfarin
Counselling Checklist ’ (APPENDIX 13) was used to ensure that all the main
points had been discussed and reinforced. Typical questions asked to reinforce
patients’ understanding of the warfarin information included:
 “Why do you believe that the warfarin has been prescribed for you?”
 “Which brand of warfarin has been prescribed for you?”
 “What dose should you take today?”
Reassurance throughout the program was promoted by ensuring that the
patients were comfortable and confident enough to seek reassurance by
addressing them in a positive, caring and motivating manner (The Royal
Pharmaceutical Society of Great Britain 1997). Even when the patients had
completely misunderstood or misinterpreted instructions, they were politely
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corrected and positively reassured about their ability to safely and successfully
manage their own warfarin therapy at home.
Informal feedback was received before, during and after the initial warfarin
education sessions, as well as during the follow-up phone calls and on
completion of the evaluation questionnaires after three months of warfarin
therapy. Positive and negative comments, as well as opinions, were perceived to
be of benefit because they could be used to improve the patient warfarin
education program. The patients’ beliefs, opinions, assumptions and attitudes
were always treated with utmost respect (The Royal Pharmaceutical Society of
Great Britain 1997). A typical example included patients perceiving that they
were endangering their lives by taking warfarin, known to them as rat poison. In
these instances, it was acknowledged that even though warfarin was rat poison
it did have many therapeutic advantages, which were then explained to the
patients.
The initial education sessions took place in the patients’ homes or in an
alternative place specified by the patients, where it was ensured that they were
relaxed and comfortable. Environments conducive to learning were sought by
recommending that all radios, televisions, computers and stereos were turned
off. Carers and family members were also positively encouraged to attend the
education sessions and to ask questions and make comments.
For patients from non-English speaking backgrounds, Illawarra Health
interpreters were made available during the education sessions to translate the
information into their native language. In an attempt to improve communication
with these patients it was always necessary to make direct eye contact with
them, rather than directing all the conversation toward the interpreters
(Williamson, Stecchi et al. 1997).
The information was presented slowly, using simple and easy-to
understand language, especially when educating the ‘high risk’ patient
population (Mayeaux Jr, Murphy et al. 1996). Main points were emphasized
using the ‘Warfarin Counselling Checklist ’ (APPENDIX 13) and the ‘New
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Warfarin Information Booklet’ (APPENDIX 12) as guides to ensure that important
points were covered.
In summary, developing good health professional/patient communication
and partnerships was a key element targeted by several interventions in the new
warfarin education program. These interventions included promoting
encouragement, reinforcement, reassurance and patient feedback, supporting a
collaborative approach by valuing the patients’ opinions and comments and
inviting them to be active participants in their own healthcare. Education
sessions were conducted in the comfort of the patients’ home and often in the
presence of carers and/or family members who were also urged to attend. NonEnglish speaking background patients were provided with an interpreter, and the
language used during the education session was always simple and easy-tounderstand, which was especially beneficial for the ‘high risk’ patient population.

5.3.3 Warfarin compliance
Good warfarin compliance was another key element targeted in the new
warfarin education program (Haynes, McDonald et al. 2002a). Interventions,
such as improving the patients’ understanding of their warfarin therapy in
treating their disease, encouraging family support and compliance aids, as well
as minimising the complexity of their medication regimens, were considered
priorities in the new warfarin education program. These interventions were
particularly important for the ‘high risk’ patient population.
Patients were educated about how warfarin works to treat their disease,
how to take it appropriately and how to monitor their warfarin therapy, as per the
‘New warfarin Education Program Objectives’ (APPENDIX 14). Examples of
patients successfully treated with warfarin were given, as per the ‘Transcript of
the new warfarin education session’ (APPENDIX 11), to try to encourage optimal
warfarin compliance. Some examples of the questions patients were asked to
ensure that they had a good understanding about why they had to comply with
their warfarin therapy, included:
 “Do you understand why you have been given warfarin tablets?”
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 “When is the best time to take your warfarin tablets?”

Family members and carers were contacted by telephone prior to the
education session and strongly urged to attend the session. Not only did they
provide the necessary support and encouragement to help optimise warfarin
compliance, especially among the ‘high risk’ patients, but they also helped
patients with information recall (Doak, Doak et al. 1996b).
Compliance aids such as blister packs, dosette boxes, medication alarms
and medication cards identified to improve medication compliance (Levings,
Szep et al. 1999; Wong and Norman 1987), were recommended to all patients.
They were especially recommended to the elderly living alone and to those
suspected to be suffering from cognitive and/or physical limitations (for example
poor eye sight, hearing impairment). Medication alert bracelets were also
recommended to these patients.
Minimising the complexity of the patients’ medication regimen was another
intervention used in the new program to help improve warfarin compliance.
Medication reviews were carried out to develop a simple, easy-to-follow dosage
regimen for the patients. They were asked to physically show the
researcher/TACT pharmacist all their prescribed, non-prescribed and
complementary medicines, which they took in addition to their warfarin therapy.
The medication review ascertained the importance of all the patients’
medications and helped to identify any potential drug-to-drug interactions,
especially between warfarin and complementary medicine, which were acted
upon in collaboration with the patients’ healthcare providers. Typical examples of
medication review recommendations included:
 suggesting that other medications, when and if possible, be taken in the
morning and warfarin be taken alone in the evening.
 advising patients to stop taking prophylactic Aspirin.
 recommending that interacting complementary medications be
discontinued until after the warfarin therapy was complete.
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In summary, improving warfarin compliance was one of the key elements
targeted in the new warfarin education program. Improving the patients’ warfarin
knowledge and understanding, encouraging family support and the use of
compliance aids, as well as conducting medication reviews were all used as
interventions in the new program to help improve warfarin compliance. Several
of these interventions, which included familial support and compliance aids, were
especially recommended for the ‘high risk’ patients.

5.3.4 Simple, easy-to-read written warfarin information
Several interventions incorporated in the new program aimed to improve
patient comprehension, especially among patients with low literacy skills. These
interventions included designing the booklet in a simple and easy-to-read format
with culturally sensitive illustrations and adhering to recommended guidelines
ensuring its good quality and suitability. As already mentioned in this chapter, it
was important to ensure that the language used during the education sessions
was simple and easy-to-understand, particularly when educating the patients
with low literacy skills (Mayeaux Jr, Murphy et al. 1996).
The new booklet (APPENDIX 12) was written in a simple and easy-to-read
format so that it could be read and understood by a wider warfarin prescribed
population, inclusive of those with low literacy skills. Several available tools,
guidelines and principles were used to ensure that the booklet was written in a
format to help improve knowledge, understanding and information recall (Houts,
Witmer et al. 2001). The manual SMOG test (McLauglin 1969) (APPENDIX 4),
the Fry Readability Formula (Fry 1968) (APPENDIX 5) and the computerized
Flesch-Kincaid instrument available on the Microsoft Office Word 2000 program
were used to ensure that the booklet was written below a grade 8 reading level.
The ‘Toolkit for producing patient information’ (The United Kingdom
Department of Health 2002) (APPENDIX 2) and the ‘Guidelines for writing
patient information’ (Doak, Doak et al. 1996a) (APPENDIX 3) were used to
ensure that the information was presented in a simple, easy-to-read format with
attention to colour, text and print size. Consequently, the booklet was written in a
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large 12 font print size, with bulleted points and ample white spaces to avoid
looking too cluttered. These modifications were especially useful for elderly
patients who have problems seeing and reading currently available written
patient information (Rutledge and Donaldson 1998).
Visual images and illustrations were included in the new booklet because
research has shown that memory has many more access points for visuals than
for words and letters (Doak, Doak et al. 1996b). The illustrations were used to
highlight important concepts (Rutledge and Donaldson 1998) and to help
encourage desired behaviour (Davidhizar and Brownson 1999), such as using
an electric razor or a soft bristle toothbrush. Twenty Illawarra Health interpreters
from different cultural backgrounds were also asked to comment on whether or
not the visual images and illustrations were culturally appropriate.
The quality and the suitability of the new warfarin booklet was assessed
by the researcher/TACT pharmacist and two of her colleagues, using the
validated ‘Suitability Assessment of Materials’ (SAM) instrument (Doak, Doak et
al. 1985)(APPENDIX 6), the ‘Bernier Instructional Design
Scale’(BIDS)(APPENDIX 7), and the ‘Checklist for print materials’ (Bidford Maine
Area Health Education Center 1996)(APPENDIX 8). The SAM instrument was
especially useful in assessing and evaluating the suitability of the booklet for
patients with limited literacy skills (Doak, Doak et al. 1985), while the BIDS
instrument identified the presence (or absence) of instructional design/learning
principles, and the Checklist provided an assessment for the appropriateness of
the written material for patients.
On completion of the first draft of the new warfarin information booklet
(APPENDIX 12), comments were sought from two literacy and educational
experts from the University of Wollongong (Professor Brian Ferry and Professor
Brian Cambourne). They were asked to give their expert opinions about the
suitability and the quality of the booklet for the general population, inclusive of
those with low literacy skills and from non-English speaking backgrounds.
Comments and opinions were also sought from ten pharmacists working in
community and hospital settings, as well as allied health colleagues from ‘The
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Ambulatory Care Team’ (TACT). All of these comments, including those made
by the Illawarra Health interpreters, were collated and, where appropriate,
changes were made to the new warfarin information booklet prior to the research
study. These changes are comprehensively detailed in the pilot study section of
this chapter.
In summary, the new warfarin information booklet was written in a simple,
easy-to-read format to ensure that a wider warfarin prescribed population,
including those with low literacy skills, could read and understand the booklet.
Several validated tests, guidelines and instruments were used to design and
develop the new booklet and to evaluate its quality and suitability. The language
used during the education sessions was simple and easy-to-understand, once
again targeting a wider patient population, inclusive of those with low literacy
skills.

5.3.5 The continuity of care between hospital and community settings
Improved continuity of care between hospital and community settings was
also specifically targeted in the new warfarin education program. The ‘Guidelines
on the continuum of care of quality use of medicines between hospital and
community’ (Australian Pharmaceutical Advisory Council 1998)(APPENDIX 9),
known as the APAC guidelines, were used. These guidelines were incorporated
in the new warfarin education program from the beginning. The customary
warfarin education program did not include these guidelines at the beginning of
the study. However, it is important to note that since TACT is a new service
undergoing continuous development, some of the interventions recommended
by the APAC guidelines were incorporated into the customary TACT program
during the study period, following directions from area health service
management. Typical examples include: faxing the patients’ general practitioner
with the details of their admission and subsequent discharge from the TACT
service; encouraging the patients to record their INR results, warfarin doses and
appointment times in their booklets; and giving patients information sheets about
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potential warfarin interactions with other drugs, including complementary
medicines (APPENDIX 27).
Each of the seven APAC principles will now be discussed with a brief
explanation of the interventions used to target these principles in the new
warfarin education program. Many of these interventions such as; medication
reviews, family support and interpreter services, have already been discussed
elsewhere in this chapter because they also target some of the other key
elements.

Principle 1: It is the responsibility of the admitting institution to ensure the
development and coordination of a medication discharge plan for each patient.
The person responsible for coordinating the development, implementation, and
monitoring of the medication discharge plan, including medication supply and
medication information, should be identified as soon as practicable after
admission.
New consenting patients requiring warfarin therapy had the details of their
admission to TACT and proposed warfarin management faxed to their general
practitioners. These patients were then placed in either the control or intervention
groups by the TACT pharmacists and educated within four days of their
admission to TACT. Non-consenting patients were not part of the study, but still
received the customary warfarin education program.

Principle 2: Hospital staff should obtain an accurate medication history,
including prescription and over-the-counter medicines and other therapies such
as herbal products, at the time of admission.
After admission to TACT and during the initial education session the
researcher/TACT pharmacist carried out a thorough medication review of all the
patients’ medications including prescription, over-the-counter medicines and
complementary medicines.
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Principle 3: Hospital staff should evaluate the current medication at the
time of admission, in consultation with the patient’s general practitioner, with a
view to;
-identifying the appropriateness and effectiveness of current medication,
and rationalising current medications if appropriate
-paying particular attention to any problems associated with current drug
therapy, including any possible relationship with the current medical
condition, and
-documenting allergies and any previous adverse drug reactions
The purpose of the medication review was to identify the appropriateness
of all the patient’s medications, to review the times that they were taken and to
minimise potential drug-to-drug interactions, side effects and/or adverse drug
events such as allergies. When changes to prescribed medications were
necessary, the researcher/TACT pharmacist collaborated with the patient’s
medical practitioners and other members of TACT staff, prior to recommending
the changes. For simple recommendations such as the timing of the warfarin
doses, the type of analgesic and/or self-prescribed complementary medicines
used, the researcher/TACT pharmacist spoke directly to the patient and/or carers
without involving any of the other healthcare practitioners.

Principle 4:

During the hospital stay, treatment plans relating to the

probable medication management during the stay and, where applicable, at
discharge, should be developed in consultation with the patient and/or carer.
Hospital staff should negotiate with the patient issues relating to treatment and
the development of a discharge plan, and these discussions should be
documented in the patient’s notes. This plan should form part of the overall care
plan or critical pathway.
-The use of interpreters may be required to ensure good communication
with people from non-English speaking backgrounds.
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-To enable the discharge process to be successful, there needs to be
effective communication and coordination between all relevant parties in
the hospital environment.
-Where appropriate, community health providers, especially the patient’s
general practitioner, should be consulted.
-Carers should also be consulted where appropriate.
During the initial warfarin education session the researcher/TACT
pharmacist informed the patients about their warfarin management plan using the
new warfarin education program.
Non-English speaking patients were provided with accredited Illawarra
Health interpreters to translate all the relevant information to them in their native
language.
All patients were informed that after their discharge from TACT, they
would be expected to promptly visit their general practitioners who would then be
responsible for monitoring their warfarin therapy. All patients, including those
from the ‘high risk’ patient population, were encouraged to visit only one general
practitioner and one local community pharmacist, in an attempt to minimise poor
therapeutic outcomes and adverse drug events (Pendleton 1992), and to improve
the continuity of care.
On discharge from TACT the patient’s general practitioner was faxed with
the details about his/her discharge, warfarin dose and INR results. When it was
appropriate, other healthcare providers who cared for the patient in the
community setting were also informed about their discharge from the service (for
example palliative care nurse).

Principle 5: Prior to discharge, pre-discharge medication review and
dispensing of adequate medication should take place in a planned and timely
fashion. Adequate medication means sufficient medication to carry the patient
through to the next arranged review (by their general practitioner, outpatient
clinic, or some other arrangement), or to complete the course of treatment.
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If patients are discharged with inadequate supplies of medication, this can
compromise quality of care for the patient. Supply of the medication from the
hospital facility must be adequate to ensure continuity of medication is not
interrupted by the inability to obtain further ongoing supplies if required, within a
reasonable timeframe.
On admission to TACT, patients were supplied with sufficient 1mg, 2mg
and 5mg warfarin tablets to maintain their warfarin therapy appropriately. Upon
discharge from TACT, only five days’ supply of the warfarin tablets were
dispensed to patients to encourage them to promptly visit their general
practitioners. In the event of a public holiday or the possibility that general
practitioner appointments could not be arranged within the five-day period, either
the patient continued to be monitored by TACT or more warfarin tablets were
provided.

Principle 6: At the time of discharge, each patient should be provided with
a discharge folio containing relevant information such as Consumer Medicine
Information, a medication record, patient/carer plan, and information on the
availability and future supply of medication.
After the initial warfarin education session patients were given the new
warfarin information booklet (APPENDIX 12) to keep as a resource and they
were instructed during the session on how to record their own INR results,
warfarin doses and appointment times in the back of the booklet. They were told
that their warfarin supplies and warfarin monitoring after their discharge from
TACT would be the responsibility of their general practitioners.

Principle 7: No patient should be discharged from hospital until the details
of the admission, medication changes (including additions/deletions) and
arrangements for follow-up have been communicated to the healthcare
provider(s) nominated by the patient as being responsible for his or her ongoing
care.
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As already discussed, once the patient had been discharged from the
TACT service, his/her general practitioners were sent a fax outlining their
warfarin management, warfarin dose and INR results upon discharge. Other
health practitioners caring for the patient were also notified of their discharge,
when and if it was appropriate to do so.
Improving the continuity of care between hospital and community settings
was a key element incorporated into the new warfarin education program.
Several interventions were included in the new program to accommodate each of
the seven APAC guidelines, which aimed to improve this continuum of care.
These interventions included: the timely transfer of both warfarin medication and
information to the patients, their carers and their healthcare practitioners;
conducting medication reviews; and effectively educating the patients about their
warfarin management. Some of these interventions, which were deemed to have
a positive impact and complied with the APAC guidelines, were also incorporated
into the customary warfarin education program during the course of the research
study. The possible impact of this on the study design and outcomes will be
discussed in the later chapters of this thesis.

5.3.6 Patient follow-up
Patient follow-up is the last of the key elements of an effective patient
warfarin education program targeted in the new warfarin education program.
Patient follow-up was incorporated as follow-up telephone calls, which took place
both one week and three months after the initial warfarin education session.
The follow-up telephone calls one week after the initial education session
encouraged patient feedback. Patients were asked whether or not they had any
problems or concerns with the warfarin therapy and/or information. These calls
were also used to reinforce and reassure the main points of warfarin information
to the patient, as per the ‘Warfarin Counselling Checklist ’ (APPENDIX 13).
The main objectives of the follow-up phone calls three months after the
initial warfarin education session were to reassure and reinforce warfarin
information to the patients and to collect evaluation data. The evaluation data
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pertained to questionnaires about their warfarin management; compliance;
knowledge and understanding; as well as their satisfaction with the warfarin
information provided, and possible warfarin-related therapeutic outcomes (Refer
to Appendices 17-21). The ‘Warfarin Knowledge’ questionnaire (APPENDIX 19)
was a particularly useful follow-up educational tool, because if patients answered
questions incorrectly, their answers were documented and they were then given
the correct answer. In other words, this questionnaire helped to reinforce correct
warfarin information to the patients.
In summary, the follow-up telephone calls allowed the patients to have
their warfarin knowledge and understanding reinforced. They also encouraged
the patients to provide feedback and to discuss any queries or concerns they
may have experienced. During the study period, the three-month follow-up
telephone calls were also used to complete patient questionnaires, which were
used for evaluation purposes.

5.3.7 Evaluation
Evaluation was incorporated into the new warfarin education program, at the
three levels of: process, impact, and outcome. These different evaluation
modalities were used to assess and analyse the readability, quality and suitability
of the new booklet (APPENDIX 12) used in the new program, and to evaluate
patient’s warfarin management, compliance, knowledge and understanding,
satisfaction with the warfarin information provided and their health outcomes.
Analysis and assessment of the evaluation information was used to compare the
new warfarin education program to the customary warfarin education program
delivered to TACT patients.
Process evaluation was used to compare the readability, quality and the
suitability of the new warfarin education program to the customary program.
Instruments used to assess the readability and the suitability of the written
warfarin information in both programs have already been described in this
chapter. These instruments included the following readability formulae: the
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SMOG test (McLauglin 1969) (APPENDIX 4); the Fry Readability Formula ((Fry
1968) (APPENDIX 5); and the computerized Flesch-Kincaid instrument available
on the Microsoft Office Word 2000 program. Quality and suitability instruments
used during the process evaluation phase included: the ‘Suitability Assessment
of Materials’ (SAM) (Doak, Doak et al. 1985)(APPENDIX 6); the ‘Bernier
Instructional Design Scale’(BIDS)(Bernier 1996) (APPENDIX 7);and the
‘Checklist for print materials’ (Bidford Maine Area Health Education Center
1996)(APPENDIX 8). Process evaluation was also used to contrast the patients’
satisfaction with both programs by using the validated ‘Satisfaction with
Information about Medicines Scale’ (SIMS) (Horne, Hankins et al. 2001)
(APPENDIX 20), immediately and three months after the initial warfarin
education session.
Impact evaluation assessed whether or not the program had met its
objectives by evaluating patient knowledge and understanding, as well as
adherence to recommended health behaviour changes, such as warfarin
management and compliance. In the absence of a validated warfarin knowledge
questionnaire, a series of questions were drafted for the ‘Warfarin Knowledge’
questionnaire (APPENDIX 19) based on several different warfarin studies
conducted over the past three decades by Scalley et al (1979), Witte et al (1980)
and Wyness (1989), as well as the ‘Warfarin Education Program Objectives’
(APPENDIX 14) and the contents of the new warfarin information booklet
(APPENDIX 12). In addition to the ‘Warfarin Knowledge’ questionnaire
(APPENDIX 19), patients were asked to complete the ‘Self-Management’
questionnaire (APPENDIX 17) adapted from Lorig et al ‘Self-Efficacy
Questionnaire’ (1996 page 41-44) and the ‘Medication-Taking-Measures’ (MTM)
questionnaire (Morisky, Green and Levine 1986)(APPENDIX 18), immediately
and three months after the initial education session. These latter questionnaires
were used to assess and compare their warfarin-related management and
compliance behaviours.
Outcome evaluation assessed whether or not the program had worked
toward achieving its goals within a three-month period, and to compare the new
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warfarin education program to the customary warfarin education program. The
‘Outcome Measures of the Warfarin Education Program’ questionnaire
(APPENDIX 21) was adapted from Lorig et al (1996 pages 53-55) ‘Health
Outcome Measures for Health Care Utilization’ and was completed over the
telephone, three months after the initial warfarin education session. Information
collected from this questionnaire included the number of healthcare provider
visits (general practitioner, hospital and/or emergency department), the number
of warfarin-related adverse drug events experienced and the patient’s INR blood
test results. When patients had neglected to record their own INR results, the
researcher/TACT pharmacist obtained their results from the relevant pathology
services.
Process evaluation data were used to assess and compare the readability,
quality and the suitability of the written warfarin information used in both
education programs. Impact evaluation data were used to contrast the patient’s
satisfaction with each of the education programs, as well as their impact on
patients’ warfarin knowledge and understanding, and his/her adherence to
recommended warfarin management and compliance behaviours. Finally,
outcome evaluation data were used to compare the effects that both programs
had on the patients’ health outcomes, which included warfarin blood test results
and healthcare utilisation (for example; the number of general practitioner visits
and/or hospital visits).

5.3.8 Summary
In summary, the new warfarin program was based on introducing
interventions and strategies to target the five key elements of an effective patient
medication education program. These five key elements were: health
professional/patient communication and partnerships, warfarin compliance,
simple, easy-to-read written warfarin information, the continuity of care between
hospital and community settings and patient follow-up. As well as targeting each
of these key elements the new warfarin education program also addressed the
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needs of the ‘high risk’ patient population, to ensure that they too would be
effectively educated about their warfarin therapy.
Evaluation was incorporated into the research study to compare the
readability, quality and suitability of the new warfarin information booklet
(APPENDIX 12) to the Boots warfarin information booklet (2003) used in the
customary warfarin education program. Data collected from the ‘SelfManagement,’ ‘Medication-Taking Measures’ and ‘Warfarin Knowledge’
questionnaires (Appendices 17-19), as well as the ‘Satisfaction with Information
about Medicines Scale’ (SIMS) and ‘Outcome Measures of the Warfarin
Education Program’ questionnaires (Appendices 20-21) were all used to
compare and contrast the overall effectiveness of the new warfarin education
program, with the customary warfarin education program delivered to TACT
patients.

5.4 THE NEW WARFARIN EDUCATION PROGRAM
The new warfarin education program and the new warfarin information
booklet (APPENDIX 12) were founded on the ‘Warfarin education program
objectives’ (APPENDIX 14). These objectives were identified in the literature as
‘best evidence’ for educating patients about their warfarin therapy (Haines 1998;
Witte, Gurwich et al. 1980; Wyness 1989) and provided well-defined and
measurable instructional aims for the education program. Not only were the
contents of the new warfarin information booklet founded on these objectives, but
they were also based on information derived from the Boots Healthcare ‘Warfarin
important instructions for patients’ (2000) and Beata Bajorek’s ‘Warfarin
medication information booklet for patients and their carers’ developed for use in
her Ph.D. study; ‘Stroke prevention in elderly patients with atrial fibrillation’
(Bajorek 2002).
The new warfarin education program consisted of an initial home- based
one-to-one verbal warfarin education session, during which the new warfarin
information booklet (APPENDIX 12) was used as a written and visual aid. At the
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end of the session the patients were given the booklet as a written information
resource and were asked to complete the first set of evaluation questionnaires
(Appendices 17-20). Follow-up phone calls for the new program were made both
one week and three months after the initial warfarin education session to offer
encouragement, reassurance, reinforcement and to promote feedback. The
three-month follow-up evaluation questionnaires (Appendices 17-21) were also
completed over the telephone.
A typical transcript of the initial warfarin education session used in the new
warfarin education program can be found in APPENDIX 11 and a complete
schematic representation of the new warfarin education program will now follow.
The new warfarin education program was based on a conceptual
framework, which incorporated interventions and strategies targeting the five key
elements of an effective patient medication education program. These
interventions and strategies were not chronologically added to the program and
often targeted more than one of the key elements. The following symbols will
therefore be used to represent the key elements targeted by the different
interventions and strategies in the new warfarin education program.
Patient/health professional communication and partnerships
♥ Warfarin compliance
 Simple, easy-to read written warfarin information
 Continuity of care between hospital and community settings
 Patient follow-up

Prior to arriving at the patient’s home


An appointment for the initial education session was made over the
telephone and the appropriate information, checklists and
questionnaires, as per APPENDIX 10, were packed ().



The patient’s general practitioner was faxed about their patient’s
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admission to TACT and their proposed warfarin therapy ().


Carers and family members were encouraged to attend the
education session (, ♥, ).



For non-English speaking background patients, Illawarra Health
interpreters were booked for the education sessions (, ♥, ).

On arrival at the patient’s home


The researcher/TACT pharmacist identified herself and reminded
the patients about the follow-up phone calls, one week and three
months after the initial education session (, ).



The researcher/ pharmacist ensured that the environment was
conducive to learning, (for example TVs, radios etc were asked to
be turned off) and it was ensured that the patients were relaxed and
comfortable)().



The researcher/TACT pharmacist completed the patients’
‘Demographic Data Sheet’ (APPENDIX 16) and the ‘Warfarin
Pretest Questionnaire’(APPENDIX 15). The pretest questionnaire
ascertained the patient’s previous experience(s), if any, with
warfarin and whether or not they had any preconceptions, feelings
or fears concerning their warfarin therapy. Each of these issues
was dealt with in a positive, reinforcing and reassuring manner (,

).


The researcher/TACT pharmacist enquired about the patient’s past
and present illnesses, as well as their current treatment, to ensure
that they would not impact upon their warfarin therapy (for example
patients with cancer receiving cytotoxic therapy would have had
problems stabilizing their INR results and warfarin therapy) (,

).
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During the Initial Warfarin Education Session (refer to APPENDIX 11 for a typical
transcript of the education session)


Encouragement, reassurance, reinforcement and positive feedback
were always used by the researcher/TACT pharmacist in an
attempt to promote collaboration and active patient participation
(, ♥).



The researcher/TACT pharmacist remained friendly, approachable
and supportive throughout the education session. Speaking in a
clear, positive, interested and enthusiastic manner, trying to help
motivate the patients to learn and comprehend the information
given to them ().



The researcher/TACT pharmacist always used simple, easy-tounderstand language, the ‘New Warfarin Information Booklet’
(APPENDIX 12) and the ‘Warfarin Counselling Checklist ’
(APPENDIX 13) to ensure that all the main points had been
carefully explained to the patients and/or their carers (, , ♥).



The new warfarin information booklet (APPENDIX 12) was written
in a simple, easy-to-read format using validated tests, guidelines
and instructions to ensure that it could be read by a wider patient
population, inclusive of those with low literacy skills ().



The new warfarin information booklet (APPENDIX 12) was used as
a written and visual aide for the verbal education session. The
researcher/TACT pharmacist underlined main points within the
booklet, referring to the illustrations as visual aids to reinforce the
information (, ).



Information provided during the education program was based on
the ‘The New Warfarin Education Program Objectives’ (APPENDIX
14) and focused on improving the patients’ knowledge and
understanding about how warfarin works, how to take it safely, what
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the INR blood test results mean, possible side effects and the
effects other medications, diet, alcohol and lifestyles can have on
warfarin therapy (♥).


Patients were given limited supplies of 5mg, 2mg and 1mg warfarin
tablets during their admission to TACT. They were asked to show
the researcher/TACT pharmacist which combinations of warfarin
tablets they would use to provide a dose equivalent to 9mg, 8mg,
4mg and 3mg of warfarin. This exercise helped to educate and
reinforce patients about how to calculate their appropriate warfarin
dose (♥, ).



The researcher/TACT pharmacist performed a medication review
on all the patient’s medications, including their complementary
medicines, to ensure that there were no drug- to-drug interactions
with their warfarin therapy. Recommendations were subsequently
given about suitable times to take their medications and when
necessary to cease or change medications which interacted with
their warfarin after collaborating with their healthcare providers (♥,

).


Patients taking complementary medicines were reminded about the
‘Patient information on potential drug-to-drug warfarin interactions’
leaflet (APPENDIX 27) and asked, if necessary, to cease the
interacting complementary medications or to discuss them with
their healthcare providers ().



Patients were shown how to keep a record of their INR results,
warfarin doses and appointment times on pages 18-21 of the new
warfarin information booklet (APPENDIX 12). They were
encouraged to continuously record this information as a valuable
resource for themselves and all their healthcare providers (, ,

).
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All patients and especially elderly patients living alone, who
suffered from any cognitive and/or physical limitations, were
strongly encouraged to use compliance aids (for example dosette
boxes, blister packs, alarms, calendars) (♥).



Patients were continuously asked questions throughout the
education session to verify their comprehension of the warfarin
information (for example Why do you think that you been started on
warfarin tablets? What is your target INR?)(, ♥).



Patients were informed that their general practitioners would be
responsible for their warfarin monitoring and further warfarin
prescriptions after their discharge from TACT ().



Patients were encouraged to use the new warfarin information
booklet (APPENDIX 12) as a simple, easy-to-read written
information resource ().



Patients were advised about other reliable warfarin information
resources such as; the TACT office, their healthcare providers, the
National Prescribing Service (NPS) (they were given a fridge
magnet with the NPS telephone number) and the internet sites
available in the back of the new warfarin information booklet
(APPENDIX 12)(, ).



Patient feedback, which included their comments and opinions, was
encouraged not only during the follow-up phone calls but also
throughout the education program ().



At the conclusion of the initial warfarin education session, patients
were encouraged to ask questions and were reassured that if they
complied with the recommendations, as per the education session,
they would be able to effectively manage their warfarin therapy at
home (, ♥).



When patients were discharged from TACT, their general
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practitioners were faxed the details of their discharge, warfarin dose
and INR values during their admission to TACT ().

Telephone Follow-up Calls (one week and three months after the initial warfarin
education session)


Patients received follow-up phone calls, one week and three

months after the initial warfarin education session. During these phone
calls warfarin information was reinforced according to the ‘Warfarin
Counselling Checklist ’ (APPENDIX 13) (, ♥, ).


The patients were also encouraged to discuss any queries or

concerns, and to express their comments and opinions about the
warfarin education program (, ♥, ).

Evaluation
The following is a summary of the evaluation instruments, tools and
questionnaires used in the new warfarin education program.


The readability, quality and the suitability of the new warfarin information
booklet was assessed using the following
 SMOG test (McLauglin 1969) (APPENDIX 4)
 The Fry Readability Formula (Fry 1968) (APPENDIX 5)
 The computerized Flesch-Kincaid instrument available on
the Microsoft Office Word 2000 program
 The ‘Suitability Assessment of Materials’ (SAM) (Doak, Doak
et al. 1985) (APPENDIX 6)
 The ‘Bernier Instructional Design Scale’ (BIDS) (Bernier
1996)(APPENDIX 7)
 The ‘Checklist for print materials’ (Bidford Maine Area Health
Education Center 1996) (APPENDIX 8)
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The patients were asked to complete the following questionnaires,
immediately and three months after the initial warfarin education session.
 ‘Self-Management’ questionnaire (APPENDIX 17)
 ‘Medication-Taking- Measures’ questionnaire (APPENDIX 18)
 ‘Warfarin Knowledge’ questionnaire (APPENDIX 19)
 ‘Satisfaction with Information about Medicines Scale’ (SIMS)
(APPENDIX 20)



Three months after the initial education session patients were also asked
to complete the ‘Outcome Measures of the Warfarin Education Program’
questionnaire (APPENDIX 21).

5.5 ETHICAL CONSIDERATIONS
Prior to the commencement of the pilot study and the research study,
ethics approval had to be sought from the following:


The University of Wollongong Ethics Committee



The Management of the Illawarra Health Service



The TACT medical director



The Illawarra Health interpreter service



Patients participating in the research study

An ethics approval request to conduct the research study was submitted
by the researcher/TACT pharmacist to the University of Wollongong Ethics
Committee in November 2002. Illawarra Health’s upper management officials,
The Ambulatory Care Team’s (TACT) medical director and the Illawarra health
interpreter service were all informed about the research study and also asked for
their written consent. Once permission and written consent were received from
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each of these committees and/or persons, the researcher/TACT pharmacist
continued with the pilot study and then the research study.
During the course of the research study there were several ethical issues,
which needed to be considered and addressed. TACT staff members were
informed about the research study in an education session presented by the
researcher/TACT pharmacist, where they also received the ‘Research
information sheet for Illawarra Health staff’ (APPENDIX 23). During this
education session, they were informed that a patient’s refusal to participate in the
study would in no way detrimentally affect their TACT healthcare service. They
were given the ‘Suggested dialogue for patient recruitment and obtaining
consent’ (APPENDIX 24) as a guide to help them approach and recruit patient
participants for the study. TACT staff members were also told that they were
under no obligation to approach and recruit patients for the study and that their
decision to do so was purely on a voluntary basis.
The researcher/TACT pharmacist was a TACT employee prior to the
study, which meant that she had ready access to the patient’s medical notes and
hospital data. The patient participants were informed about the study and the
researcher/TACT pharmacist’s access to this information in the ‘Patient
participant information sheet’ (APPENDIX 25). The patients consented to
participate in the study and granted their permission for the researcher/TACT
pharmacist to access their medical information by signing the ‘Patient participant
consent form’ (APPENDIX 26).
Written confirmation about patient confidentiality and the de-identification
of patient details was made available to all participants through the ‘Patient
participant consent form’ (APPENDIX 26). The patients were also verbally
informed about these confidentiality issues during the recruitment phase of the
study. The ‘Patient participant information sheet’ (APPENDIX 25), the ‘Patient
participant consent form’ (APPENDIX 26) and the TACT staff, reassured patients
that their refusal to participate and/or to withdraw from the study at any time
would in no way impact detrimentally on their TACT healthcare service.

103

As already mentioned in this chapter, when interventions incorporated into
the new warfarin education program were perceived to be best practice and
complied with the APAC guidelines, they were also at times incorporated into the
customary warfarin education program, during the course of the study. These
changes were based on recommendations from area health service management
and were out of the control of the researcher. The implications of these changes
on the study results will be discussed in a later chapter.

5.6 THE PILOT STUDY
Prior to the research study being conducted, a pilot study was completed
to trial the new warfarin education program. Ten pilot group participants were
educated using the new program as a ‘one off’ education session, including
being given the new warfarin information booklet (APPENDIX 12). The 10 pilot
group participants had similar demographic variables such as age, social status
and educational backgrounds to the eligible TACT patient participants, ensuring
that their answers to the evaluation questionnaires, their comments and opinions
would benefit the eligible patient participants (Doak, Doak et al. 1996b). The 10
pilot group participants had never been prescribed warfarin but they volunteered
to take part in the trial warfarin education session.
At the end of their single education session, each of the pilot participants
was asked to complete the same four evaluation questionnaires which were to
be used in the research study. These questionnaires included the ‘SelfManagement’, ‘Medication-Taking-Measures’ and the ‘Warfarin Knowledge’
questionnaires (Appendices17-19), as well as the ‘Satisfaction with Information
about Medicines Scale’ (SIMS) questionnaire (APPENDIX 20). As an added
measure, they were also asked to complete the DISCERN questionnaire
(Charnock, Shepperd, Needham and Gann 1998) (APPENDIX 22) which would
help to identify their perception about the reliability and the quality of the new
warfarin information booklet. At the completion of their individual education
sessions, they were asked for their opinions and/or comments about the warfarin
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education session, the booklet and the questionnaires. The results of the pilot
group study will now be briefly discussed.
There were five male and five female pilot group participants, ranging in
age from 38 to 70 years. Their educational status varied from a grade 4 level to
a tertiary level, with four of the participants coming from non-English speaking
backgrounds. All of the participants were able to readily answer each of the
questionnaires, except for the ‘Warfarin Knowledge’ questionnaire (APPENDIX
19). A few of the participants found some of the knowledge questions to be
ambiguous and confusing, which is why these questions were revised after the
pilot study. The changes made to the ‘Warfarin Knowledge’ questionnaire prior
to it being used in the research study as per APPENDIX 19, included:
Question 1: “What is your medicine called (generic and brand name)?”
Revised Q1: “Which brand of warfarin is prescribed for you?”

Question 9

“What are the appropriate levels for an INR blood test?”

Revised Q 9 “What is your target INR blood test range?”

Question 17 “Do you need to make any modifications to your daily
activities while you are taking warfarin?”
Revised Q 17 ”Name TWO activities or things you need to be careful
doing while taking warfarin.”

The warfarin education session was not changed after the pilot study
because over 80 percent of the pilot group participants were satisfied with the
information given to them, according to the results of the ‘Satisfaction with
Information About Medicines Scale’ (SIMS) (APPENDIX 20) and their positive
comments. Overall, the new warfarin information booklet remained largely
unchanged after the pilot study, because the results of the DISCERN
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questionnaire (APPENDIX 22) indicated that 90 percent of the pilot group
participants perceived the booklet to be of a ‘high’ to ‘very high’ quality with
minimal short comings. The minor changes made to the booklet, based on the
pilot participants’ comments and opinions, included: having a bright front cover
on the booklet; showing people living a normal life while taking warfarin; a
contents page for easy access to page numbers; and making the MedicAlert
bracelets an ‘optional’ alternative for the patient.
At the conclusion of the pilot study and once the minor changes had been
made, the researcher/TACT pharmacist then collated the comments and
opinions about the draft version of the new warfarin information booklet from the
literacy experts at the University of Wollongong, her work colleagues and the
Illawarra Health interpreters. Once again, a few minor changes were made to the
booklet, prior to it being printed in its final version as per APPENDIX 12. These
minor changes included:
Page 2: ‘This booklet will help you lead a normal life whilst on this
therapy. This booklet will help you understand….’ was replaced with ‘The
purpose of this book is to help you understand:’
Page 8: ‘Have the INR test done every time your doctor orders one’ was
replaced with ‘Follow your doctor’s orders for INR testing’
Page 10: ‘ To help let people know, you can order a MedicAlert bracelet
from your pharmacist’ was replaced with ‘You can also wear a MedicAlert
bracelet (which you can buy from your pharmacist) to let people know that
you take warfarin’
Page 15 ‘Additional things to remember’ was replaced with ‘Other factors
to consider’
Other changes throughout the booklet also involved replacing the term
“healthcarers” with “healthcare providers”, clearly labelling illustrations and
deleting those which were deemed unnecessary, as well as altering some
of the formatting in the booklet.
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On the completion of these changes to the new warfarin information
booklet and the questionnaires, based on the results of the pilot study as well as
the comments and opinions of the literacy experts, work colleagues and
interpreters, the booklets were printed and the research study commenced in
January 2003. The methodological process of this research study will now be
discussed.

5.7 THE RESEARCH STUDY
5.7.1 Background
Illawarra Health’s The Ambulatory Care Team (TACT) is a
multidisciplinary team consisting of medical practitioners, pharmacists,
physiotherapists and registered nurses. TACT provides a home-based outpatient
management service for conditions that would otherwise be managed in hospital
including; intravenous antibiotics, subcutaneous enoxaparin injections and
warfarin management, pre- and post-operative care, as well as wound
management. Patients who are treated with the oral anticoagulant warfarin and
educated in their own homes are focused upon for the purpose of this research
study. It is also important to note that both the educators involved in this study
were pharmacists employed by the TACT team for at least four years.

5.7.2 Eligible participants, informed consent and confidentiality
Once permission to conduct the research study was received from the
University of Wollongong Ethics Committee, the Illawarra Health management,
the TACT medical director and the Illawarra Health interpreter service, the
researcher/TACT pharmacist conducted an education session to inform the other
TACT staff members about the study. During this education session, the TACT
staff members were given the ‘Research information sheet for Illawarra Health
staff’ (APPENDIX 23) and the step-by-step guide on how to go about recruiting
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patients on a voluntary basis, as per the ‘Suggested dialogue for patient
recruitment and obtaining consent’ (APPENDIX 24).
All patients accepted for admission to The Ambulatory Care Team (TACT)
during the study period who were over 18 years of age, resided in the Illawarra
Health area and were newly prescribed warfarin, or those who were
recommencing warfarin therapy after at least 15 years, were considered eligible
for the research study. For the purposes of this study patient participants aged 65
years and over were referred to as elderly, and those educated at or below a
grade 6 level were referred to as having low literacy skills, as deemed by Davis
et al (1990) and Rolland (2000). Patients from non-English speaking
backgrounds were also considered eligible for the research study because
Illawarra Health interpreters were made available to translate all the relevant
information to them. On admission to TACT eligible patients were verbally
informed about the study as detailed below and asked to consent to becoming
patient participants by signing the ‘Patient participant consent form’ (APPENDIX
26).
Informed consent is an ethical obligation fundamental to research.
Obtaining informed consent and maintaining confidentiality are critical to the way
we deliver healthcare and remain a crucial part of our medico legal responsibility
to the patient and to society (Betancourt and Jacobs 2000). Thus, eligible patient
participants were informed about the study by having the ‘Patient participant
information sheet’ (APPENDIX 25) read out to them by either a TACT pharmacist
or another TACT staff member during one of their initial home visits.
Subsequently, after reading through the ‘Patient participant consent form’
(APPENDIX 26), consenting patients were asked to sign the consent form and
reminded about their right to withdraw from the study at any time.
All data collected during the course of the research study were processed
in a way that protected the patients’ confidentiality and anonymity, with only the
data containing fully completed evaluation questionnaires (Appendices 15-21),
immediately and after three months, being used for analysis. Patient participant
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details and consent forms were securely stored separately from the other data
and coding was used during data collection. Patient participants were given
sufficient time, prior to and following education and evaluation sessions, to raise
any questions or concerns they may have had in relation to the research study
and/or the data collection process.

5.7.3 Research participants and the study
For the purposes of this research, over 100 consenting patient participants
were recruited for the study, with the intention to allocate 50 patient participants
to the control group and 50 patient participants to the intervention group. Patient
recruitment continued until there were at least 50 control patients and 50
intervention patients who had completed all questionnaires, inclusive of the three
month follow-up questionnaires. To ensure consistency, the control group
patients were educated by a TACT pharmacist using the customary warfarin
education program and the Boots warfarin information booklet (2003).The
intervention group patients, on the other hand, were educated by the TACT
researcher/pharmacist, using the new warfarin education program and the new
warfarin information booklet (APPENDIX 12). Typical transcripts for both the
customary and the new warfarin education sessions can be found in APPENDIX
28 and APPENDIX 11, respectively.
The patient participants in the study were allocated into the control or the
intervention group depending on what day of the week they were admitted to
TACT and which TACT pharmacist, the researcher - referred to as the
researcher/TACT pharmacist - using the new warfarin education program or the
non-researcher pharmacist – referred to as the TACT pharmacist - using the
customary warfarin education program was available at work. It was an allocation
by convenience because the non-researcher TACT pharmacist worked with
TACT on a Monday and the researcher/TACT pharmacist worked with TACT on
a Thursday and it was common practice that all new warfarin prescribed patients
admitted to TACT received warfarin education within four days. As a result, the
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patient participants who consented between Friday and Sunday were allocated
into the control group, for the TACT pharmacist to educate with the customary
warfarin education program. The patient participants who consented between
Monday and Thursday, on the other hand, were allocated to the intervention
group, for the researcher/TACT pharmacist to educate with the new warfarin
education program. The allocation of patients to the control or intervention
groups could be problematic if there were different referral patterns over different
days of the week. From experience with TACT referral patterns this was not
expected to occur, however referral and other patient data were collected for
each patient and compared as part of the data analysis to confirm that this
method of patient allocation resulted in comparable patient samples for both
groups.
Non-English speaking background patients were also recruited by inviting
an Illawarra Health interpreter to translate all the relevant information to the
patients. The researcher/TACT pharmacist was especially interested in the nonEnglish speaking background patients because they are often excluded from
similar studies based on their language barriers, and yet they are in the ‘high risk’
group, which we know little about.
Demographic variables such as age, nationality, sex, educational level
and morbidities were recorded on the ‘Patient Demographic Data’ (APPENDIX
16). Demographic data were collected by the pharmacists from the patients, their
inpatient notes and/or the Illawarra Health DRACIS database. These
demographic data were used in the analysis to investigate their possible effects
on the patients’ warfarin knowledge and understanding, self-management and
compliance, as well as to compare their effects on the two different warfarin
education programs.
Evaluation questionnaires were completed in the patients’ homes,
immediately after the initial warfarin education sessions, and then over the
telephone during the three-month follow-up. The purpose of the evaluation
questionnaires was to assess and analyse the effectiveness of the new warfarin
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education program, and to compare and contrast it with the customary warfarin
education program, given to TACT patients receiving warfarin therapy.
Data collected from the ‘Self-Management’ (APPENDIX 17) and
‘Medication-Taking-Measures’ (APPENDIX 18) questionnaires from both
intervention and control patients helped to compare the impact of the two
programs on the patients’ perception about warfarin self-management and
compliance. Comparing the results of the data collected from the ‘Warfarin
Knowledge’ questionnaires (APPENDIX 19) assisted with analysing which
program - the new or the customary - was superior in terms of improving warfarin
knowledge and understanding. Reviewing the ‘Satisfaction with Information about
Medicines Scale’ (SIMS)(APPENDIX 20) established whether or not the patients
were more or less satisfied with either of the two education programs. Finally,
data collected from the ‘Outcome Measures of the Warfarin Education Program’
questionnaire (APPENDIX 21) was used to compare the therapeutic outcomes of
both education programs over the three-month period. The outcomes reviewed
included; therapeutic INR blood test results, visits to general practitioners,
hospitals and emergency departments, as well as possible warfarin-related
adverse drug events.

5.7.4 Data processing and analysis
All information gathered from patient participants for the purposes of this
study, including personal details and questionnaires, was de-identified and
secured in a locked cabinet at the University of Wollongong. No personal details
were provided to other patient participants nor were they identified in any of the
journal articles, conference presentations and thesis publications resulting from
this research study. Clinical data collected from patient participants were kept by
Illawarra Health’s medical records department and stored according to its
standard record keeping practices. No information was left on the network
computer that could be accessed by anyone other than the researcher/TACT
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pharmacist herself. On completion of the research study and after the required
time all identifying details will be appropriately destroyed.
On completion of the research study, a period of approximately 12
months, all the information was collected and collated by the researcher/TACT
pharmacist. The information collected from the questionnaires was quantitatively
coded and entered into a JMP database created for the study by the
researcher/TACT pharmacist in the JMP statistical computer program (Sall
2000). The ‘Self-Management,’ ‘Medication-Taking- Measures’ and the
‘Satisfaction with Information about Medicines Scale’ (SIMS) questionnaires
(APPENDIX 17, 18 and 20) are all scale form questions which are readily
entered quantitatively into the database. On the other hand, the ‘Warfarin
Knowledge’ questionnaire (APPENDIX 19), which consisted of open-ended
questions, was coded ‘post facto’ by the researcher/TACT pharmacist following
the pilot phase, and also entered quantitatively into the database. The ‘Outcome
Measures of the Warfarin Education Program’ questionnaire’ (APPENDIX 21)
had a combination of numerical values, pre-coded answers and open-ended
questions. The numerical values and pre-coded answers were quantitatively
added to the database, whereas the answers to the open-ended questions were
typed into the database for thematic analysis. Similarly, any comments that were
made by the patients and/or their carers during the three-month follow-up period
were also typed into the database for thematic analysis.
On completion of data entry, the quantitative data were analysed by the
researcher/TACT pharmacist with the assistance of a qualified statistician at the
University of Wollongong. Several statistical tests were used to compare the new
warfarin education program against the customary warfarin education program.
These tests included: t-tests to determine whether or not mean scores for the
different questionnaires were significantly different for the two programs; paired ttest to compare immediate scores and follow-up scores within the same groups
of patients; ANOVA tests to compare the mean scores for both groups taking into
account several variables at once; correlation coefficients to analyse the
relationships between the mean scores for each of the questionnaires and the
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number of healthcare visits, as well as the percentage of International
Normalised Ratio (INR) blood test results within therapeutic range; and chisquared tests to evaluate whether or not there were any relationships between
two variables such as category (i.e. intervention or control) and education level.
The results of these tests and analyses will be discussed at length in the
following chapter.

5.7.5 Summary of the methodological process of the research study
The following is a summary of the methodological processes of the study.
Table 1 gives an overview of the differences between the new warfarin education
program given to the intervention group patients and the customary warfarin
education program given to the control group patients.

Table 1: Summary of the methodological processes of the research study

METHODOLOGY PROCESS

50
INTERVENTION
PATIENTS

TACT staff member will invite eligible patients
to participate in the research study as per
APPENDIX 24. If they agree to participate they 
will be given the ‘Patient participant
information sheet’ (APPENDIX 25) and asked
to sign the ‘Patient participant consent form’
(APPENDIX 26). The consent form will then be
filed in a secured cabinet in the TACT office.

50
CONTROL
PATIENTS


Note: For non-English speaking background
patients an Illawarra Health interpreter will be
present to translate the information to the
patient.
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METHODOLOGY PROCESS
Consenting patient participants will be
allocated to the intervention or control groups
and then telephoned by the TACT pharmacists
to make a suitable appointment time for the
initial education session to take place. They
will also be reminded about the evaluation
questionnaires and the follow-up telephone
calls.

50
INTERVENTION
PATIENTS

50
CONTROL
PATIENTS





Carers and/or family members will be strongly
encouraged to attend the initial warfarin
education session.



Initial warfarin education sessions will be
delivered in the patient’s home or an
alternative place specified by the patient.



A collaborative approach to the education
session will be highly promoted, using
encouragement, reassurance, reinforcement
and positive feedback.
Intervention patients will be asked many
questions and will be encouraged to make
comments and given their opinions throughout
the education program.
An Illawarra Health interpreter will be in
attendance for all non-English speaking
background patients.
Researcher/TACT pharmacist will ensure that
the environment is conducive to learning i.e.
turn off any televisions, radios etc, and ensure
that the patient is comfortable and relaxed.
All patient participants will have their
‘Demographic Data’ (APPENDIX 16) recorded
by the TACT pharmacist.
Patient participants will be pre-tested for their
understanding about warfarin (APPENDIX 15).
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METHODOLOGY PROCESS
Researcher/TACT pharmacist will educate the
intervention patient participants with the new
warfarin education program using the
‘Transcript of the new warfarin education
session’ (APPENDIX 11), the ‘New warfarin
information booklet’ (APPENDIX 12), the
‘Warfarin Counselling Checklist ’(APPENDIX
13) and the ‘New Warfarin Education
Objectives’ (APPENDIX 14) to ensure that all
main points have been taught and reinforced.
Researcher/TACT pharmacist will speak in
simple, easy-to-understand language,
underlining key points in the new warfarin
information booklet (APPENDIX 12), which will
also be used as a visual aid.

50
INTERVENTION
PATIENTS





TACT pharmacist will educate the control
patient participants with the customary
warfarin education program as per the
‘Transcript for the customary warfarin
education program’ (APPENDIX 28) using the
Boots warfarin information booklet (2003).
Intervention patients will be encouraged to
disclose the use of all other medicines
including complementary medicines in order to
check for drug-to-drug interactions, by way of
a complete medication review.
Control patients will be asked to disclose other
prescribed medication
‘Patient information on potential drug-to-drug
warfarin interactions’ (APPENDIX 27) will be
issued to all patient participants.
Intervention patients will be encouraged to
record their INR blood test results, warfarin
doses and appointment times in the back of
their new warfarin booklets.

50
CONTROL
PATIENTS
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METHODOLOGY PROCESS
Compliance aids will be highly recommended
for ‘high risk’ patients living alone or believed
to be suffering from any physical and/or
cognitive limitations.
Intervention patients will be asked to show the
researcher/TACT pharmacist how to make up
warfarin doses equivalent to 9mg, 8mg, 4mg
and 3 mg.
The National Prescribing Service ‘Medicines
Line’ 1300 888 763 (given as a fridge magnet)
and other suitable websites available in the
new warfarin information booklet will be
recommended to intervention patients as
suitable resources for more warfarin
information.
TACT office number 42 225 328 will be made
available for any patient queries and concerns.
Intervention patients will be given telephone
reinforcement, reassurance and follow-up, one
week after the initial warfarin education
session.
All patient participants will be given evaluation
questionnaires (Appendices 17-20) to
complete, immediately and three months after
the initial warfarin education session. The
immediate questionnaires will be completed in
the patient’s home, and the three-month
follow-up questionnaires will be completed
over the telephone.
All patient participants will complete the
‘Outcome Measures of the Warfarin Education
Program’ questionnaire (APPENDIX 21) over
the telephone three months after the initial
education sessions.

50
INTERVENTION
PATIENTS

50
CONTROL
PATIENTS
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A simplified version of this table is presented on the following page, as a
flowchart of the research study
Figure 3: FLOWCHART FOR THE RESEARCH STUDY
100 Consenting patient
participants

50 Control
patients

50 Intervention
patients

Pretest Questionnaire

Pretest Questionnaire

(APPENDIX 15)

(APPENDIX 15)

Customary warfarin
education program

New warfarin education
program

Evaluation Questionnaires

Evaluation Questionnaires

(APPENDICES 17-20)

(APPENDICES 17-20)

(immediately and three-month follow-up)

(immediately and three-month follow-up)






‘Self-Management’
‘Medication-Taking-Measures’
‘Warfarin Knowledge’
SIMS

Three months after initial
warfarin education session
 ‘Outcome Measures of
the Warfarin Education
Program’ questionnaire
(APPENDIX 21)






‘Self-Management’
‘Medication-Taking-Measures’
‘Warfarin Knowledge’
SIMS

Three months after initial
warfarin education session
 ‘Outcome Measures of
the Warfarin Education
Program’ questionnaire
(APPENDIX 21)
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5. 8 SUMMARY
This chapter has provided an overview of the process for the design,
implementation and the development of the new warfarin education program
including the new warfarin information booklet (APPENDIX 12). The new warfarin
education program has been discussed at length detailing which of the
interventions and strategies have been used to target the five key elements of an
effective medication education program. Evaluation has also been incorporated
as a major component of the research study. Data collected from the evaluation
questionnaires, as well as the tools, instruments and guidelines used to assess
the new booklet (APPENDIX 12) and the Boots warfarin information booklet
(2003) will be used to compare and contrast the process, impact and the
outcomes of the new and customary warfarin education programs.
Ethical considerations were reported on, as were the changes made to the
new program and the booklet based on the results of the pilot study and the
comments made by the literacy experts from the University of Wollongong, the
researcher/pharmacist’s colleagues, the Illawarra Health interpreters and the pilot
group participants. Finally, the methodological process of the research study
itself was discussed and summarised as a table and a flowchart.
The time has now come to analyse the data and discuss the findings of
the different evaluation modalities used in this research study. These analyses
and evaluations will be described in detail throughout the next chapter of this
thesis.
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CHAPTER 6
RESULTS
6.1 INTRODUCTION
The analysis of the findings is presented in this chapter. Initially, there is a
discussion about the results of the tests used to assess the readability of the new
warfarin information booklet compared with the typically used Boots warfarin
information booklet (2003). The readability tests used included the SMOG test
(McLauglin 1969), the Fry test (Fry 1968)(See Appendices 4-5), and the
computerised Flesch-Kincaid instrument available on the Windows 2000 Word
program. The chapter then discusses the results of the ‘Suitability Assessment of
Materials’ (SAM)(Doak, Doak et al. 1985) instrument, the ‘Bernier Instructional
Design Scale’(BIDS) (Bernier 1996) (See APPENDIX 6-7) and the ‘Checklist for
print materials’ (Bidford Maine Area Health Education Center 1996), used to
compare the quality and the suitability of the new booklet to the Boots warfarin
information booklet (2003).
Throughout the rest of the chapter, discussion focuses on comparing and
contrasting data collected from evaluation questionnaires and the outcome
measures of the new warfarin education program against the same evaluation
questionnaires collected for the customary warfarin education program. Data
were collected using the ‘Self-Management’ questionnaire (APPENDIX 17); the
‘Medication-Taking Measures’ questionnaire (APPENDIX 18); the ‘Warfarin
Knowledge’ questionnaire (APPENDIX 19) and the ‘Satisfaction with Information
about Medicines Scale’ (APPENDIX 20). These questionnaires were completed
immediately and then three months after the initial warfarin education sessions.
Analysis of the ‘Patient Demographic Data’ (APPENDIX 16) and the ‘Outcome
Measures of the Warfarin Education Program’ questionnaire’ (APPENDIX 21)
were also used to compare the new warfarin education program to the customary
warfarin education program.
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6.2 COMPARING AND CONTRASTING THE READABILITY OF THE NEW
WARFARIN INFORMATION BOOKLET WITH THE BOOTS WARFARIN
INFORMATION BOOKLET (2003).
Readability scores for the new warfarin information booklet (APPENDIX
12) and the Boots warfarin information booklet (2003) were derived from the
SMOG test (McLauglin 1969), the Fry test (1968) and the Microsoft Word 2000
computeriSed Flesch-Kincaid test. These test results are presented below.
The SMOG test (McLauglin 1969) was performed twice on 30 sentences
from the new booklet. The first test was performed on 10 consecutive sentences
taken from pages 3, 8 and 14 - 15 of the new booklet, and the second test was
conducted on the contents page, as well as pages 7 - 8 and 15 of the booklet.
These pages were chosen because they provided 10 consecutive sentences for
testing from the beginning, middle and end of the booklet as per the test
instructions. In both instances, the SMOG test results indicated that the new
booklet was written at a grade 8 reading level. In comparison, the two SMOG
tests carried out on the Boots warfarin information booklet (2003) analysing 10
consecutive sentences from pages 2, 10 and 17; as well as pages 3 - 4,10 and
18 of the booklet, indicated that it was written at a grade 10 - 11 reading level.
The Fry Readability Formula (1968) otherwise known as the Fry test, was
performed on three 100 word passages from the text, omitting the headings.
Specific pages from each booklet were chosen and tested. According to the Fry
test (1968), carried out on 100 words from pages 3, 8 and 10, the new warfarin
information booklet was written at a grade 6 reading level. The following is a
summary of these Fry test results:
Page 3 (100 words) 8.3 sentences; 149 syllables
Page 8 (100 words) 7.7 sentences; 125 syllables
Page 10 (100 words) 13 sentences; 151 syllables.
In contrast, the results of the Fry test (1968) conducted on pages 2, 8 and 14 of
the Boots warfarin information booklet (2003) found that it was written at a grade
14 reading level. The following is a summary of these Fry test results:
Page 2 (100 words) 6.5 sentences; 155 syllables
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Page 8 (100 words) 4 sentences; 180 syllables
Page 14 (100 words) 8. 3 sentences; 185 syllables
The Fry test results indicate that, on average, the readability scores for the new
warfarin information booklet (APPENDIX 12) were 8 grades lower than the Boots
warfarin information booklet (2003). Also, the new booklet had, on average, a
larger number of sentences per page and a smaller number of multi-syllable
words, implying that it was easier to read than the Boots booklet.
The last readability test used to compare the two booklets was the
Microsoft Word 2000 computerised Flesch-Kincaid test. This test also calculated
reading ease level, which was based on the average number of syllables per
word and the average number of words per sentence. Scores for the reading
ease level range from 0 (zero) to 100 and the higher the score, the greater the
number of people who can readily understand the written information (Flesch
1974).This final test found the new warfarin information booklet had been written
at a grade 6.7 reading level, with a 62 percent reading ease level. The results for
the Boots warfarin information booklet (2003) on the other hand, indicated that it
had been written at a grade 8.9 reading level with a 58.5 percent reading ease
level. Once again, these results found that the reading grade level of the new
warfarin information booklet was lower than the Boots warfarin information
booklet. This test also found that the new warfarin information booklet had a
slightly higher reading ease level than the Boots warfarin booklet, suggesting that
it could be read and understood by a greater proportion of the population.
The scores for each of the different readability tests indicated that the new
warfarin information booklet (APPENDIX 12) was written between a grade 6 - 8
level and that the Boots warfarin information booklet (2003) was written between
a grade 8.9 –14 level. Thus, the new booklet was written at a reading level at
least 2 - 3 grades lower than the Boots booklet (2003) used in the customary
warfarin education program. The researcher/TACT pharmacist chose the actual
sentences and words used in the readability tests but the potential for bias was
small, as the choices of sentences were limited within each of the booklets.
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6.3. COMPARING AND CONTRASTING THE QUALITY AND THE
SUITABILITY OF THE NEW WARFARIN INFORMATION BOOKLET WITH
THE BOOTS WARFARIN INFORMATION BOOKLET (2003).
In order to compare the quality and the suitability of the new warfarin
information booklet to the Boots warfarin information booklet, the
researcher/TACT pharmacist and two of her colleagues completed the following
tests on both booklets; the ‘Suitability Assessment Materials’ (SAM) (Doak, Doak
et al. 1985), the ‘Bernier Instructional Design Scale’ (BIDS) (Bernier 1996) and
the ‘Checklist for print materials’ (Bidford Maine Area Health Education Center
1996) (Appendices 6 - 8). The results for each of these tests, which are
especially useful for assessing the quality and the suitability of the written
information for patients with low literacy skills, will now be presented.
The ‘Suitability Assessment Materials’ (SAM) (Doak, Doak et al.
1985)(APPENDIX 6) is an instrument used to obtain a numerical rating for
suitability factors other than readability. SAM addresses suitability in terms of
content, literacy, demand, graphics, layout, learning stimulation/motivation, and
the culture of the intended audience. The SAM ratings were analysed as
percentage ratings according to the following criteria: superior material = 70 -100
percent; adequate material = 40 - 69 percent; and not suitable material = 0 - 39
percent.
The SAM scores for the new warfarin information booklet completed by
the researcher/TACT pharmacist and two of her colleagues were 92 percent,
95.2 percent and 83 percent. Each of the raters indicated that the new booklet
was well within the superior rating (70 -100 percent) for the SAM instrument.
None of the raters gave the new booklet a ‘not suitable’ rating (0 – 39 percent) for
any of the factors in the SAM instrument. In contrast however, two of the raters
assigned SAM scores of 55 percent and 44.7 percent within the adequate rating
range (40 – 69 percent) and one rater assigned 33.3 percent within the not
suitable rating range (0 – 39 percent) for the Boots warfarin information booklet
(2003). Thus, according to the SAM scores, the new warfarin information booklet
was superior to the Boots warfarin information booklet (2003) in terms of quality
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and suitability. It could therefore be suggested that the new booklet was more
suitable than the Boots booklet especially for patients with low literacy skills.
The ‘Bernier Instructional Design Scale’ (BIDS)(1996) (APPENDIX 7) is an
instrument used to identify the presence (or absence) of instructional design and
learning principles contained in printed educational materials (Bernier 1996). The
rating scale for the BIDS instrument is based on the following numerical scores
given to each of the 35 items in the instrument: 0 = not met; 1 = partially met;
2 = met; and, NA= Not Applicable.
Based on the same results for all three raters, analysis of the BIDS
instrument on the new booklet, using the criteria discussed above, found that 26
items met the instructional design and learning principles and that no items were
found not to meet the instructional design and learning principles. For the Boots
warfarin information booklet (2003) on the other hand, all three raters found that
only 8 items met the instructional design and learning principles and that the
following four items did not meet the instructional design and learning principles
(BIDS score= 0);
 Q.4 Drawings/illustrations are recognisable to the target group
with or without explanatory text.
 Q.5 Drawings/illustrations are labelled clearly.
 Q.6 Drawings/illustrations represent racial and ethnic groups
appropriate to the target audience.

Therefore, according to the three raters and the results of the BIDS
instrument, the new warfarin information booklet met the instructional design and
learning principles much more so than did the Boots warfarin information booklet
(2003). Unlike the new booklet, the Boots booklet (2003) was found not to meet
the instructional design and learning principles for drawings, illustrations and their
cultural sensitivity. All in all, therefore, the new booklet appeared to suit the
needs of the wider patient population, much more so than did the Boots booklet
(2003), because of its adherence to instructional design and learning principles.
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The third and last instrument used by the three raters to compare the
quality and the suitability of the two booklets was the ‘Checklist for print
materials’ (Bidford Maine Area Health Education Center 1996) (APPENDIX 8).
This 17-item checklist provided a quick and easy way in which to assess the
appropriateness of the written material for patients. Points in the checklist which
were not ticked and identified as missing by all three raters, were recorded as
potential deficiencies in the suitability of the written information within the
booklets.
According to the results of the ‘Checklist for print materials’ (Bidford Maine
Area Health Education Center 1996) (APPENDIX 8) there were no potential
deficiencies in the suitability of the new warfarin information booklet because
each of the 17 items in the checklist was ticked by at least two of the raters. The
Boots warfarin information booklet (2003), however, was found to have potential
deficiencies in 7 of the 17-item checklist because they were not ticked by any of
the three raters. These items included:
 1. The cover is attractive. It indicates the core content and intended
audience.
 5. A summary that stresses what to do is included.
 8. Text is vivid and interesting. Tone is friendly.
 9. Pages or sections appear uncluttered. Ample white spaces.
 13. Illustrations are simple - preferably line drawings.
 14. Illustrations serve to amplify text.
 17. Interaction is invited via questions, responses, suggested action, etc.
In other words, the Boots booklet was found not to have an attractive cover, it did
not include summaries and interesting text, the pages appeared cluttered and
there was a lack of illustrations and invitations for patients to interact. Once again
the new warfarin information booklet was found to have fewer potential
deficiencies in appropriateness and suitability than the Boots warfarin information
booklet (2003).
In summary, the results of the ‘Suitability Assessment Materials’ (SAM)
(Doak, Doak et al. 1985), the ‘Bernier Instructional Design Scale’ (BIDS) (Bernier
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1996) and the ‘Checklist for print materials’ (Bidford Maine Area Health
Education Center 1996) independently performed by the researcher/TACT
pharmacist and two of her colleagues, indicated that the new warfarin information
booklet was considered to be superior in terms of quality and suitability, as
compared to the Boots warfarin information booklet (2003). The new booklet was
also found to comply with instructional design, learning principles and have fewer
potential deficiencies in terms of appropriateness and suitability than the Boots
booklet. These results imply that the new booklet in terms of quality and
suitability, as compared to the Boots booklet, would better suit the needs of a
wider patient population, inclusive of those with low literacy skills.

6.4 COMPARING AND CONTRASTING THE NEW WARFARIN EDUCATION
PROGRAM WITH THE CUSTOMARY WARFARIN EDUCATION PROGRAM.

6.4.1 Patient participants and demographic variables

6.4.1.1 Introduction
Data collection was conducted from February 2003 to February 2004. All
consenting patients who were admitted to The Ambulatory Care Team (TACT)
and commenced warfarin therapy for the first time, or recommenced warfarin
after a period of at least 15 years, were included. Of the 114 patients who
consented to participate, five patients could not be contacted for the three month
follow-up evaluations, five patients had their warfarin therapy discontinued by
their general practitioners, one died from cancer-related illness and one withdrew
from the study. Consequently, complete data were collected from 102 patient
participants, 55 females and 47 males. Fifty intervention patients had received
the new warfarin education program and 52 control patients had received the
customary warfarin education program delivered to Illawarra Health’s The
Ambulatory Care Team (TACT) warfarin prescribed patients.
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This next section of the chapter compares and contrasts the intervention
and control patient participants’ demographic variables including: gender, age,
educational level, ethnicity, source of referral and referral diagnosis. The last
demographic variable reported in this section is the percentage of patient
participants who had a carer and/or a family member present during the initial
warfarin education session.

6.4.1.2 Gender
The results in table 2 indicate that there was a reasonable balance of
males and females in the research sample population (N=102). Forty-six percent
(47) of the patient participants were male and 54 percent (55) were females. The
intervention group had a smaller percentage of male participants, 38 percent
(19), than did the control group, 54 percent (28). Consequently, the female
participants in the intervention group outnumbered those in the control group, 62
percent (31) as compared to 46 percent (24). A Pearson’s correlation chi-square
test, p-value equal to 0.1085, indicates that there were no significant differences
in the gender between the intervention and control group participants.

Table 2: Gender of patient participants.
Patient Participant
Intervention (n=50)
Control (n=52)
Total number of participants (N=102)

Male
38% (19)
54% (28)
46% (47)

Female
62% (31)
46% (24)
54% (55)

6.4.1.3 Age
Table 3 shows that the ages of the patient participants were similar for
both groups, with patients aged between 65-74 years being the most common
age group. Interestingly, 62.8 percent (64) of all participating patients were aged
65 years and over, which means that they were elderly and in the ‘high risk’
group. This elderly population can be further subdivided into 68 percent (34) of
the intervention patients and 57.7 percent (30) of the control patients. A
Pearson’s correlation chi-square test, p-value equal to 0.3715, indicates that
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there were no significant differences in the ages between the intervention and
control group participants.

Table 3: Age of patient participants.
Age
Percentage of
(years)

Percentage of

Percentage of total

intervention

control population

patient population

population (n=50)

(n=52)

(N=102)

>85

2.0% (1)

5.77% (3)

3.92% (4)

75-84

22% (11)

25.0% (13)

23.53% (24)

65-74

44% (22)

26.9% (14)

35.29% (36)

55-64

18% (9)

17.3% (9)

17.64% (18)

45-54

10% (5)

11.53% (6)

10.78% (11)

<44

4% (2)

13.47% (7)

8.82% (9)

6.4.1.4 Education level
As shown in table 4, the intervention group patients had been educated
from between grade 1 and tertiary levels, and the control group patients had
been educated between grade 4 and tertiary level. These results suggest that
the intervention group patients experienced a wider range of educational levels
than did the control group patients.
Table 4 also shows that 36 percent (18) of the intervention group patients
and 30.8 percent (16) of the control group patients were educated at or above a
grade 10 level. Thirty-two percent (16) of the intervention group patients and 50
percent (32) of the control group patients were educated between grades 7 and
9. Finally, and most importantly, 32 percent (16) of the intervention group
patients and 19.23 percent (10) of the control group patients were educated at or
below a grade 6 level, which, according to the literature means they are
classified as patients with low literacy skills (Doak, Doak et al. 1996b). These
results indicate, therefore, that similar percentages of patients in both groups
were educated at or above a grade 10 level. Whereas more control group
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patients were educated between grade 7-9 levels, and considerably more
intervention group patients were educated at or below a grade 6 level. In other
words, the intervention group had a larger proportion of ‘high risk’ patients with
low literacy skills than did the control group.

Table 4: Educational levels of patient participants.
Educational
Percentage of
Percentage of
Level
intervention patient
control patient
participants
participants
(n=50)
(n=52)
Grade 1
2.00% (1)
0.00% (0)
Grade 2
6.00% (3)
0.00% (0)
Grade 3
4.00% (2)
0.00% (0)
Grade 4
8.00% (4)
1.92% (1)
Grade 5
4.00% (2)
1.92% (1)
Grade 6
8.00% (4)
15.38% (8)
Grade 7
8.00% (4)
3.85 % (2)
Grade 8
12.0% (6)
23.08% (12)
Grade 9
12.0% (6)
23.08% (12)
Grade 10
20.0% (10)
15.38% (8)
Tertiary
16% (8)
15.38% (8)

Percentage of total
patient participants
(N=102)
0.98% (1)
2.94% (3)
1.96% (2)
4.90% (5)
2.94% (3)
11.76% (12)
5.88% (6)
17.65% (18)
17.65% (18)
17.65% (18)
15.69% (16)

According to the data in table 4, the median grade educational level for the
intervention group was grade 8, and grade 9 for the control group. The mean
grade level for the intervention group was grade 7.94, and grade 8.83 for the
control group, assuming that patients educated at a tertiary level were educated
to an equivalent of a grade 13 level. The mode level of education for the
intervention group was grade 10, and grade 8 and 9 for the control group. It is
important to note, that 20 percent (10) of the intervention group patients, as
opposed to 46.16 percent (24) of the control group patients, achieved the modal
level of education. Even though the mode level of education was higher in the
intervention group than that for the control group, a much smaller percentage of
intervention group patients achieved the mode level of education than did the
control group patients.
A chi-squared test was used to analyse whether or not there was a
relationship between the two groups (i.e. intervention and control) and the
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patients’ level of education. The results of this chi-squared test found no
significant difference (p-value 0.2992), suggesting that there was no difference in
the patients’ level of education between the two groups. While these results
were found to be insignificant, a larger proportion of the intervention group
patients, as compared to the control group patients, were educated at or below a
grade 6 level (32 percent compared to 19.2 percent, respectively).

6.4.1.5 Ethnicity
Table 5 indicates that 14.7 percent (15) of the patient participants were
from non-English speaking backgrounds (NESB). Both the intervention (18
percent (9) and control (11.5 percent (6) groups had similar small numbers of
NESB patients. The nationalities represented by these NESB patients (n=15)
were: Greek, 20 percent (3); Croatian, 13.3 percent (2); Italian, 13.3 percent (2);
Turkish, 13.3 percent (2); German, 6.7 percent (1); Lebanese, 6.7 percent (1);
Macedonian, 6.7 percent (1); Maltese, 6.7 percent (1); Serbian, 6.7 percent (1)
and Spanish, 6.7 percent (1). No single nationality significantly outnumbered
another within the two groups.
Interestingly, seven of the nine NESB intervention group patients were
educated at or below a grade 4 level, whereas only one of the six NESB control
group patients was educated at or below grade 4 level. Overall, therefore, even
though both groups had similar numbers of NESB patients, the NESB
intervention group patients were less educated than the NESB control group
patients.

Table 5: Percentage of patient participants from non-English speaking
backgrounds.
Patient Participants
Non-English Speaking
English Speaking
Background (NESB)
Background
Intervention (n=50)
18% (9)
82% (41)
Control (n=52)
11.5% (6)
88.5% (46)
Total number of
participants (N=102)
14.7% (15)
85.3% (87)
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6.4.1.6 Source of referral
The results in table 6 show that the sources of referral for the patient
participants in both groups were similar. The hospital ward referrals to The
Ambulatory Care Team (TACT) for both groups significantly outnumbered the
emergency department and general practitioner referrals.

Table 6: Referral sources of patient participants.
Referral Source
Patient Participants Emergency
General
Department
Practitioner
Intervention (n=50)
26% (13)
20% (10)
Control (n=52)
19.2% (10)
17.3% (9)
Total number
22.6 % (23)
18.6% (19)
(N=102)

Hospital Ward
54% (27)
63.5 % (33)
58.8 % (60)

6.4.1.7 Referral diagnosis
The results in table 7 indicate that the most common referral diagnosis for
both the intervention and control group patients was deep venous thrombosis,
followed by atrial fibrillation. The table also shows that similar percentages of
patients in both groups were diagnosed with deep venous thrombosis, atrial
fibrillation and pulmonary embolus.

Table 7: Referral diagnoses of patient participants.

Patient
Participants
Intervention
(n=50)
Control
(n=52)
Total number
(N=102)

Referral Diagnosis
Pulmonary
Other
Embolus
(Transient Ischaemic
(PE)
Attacks, Cerebrovascular
Accident,
Cardiac Valve, Leg Stent)

Deep
Venous
Thrombosis
(DVT)

Atrial
Fibrillation
(AF)

46% (23)

24% (12)

16% (8)

14% (7)

36.5% (19)

32.7% (17)

9.6% (5)

21.2% (11)

41.2% (42)

28.4% (29)

12.8% (13)

17.65% (18)
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6.4.1.8 Carers and/or family members
Over half the participating patient population had a carer and/or family
member present during the initial warfarin education session (60 percent
intervention and 52 percent control). Interestingly, only five of the nine NESB
intervention group patients, as compared to five of the six NESB control group
patients, had a carer present during the education sessions.

6.4.1.9 Summary
In summary, the results of the demographic data indicate that overall the
intervention and control group patients had similar demographic variables. There
was an even distribution of males and females in the participating patient
population, with a large proportion of the patients classified as ‘high risk’ because
they were aged 65 years and over (62.8 percent), educated at or below grade 6
levels (25.5 percent) and/or came from non-English speaking backgrounds (14.7
percent). The patients in both groups were referred to The Ambulatory Care
Team (TACT) mainly from the hospital ward, with a variety of diagnoses, the
most common of which was deep venous thrombosis. Interestingly, over half of
the participating patient population had a carer and/or family member present
during the initial warfarin education session.
6.4.2 ‘Self-Management’ questionnaire (APPENDIX 17) results
The ‘Self-Management’ questionnaire (APPENDIX 17) adapted from Lorig
et al ‘Self-Efficacy Questionnaire’ (1996 page 41- 44), was used to evaluate the
patient participants’ perception about their ability to manage their warfarin
therapy at home, and to compare the scores between the intervention and
control groups. The scores for this questionnaire, which were completed
immediately and three months after the initial warfarin education session, were
combined to give a score out of 20. A score between 16 and 20 suggested that
the patient was highly confident, a score between 8 and 15 suggested that the
patient was moderately confident, and a score below 8 suggested that the patient
was not confident about managing their own warfarin therapy at home.
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To assess whether or not there was a difference in the ‘Self-Management’
questionnaire scores between the intervention and control groups, a mean score
for the ‘Self-Management’ questionnaire was calculated and then t-tests were
performed on these mean scores. As shown in table 8, the mean ‘SelfManagement’ questionnaire scores were higher for the intervention group
patients than the control group patients, immediately and after three months.
Results of the t-tests for the immediate scores (p-value 0.1727), and for the
three-month follow-up scores (p-value 0.207), indicate that they did not differ
significantly. In other words, both groups perceived that they were highly
confident about managing their warfarin therapy at home, immediately and three
months after the commencement of their warfarin therapy.
Table 8: t-test results comparing intervention and control group patients’
mean ‘Self-Management’ questionnaire scores immediately and three
months after the initial warfarin education session.
Self-Management Intervention patients’ Control patients
questionnaire
mean SM score
mean SM score
p-value
(n=50)
(n=52)
Immediate
19.08
18.44
0.1727
Three-month
19.90
19.73
0.2007
follow-up
(In the table ‘immediate’ = questionnaire completed immediately after the initial warfarin
education session; ‘three-month follow up’ = questionnaire completed three months later; SM =
Self-Management)

The results in table 8 also indicate that the mean ‘Self-Management’
questionnaire scores for both groups improved over the three-month period.
Paired t-tests were used to analyse whether or not the mean three-month followup ‘Self-Management’ questionnaire scores differed to the immediate mean
scores for each of the groups.
Table 9 shows that the mean ‘Self-Management’ questionnaire scores
were significantly different for both groups three months after the initial warfarin
education session, with a p-value equal to 0.0009*** for the intervention group
patients and a p-value equal to 0.0024** for the control group patients. Although,
the mean scores were not significantly different between the two groups, they
both significantly increased after three months of warfarin therapy. The

132

intervention group patients’ scores increased by approximately 0.82 and the
control group patients’ scores increased by 1.288. Both groups therefore,
perceived that their warfarin management at home had improved over the threemonth period.

Table 9: Paired t-test results comparing intervention and control group
patients’ ‘Self-Management’ mean scores immediately and three months
after the initial warfarin education session.
Difference between Lower Mean Upper Degrees of
t
p-value
mean SM scores
CL
CL
Freedom value
(SM1-SM2)
Mean
Mean
(df)
Intervention group
-1.285 -0.82 -0.355
49
-3.54 0.0009***
(SM1-SM2)
Control group
-2.097 -1.29 -0.479
51
-3.20 0.0024**
(SM1-SM2)
(In the table: SM1 = immediate ‘Self-Management’ questionnaire score; SM2 = three-month followup ‘Self-Management’ questionnaire score; CL = 95% confidence interval of the difference)

Upon completion of their ‘Self-Management’ questionnaire (APPENDIX 17),
all participating patients were asked to make comments about whether or not
they were worried about taking warfarin tablets. Similar comments were made by
patients in both groups expressing their concerns. These concerns related to
having to adjust their lifestyle behaviours (diet, alcohol intake and sporting
activities), recognising serious side effects, having to take the warfarin regularly
and undergoing regular blood tests. Examples of some of these immediate
comments included:
 Intervention 4 “..worried about side effects and blood tests…”
 Intervention 97 “ I’m worried because it is a heavy duty drug…”
 Control 5 “Worried about restrictions…”
 Control 113: “A little worried about adjusting habits…”
Other examples of comments made three months after the commencement of
warfarin therapy included:
 Intervention 97 “Don’t like taking warfarin…”
 Control 5 “Don’t want restrictive lifestyle…”
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Importantly, some of the initial concerns relating to lifestyle behaviours appear to
have been maintained over the three-month period.
In summary, even though the intervention group patients achieved higher
mean scores for their ‘Self-Management’ questionnaire, immediately and after
three months, t-tests found that these mean scores were not significantly
different. Paired t-test results, however, found that the mean scores for the ‘SelfManagement’ questionnaires for both groups improved significantly over the
three month period. This indicates that the patients in both groups perceived that
their warfarin management at home improved over time. Interestingly, the
comments expressed by patients in both groups reflected their concerns about
having to adjust their lifestyle behaviours while on warfarin medication, and these
concerns persisted over the three-month period.
6.4.3 ‘Medication-Taking Measures’ questionnaire (APPENDIX 18) results
The ‘Medication-Taking-Measures’ (MTM) questionnaire (APPENDIX 18)
is a validated scale designed to test medication compliance. A score of 4 is
considered high compliance, 3 moderate compliance, and 2 or less is low
compliance.
A summary of the ‘Medication-Taking-Measures’ (MTM) scores for the
questionnaires, completed immediately and three months after the initial warfarin
education session, is presented in table 10. The results in this table suggest that
even though similar trends in the MTM questionnaire scores were found for both
groups, the actual percentages and numbers of patients with low, moderate and
high compliance scores differ between the two groups. A higher proportion of the
intervention group patients, rather than the control group patients, achieved high
compliance scores for the immediate (62 percent versus 53.85 percent) and the
three month follow-up (80 percent versus 71.15 percent) MTM questionnaires.
These results imply that the new warfarin education program encouraged
patients to be more confident about their warfarin compliance, than did the
customary warfarin education program.
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Table 10: ‘Medication-Taking-Measures’ questionnaire scores for
intervention and control group patients immediately and three months after
the initial warfarin education session.
MTM Score
Low
Compliance

Intervention Control
Patients
Patients
(n=50)
(n=52)

Intervention
Patients
(n=50)

Control
Patients
(n=52)

(immediate)

(immediate)

(3-month follow-up)

(3-month follow-up)

30% (15)

23.08%
(12)

8% (4)

11.54% (6)

8% (4)

23.08%
(12)

12% (6)

17.31% (9)

62% (31)

53.85%
(28)

80% (40)

71.15% (37)

(MTM Score  2)

Moderate
Compliance
(MTM Score=3)

High
Compliance
(MTM Score=4)

(In the table: MTM Score = ‘Medication-Taking-Measures’ questionnaire score; immediate =
immediate scores after the initial warfarin education session; and 3-month follow-up = scores
achieved three months after the initial warfarin education session)

To ascertain whether or not there was a significant difference in the mean
MTM questionnaire scores for both groups, t-tests were performed. Table 11
shows the results of these t-tests. P-values equal to 0.7389 and 0.2592
respectively, for the immediate and the three-month follow-up scores, suggest
that the mean scores were not significantly different. Although the compliance
scores for both groups appeared to differ in table 10, the results in table 11
suggest that they were not significantly different. This means that the new
warfarin education program appeared to be equally as effective as the customary
warfarin education in encouraging patients to be confident about their warfarin
compliance.
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Table 11: t-test results comparing intervention and control group patients’
mean ‘Medication-Taking-Measures’ questionnaires scores immediately
and three months after the initial warfarin education session.
Patient
Mean MTM score
Mean MTM score
participants
intervention patients
control patients
p-value
(n=50)
(n=52)
Immediate
2.92
3.0192
0.7389
Three-month
3.7
3.5192
0.2592
follow-up
(In the table: Immediate = questionnaire completed immediately after the initial warfarin education
session; Three-month follow-up = questionnaire completed three months after initial warfarin
education session; MTM = ‘Medication-Taking-Measures’ questionnaire)

The results in table 11 also indicate that the MTM questionnaire scores
increased for both groups after three months of warfarin therapy. To assess
whether or not this increase over the three-month period was statistically
significant, a paired t-test was performed comparing the mean scores for each
group. The results of the paired t-tests are summarised in table 12 and indicate
that there was a significant difference between the immediate and three-month
follow-up mean MTM questionnaire scores for both groups. The p-value for the
intervention group patients was 0.0017** and the p-value for the control group
patients was 0.0243*. On average, the three-month follow-up mean MTM
questionnaire scores increased by 0.78 for the intervention group patients and
0.5 for the control group patients. Therefore, the paired t-tests for both groups
suggest that there was a significant improvement in the MTM questionnaire
scores over the three-month period. This means that the patients in both groups
became significantly more confident about their warfarin compliance over time.
Table 12: Paired t-test results comparing intervention and control group
patients’ ‘Medication-Taking-Measures’ mean scores immediately and three
months after the initial warfarin education session.
Difference between Lower Mean Upper Degrees
t
p-value
mean MTM scores
CL
CL
of
value
(MTM1-MTM2)
Mean
Mean
Freedom
(df)
Intervention group
-1.251 -0.78 -0.309 49
-3.33
0.0017**
(MTM1-MTM2)
Control group
-0.932 -0.50 -0.068 51
-2.32
0.0243*
(MTM1-MTM2)
(In the table: MTM1 = immediate ‘Medication-Taking-Measures’ questionnaire score; MTM2
=three-month follow-up ‘Medication-Taking-Measures’ questionnaire score; CL = 95% confidence
interval of the difference)
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Comments made by the patients in both groups on the completion of their
‘Medication-Taking-Measures’ questionnaire (APPENDIX 18) were also
comparable. Initially, the comments reflected their carelessness toward
medication compliance, especially when they had never taken regular medication
before. Some of these initial comments included:
 Intervention 19 “I’m a little careless and forgetful…”
 Intervention 28 “Have never had to take regular medicines before…”
 Control 9 “Never really taken medication before…”
 Control 54 “Always do what the doctor tells me to…”

The comments made three months later were mainly about forgetting to take
their warfarin tablets on a few occasions. Eighteen percent (9) of the intervention
group patients and 32.7 percent (17) of the control group patients commented on
how many times they had forgotten to take their warfarin during the three-month
period. These comments may be an indication that both groups of patients
understood the importance of good warfarin compliance and may have been
more diligent about their warfarin compliance. From their initial education
sessions, they also knew that they would be followed-up and that their INR blood
test results would be an objective measure of their true warfarin compliance
rates.
In summary, even though the trends for the ‘Medication-Taking-Measures’
(MTM) questionnaire (APPENDIX 18) scores were higher for the intervention
group patients than for the control group patients, both immediately and after
three months of therapy, t-tests ascertained that these scores were not
significantly different. There was, however, a significant improvement in the
‘Medication-Taking Measures’ (MTM) questionnaire scores for both groups over
the three-month period, suggesting that they had become significantly more
confident with their warfarin compliance over time. The patients’ comments
received during this time mainly reflected their fears about being careless or
forgetting to take their warfarin medication, which may also be representative of
their improved understanding about the importance of good warfarin compliance.
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6.4.4 ‘Warfarin Knowledge’ questionnaire (APPENDIX 19) results.
6.4.4.1 Introduction
The ‘Warfarin Knowledge’ questionnaire (APPENDIX 19) was used to
estimate the patients’ warfarin knowledge and understanding following the
education sessions. In the absence of a validated or reliable instrument in the
literature this questionnaire was drafted from several different warfarin studies
performed over the past three decades (Scalley, Kearney et al. 1979; Witte,
Gurwich et al. 1980; Wyness 1989), the ‘Warfarin Education Program Objectives’
(APPENDIX 14) and the contents of the new warfarin information booklet
(APPENDIX 12). The answers to the ‘Warfarin Knowledge’ questionnaire
(APPENDIX 19) were coded as True (for correct answers) and False (for
incorrect answers). Adding the number of correct responses in the questionnaire
gave a score out of 26. The ‘Warfarin Knowledge’ questionnaire scores were
then further subdivided into the following categories (score  22.0 excellent; 19.021.9 good; 16.0-18.9 average; 15.9 poor) to allow for a more meaningful
analysis and discussion.
6.4.4.2 t-test used to compare the mean ‘Warfarin Knowledge’ questionnaire
scores for the intervention and control groups
To establish whether or not there was a difference in the warfarin
knowledge scores between the intervention and the control groups, a t-test was
performed on the mean ‘Warfarin Knowledge’ questionnaire scores recorded
immediately and three months after initiation of warfarin therapy. The mean score
for the immediate ‘Warfarin Knowledge’ questionnaire for the intervention group
was 21.0 (80.8 percent) and 19.0 (73.0 percent) for the control group, both of
which were classified as good warfarin knowledge scores. A t-test indicated that
there was a significant difference in the scores between the groups with a pvalue equal to 0.0173*. This result identified that the intervention group patients
had a significantly higher immediate ‘Warfarin Knowledge’ questionnaire score
than did the control group patients. In other words, the new program improved
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the patients’ warfarin knowledge and understanding more so than did the
customary program, immediately after the initial warfarin education session.
The mean ‘Warfarin Knowledge’ questionnaire scores three months after
the initial warfarin education session was 18.04 (69.4 percent) for the intervention
group, and 17.04 (65.5 percent) for the control group. These results show a
deterioration in the mean ‘Warfarin Knowledge’ scores for both groups over the
three month period. Both the intervention and control group mean scores were
therefore reclassified, falling from good to average. A p-value equal to 0.1805 for
the t-test, used to compare the mean scores for both groups, indicated that there
was no significant difference between scores achieved by both groups after three
months. This demonstrates that, the initial positive influence of the new warfarin
education program on the patients’ warfarin knowledge and understanding had
become less significant over time.

6.4.4.3 Chi-Squared tests used to assess whether or not there was a relationship
between the patient group and the correct answer to questions in the ‘Warfarin
Knowledge’ questionnaire.
A chi-squared test was used to assess whether or not there was a
relationship between the patient group (intervention or control group) and the
correct answers for each of the questions in the ‘Warfarin Knowledge’
questionnaire (APPENDIX 19). The chi-squared test performed on the ‘Warfarin
Knowledge’ questionnaire completed immediately after the initial warfarin
education session produced p-values below 0.05 for the following six questions,
suggesting a relationship between the patient group (intervention or control) and
the correct answers to these questions.
 Q.1 Which brand of warfarin is prescribed for you? (p-value 0.0049**)
 Q.2. Why is the warfarin prescribed for you? (p-value 0.0262*)
 Q.7a. What should you do if you forget to take a dose of warfarin?
(p-value 0.0045**)
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 Q.8b. Can you suggest two things, which you could use to remind you
about taking your warfarin tablets (if necessary)?
(p-value 0.0012**)
 Q.11a What are FOUR signs of bleeding from too much warfarin?
(p-value 0.0149*)
 Q.15 Are there any foods which can affect how warfarin works?
(p-value 0.0122*)

The direction of the relationship between these questions and the patient
group is summarised in table 13, which shows that a larger proportion of the
intervention group patients correctly answered Questions 2, 7a, 8b, 11a and 15,
as compared to the control group patients. A greater proportion of the control
group patients, however, correctly answered Question 1. Initially, therefore, the
intervention group patients had a better understanding about: why warfarin was
prescribed for them; what to do if they forgot to take a dose of warfarin; how to
remind themselves about their warfarin dose; what side effects to look out for as
a result of too much warfarin; and which foods could interact with their warfarin
medication. The control group patients, on the other hand, were more
knowledgeable about the brand name of their warfarin medication.

Table 13 Percentage of intervention and control group patients to correctly
answer ‘Warfarin Knowledge’ (APPENDIX 19) questions 1, 2, 7a, 8b, 11a
and 15 immediately after the initial warfarin education session.
Question from the
Intervention patients
Control patients
‘Warfarin Knowledge’ (n=50) who answered (n=52) who answered
questionnaire
question correctly
question correctly
(APPENDIX 19)
Q.1
30% (15)
57.7% (30)
Q.2
94% (47)
76.9% (40)
Q.7a
72% (36)
42.3% (22)
Q.8b.
52% (26)
19.2% (10)
Q.11a
94% (47)
75% (39)
Q.15
92% (46)
73.1% (38)
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The chi-squared tests performed on the questions in the ‘Warfarin
Knowledge’ questionnaire completed after three months, found that only the
correct answer to one question differed significantly between the two groups.
This was Question 10 “What is your target INR blood test range?” with a p-value
of 0.008*. For this particular question, 72 percent (36) of the intervention group
patients, as compared to 44.2 percent (23) of the control group patients,
answered the question correctly. This means that a significantly greater
proportion of the intervention group patients knew what their therapeutic
International Normalised Ratio (INR) blood test ranges should be during their
warfarin treatment, as compared to the control group patients.

6.4.4.4 Two-way ANOVA test to assess whether or not there was a relationship
between the patients’ group, educational level and ‘Warfarin Knowledge’
questionnaire score.
Two-way ANOVA tests were used to determine whether or not the
patients’ warfarin knowledge scores, immediately and after three months were
affected by their group (i.e. intervention or control) and educational level. The
ANOVA test was used in place of the t-test because three variables; group,
educational level and warfarin knowledge score were being assessed in place of
two variables. The ANOVA test is more appropriate in this instance because it
can compare means between the two groups taking into account several factors.
The results from the two-way ANOVA tests produced a p-value equal to 0.0058*
immediately, and a p-value equal to 0.0278* for the three-month follow-up
scores. These results suggest that there was a significant difference between the
mean ‘Warfarin Knowledge’ questionnaire scores (calculated from the General
Linear Models (GLM) procedure for the Least Square Means), taking into
account their group (intervention or control) and their educational level, as per
Table 14. In other words, the more educated patients in both the intervention and
control groups achieved higher mean scores for their ‘Warfarin Knowledge’
questionnaires.
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Table 14: Summary of intervention and control group patients’ mean GLM
‘Warfarin Knowledge’ questionnaire scores immediately and three months
after the initial warfarin education session, based on education level.
Mean WK
Mean WK
Mean WK
Mean WK
score for
score for
score for
score for
Level of
intervention
control
intervention
control
Education
patients
patients
patients
patients
(n=50)
(n=52)
(n=50)
(n=52)
≤ Grade 6
Grade 7-9
≥ Grade 10

(immediate)

(immediate)

19.8 (16)
21.1 (16)
22.0 (18)

17.7 (10)
18.2 (26)
21.5 (16)

(3-month follow-up)

16.6 (16)
18.3 (16)
19.1 (18)

(3-mth follow-up)

15.0 (10)
16.0 (26)
20.0 (16)

(In the table: Mean scores were calculated from the General Linear Models (GLM) procedure for
the Least Square Means; WK = ‘Warfarin Knowledge’ questionnaire; immediate = WK scores
achieved immediately after the initial warfarin education session; 3-month follow-up= WK scores
achieved three months after the initial warfarin education session)

Based on the warfarin knowledge score classifications (WK scores  22.0
excellent; 19.0-21.9 good; 16.0-18.9 average; 15.9 poor), the results in table 14
indicate that immediately after the initial warfarin education session, the
intervention group patients educated at all three levels (i.e. ≤ grade 6, between
grade 7-9, and, ≥ grade 10) achieved higher mean scores than did the control
group patients educated at the same levels. The immediate score for the
intervention group patients educated at or below 9 levels, including those
educated at or below grade 6 levels, were good, compared to average for control
group patients educated at the same level. Similarly, the immediate mean score
for intervention group patients educated at or above grade 10 levels was
excellent, compared to good for control group patients in the same education
category. This indicates that the new warfarin education program was initially
more effective than the customary education program in educating patients from
all different educational backgrounds about their warfarin therapy and improving
their warfarin knowledge and understanding.
Table 14 also shows that after three months of warfarin therapy the mean
‘Warfarin Knowledge’ scores were much lower than the initial scores for both
groups. The mean scores for the intervention group patients educated at or
below grade 6 levels, and between grade 7-9 deteriorated to average scores,
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and the scores for those educated at or above grade 10 levels deteriorated to
good scores. The mean scores for the control group patients educated at the
different levels also deteriorated, with those educated at or below grade 6 levels
achieving poor scores, the lowest recorded for all patient participants. It could be
argued, therefore, that the customary warfarin education program did not
appropriately cater for the needs of the patients with low literacy skills (educated
at or below a grade 6 level), which is why their warfarin knowledge scores were
the lowest recorded.
Interestingly, the only mean scores for the ‘Warfarin Knowledge’
questionnaire achieved by the control group patients which were higher than
those achieved by the intervention group patients, were the three-month followup scores achieved by patients educated at or above grade 10 level (20.0 versus
19.1). Importantly, however, these scores were not significantly different which
means that both programs were equally effective at educating patients with
educational levels at or above grade 10 about their warfarin therapy.
Overall, therefore, the intervention group patients achieved higher mean
‘Warfarin Knowledge’ questionnaire scores than did the control group patients,
immediately and three months after the commencement of warfarin therapy. In
fact, the immediate scores were significantly higher for the intervention group
patients than they were for the control group patients. Not surprisingly, the more
educated patients in both groups achieved the higher mean warfarin knowledge
scores and those educated at or below a grade 6 level achieved the lowest mean
scores. The control group patients educated at or below a grade 6 level achieved
the lowest mean ‘Warfarin Knowledge’ questionnaire scores.
6.4.4.5 Paired t-tests used to compare the immediate ‘Warfarin Knowledge’
questionnaire score against the three-month follow-up ‘Warfarin Knowledge’
questionnaire score.
Paired t-tests were used to assess whether or not the deterioration in the
‘Warfarin Knowledge’ (WK) questionnaire scores over the three-month period for
both groups was significant. Table 15 provides a summary of the paired t-test
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results and suggests that there was a significant difference between the
immediate and three-month follow-up scores for both groups. The three-month
follow-up ‘Warfarin Knowledge’ questionnaire scores for the intervention group
patients were on average 2.9 marks lower than the immediate scores (p-value
less than 0.0001***). Similarly, the three-month follow-up scores for the control
group patients were on average 2.12 marks lower than the immediate scores (pvalue 0.0019*). Thus there was a significant deterioration in the mean ‘Warfarin
Knowledge’ questionnaire scores over the three-month period for both groups.
This deterioration in warfarin knowledge and understanding could have serious
implications for patients on long-term warfarin therapy.
Table 15: Paired t-test results comparing intervention and control group
patients ‘Warfarin Knowledge’ mean scores immediately and three months
after the initial warfarin education session.
Difference between Lower Mean Upper Degrees
t
p-value
WK scores
CL
CL
of
value
(WK1-WK2)
Mean
Mean Freedom
(df)
Intervention group
1.76
2.9
4.04
49
5.10
<0.0001***
(WK1-WK2)
Control group
0.82
2.12
3.41
51
3.28
0.0019**
(WK1-WK2)
(In the table: WK = ‘Warfarin Knowledge’ questionnaire; WK1 = immediate mean ‘Warfarin
Knowledge’ questionnaire score; WK2 = three-month follow-up mean ‘Warfarin Knowledge’
questionnaire score; CL = 95% confidence interval of the difference)

6.4.4.6 Summary
In summary, a number of tests were performed to evaluate the results of
the ‘Warfarin Knowledge’ questionnaire (APPENDIX 19). The results of t-tests
indicated that the new warfarin education program, used to educate the
intervention group patients, significantly improved warfarin knowledge and
understanding immediately after the initial warfarin education session, as
compared to the customary warfarin education program used to educate the
control group patients. This significant improvement, however, was not
maintained because there was no significant difference identified between the
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‘Warfarin Knowledge’ questionnaire scores achieved by both groups after three
months of warfarin therapy.
Chi-squared tests identified relationships between the patient group
(intervention or control) and the correct answers to several questions in the initial,
and only one question in the three-month follow-up ‘Warfarin Knowledge’
questionnaire. Compared to control group patients more intervention group
patients had a better understanding about: why warfarin was prescribed; how to
manage and improve warfarin compliance; how to recognise serious side effects;
and possible food interactions. A two-way ANOVA test also identified that the
more educated patients in both groups achieved higher mean scores for their
‘Warfarin Knowledge’ questionnaires. Finally, paired t-tests confirmed that the
three-month follow-up ‘Warfarin Knowledge’ questionnaire scores for both groups
were significantly lower than their immediate scores, suggesting that warfarin
knowledge had deteriorated over time.
Overall, therefore, the new warfarin education program improved the
patients’ warfarin knowledge and understanding, especially immediately after the
initial warfarin education session, more so than did the customary warfarin
education program. Notably, the low literacy skilled patients educated at or below
a grade 6 level, who received the customary warfarin education program,
achieved the lowest mean ‘Warfarin Knowledge’ questionnaire scores after three
months of warfarin therapy. This suggests that the new warfarin education
program, as compared to the customary warfarin education program, more
effectively improved warfarin knowledge and understanding in all patients,
including those with low literacy skills.
6.4.5 t-tests to compare the mean scores for the ‘Self-Management,’
‘Medication-Taking-Measures’ and the ‘Warfarin Knowledge’
questionnaires
6.4.5.1 Introduction
t-tests were used to evaluate whether or not a number of different factors
affected the mean scores for the ‘Self-Management’, ’Medication-Taking-

145

Measures’ and ‘Warfarin Knowledge’ questionnaires (Appendices 17-19)
immediately and three months after the initial warfarin education session. The
factors assessed included patient participants: having prior warfarin knowledge;
coming from non-English speaking backgrounds; being elderly (aged 65 years
and over); having a carer and/or family member present during the initial warfarin
education session; and seeking more warfarin information. The results of these ttests will now be discussed.
6.4.5.2 Comparing mean scores for the various questionnaires for participating
patients with and without prior warfarin knowledge
In order to establish whether or not prior warfarin knowledge affected the
mean ‘Self-Management’, ‘Medication-Taking-Measures’ and ‘Warfarin
Knowledge’ questionnaire scores immediately and three months after the initial
warfarin education session, t-tests were performed on each of these scores. The
t-tests were carried out on the scores of intervention and control group patients
with and without prior warfarin knowledge.
The results of these t-tests for the intervention group patients’ mean
questionnaire scores are summarised in table 16, which shows that no p-values
were below 0.05. Thirty percent (15) of the intervention group patients who had
prior warfarin knowledge, achieved mean scores for the ‘Self-Management’, the
‘Medication-Taking-Measures’ and the ‘Warfarin Knowledge’ questionnaires
which were not significantly different to the mean scores achieved by the 70
percent (35) of the intervention group patients who had no prior warfarin
knowledge. Thus, the intervention group patients with and without prior warfarin
knowledge were equally confident about their warfarin management and
compliance at home, and they had similar levels of warfarin knowledge and
understanding.
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Table 16: t-test results comparing mean scores for the ‘Self-Management’,
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires of
intervention group patients with and without prior warfarin knowledge
immediately and three months after the initial warfarin education session.
Mean score for
Mean score for
Questionnaire
intervention patients intervention patients
p-value
score
with prior warfarin
with no prior warfarin
knowledge (n=15)
knowledge (n=35)
SM score
19.133
19.057
0.8615
(immediate)

SM score

19.933

19.886

0.6488

2.6

3.0571

0.3603

3.8

3.6571

0.5002

20.333

21.229

0.4022

18

18.086

0.9418

(3-month follow-up)

MTM score
(immediate)

MTM score
(3-month follow-up)

WK score
(immediate)

WK score

(3-month follow-up)
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4); WK score =
‘Warfarin Knowledge’ questionnaire score (maximum score= 26); immediate = questionnaire
completed immediately after the initial warfarin education session and 3-month follow-up =
questionnaire completed three months after the initial warfarin education session)

Table 17 also shows that there were no p-values below 0.05 for the t-tests
carried out on mean scores for the control group patients with and without prior
warfarin knowledge. The 48.1 percent (25) of control group patients with prior
warfarin knowledge did not achieve significantly different mean scores to the
51.9 percent (27) of control group patients with no prior warfarin knowledge.
Therefore, the mean scores for the ‘Self-Management ’, ‘Medication-TakingMeasures’ and ‘Warfarin Knowledge’ questionnaires, completed immediately
and three months after the initial warfarin education session, were similar for the
control group patients with and without prior warfarin knowledge. Here again, the
control group patients with and without prior warfarin knowledge were equally
confident about their warfarin management and compliance at home, and they
had similar levels of warfarin knowledge and understanding.
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Table 17: t-test results comparing mean scores for the ‘Self-Management’,
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires of
control group patients with and without prior warfarin knowledge
immediately and three months after the initial warfarin education session.
Mean score for
Mean score for control
Questionnaire control patients with
patients with no prior
p-value
score
prior warfarin
warfarin knowledge
knowledge (n=25)
(n=27)
SM score
18.96
17.963
0.2022
(immediate)

SM score

19.56

19.889

0.1904

3.2

2.8519

0.3663

3.68

3.3704

0.2278

20

18.333

0.1492

17.16

16.889

0.8115

(3-mth follow-up)

MTM score
(immediate)

MTM score
(3-mth follow-up)

WK score
(immediate)

WK score

(3-mth follow-up)
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4); WK score =
‘Warfarin Knowledge’ questionnaire score (maximum score= 26); immediate = questionnaire
completed immediately after the initial warfarin education session and 3-month follow-up =
questionnaire completed three months after the initial warfarin education session)

The combined results for both groups, as shown in tables 16 and 17,
indicate that patients who had prior warfarin knowledge did not achieve
significantly different mean scores for any of the questionnaires, as compared to
the patients without prior warfarin knowledge. Hence, prior warfarin knowledge
did not seem to positively impact upon the patients’ confidence to manage or
comply with their warfarin therapy at home, nor did it improve warfarin
knowledge and understanding. Possibly the most important aspect of these
results is that even though the participating patients’ confidence about their
warfarin management and compliance improved over time, their warfarin
knowledge and understanding deteriorated over time.
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6.4.5.3 Comparing mean scores for the ‘Self-Management’ ‘Medication-TakingMeasures’ and the ‘Warfarin Knowledge’ questionnaires for participating patients
from English and non-English speaking backgrounds.
t-tests were used to evaluate whether or not coming from an English
speaking background or a non-English speaking background affected the mean
scores for the ‘Self-Management’, ‘Medication-Taking-Measures’ and ‘Warfarin
Knowledge’ questionnaires completed immediately and three months after the
initial warfarin education session. The t-test results for the intervention group
patients are summarised in table 18 and in table 19 for the control group patients.
As shown in table 18, the English speaking background intervention group
patients, as opposed to the non-English speaking background intervention group
patients, achieved higher mean scores for each of the ‘Self-Management’,
’Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires. The
only significant differences between the two were achieved for the immediate
‘Self-Management’ questionnaire score with a p-value of 0.0047**, and the
immediate ‘Warfarin Knowledge’ questionnaire score with a p-value of 0.0248*.
The English speaking background intervention group patients, as compared to
the non-English speaking background intervention patients, appeared to be more
confident about their warfarin management at home and had a better warfarin
knowledge and understanding immediately after their initial warfarin education
session. Notably, even though these results were expected, the small number of
non-English speaking background intervention group patients in this sample
(n=9) makes it difficult to draw any firm conclusions from the data.
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Table 18: t-test results comparing mean scores for the ‘Self-Management’,
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires of
intervention group patients from English and non-English speaking
backgrounds immediately and three months after the initial warfarin
education session.
Mean score for
Mean score for
Questionnaire
intervention patients
intervention patients
p-value
score
from English
from non-English
speaking
speaking backgrounds
backgrounds (n=41)
(n=9)
SM score
19.4
17.7
0.0047**
(immediate)

SM score

19.9

19.8

0.3361

3.1

2.3

0.229

3.7

3.6

0.4857

21.5

18.67

0.0248*

18.3

16.8

0.2608

(3-month follow-up)

MTM score
(immediate)

MTM score
(3-month follow-up)

WK score
(immediate)

WK score

(3-month follow-up)
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4); WK score =
‘Warfarin Knowledge’ questionnaire score (maximum score= 26); immediate = questionnaire
completed immediately after the initial warfarin education session and 3-month follow-up =
questionnaire completed three months after the initial warfarin education session)

Table 19 summarises the results for the control group patients. Again, the
English speaking background control group patients achieved higher mean
scores overall for each of the ‘Self-Management’, ’Medication-Taking-Measures’
and ‘Warfarin Knowledge’ questionnaires, than did the non-English speaking
background control group patients. In this instance, none of these questionnaire
mean scores were significantly different between the English speaking and the
non-English speaking background control patients. Based on the small number of
control group patients from non-English speaking backgrounds (n=6) however,
these results cannot be considered to be conclusive.
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Table 19: t-test results comparing mean scores for the ‘Self-Management’,
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires of
control group patients from English and non-English speaking
backgrounds immediately and three months after the initial warfarin
education session.
Mean score for
Mean score for control
Questionnaire
control patients from
patients from nonp-value
score
English speaking
English speaking
backgrounds (n=46)
backgrounds (n=6)
SM score
18.6
17.5
0.396
(immediate)

SM score

19.8

19.2

0.0899

3.1

2.5

0.337

3.5

3.8

0.3781

19.33

17.67

0.3614

17.4

14.0

0.0504

(3-month follow-up)

MTM score
(immediate)

MTM score
(3-month follow-up)

WK score
(immediate)

WK score

(3-month follow-up)
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4); WK score =
‘Warfarin Knowledge’ questionnaire score (maximum score= 26); immediate = questionnaire
completed immediately after the initial warfarin education session and 3-month follow-up =
questionnaire completed three months after the initial warfarin education session.)

In summary, tables 18 and 19 showed that English speaking background
patients in both the intervention and control groups achieved higher mean
scores overall for each of the questionnaires (Appendices 17-19), than did the
non-English speaking background patients. When tables 18 and 19 were
compared to each other, it was also identified that the non-English speaking
backgrounds intervention group patients, as compared to the non-English
speaking backgrounds control group patients, achieved higher mean scores for
the ‘Self-Management’ and ‘Warfarin Knowledge’ questionnaires (Appendices 17
and 19), immediately and after three months of warfarin therapy. On the other
hand, the non-English speaking background control group patients achieved
slightly higher mean scores for the immediate and three-month follow-up
‘Medication-Taking-Measures’ questionnaire scores. These results suggest that
the new warfarin education program improved the non-English speaking
background patients’ confidence about their warfarin management at home, as
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well as their warfarin knowledge and understanding, whereas the customary
warfarin education program improved the non-English speaking background
patients’ confidence with their warfarin compliance. Unfortunately, the number of
non-English speaking background patients, in both groups, was too small to
analyse statistically and conclusively.
6.4.5.4 Comparing mean scores for the ‘Self-Management’, ‘Medication-TakingMeasures’ and the ‘Warfarin Knowledge’ questionnaires for participating patients
aged above and below 65 years.
t-tests were used to analyse whether or not being elderly (aged 65 years
and over) affected the mean scores for the ‘Self-Management’, ‘MedicationTaking-Measures’ and ‘Warfarin Knowledge’ questionnaires. At first, the t-tests
were conducted on the mean scores achieved by all the patient participants in
both groups aged 65 years and over, and compared to the scores achieved by
all patient participants in both groups aged below 65 years. There were no
significant differences found for the mean scores of the ‘Self-Management’ and
‘Medication-taking-Measures’ questionnaires. However, there were significant
differences in the immediate and three-month follow-up ‘Warfarin Knowledge’
questionnaire mean scores.
The participating patients aged 65 years and over achieved an immediate
‘Warfarin Knowledge’ mean score of 19.16 (73.7 percent) and a three-month
follow-up score of 16.59 (63.8 percent). On the other hand, participating patients
aged below 65 years achieved an immediate mean score of 21.5 (82.7 percent)
and a three-month follow-up mean score of 19.105 (73.5 percent). The results of
the t-tests found a p-value equal to 0.0012** for the immediate scores, and a pvalue equal to 0.0014** for the three-month follow-up scores. These results are
indicative of the fact that the warfarin knowledge and understanding was poorer
in all participating patients aged 65 years and over, as compared to those aged
65 years and under.
To investigate possible differences in the questionnaire mean scores
within the two groups (intervention and control), further t-tests were performed.
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Firstly, t-tests were conducted on the mean scores of the intervention group
patients aged above and below 65 years of age and the results of these tests
are summarised in table 20. Secondly, t-tests were performed on the mean
scores of the control group patients aged above and below 65 years and the
results of this test are summarised in table 21.
Table 20: t-test results comparing mean scores for the ‘Self-Management’,
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires of
intervention patients aged above and below 65 years immediately and
three months after the initial warfarin education session.
Mean score for
Mean score for
Questionnaire
intervention
intervention patients
p-value
score
patients aged 65
aged below 65 years
years and over
(n= 16)
(n=34)
SM score
19.088
19.063
0.9608
(immediate)

SM score

19.912

19.875

0.7743

2.971

2.813

0.7484

3.735

3.625

0.5965

20.412

22.125

0.0991

17.0

20.313

0.0026**

(3-month follow-up)

MTM score
(immediate)

MTM score
(3-month follow-up)

WK score
(immediate)

WK score

(3-month follow-up)
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4); WK score =
‘Warfarin Knowledge’ questionnaire score (maximum score= 26); immediate = questionnaire
completed immediately after the initial warfarin education session and 3-month follow-up =
questionnaire completed three months after the initial warfarin education session.)

Table 20 shows that between intervention group patients aged above and
below 65 years, the only significant difference in scores was in the three-month
follow-up ‘Warfarin Knowledge’ questionnaire scores (p-value 0.0026**). In this
questionnaire, the results show that elderly intervention group patients (aged 65
years and over) achieved significantly lower scores than those intervention
group patients aged less than 65 years. This demonstrates that after three
months of warfarin therapy, elderly patients who have received the new warfarin
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education program had significantly less warfarin knowledge and understanding
than did their younger counterparts.
Table 21: t-test results comparing mean scores for the ‘Self-Management’,
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires of
control patients aged above and below 65 years immediately and three
months after the initial warfarin education session.
Mean score for
Mean score for
Questionnaire
control patients aged control patients aged p-value
score
65 years and over
below 65 years
(n=30)
(n=22)
SM score
18.967
17.727
0.1236
(immediate)

SM score

19.633

19.864

0.3484

3.233

2.727

0.1986

3.6

3.409

0.4642

17.733

21.045

0.0034**

16.133

18.227

0.0640

(3-month follow-up)

MTM score
(immediate)

MTM score
(3-month follow-up)

WK score
(immediate)

WK score

(3-month follow-up)
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4); WK score =
‘Warfarin Knowledge’ questionnaire score (maximum score= 26); immediate = questionnaire
completed immediately after the initial warfarin education session and 3-month follow-up =
questionnaire completed three months after the initial warfarin education session.)

Table 21 shows that between control group patients aged above and
below 65 years, the only significant difference was in the immediate ‘Warfarin
Knowledge’ questionnaire’ (p-value 0.0034**). These results suggest that the
elderly control group patients (aged 65 years and over) achieved significantly
lower mean scores than those control group patients aged below 65 years,
immediately after the initial warfarin education session. This demonstrates that
the elderly patients who received the customary warfarin education program had
significantly less warfarin knowledge and understanding than did the younger
patients from the initiation of their warfarin therapy.
Comparing tables 20 and 21 also identified that the mean scores achieved
by the elderly intervention group patients were, on the whole, higher than the
average mean scores achieved by the elderly control group patients. According
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to t-tests results, however, only the immediate ‘Warfarin Knowledge’
questionnaire scores were significantly higher for the elderly intervention group
patients compared to the elderly control group patients (p-value 0.0092**). This
demonstrates that the new warfarin education program, as compared to the
customary warfarin education program, significantly improved the elderly
patients’ warfarin knowledge and understanding immediately after the initial
warfarin education program. The higher mean scores achieved by the elderly
intervention group patients compared to the elderly control group patients for the
‘Self-Management’ and ‘Medication-Taking-Measures’ questionnaires, also
suggests that the new program was more effective than the customary program,
in promoting warfarin self-management and compliance at home for elderly
patients.
In summary, the elderly patient participants (aged 65 years and over)
achieved lower overall mean scores for the ‘Self-Management’, ‘MedicationTaking-Measures’ and ‘Warfarin Knowledge’ questionnaires, than did the patient
participants aged below 65 years. Statistical analysis, however, found that only
the elderly patient participants’ ‘Warfarin Knowledge’ questionnaire scores were
significantly lower than those of the younger patient participants. These results
demonstrate, that the customary warfarin education program was less effective
at educating the elderly patients than the younger patients from the beginning,
whereas the new warfarin education program lost its initial benefit over time.
Interestingly, the new warfarin education program, as compared to the customary
warfarin education program, was more effective at improving elderly patients’
warfarin knowledge and understanding, as well as their overall confidence with
warfarin management and compliance.
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6.4.5.5 Comparing mean scores for the ‘Self-Management’, ‘Medication-TakingMeasures’ and the ‘Warfarin Knowledge’ questionnaires for participating patients
with and without the presence of a carer and/or family member during the initial
warfarin education session.
t-tests were used to analyse whether or not having a carer and/or family
member present during the education session had an effect on the patients’
mean scores for the ‘Self-Management’, ‘Medication-Taking-Measures’ and
‘Warfarin Knowledge’ questionnaires (Appendices 17-19), completed
immediately and three months after the initial warfarin education session. Pvalues for both the intervention and the control groups were all above 0.05
indicating that there was no difference in results based on having a carer and/or
family member present during the initial warfarin education session. Nor did it
have an apparent effect on the patients’ confidence to manage and comply with
their warfarin therapy at home, or affect their warfarin knowledge and
understanding. However, this result does not provide any indication of the role of
the carer – whether those with a carer present were better off than those without
a carer present. It was not possible to address this question in the present study.
6.4.5.6 Comparing mean scores for the three-month follow-up ‘SelfManagement’, ‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’
questionnaires for patients seeking more warfarin information from their general
practitioners, medicines information telephone lines, the internet, etc.
In order to analyse whether or not the patients who had sought more
warfarin information achieved different mean scores for their ‘Self-Management’,
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires
(Appendices 17-19) compared to those who did not, t-tests were performed.
These t-tests were performed on the mean scores for each of these
questionnaires completed after three months of warfarin therapy (it was assumed
that they did not seek information before their initial warfarin education sessions).
The results for the intervention and control group patients, who did and didn’t
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seek more warfarin information, are summarised in tables 22 and 23,
respectively.
As shown in table 22 the only mean score which was significantly different
for the intervention group patients who sought more warfarin information
compared to those who did not was the ‘Warfarin Knowledge’ questionnaire (pvalue 0.0072**). Arguably the most interesting point to make here is that the
average mean ‘Warfarin Knowledge’ questionnaire score for the intervention
group patients who had sought more information was lower than the mean score
achieved by intervention group patients who did not. In reality, this result may
not be considered conclusive because of the small number of intervention group
patients who sought more warfarin information, 16 percent (8). Alternatively, it
may also reflect that the quality and readability of the warfarin information
available from these other sources is poor and/or incomprehensible, making
them more confused about their warfarin therapy.
Table 22: t-test results comparing the mean scores for the ‘SelfManagement’, ‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’
questionnaires of intervention group patients who sought more warfarin
information compared to those who did not.
Mean scores for
Mean scores for
Questionnaire
intervention patients
intervention patients
p-value
score
who sought more
who did not seek more
warfarin information
warfarin information
(n=8)
(n=42)
SM score
19.75
19.929
0.5053
(3-month follow-up)

MTM score

3.75

3.6905

0.8226

17.452

21.25

0.0072**

(3-month follow-up)

WK score

(3-month follow-up)
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4) and WK score =
‘Warfarin Knowledge’ questionnaire score (maximum score= 26))

Table 23 shows that the only significant difference in any of the mean
scores for the questionnaires completed by the control group patients, who did
and did not seek more warfarin information, was the ‘Medication-TakingMeasures’ (MTM) questionnaire (p-value 0.0004***). In this case, all 7.7 percent
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(4) of the control group patients who sought more warfarin information had a
perfect MTM score equal to 4, as compared to the mean MTM score of 3.4792
for the 92.3 percent (48) control group patients who did not seek more warfarin
information. Once again, given that only a small number of control group patients
actually sought more warfarin information and that the MTM mean scores were
representative of ‘high’ compliance scores in both instances, it cannot be
concluded that the patients who sought more warfarin information were truly
more confident about their warfarin compliance, than were patients who did not.
Table 23: t-test results comparing the mean scores for the ‘SelfManagement’, ‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’
questionnaires of control group patients who sought more warfarin
information compared to those who did not.
Mean scores for
Mean scores for
Questionnaire
control patients who control patients who
p-value
score
sought more warfarin
did not seek more
information
warfarin information
(n=4)
(n=48)
SM score
19
19.792
0.4874
(3-mth follow-up)

MTM score

4

3.4792

0.0004***

20.75

16.708

0.0534

(3-month follow-up)

WK score

(3-month follow-up)
(In the table: SM score = ’Self-Management’ questionnaire score (maximum score =20); MTM
score = ‘Medication-Taking-Measures’ questionnaire score (maximum score=4) and WK score =
‘Warfarin Knowledge’ questionnaire score (maximum score= 26))

Importantly, tables 22 and 23 indicate that only a small proportion of the
intervention group patients (16 percent (8)) and control group patients (7.7
percent (4)), actually sought more warfarin information. Therefore, it is not
possible to generalise that the results in these data are representative of the
general warfarin prescribed patient population. It could be argued, however, that
because both of the education programs were so effective and informative,
many patient participants did not feel the need to seek more warfarin
information.
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6.4.5.7 Summary
In summary, the results of the t-tests did not show a significant difference
in either of the groups for the ‘Self-Management’, ‘Medication-Taking-Measures’
or the ‘Warfarin Knowledge’ questionnaire scores when patient participants’ had
prior warfarin knowledge or when they had a carer and/or family member present
during the initial warfarin education session. Compared to English speaking
background patient participants, non-English speaking background patient
participants were found to have poorer warfarin knowledge and less confidence
with their warfarin management and compliance. The data indicated, however,
that the non-English speaking background patients who received the new
warfarin education program had a better understanding of their warfarin
knowledge and were more confident about their warfarin management, than were
the non-English speaking background patients who received the customary
warfarin education program. Similarly elderly patient participants (aged 65 years
and over) had poorer warfarin knowledge and less confidence with their warfarin
management and compliance, than did the younger patients. Here again, the
elderly intervention group patients who received the new warfarin education
program had a better understanding of their warfarin knowledge and were,
overall, more confident about their warfarin management and compliance, than
were elderly control group patients who received the customary warfarin
education program. The new warfarin education program, therefore, seemed to
be more effective than the customary warfarin education program at improving
these ‘high risk’ participating patients’ warfarin knowledge and understanding, as
well as confidence with their warfarin management and compliance.
Given the small number of patient participants who sought more warfarin
information, it is difficult to draw and real conclusions from the data. However, the
fact that so few patient participants did actually seek more warfarin information
may be an indication that both the new and the customary warfarin education
programs provided patients with sufficient warfarin information.
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6.4.6 ‘Satisfaction with Information about Medicines Scale’ (SIMS)
(APPENDIX 20) results
6.4.6.1 Introduction
The patients’ satisfaction with the warfarin information they were given
was measured with the established and validated ‘Satisfaction with Information
about Medicines Scale’ (SIMS) (APPENDIX 20)(Horne, Hankins et al. 2001).
Questions 1 - 9 were used to analyse the patients’ satisfaction with the
information they received about warfarin’s action and usage and questions 10 17 were used to analyse their response to the information they received about
warfarin’s potential problems. The following rating criteria were used:
a) too much
b) about right
c) too little
d) none received
e) none needed
6.4.6.2 Analysis of questions 1-9 of the ‘Satisfaction with Information about
Medicines Scale’ (SIMS) questionnaire.
Analysis of questions 1-9 of the SIMS data collected immediately after the
initial warfarin education session showed that both groups rated highly the
information they received for questions 1- 4, 6 and 8 of the scale, as per
APPENDIX 20. These questions refer to warfarin’s name, indication, action, and
duration of therapy. More than 90 percent of both groups rated the information
they received for these questions as about right (b). The ratings for questions 5,
7 and 9 of the questionnaire, however, varied somewhat and a summary of the
findings is listed below.
 Question 5 How long warfarin will take to act.
100 percent (50) of the intervention group patients and 86.5 percent (45) of
the control group patients felt that the information they received about
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question 5 was about right (b). However, 11.54 percent (6) of the control
group patients felt that too little information (c) was received, and 1.92 percent
(1) felt that no information had been received (d).
These results show that the intervention group patients were more
satisfied with the information they received about how long it takes for
warfarin to act.
 Question 7 How long you will need to be on your medicine.
92 percent (46) of the intervention group patients and 88.46 percent (46) of
the control group patients felt that they had received the right amount of
information (b) for question 7. However, 8 percent (4) of the intervention
group patients and 7.69 percent (4) of the control group patients felt that they
had received too little information (c), and, 3.85 percent (2) of the control
group patients felt that they had not received any information (d).
This shows that the intervention group patients appeared to be more
satisfied than the control group patients about the information received
regarding how long they would need to be on warfarin therapy.
 Question 9 How to get a further supply
86 percent (43) of the intervention group patients and 67.31 percent (35) of
the control group patients felt that they had received the right amount of
information (b) for question 9. However, 8 percent (4) of the intervention
group patients and 21.15 percent (11) of the control group patients felt that
they had received too little information (c), whereas 9.4 percent (2) of the
intervention group patients and 7.69 percent (4) of the control group patients
felt that they had received no information (d). Interestingly, 2 percent (1) of
the intervention and 3.85 percent (2) of the control group patients felt that
they hadn’t needed any information (e) about question 9.
Intervention group patients therefore appeared to be much more satisfied
than control group patients with the information about how to obtain further
supplies of warfarin tablets.
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Overall, for each of these initial SIMS (APPENDIX 20) warfarin action and
usage questions, the intervention group patients were more satisfied than the
control group patients about the information they received. It would be fair to say
however, that even though the satisfaction scores were high for both groups,
educating patients about: how long warfarin takes to work; how long warfarin
needs to be taken; and where to get further supplies, would help to improve
patients’ satisfaction with the current customary warfarin education program
given to TACT patients.
The three-month follow-up SIMS data found that 96 percent (98) of the 102
participating patients in both groups felt that all the information given to them
about warfarin’s action and usage (Questions 1-9 of APPENDIX 20) was about
right (b). This demonstrates that their satisfaction scores improved over time.
6.4.6.3 Analysis of questions 10-17 of the ‘Satisfaction with Information about
Medicines Scale’ (SIMS) questionnaire
Focus will now turn to Questions 10 - 17 of the data, which analysed
patients’ satisfaction with information they received about warfarin’s potential
problems. Once again, the overall results were high with over 90 percent of the
participating patients immediately - and over 95 percent of patients after three
months - describing the information they received for Question 12 to 15 in
APPENDIX 20 was about right (b). These questions referred to their satisfaction
with the information they received about: what to do if they experienced
unwanted side effects; whether or not they could drink alcohol while on warfarin
therapy; whether or not other medicines interacted with warfarin; and what they
should do if they forgot to take a dose.
The questions which did not highly satisfy the participating patients were
questions 10 and 11 initially, and questions 16 and 17 both initially and after
three months of warfarin therapy. The following is a brief summary of the
immediate satisfaction scores for questions 10 and 11 of the SIMS questionnaire
(APPENDIX 20).
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 Question 10 Whether the medicine has any unwanted effects (side
effects).
Ninety-eight percent (49) of intervention group patients and 88.46 percent
(46) of control group patients felt that they had received the right amount of
information (b) about side effects. However, 2 percent (1) of the intervention
and 9.62 percent (5) of the control group patients felt that they had received
too little information (c), and only one control patient or 1.92 percent,
indicated that no information had been received (d).
Intervention group patients were slightly more satisfied than the control
group patients with the initial information they received about warfarin’s side
effects.
 Question 11 What are the risks of you getting side effects?
Ninety-two percent (46) of the intervention group patients and 76.92 percent
(40) of the control group patients felt that they received the right amount of
information (b) about their risks of suffering side effects. However, 6 percent
(3) of the intervention group patients and 21.15 percent (11) of the control
group patients felt that they had received too little information (c), and one
intervention patient, or 2 percent, and one control patient, 1.92 percent,
indicated that they had not received any information (d) about the risk of side
effects.
Once again, intervention group patients appeared more satisfied than
control group patients about the information they received concerning the risk
of suffering from warfarin-related side effects.

More than 60 percent (72) of the participating patients were not satisfied with
the information referred to in Questions 15 and 16 of the SIMS questionnaire
(APPENDIX 20), either immediately or after three months of warfarin. The
satisfaction results were low, primarily because warfarin has no major effects on
drowsiness or normal heterosexual sexual behaviour and hence these issues
were not discussed during the education sessions. These results are not
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surprising because prior to the research study it was decided to use the SIMS
questionnaire (APPENDIX 20) in its entirety inclusive of these two questions
which were not considered to be highly relevant to warfarin therapy.

6.4.6.4 Chi-square test results and patient comments used to compare and
contrast the ‘Satisfaction with Information about Medicines Scale’ (SIMS)
questionnaire scores for both groups.
Chi-squared tests, in place of the inappropriate t-tests, were used to
identify significant differences between the two groups’ satisfaction scores for
questions 5, 7, 9, 10,11, 16 and 17 of the ‘Satisfaction with Information about
Medicines Scale’ (SIMS)(APPENDIX 20), identified above. A significant
difference in the scores was only identified for Question 5 with a p-value of
0.027*. Therefore, the intervention group patients’ satisfaction with the
information they received about how long it takes for warfarin to act was
significantly better than the control group patients’ satisfaction with this
information. It should be noted however, that this satisfaction score was
significantly better immediately, as compared to three months after the initial
warfarin education session. This shows that patients in the new warfarin
education program were more satisfied than those in the customary program with
information provided in the first education session about how long warfarin takes
to act.
Patients’ comments were once again encouraged during this data
collection period and, as a result, several comments were documented. These
comments were similar for both groups and reflected their satisfaction with being
educated at home and having the information reinforced in a simple and easy-tounderstand manner. Some examples of these comments included:
 Intervention 2 “Good to get info at home…”
 Intervention 28 “I like the simplicity of the booklet…”
 Control 16 “Boots booklet and information from TACT is extremely
useful and easy to understand…”
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 Control 16 “I found answering the questions reassured my
knowledge ..”

6.4.6.5 Summary
In summary, a key arbiter of the quality of medicines information given to
patients is the extent to which individuals perceive that it has met their needs and
they are satisfied (Horne, Hankins et al. 2001). Overall, the satisfaction scores
were high for both groups in relation to the information provided about warfarin’s
action, usage and potential problems. The ‘Satisfaction with Information about
Medicines Scale’ (SIMS)(APPENDIX 20) data however identified that the new
warfarin education program addressed the information about how long warfarin
will take to act significantly better than did the customary warfarin education
program.
6.4.7 ‘Outcome Measures of the Warfarin Education Program’ questionnaire
(APPENDIX 21) results
6.4.7.1 General practitioner visits
To identify whether or not general practitioner visits affected patients’
‘Self-Management’, ‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’
questionnaire scores, a correlation coefficient test was used. The correlation
coefficient test calculated whether or not there was a relationship between the
mean three-month follow-up questionnaire scores and the number of general
practitioner visits (a coefficient of 0 indicates no linear relationship between two
variables, whereas a coefficient of 1 indicates a linear relationship between two
variables). The general practitioner visits averaged about 7 visits per patient for
both the intervention and the control group patients. Interestingly however, the
general practitioner visits varied between 0 to 30 visits for the intervention
patients, and 2 to 16 visits for the control patients. The results of the correlation
coefficient test scores are summarised in table 24.
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Table 24: Pearson correlation coefficient scores assessing any relationship
between ‘Self-Management’, ‘Medication-Taking-Measures’ and ‘Warfarin
Knowledge’ questionnaire scores and the number of general practitioner
visits after three months.
Intervention Group
Control Group
Questionnaire
(n=50)
(n=52)
score
Pearson
Pearson
Correlation
Correlation
p-value
p-value
Coefficient
Coefficient
SM score
-0.14704
0.3082
-0.30512
0.0278*
(3-month follow-up)

MTM score

0.01807

0.9009

0.17809

0.2065

-0.04010

0.7822

-0.43277

0.0014**

(3-month follow-up)

WK score

(3-month follow-up)
(In this table: SM score = ‘Self-Management’ questionnaire score; MTM score = ‘MedicationTaking-Measures’ questionnaire score and WK score = ’Warfarin Knowledge’ questionnaire
score; 3-month follow-up = questionnaires scores three months after the initial warfarin education
session)

According to the results in table 24, only the control group’s ‘SelfManagement’ (SM) questionnaire scores (p-value 0.0278*) and ‘Warfarin
Knowledge’ questionnaire (WK) scores (p-value 0.0014**) had coefficients
significantly different to zero, three months after the initial warfarin education
session. In both these cases, even though correlations were poor, there was a
direct relationship between the ‘Self-Management’ and ‘Warfarin Knowledge’
questionnaire scores and the number of general practitioner visits. Interestingly,
the coefficients for both of these scores were negative, indicating a negative
relationship or a reduction in the mean scores for both questionnaires as the
number of general practitioner visits increased. In other words, as the number of
general practitioner visits increased for the control group patients, their
confidence with their warfarin management and their warfarin knowledge
deteriorated. A possible implication of this finding is that the control group
patients who had poor self-management skills and poorer warfarin knowledge
visited their general practitioners more frequently during the initial three months
of warfarin therapy.
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6.4.7.2 Hospital visits
Eighteen percent (9) of the intervention group patients and 21.2 percent
(11) of the control group patients visited hospital within the first three months of
their warfarin therapy. The reasons for hospital visits are listed below, with the
number of patients who presented from each group shown in brackets;
Intervention Patients (n=9)

Control Patients (n=11)

Atrial fibrillation (1)

Heart key hole surgery (1)

Chemotherapy (1)

Chemotherapy (2)

Chest pain (3)

Shortness of breath (1)

Osteomyelitis (1)

Surgical procedures (5)

Pain management (1)

Pacemaker inserted (1)

Surgical procedures (2)

Transient ischaemic attacks (1)

These results suggest that similar proportions of patients from both the
intervention and control groups visited hospital during their first three months of
their warfarin therapy for reasons which were not related to poor warfarin
therapeutic outcomes or warfarin-related adverse drug events.

6.4.7.3 Emergency department visits
Sixteen percent (8) of the intervention group patients and 11.54 percent
(6) of the control group patients visited the emergency department during the first
three months of their warfarin therapy. The reasons for their emergency
department visits are listed below with the number of patients from each group
once again represented in brackets;
Intervention Patients (n=8)

Control Patients (n=6)

Allergic reaction to antibiotics (1)

Asthma attack (1)

Atrial fibrillation (1)

Burst blood vessel in eye (1)

Chest pain (2)

Chest pain (1)

Minor bleeding (3)

Falls (2)

Shortness of breath (1)

Worried post stroke (1)
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Of the patients in both groups who presented to the emergency department
during the first three-month period, only 6 percent (3) of the intervention and 1.9
percent (1) of the control group patients had minor bleeds associated with
possible warfarin-related adverse events. In total therefore, 3.92 percent (4) of
the participating patients presented to the emergency department suffering from
minor bleeds potentially due to warfarin therapy which did not require
hospitalisation.

6.4.7.4 Warfarin-related adverse drug events
Very few patients in both groups reported any possible warfarin-related
adverse drug events. Six percent (3) of the intervention group patients and 4
percent (2) of the control group patients reported possible minor bleeding. All of
the intervention group patients reported to the emergency department for medical
advice, whereas only one of the two control group patients presented to the
emergency department for advice. Importantly, only 4.9 percent (5) of the patient
participants experienced minor possible warfarin-related adverse drug events
and none of them experienced major possible warfarin-related adverse drug
events during the three-month follow-up period.

6.4.7.5 Possible drug-to-drug interactions between warfarin and complementary
medicines
Twenty-four percent (12) of the intervention group patients and 19 percent
(10) of the control group patients were found to be taking complementary
medicines. Of the 21.6 percent (22) of participating patients who took
complementary medicines, approximately half of these (10) admitted that their
general practitioners were unaware of their use of complementary medicines. It
was only after having been shown the ‘Potential drug-to-drug warfarin interaction
sheet’ (APPENDIX 27) that they realised the possibility of an interaction and
agreed to either cease taking the complementary medicines or to continue taking
them after consultation with their general practitioners.
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6.4.7.6 International Normalised Ratio (INR) stability
The results indicated that there was an inconsistency in the number of
International Normalised Ratio (INR) blood tests processed per patient during the
three-month follow-up period. Even though participating patients in both the
intervention and control groups had an average of 11 INR blood tests, the range
of INR blood tests processed was between four and 26 over the three-month
period.
In order to evaluate the number of patients in both groups who had
achieved a therapeutic International Normalised Ratio (INR) score (within the
2.0-3.5 therapeutic range), their therapeutic INR scores were calculated as a
percentage of their total number of INR blood tests processed during the threemonth period. This calculation was used because of the inconsistent number of
blood tests processed per patient during the study period. The following formulae
were used to calculate the percentage of INR scores within therapeutic range
(INR=2-3.5) and outside therapeutic range (INR = <2 or >3.5).

The percentage of INRs = Total number of INR scores between 2 and 3.5
(within therapeutic range)
Total number of INR scores

The percentage of INRs = Total number of INR scores outside 2 and 3.5
(outside therapeutic range)
Total number of INR scores

Using these formulae it was found that on average, 71.86 percent of the
intervention group patients’ INR scores, and 69.42 percent of the control group
patients’ INR scores, were within therapeutic ranges: Thus, 28.14 percent of the
intervention group patients’ and 30.58 percent of the control group patients’ INR
scores were outside therapeutic ranges. These results suggest that patients who
received the new warfarin education program had a slightly higher percentage of
therapeutic INR scores during the initial three-month period of their warfarin
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therapy, than did the patients who received the customary warfarin education
program.
A t-test was then used to analyse whether or not there was a significant
difference in the percentage of therapeutic INR scores between the two groups.
A p-value of 0.5568 suggested that there was no statistically significant
difference in the percentage of intervention and control group patients’
therapeutic INR scores for the first three months of warfarin therapy.
A Pearson correlation coefficient test was used to investigate whether or
not there was a relationship between the percentages of INR scores inside and
outside the therapeutic range (INR=2.0-3.5) and the actual mean scores for the
‘Self-Management’, ‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’
questionnaires (Appendices 17-19). The results of these correlation coefficient
tests are summarised in tables 25 and 26 below.
Table 25 summarises the correlation coefficient test results used to
identify a relationship between the questionnaire scores and the percentage of
INR scores within therapeutic range. This table shows that after three months of
warfarin therapy, only the intervention group patients’ mean ‘Medication-TakingMeasures’ (MTM) questionnaire score (p-value 0.0328*) had a linear relationship
with the percentage of therapeutic INR scores (INR = 2.0 - 3.5). The positive
correlation coefficient for this score suggests that as the MTM questionnaire
scores increased, so too did the percentage of therapeutic INR scores. In other
words, as the intervention group patients’ confidence with their warfarin
compliance increased, so too did their percentage of therapeutic INR scores.
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Table 25: Pearson correlation coefficient results assessing any relationship
between the ‘Self-Management’, ‘Medication-Taking-Measures’ and
‘Warfarin Knowledge’ questionnaire scores and the percentage of
therapeutic INR results after three months
Percentage INR results within therapeutic range
(INR = 2.0 - 3.5)
Questionnaire
Intervention Group
Control Group
score
(n=50)
(n=52)
Pearson
Pearson
Correlation
p-value
Correlation
p-value
Coefficient
Coefficient
SM score
0.07542
0.6027
0.10190
0.4768
(3-month follow-up)

MTM score

0.30243

0.0328*

-0.14101

0.3237

0.00438

0.9759

-0.02418

0.8662

(3-month follow-up)

WK score

(3-month follow-up)
(In this table: SM score = ‘Self-Management’ questionnaire score; MTM score = ‘Medication Taking-Measures’ questionnaire score and WK score = ’Warfarin Knowledge’ questionnaire
score; the 3-month follow-up = questionnaire results three months after the initial warfarin
education session; therapeutic INR = 2.0 – 3.5)

Table 26 summarises the correlation coefficient test results used to
identify a relationship between the questionnaire scores and the percentage of
INR scores outside the therapeutic range. Not surprisingly, this table shows that
only the intervention group patients’ ‘Medication-Taking-Measures’ questionnaire
mean score had a linear relationship with the percentage of INR scores outside
the therapeutic range (p-value 0.0408*). The negative correlation coefficient in
this instance, suggested that as MTM questionnaire scores decreased the
percentage of INR scores outside the therapeutic range increased. Therefore,
when the intervention group patients’ confidence about their warfarin compliance
deteriorated, they experienced an increase in the percentage of INR scores
outside of the therapeutic range.

171

Table 26: Pearson correlation coefficient results assessing any relationship
between the ‘Self-Management’, ‘Medication-Taking-Measures’ and
‘Warfarin Knowledge’ questionnaire scores and the percentage of nontherapeutic INR results after three months.

Questionnaire
score

SM score

Percentage INR results outside therapeutic range
(INR<2.0 or > 3.5)
Intervention Group
Control Group
(n=50)
(n=52)
Pearson
Pearson
Correlation
p-value
Correlation
p-value
Coefficient
Coefficient
-0.07005
0.6288
-0.10190
0.4768

(3-month follow-up)

MTM score

-0.29040

0.0408*

0.14101

0.3237

-0.00747

0.9589

-0.07807

0.5860

(3-month follow-up)

WK score

(3-month follow-up)
(In this table: SM score = ‘Self-Management’ questionnaire score; MTM score = ‘Medication Taking-Measures’ questionnaire score and WK score = ’Warfarin Knowledge’ questionnaire
score; the 3-month follow-up = questionnaires results three months after the initial warfarin
education session; non-therapeutic INR = INR< 2.0 or >3.5)

The combined results of the Pearson correlation coefficient tests (Tables
25 and 26), show that as the intervention group patients’ confidence with their
warfarin compliance increased so too did their therapeutic INR scores (INR =
2.0-3.5). Therefore, as expected, the reverse was also true because as the
intervention group patients’ confidence with their warfarin compliance
deteriorated there was an increase in their percentage of INR scores outside the
therapeutic range (INR scores <2 and/or >3.5). Notably, however, the
percentage of therapeutic INR scores was relatively high for both groups, 71.86
percent for the intervention group and 69.42 percent for the control group. In
other words, both warfarin education programs empowered patient participants
with the knowledge and confidence to achieve good warfarin therapeutic control.
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6.5 Summary
In summary, according to the results of the readability tests the new
warfarin information booklet (APPENDIX 12) was much easier to read than the
Boots warfarin information booklet (2003) because it was written between a
grade 6 - 8 level as compared to a grade 8.9 –14 level. The higher scores for the
‘Suitability Assessment Materials’ (SAM) (Doak, Doak et al. 1985), the ‘Bernier
Instructional Design Scale’ (BIDS) (Bernier 1996) and the ‘Checklist for print
materials’ (Bidford Maine Area Health Education Center 1996) also indicated that
the new warfarin information booklet, as compared to the Boots warfarin
information booklet (2003), was a better quality booklet, produced at a higher
standard, catering for the needs of a wider patient population, inclusive of the
‘high risk’ group.
Data collection commenced in February 2003 and was completed within
12 months with a total of 102 of the 114 patient participants providing fully
completed questionnaires. Fifty intervention patients received the new warfarin
educational program and 52 control patients received the customary warfarin
education program delivered to warfarin-prescribed TACT patients. The
participating patients in both groups were referred to The Ambulatory Care Team
(TACT) from similar sources and for similar diagnoses, the most common of
which was deep venous thrombosis. Many of the participating patients came
from the ‘high risk’ patient population with: 62.8 percent (64) aged 65 years and
over; 25.5 percent (26) educated at or below a grade 6 level; and 14.71 percent
(15) coming from non-English speaking backgrounds.
Although the research data suggest that patients receiving the new
warfarin education program achieved higher mean scores than patients receiving
the customary warfarin education program in the ‘Self-Management’,
‘Medication-Taking-Measures’ and ‘Warfarin Knowledge’ questionnaires
(Appendices 17-19), statistical analysis found that only the immediate ‘Warfarin
Knowledge’ questionnaire scores were significantly better for those receiving the
new warfarin education program. The difference in the ‘Warfarin Knowledge’
questionnaire scores became less significant over time, with the scores
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significantly deteriorating for both groups over the three-month period of data
collection. Interestingly as ‘Warfarin Knowledge’ scores deteriorated in both
groups ‘Self-Management’ and ‘Medication-taking-Measures’ scores significantly
improved. This could have serious implications for patients on long-term warfarin
therapy because they may not have the warfarin knowledge and understanding
to achieve optimal therapeutic outcomes, even though they may feel confident
about their warfarin management and compliance at home.
The ‘high risk’ patients in both groups which included - the elderly (aged
65 years and over), those with low literacy skills (education at a level ≤ grade 6)
and those from non-English speaking backgrounds - achieved lower mean
scores than other participants for the ‘Self-Management’, ‘Medication-TakingMeasures’ and the ‘Warfarin Knowledge’ questionnaires. However, the trend in
the data found that intervention group ‘high risk’ patients achieved higher mean
scores for these questionnaires than did the control group ‘high risk’ patients.
These results, and especially the higher mean scores for the immediate ‘Warfarin
Knowledge’ questionnaire, suggest that the new warfarin education program
more effectively educated the ‘high risk’ patients about their warfarin therapy.
Although data from the ‘Satisfaction with Information about Medicines
Scale’ (SIMS) (APPENDIX 20) showed that all patient participants were highly
satisfied with the warfarin information they received, the intervention group
patients were more satisfied with the information they received about how long
warfarin will take to act than were the control group patients.
Similar results for both groups of patients were achieved for the outcome
measures during the three-month follow-up period. Both groups had similar
numbers of general practitioner, hospital, and emergency department visits, with
only a small percentage of patients (4.9 percent) experiencing minor possible
warfarin-related adverse drug events. The high percentage of therapeutic INR
scores (INR = 2 and 3.5) for both groups are indicative of the effectiveness of
both education programs in empowering the patient participants with the
knowledge and confidence to achieve good therapeutic control.
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Overall, therefore, the new warfarin information booklet (APPENDIX 12)
was written in a better quality, easier-to-read format, than was the Boots warfarin
information booklet (2003). Comparing and contrasting the new warfarin
education program against the customary warfarin education program found that
it was more effective in terms of improving the patients’ warfarin knowledge,
management and compliance, knowing when to look for medical assistance, as
well as improving their overall satisfaction with the information received. Similar
results were also found for the ‘high risk’ patients, including the elderly, those
with low literacy skills and those from non-English speaking backgrounds.
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CHAPTER 7
Discussion, Limitations and Recommendations

7.1 INTRODUCTION
For almost two decades, the efficacy of warfarin education programs has
been the subject of significant debate. Fifteen years ago, Wyness (1989)
examined the need for clear program design and, some nine years later, Haines
(1998) proposed a more structured education program for better outpatient
anticoagulant management. It appears that such calls for a more structured
education program have been largely ignored. This is evident in the everincreasing reports of warfarin knowledge deficiencies in patients prescribed
warfarin, and particularly the ‘high risk’ patients (Cheah and Martens 2003;
Lambert and Wynne 2003; Nadar, Begum et al. 2003; Tang, Lai et al. 2003;
Wilson, Racine et al. 2003).
The research study, therefore, focused on developing and evaluating a
new, home based warfarin education program to help improve warfarin
knowledge, management and compliance in a wider patient population, inclusive
of the ‘high risk’ group. This ‘high risk’ group includes the elderly, those with low
literacy skills and those from non-English speaking backgrounds. The conceptual
framework for the new program incorporated interventions and strategies which
targeted the five key elements of an effective patient education program.
Importantly, this framework can be used as a blueprint for other patient
medication education programs in both hospital and community settings.
The impact of this new warfarin education program was compared and
contrasted with the customary home-based warfarin education program used by
The Ambulatory Care Team (TACT) at Illawarra Health. Evaluations included
comparing and contrasting the participating patients’ warfarin knowledge and
understanding, as well as their ability to manage and comply with their warfarin
therapy at home. Warfarin knowledge was evaluated using the ‘Warfarin
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Knowledge’ questionnaire (APPENDIX 19) and the participants’ ability to manage
and comply with warfarin therapy at home was evaluated using the ‘SelfManagement’ and ‘Medication-Taking-Measures’ questionnaires (APPENDIX 17
and 18). Patient participants’ satisfaction with the warfarin information they
received was measured by using the ‘Satisfaction with Information About
Medicines Scale’ (SIMS) (APPENDIX 20), and outcome measures (therapeutic
INR scores and healthcare visits) were used as objective measures to analyse
and compare the effectiveness of both programs.
This chapter discusses the data in relation to the patient participants’
warfarin knowledge, management and compliance, as well as their therapeutic
outcomes based on the interventions and strategies used in the conceptual
framework. The five key elements targeted by interventions and strategies in the
conceptual framework included: health professional/patient communication and
partnerships; warfarin compliance; simple, easy-to-read warfarin information; the
continuity of care between hospital and community settings; and patient followup. The impact of the new warfarin education program was assessed both
generally across the wider population and more specifically in respect to the ‘high
risk’ patient populations. Based on the results of the study recommendations are
made for both current and future practice in patient warfarin education programs.
Finally, limitations are acknowledged and conclusions are drawn from the study
results and, when necessary, from evidence available in the literature.
The implications of this study are that the incorporation of the five key
elements of an effective patient education program into a warfarin education
program will benefit all patients, including those from the ‘high risk’ group. These
patients will be empowered to confidently manage and comply with their warfarin
therapy because of their improved warfarin knowledge, which in turn will help
them to optimise their therapeutic outcomes and minimise adverse drug events.
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7.2 OVERVIEW OF THE PARTICIPATING PATIENTS’ WARFARIN
KNOWLEDGE AND UNDERSTANDING, RESULTING FROM THE WARFARIN
EDUCATION PROGRAMS.

7.2.1 Introduction
From an educational perspective, good knowledge and understanding of
warfarin therapy underpins optimum therapeutic outcomes (Barcellona, Contu et
al. 2002) and a reduction in warfarin-related adverse drug events (Kagansky,
Knobler et al. 2004). Inadequacies in existing warfarin education programs
(Connor 1998) and consequent patient knowledge deficiencies (Cheah and
Martens 2003; Tang, Lai et al. 2003), highlight the urgent need for a new more
effective warfarin education program.
The new education program developed and tested in this research study
was based on five aforementioned key elements of education. These methods
were incorporated with the specific aim of improving warfarin knowledge and
understanding. However, during the course of the study, several of these specific
strategies and interventions were also incorporated into the customary warfarin
education program following directions from the area health service
management. This unforeseen action was out of the control of the researcher. It
had the potential to affect findings of the research, particularly the overall
patients’ warfarin knowledge and understanding results. However, because many
of these intervention were perceived to be best practice with the potential to
reduce the incidence of adverse drug events and improve overall therapeutic
outcomes (Australian Council for Safety and Quality in Health Care 2002;
Bhasale, Miller et al. 1998; Mullen, Simons-Morton et al. 1997), the area health
service management recommended that they be included into the customary
practice for TACT.
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7.2.2 Participating patients’ warfarin knowledge and understanding
Data from the ‘Warfarin Knowledge’ questionnaires (APPENDIX 19)
indicate that higher mean scores were achieved by the intervention group
patients compared to the control group patients. The initial mean scores were
21.0 (80.8 percent) for the intervention group patients versus 19.0 (73 percent)
for the control group patients. After three months, the mean scores were 18.04
(69.4 percent) for the intervention group patients and 17.04 (65.5 percent) for the
control group patients. These results suggest that the new warfarin education
program educated patients and improved their warfarin knowledge and
understanding more effectively than the customary warfarin education program.
Shortcomings in current warfarin education programs are evident in the
literature which has identified that patients prescribed warfarin often have
deficiencies in their warfarin knowledge (Cheah and Martens 2003; Lambert and
Wynne 2003; Roche-Nagle, Chambers et al. 2003; Tang, Lai et al. 2003). In the
absence of a validated warfarin knowledge questionnaire, each of these studies
used a different instrument to measure the patients’ warfarin knowledge, making
it difficult to compare them against each other and against the data collected in
this research study. The average percentage of correct warfarin knowledge
answers achieved by the intervention and control group patients in this study,
both initially (80.8 percent intervention and 73.0 percent control) and after three
months (69.4 percent intervention and 65.5 percent control), were higher than the
46.9 percent achieved by patients in a study by Cheah et al (2003), the 48
percent achieved in a study by Tang et al (2003) and the 61.1 percent achieved
in study by Nadar et al (2003). These results suggest that the new warfarin
education program more effectively educated patients and improved their
warfarin knowledge and understanding, than not only the customary warfarin
education program but also many other available warfarin education programs.
Further studies need to be undertaken, using a common warfarin knowledge
questionnaire, to contrast the effectiveness of the new warfarin education
program with other warfarin education programs, available in both Australia and
overseas.
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Another explanation for the improved warfarin knowledge and
understanding of the patient participants in both the intervention and control
groups of this study is that they had to complete the warfarin knowledge
questionnaires on two occasions during the study. On both occasions,
immediately and after three months of warfarin therapy, when and if they
answered a question incorrectly, their answers were documented and the correct
answers were reinforced. The higher than average warfarin knowledge scores
and therapeutic INR scores achieved by patients in both groups, as well as
comments such as “I found answering the questions reassured my knowledge”
concur with the results of a recent study (Barcellona, Contu et al. 2002) which
found that patients who completed a warfarin knowledge questionnaire spent
more time in the therapeutic range. A recommendation based on these results is
that a standardised warfarin knowledge questionnaire should be developed and
completed by all patients receiving warfarin education. Not only would the
questionnaire help to reinforce warfarin information, it would also help to identify
deficits in the patients’ knowledge, which could then be addressed by the
educating health professional.
Further analysis of the data collected from the initial ‘Warfarin Knowledge’
questionnaire found that the intervention group patients had a better knowledge
and understanding of certain aspects of their warfarin therapy, than did the
control group patients. These findings suggest that the new program, more so
than the customary program, improved the intervention patients awareness about
why their warfarin was prescribed, how to manage missed doses and how to
recognise side effects and possible drug and/or food interactions with their
warfarin.
Pharmacists, nurses, medical practitioners and carers should be aware of
the difference between the reality of what the patient actually knows and what the
patient thinks they know (Barat, Andreasen et al. 2001). It is important to
understand that patients can be overwhelmed by the information they receive
and often forget what has been communicated to them (Ansell, Buttaro et al.
1997). The intervention and control group patients’ deterioration in warfarin
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knowledge over the three-month follow-up period agrees with the literature
reporting warfarin knowledge deficits following discharge from hospital
(MacDonald 1998). These results highlight the importance of continuous
reinforcement of warfarin information (Haynes, McDonald et al. 2002a) which
according to the data should occur every three months.
In summary, based on the ‘Warfarin Knowledge’ questionnaire
(APPENDIX 19) data, it would appear that the new warfarin education program is
better placed than the customary and other available warfarin education
programs to improve patients’ warfarin knowledge and understanding. The new
program has provided patients with a better understanding about why warfarin
was prescribed for them, possible drug and/or food interactions, how to manage
missed doses and which side effects to look out for. According to the overall high
warfarin knowledge scores achieved by all the patient participants, a
recommendation has been made to develop a standardised warfarin knowledge
questionnaire to be completed by all patients prescribed warfarin, which will help
to reinforce and reassure them about their warfarin information. The significant
deterioration in patients’ warfarin knowledge over time highlights the importance
of continuous patient follow-up and information reinforcement.
7.2.3 ‘High risk’ patients’ warfarin knowledge and understanding

7.2.3.1 Introduction
The patient populations at ‘high risk’ of experiencing poor warfarin-related
therapeutic outcomes and adverse drug events because of poor warfarin
knowledge and understanding include the elderly, those with low literacy skills
(Lambert and Wynne 2003; Tang, Lai et al. 2003) and people from non-English
speaking backgrounds (Nadar, Begum et al. 2003). The research study’s
participating patient population had a good representation of these ‘high risk’
patient population with 62.74 percent (64) of the patients aged 65 years and
over, 25.5 percent (26) educated at or below grade 6 level, and 14.7 percent (15)
coming from non-English speaking backgrounds.
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7.2.3.2 Warfarin knowledge and the elderly patient participants
Poor quality warfarin education is a common risk factor for poor warfarinrelated therapeutic outcomes and adverse drug events among the elderly
(Kagansky, Knobler et al. 2004). Current warfarin education programs do not
cater for elderly patients, aged 65 years and over, who typically score poorly, or
less than 50 percent for their warfarin knowledge questionnaire scores (Cheah
and Martens 2003; Lambert and Wynne 2003; Tang, Lai et al. 2003).
Interestingly, in this study the mean scores for the ‘Warfarin Knowledge’
questionnaire achieved by the elderly patient participants in both groups were
higher than the 50 percent average reported in the literature (Cheah and Martens
2003; Tang, Lai et al. 2003).
The elderly intervention group patients initially scored 20.4 (78.5 percent)
out of a possible 26, compared to the elderly control group patients who scored
17.7 (68.2 percent) for their ‘Warfarin Knowledge’ questionnaire. After three
months of therapy, the elderly intervention group patients scored 17.0 (65.4
percent), compared to the elderly control group patients who scored 16.1 (62.05
percent). These results suggest that even though the new program more
effectively improved warfarin knowledge in the elderly patients than did the
customary program, both programs improved warfarin knowledge and
understanding in elderly patients more so than did other available warfarin
education programs.
Notably, the deterioration in warfarin knowledge scores over the threemonth period in the study was more significant for all the elderly participating
patients than it was for the younger participating patients, aged below 65 years.
Not only does this agree with evidence in the literature (Lambert and Wynne
2003; Taylor, Ramsay et al. 1994) but it also highlights the need to provide
elderly patients with regular follow-up and reinforcement of their warfarin
information.
These results suggest that the new warfarin education program more
effectively improved warfarin knowledge and understanding in elderly patients,
than did the customary warfarin education program. Importantly however, both
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programs appear to be more effective at improving warfarin knowledge and
understanding in elderly patients compared to other available warfarin education
programs. To confirm this possibility further studies with a much larger sample
size of elderly patients would need to conducted, comparing the new warfarin
education program to other available warfarin education programs.

7.2.3.3 Warfarin knowledge and patient participants with low literacy skills
According to the literature a significant relationship exists between the
patients’ literacy level and warfarin knowledge (Barcellona, Contu et al. 2000;
Estrada, Martin-Hryniewicz et al. 2004; Wilson, Racine et al. 2003). It is not
surprising therefore, that all patient participants educated at or above grade 10
levels achieved the highest mean scores for the ‘Warfarin Knowledge’
questionnaires and those educated at or below grade 6 levels achieved the
lowest mean scores.
Overall, the intervention group participants with low literacy skills
(educated at or below a grade 6 level) achieved higher mean scores for the
‘Warfarin Knowledge’ questionnaire, than did the control group patients with low
literacy skills, both initially (19.8 versus 17.7); and after three months of warfarin
therapy (16.6 versus 15.0). Importantly, there were more intervention group
patients with low literacy skills (n = 16) than there were control group patients
with low literacy skills (n = 10), which may have negatively impacted on the final
results. This means that the final results may not be a true indication of the
positive impact of the new warfarin education program on warfarin knowledge of
patients with low literacy skills. Based on the study results however, it could be
suggested that the new warfarin education program more effectively educated
patients with low literacy skills about their warfarin therapy, than did than the
customary warfarin education program. Further studies examining the impact on
warfarin knowledge of this new program, for a much larger sample size of
patients with low literacy skills, would need to be undertaken to verify this
possibility.
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7.2.3.4 Warfarin knowledge and patient participants from non-English speaking
backgrounds
Recent studies have found that non-English speaking background (NESB)
patients have significant gaps in their warfarin knowledge (Nadar, Begum et al.
2003; Wilson, Racine et al. 2003). The results of this study suggest that the
needs of the NESB patients are being met to some degree by the new warfarin
education program, as compared with the customary warfarin education
program. The NESB intervention group patients achieved higher mean scores for
the ‘Warfarin Knowledge’ questionnaire than did the NESB control group
patients, both initially (18.7 versus 17.7), and after three months of warfarin
therapy (16.8 versus 14.0). These results suggest that the new program, more so
than the customary program, improved warfarin knowledge in the NESB patients.
It cannot be denied, however, that these results were based on a small sample
size of NESB patient participants (n=14) in total. Further investigations on a
much larger sample size of NESB patients would therefore need to be conducted
to assess the true impact of the new warfarin education program on warfarin
knowledge of NESB patients, as compared to other available warfarin education
programs.
Interestingly, only 5 of the 9 NESB intervention group patients, compared
to 5 of the 6 NESB control group patients, had a carer and/or family member
present during the initial warfarin education session. In view of the fact that
carers and/or family members can help with overcoming possible language and
cultural barriers (Davidhizar and Brownson 1999; Minas, Lambert et al. 1996), it
is even more impressive that the NESB intervention group patients still managed
to achieve higher mean warfarin knowledge scores than did the NESB control
group patients.

7.2.3.5 Summary
The data implied that compared to the customary warfarin education
program, the new warfarin education program more effectively improved warfarin
knowledge in the ‘high risk’ group, which included the elderly, those with low
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literacy skills and those from non-English speaking backgrounds. The data also
suggested that the mean warfarin knowledge scores achieved by the ‘high risk’
patients in both groups were higher than the mean score of 50 percent achieved
by patients from the general population in other recent studies (Cheah and
Martens 2003; Tang, Lai et al. 2003). Unfortunately, this cannot be stated
conclusively because the other studies used different warfarin knowledge
questionnaires. Further research is needed, therefore, on a much larger sample
size of patients from the ‘high risk’ group, to test the effectiveness of the new
warfarin education program against other available warfarin education programs,
with regard to improving warfarin knowledge and understanding.
7.2.4 Summary of the participating patients’ warfarin knowledge and
understanding
The research study focused on developing a new structured home-based
warfarin education program to help improve warfarin knowledge and
understanding in a wider patient population, inclusive of the ‘high risk’ group. This
new program, based on a conceptual framework targeting five key elements, was
then compared and contrasted with the customary warfarin education program
delivered to patients admitted to Illawarra Health’s The Ambulatory Care Team.
The higher mean scores for the ‘Warfarin Knowledge’ questionnaires
(APPENDIX 19) achieved by the intervention group patients, compared to the
control group patients, suggests that the new warfarin education program more
effectively educated patients, including the ‘high risk’ patients, about their
warfarin therapy. In fact, based on the high mean scores achieved by all the
patient participants, it could be argued that both warfarin education programs
more effectively improved warfarin knowledge and understanding than do other
available warfarin education programs. Notably, the ‘Warfarin Knowledge’
questionnaire used in this study differed to the questionnaires used in other
studies (Cheah and Martens 2003; Nadar, Begum et al. 2003; Tang, Lai et al.
2003) making it difficult to state categorically that the new warfarin education
program was the most effective. Therefore, further research, using a
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standardised warfarin knowledge questionnaire is recommended to compare and
contrast the effectiveness of the new program with other available programs.
An important finding of the research study was the deterioration in warfarin
knowledge for patients in both groups, and especially elderly patients, over the
three-month period. This in itself highlights the need to continuously follow-up
and reassure patients about their warfarin therapy, especially if they are elderly
and on long-term therapy. Based on the results of this study it is recommended
that warfarin information be reinforced every three months.
With the inadequacies in current warfarin education programs (Connor
1998) leading to gaps in patients knowledge (Cheah and Martens 2003; Lambert,
Stoll, Singy, Zobel, Molina and Guex 1999; Nadar, Begum et al. 2003), and in the
absence of a best practice model for home-based warfarin education programs, it
would be reasonable to recommend the new program as a best practice model
for an effective warfarin education program. Importantly, this new home-based
program could be readily adapted to other hospital and community based
settings.

7.3 HEALTH PROFESSIONAL/PATIENT COMMUNICATION AND
PARTNERSHIPS

7.3.1 Background
Poor health professional/patient communication and partnerships have
been identified as major contributors to poor warfarin-related therapeutic
outcomes and adverse drug events (Bhasale, Miller et al. 1996; Gandhi,
Weingart et al. 2003). The patient populations most likely to have problems with
communication and establishing partnerships include the elderly, those with low
literacy skills and patients from non-English speaking backgrounds (Bhasale,
Miller et al. 1998).
The new warfarin education program placed special emphasis on the
improvement of patient/health professional partnerships and communication to
help patients make educated decisions about their warfarin compliance and
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management. Interventions of an administrative nature included: one-on-one
education sessions with the patients and/or their carers at home; follow-up;
communication directly with the patients, their carers and allied health
professionals; as well as availing the patients of other important resources (for
example interpreters for non-English speaking background patients, blister packs
for the elderly). Other interventions of a more abstract nature included: ensuring
that the home environment was conducive to learning by making certain that all
televisions, radios and stereo players were turned off; speaking in an
encouraging, reinforcing and reassuring manner; asking lots of questions; and
encouraging feedback from the patients and/or their carers.
The Ambulatory Care Team (TACT) staff members were also keen to
incorporate many of these interventions, to help improve health
professional/patient communication and partnerships, into the customary warfarin
education program. The very nature of the service provided by TACT and the
pride of the team members in providing an excellent service, meant that
professionally it was inevitable that these interventions would be incorporated in
the customary program. This dynamic made it very difficult to compare the
customary warfarin education program with the new warfarin education program
and could be viewed as a limitation of the study. However, in light of recent
reports identifying that poor health professional/patient communication and
partnerships contribute to poor warfarin-related therapeutic outcomes and
adverse events (Dantas, Thompson et al. 2004; Gandhi, Weingart et al. 2003) it
could be argued that it would have been unconscionable not to have included
them into the customary program.
Discussions will now focus on comparing the effectiveness of the new and
customary warfarin education programs in the area of health professional/patient
communication and partnerships.
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7.3.2 Comparing the effectiveness of the new and customary warfarin
education programs in the area of health professional/patient
communication and partnerships
One of the first indications that good health professional/patient
communication and partnerships had been established was that all patients
admitted to TACT for anticoagulation therapy from January 2003 to October 2003
consented to be part of the study. Of the 114 consenting patients who were
eligible, only one withdrew from the study voluntarily, while the other 11 were no
longer eligible because of warfarin cessation, death or simply because they could
not be re-contacted for evaluation follow-up. In other words, all the patient
participants who consented to be part of the study initially were happy to continue
being part of the study, until its completion, without feeling threatened or coerced.
Data from the ‘Satisfaction with Information about Medicines Scale’
(SIMS) (APPENDIX 20) found that most patient participants (over 90 percent)
were very satisfied with the information they received about warfarin’s action,
usage and potential problems. Statistical analysis found that only the information
about how long it takes for warfarin to act significantly satisfied more of the
intervention group patients than the control group patients (p-value 0.027). It
could be argued that the similar interventions to improve health
professional/patient communication and partnerships used in both warfarin
education programs may have contributed to fewer significant differences
between the two. Both education programs equally satisfied and met the needs
of all patient participants who were satisfied with the collaborative interchange
between themselves and their health professional.
Improved health professional/patient communication and partnerships for
both programs can also be inferred from the high mean scores for the ‘SelfManagement’ and ‘Medication-Taking-Measures’ questionnaires (Appendices 1718), which will be discussed later in this chapter. Further studies need to be
conducted to assess the extent to which the new warfarin education program, in
particular, improves health professional/patient communication and partnerships
compared to other available warfarin education programs.
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Another limitation of the study was that several interventions and
strategies targeting the key elements, which included health professional/patient
communication and partnerships, were introduced into both warfarin education
programs at the same time. This makes it difficult to analyse the impact of
improved health professional/patient communication and partnerships alone.
Future studies should therefore focus on identifying the impact that improving
health professional/patient communication and partnerships alone has on
warfarin knowledge, management and compliance, as well as long-term warfarinrelated therapeutic outcomes and adverse drug events.
The literature identifies that even though patients were satisfied with the
information they received there were gaps in their warfarin knowledge (Lambert
and Wynne 2003; Nadar, Begum et al. 2003). In the present study, data from the
‘Satisfaction with Information about Medicines Scale’ (SIMS)(APPENDIX 20) and
the high mean scores in the ‘Warfarin Knowledge’ questionnaire scores
(APPENDIX 19), suggest that the new warfarin education program, as compared
to the customary warfarin education program, satisfied more of the patients’
needs and improved their level of warfarin knowledge. Further research is
needed to establish whether or not the new warfarin education program does in
fact improve patients’ warfarin knowledge and their satisfaction with the
information provided, as compared to other available warfarin education
programs.
Based on the promising results of this study, especially with regard to
patient satisfaction and improved warfarin knowledge, it could be recommended
that all warfarin education programs should target improved health
professional/patient communication and partnerships. In doing so, these
programs would not only improve patients’ warfarin knowledge, management and
compliance, but they would also help to promote optimal therapeutic outcomes
and minimise adverse drug events.
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7.3.3 Summary of the effectiveness of health professional/patient
communication and partnerships in the study
Several interventions were incorporated into both the new and the
customary warfarin education programs to help improve health
professional/patient communication and partnerships. These interventions
included: home based one-on-one education sessions; offering the patients
and/or their carers encouragement, reinforcement, reassurance and feedback;
asking lots of questions; and providing an interpreter when necessary.
The high mean scores achieved by all participating patients in the ‘SelfManagement’, ‘Medication-Taking-Measures’ and the ‘Warfarin Knowledge’
questionnaires, as well as the ‘Satisfaction with Information about Medicines
Scale’ (SIMS) (Appendices 17-20), suggest that both warfarin education
programs improved patients’ warfarin knowledge, management and compliance
as well as their satisfaction with the information received. These results imply
that both programs achieved good health professional/patient communication
and partnerships which is an improvement on many other available programs
identified in the literature (Cox, Stevenson et al. 2004; Dantas, Thompson et al.
2004; Elwyn, Edwards et al. 2003).

7.4 WARFARIN COMPLIANCE

7.4.1 Introduction
Research has shown that poor warfarin compliance contributes
significantly to poor therapeutic outcomes (Arnsten, Gelfand et al. 1997) and
adverse drug events (Brigden, Kay et al. 1998; Hirri and Green 2002). Several
interventions were incorporated into the new warfarin education program based
on ‘best evidence’ to improve medication compliance (Haynes, McDonald et al.
2002a). These interventions included: educating the patients, their carers and/or
family members about the importance of taking warfarin on a regular basis;
explaining the implications of not complying with regular warfarin dosage;
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recommending compliance aids when and if required; offering reinforcement,
reassurance and telephone follow-up; and undertaking medication reviews.
Data collected from the ‘Self-Management’ (APPENDIX 17) and
‘Medication-Taking-Measures’ (APPENDIX 18) questionnaires, as well as the
percentage of therapeutic International Normalised Ratio (INR) scores, were
used to evaluate the patient participants’ warfarin compliance. These results for
the intervention and control group patients were compared and contrasted to
analyse the impact of both warfarin education programs on the patients’
compliance.
7.4.2 ‘Self-Management’ questionnaire
The ‘Self-Management’ questionnaire scores for both the intervention and
the control group, tested immediately and after three months of therapy, were
high and well within the highly confident range. These high scores suggest that
both education programs promoted patient confidence to manage and comply
with their warfarin therapy at home
The ‘Self-Management’ questionnaire scores significantly improved over
the three-month period for both groups (p-value equal to 0.0009*** for the
intervention group and p-value equal to 0.0024** for the control group),
suggesting that all patient participants became increasingly confident about their
warfarin management over time. The trend for the mean ‘Self-Management’
questionnaire scores was found to be higher for the intervention group patients
than the control group patients. Even though these scores were not significantly
different between the two groups, they do suggest that the new warfarin
education program encouraged the patients to be more confident about their
warfarin management, than did the customary warfarin education program.
The ‘Self-Management’ questionnaire used in this study was adapted from
Lorig et al’s ‘Self-Efficacy Questionnaire’ (1996 p.41-44), making it difficult to
directly compare these results with other studies. Indirectly, however, it could be
argued that both warfarin education programs promoted good warfarin
management at home, which is known from the literature (Lorig and Gonzales
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2000; Lorig, Ritter, Stewart, Sobel, Brown, Bandura, Gonzalez, Laurent and
Holman 2001) to contribute to good therapeutic outcomes in patients with chronic
disease. Future research should endeavour to test the impact of the new warfarin
education program against other community and/or warfarin education programs
for its impact on the patients’ confidence to manage their warfarin therapy at
home.
It is worrying that the significant increase in confidence to manage
warfarin therapy over the three month period was accompanied by a significant
decrease in the patients’ warfarin knowledge, as per the ‘Warfarin Knowledge’
questionnaire scores already discussed. Similar results were also found in other
studies which showed that even though patients were confident and satisfied with
the warfarin information they received, they had deficiencies in their warfarin
knowledge (Lambert and Wynne 2003; Nadar, Begum et al. 2003). This is a
major concern because deficiencies in warfarin knowledge can predispose
patients to poor therapeutic outcomes and adverse drug events (Haines 1998;
Kagansky, Knobler et al. 2004). This research study was too short to investigate
this anomaly any further, however future research studies should investigate the
possible impact of such changes over at least a six to 12 month period with a
view to assessing the importance of regularly following-up patients, as well as
reassuring them and reinforcing their warfarin information.
The deterioration in warfarin knowledge accompanied by improved
confidence in warfarin management over time gives rise to one other possibility
for further investigation – patient complacency. Certainly the literature identifies
that poor compliance (Haynes, McDonald et al. 2002a), especially in the ‘high
risk’ patient population (Barat, Andreasen et al. 2001; Davidhizar and Brownson
1999; Esposito 1995; Feifer 2003), leads to poor therapeutic outcomes and
increased adverse drug events. It would be interesting, therefore, to investigate
whether or not the patients become complacent with their warfarin therapy and
what impact this could have on their therapeutic outcomes over time.
In summary, the high mean scores for the ‘Self-Management’
questionnaires indicate that both warfarin education programs, and especially the
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new program, empowered all patients, including those from the ‘high risk’ group,
to feel confident about managing their warfarin therapy at home. Importantly,
however, this improved confidence was accompanied by a deterioration in
warfarin knowledge, highlighting the need to follow-up, reassure and reinforce
warfarin information on a regular basis.
7.4.3 ‘Medication-Taking-Measures’ questionnaire
Intervention group patients achieved higher scores in the ‘MedicationTaking-Measures’ (MTM) questionnaire (APPENDIX 18) than control group
patients. Intervention group patients achieved more ‘high compliance’ scores
than control group patients, both initially (62 percent versus 53.85 percent) and
after three months (80 percent versus 71.15 percent). Although statistical
analysis did not find these results to be significantly different, they suggest that
the new warfarin education program promoted better warfarin compliance among
patients than did the customary warfarin education program. This is also evident
in the positive correlation coefficient test (p-value equal to 0.0328*), which found
that as the intervention group patients’ MTM scores increased, so too did their
percentage of therapeutic INR scores. In other words, as the intervention
patients’ confidence about their warfarin compliance improved, so too did their
therapeutic control of warfarin.
Analysis of the MTM data after a three-month period showed significant
increases in the scores for both groups (p-value equal to 0.0017** for the
intervention group and p-value equal to 0.0243* for the control group). In fact, the
follow-up scores for both groups were approximately 20 percent higher than the
initial scores, suggesting that, from the patients’ perspective, compliance
improved over time. The three-month follow-up ‘high compliance’ MTM scores for
the intervention and control groups (80 percent versus 71.15 percent) were
considerably higher than the average 50-65 percent medication compliance rates
reported in the literature for long-term medications (Haynes, McDonald et al.
2002a; Haynes, McKibbon et al. 1996). These results suggest that both warfarin
education programs, and especially the new program, were more effective at
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promoting good compliance than were other available medication education
programs. Further investigations over a longer period of time, however, would
need to be carried out to ensure that the patients’ compliance with long-term
warfarin therapy remained stable.
It is also worth noting, that the initial comments made by many of the
patient participants in both groups were that they did not take regular
medications prior to their warfarin being prescribed. It could be argued, therefore,
that the significantly higher MTM scores after three months were due in part to
the effectiveness of both programs in encouraging patients to be compliant with
their warfarin therapy. The most worrying aspect of the significantly improved
MTM scores over the three-month period was the concurrent deterioration in the
patients’ warfarin knowledge. Future studies need to research the effects that this
deterioration has on the patients’ warfarin compliance over time (at least 6-12
months). It would also be useful to investigate what elements of ‘warfarin
knowledge’ are critical to maintain good compliance and which could be left out,
although this could be difficult to research ethically.
When the three-month MTM scores were compared to the percentage of
INR scores within therapeutic range, an interesting observation was made.
Similar to the findings in a study by Barcellona et al (2002), the intervention
group patients in this study who were highly compliant also achieved the highest
therapeutic control, probably because they understood the relationship between
regular compliance and good therapeutic control. In this study, the intervention
group patients who declared a high level of compliance (MTM=4) achieved the
highest mean percentage for therapeutic INR scores (73.7 percent). Whereas,
the intervention group patients who declared a low level of compliance (MTM=1)
achieved a lower mean percentage for therapeutic INR scores (64.7 percent). In
contrast, however, the control group patients who declared a high level of
compliance (MTM=4) achieved the lowest mean percentage for therapeutic INR
scores (66.2 percent), and the control group patients who declared a low level of
compliance (MTM=1) achieved the highest mean percentage of therapeutic INR
scores (72 percent). These results suggest that the new warfarin education
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program was more effective than the customary warfarin education program in
educating patients about the importance of regular warfarin compliance, which
improved their therapeutic control. Further research is needed, to confirm that the
new warfarin education program does in fact promote better warfarin compliance
resulting in improved therapeutic control over prolonged periods of time, as
compared to other warfarin education programs.
In addition to the positive impact of both education programs, another
possible explanation for the significantly higher MTM scores after three months of
therapy for both groups was that since patient participants knew that they were
being followed-up, they were more diligent with their warfarin compliance. This
result is consistent with evidence in the literature which states that patient followup does help to improve medication compliance (Waterman, Milligan et al. 2001).
There will be more discussion about the impact of patient follow-up later in this
chapter
In summary, the ‘Medication-Taking-Measures’ (MTM) questionnaire
(APPENDIX 18) scores were high for both programs and especially the new
warfarin education program. These results suggest that even though both
programs promoted good warfarin compliance, the new program promoted it
more effectively than did the customary warfarin education program. The
significantly higher MTM scores after three months indicated that both programs
continued to effectively promote warfarin compliance over time. Interestingly, the
intervention group patients who were most confident about their warfarin
compliance also achieved the highest therapeutic control. Further research is
needed to analyse the long-term benefits of the new program with regard to
warfarin compliance and therapeutic control over time.
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7.4.4 International Normalised Ratio (INR) scores

7.4.4.1 Discussion of the INR results
An important aspect of both the ‘Self-Management’ and ‘MedicationTaking-Measures’ (MTM) questionnaires was that they relied on the patients’
own reporting if their confidence levels for management and compliance at
home. International Normalised Ratio (INR) blood tests, on the other hand, are
laboratory results, which give an objective measure of the patients’ warfarin
compliance.
The high percentage of therapeutic INR scores (69 percent) corresponded
with the high mean scores for the ‘Self-Management’ and ‘Medication-TakingMeasures’ questionnaires for both groups. These results imply that patient
participants who were confident with their warfarin management and compliance
also achieved good therapeutic control. The association between the MTM
scores and the INR scores has already been discussed and will not be revisited.
The association between the ‘Self-Management’ and INR scores will be
discussed now.
The data revealed that as the ‘Self-Management’ scores increased for
both the intervention and control group patients, so too did the percentage of
therapeutic INR scores. The ‘highly confident’ patients in both groups achieved a
higher percentage of therapeutic INR scores, 70.9 percent for the intervention
group and 71.8 percent for the control group, whereas the less confident patients
in both groups achieved a lower percentage of therapeutic INR scores, 67.8
percent for the intervention group and 66.7 percent for the control group. These
results suggest that both the new and the customary warfarin education
programs effectively empowered a large proportion of the patients to feel
confident about managing and complying with their warfarin medication, which in
turn resulted in better therapeutic control. Both programs also appear to be more
effective than other available programs, based on the fact that they both
achieved higher than average therapeutic INR scores, 69 percent, as compared
to the 30 percent to 60 percent average reported in the literature (Gray,
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Garabedian-Ruffalo and Chretien 1985; Khan, Kamali, Kesteven, Avery and
Wynne 2004).
The finding that improved confidence with compliance and management
promotes improved therapeutic control, is also evident in the literature (Beyth,
Quinn and Landefeld 2000). This finding emphasises the importance of
incorporating interventions and strategies to improve patients’ confidence with
their warfarin compliance and management, which in turn will help to improve
therapeutic control. Similar results achieved by both the new and customary
warfarin education programs may have been due to the inclusion of similar
interventions to target improved warfarin compliance. Further research is needed
to establish which of the following interventions most effectively improve warfarin
compliance, especially for elderly patients taking life-long warfarin therapy:
educating the patients and/or their carers; compliance aids; general
encouragement, reinforcement, reassurance and follow-up; and/or medication
reviews.

7.4.4.2 A structured self-management warfarin education program
Even though therapeutic control for both programs was good overall, there
still remains the problem of the 30 percent of INR scores which were outside the
therapeutic range. These are a problem because they could potentially cause
adverse drug events (Gallus, Baker et al. 2000). One of the ways in which to
remedy this would be to combine the new warfarin education program with a selfmonitoring program, often referred to as a self-management program. Patients
could be educated about their warfarin therapy with the new warfarin education
program and taught how to adjust their own warfarin doses according to their INR
results. Recent studies examining the therapeutic control of patients performing
self-monitoring have found that they spend significantly more time within
therapeutic range compared with patients who do not self-monitor (Ansell,
Jacobson, Levy, Voller and Hasenkam 2005; McCahon, Fitzmaurice, Murray,
Fuller, Hobbs, Allan and Raftery 2003; Sawicki 1999). The researcher
recommends further research into the benefits of combining the new warfarin
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education program with a structured self-management (self-monitoring) program.
If the evaluation for this new structured self-management warfarin education
program was good, it could be recommended as a best practice model for a
home-based warfarin self-management program.

7.4.4.3 Best practice guidelines for the number of INR blood tests
Analysis of the INR data revealed that there was no consistency with the
number of INR blood tests ordered by the patient participants’ general
practitioners. An average of 11 INR blood tests, ranging from 4 - 26 INR blood
tests, were ordered by the patient participants’ general practitioners during the
three month period after their discharge from TACT.
There is abundant literature which provides information about the
importance of therapeutic INR monitoring (Ansell, Hirsh, Dalen, Bussey,
Anderson, Poller, Jacobson, Deykin and Matchar 2001; Dzung The Le 1994).
However, there is limited information (AMH 2003) about the recommendations for
the frequency of these blood tests. Evidence suggests that 50 - 60 percent of
patients will remain within therapeutic range if monitoring of INR occurs monthly,
77 - 85 percent if monitored weekly and up to 92 percent if monitored every third
day (Oral Anticoagulation Monitoring Study Group 2001). Best practice
guidelines about the number of INR blood tests which should be ordered need to
be developed and distributed to all health professionals prescribing warfarin.
Also, with the evolving trend for patients to self-monitor their INR at home using
especially designed devices (Ansell, Jacobson et al. 2005; Fitzmaurice and
Machin 2001; Koertke, Minami, Bairaktaris, Wagner and Koerfer 2000),
guidelines need to be given to patients about how often to test their INR. In other
words, they also need to be provided with best practice guidelines about how
often their INR should be tested to achieve optimal therapeutic control.
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7.4.5 Carers and/or family members
Over 50 percent of both intervention and control group patients, many of
whom were from the ‘high risk’ group, had a carer and/or family member present
during the initial warfarin education session. Based on the high proportion of
therapeutic INR scores (above 70 percent) and the low incidence of minor
potential warfarin-related adverse drug events (4.9 percent), it could be argued
that these patients benefited from the assistance of their carers and/or family
members.
There is ample evidence to support the benefits of carers and/or family
members being in attendance during medication education sessions to help
improve medication compliance (Haynes, McDonald et al. 2002a), memory recall
(Doak, Doak et al. 1998) and overcoming possible language, cultural, cognitive
and/or physical barriers (Davidhizar and Brownson 1999; Minas, Lambert et al.
1996). These benefits, however, are not reflected in higher scores for the threemonth follow-up ‘Self-Management’, ‘Medication-Taking-Measures’ and ‘Warfarin
Knowledge’ questionnaires. This suggests that participating patients who had a
carer present during the initial warfarin education session were not more
confident about their warfarin management and compliance, nor did they have a
better warfarin knowledge and understanding than did the participating patients
without a carer present. One of the possible reasons for these unexpected
results is that the follow-up questionnaires were completed over the telephone by
the patients themselves. This could be seen as a limitation of the study because
if the carer and/or family member had been responsible for the patients’ warfarin
management then they should have been asked to complete the evaluation
questionnaires. In order to investigate this further, future research needs to focus
on the impact that carers and/or family members have on warfarin management,
by having all the evaluation questionnaires completed by the person responsible
for administering and managing the warfarin therapy at home, whether it be the
patient, carer and/or family member. Other important factors to investigate in
future studies would be whether or not carers and/or family members actually do
improve warfarin knowledge, management and compliance.
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Although the literature identifies that carers and/or family support can play
a significant role in assisting with medication compliance (Schlenk, Dunbar-Jacob
et al. 2004), very little attention has been paid to the role of families, their
knowledge and/or expressed emotion toward medication compliance (Sellwood,
Tarrier, Quinn and Barrowclough 2003). Another recommendation for future
research would therefore be to compare warfarin management and compliance
for all patients, especially the ‘high risk’ patients, with and without the physical
and emotional support of a carer and/or family member.

7.4.6 Compliance aids
Based on the evidence that compliance aids help to improve medication
compliance (Levings, Szep et al. 1999; Wong and Norman 1987) several aids,
including dosette boxes, alarm clocks and calendars, were strongly
recommended, especially for the ‘high risk’ patients, as part of the new warfarin
education program. These aids were also recommended in the customary
warfarin education program, making it difficult to compare and assess their
effectiveness.
During data collection, most patient participants could readily suggest two
aids (for example dosette box, alarm clock) to help them with their warfarin
compliance. This suggests that both programs effectively increased the patients’
awareness of compliance aids, which they could readily use to assist them with
their warfarin compliance when and if they felt it was necessary. In the past,
single strategies employed to improve long-term medication compliance such as
compliance aids have not been found to be very effective (Haynes, McKibbon et
al. 1996; McDonald, Garg et al. 2002; Roter, Hall et al. 1998), which is why these
aids were recommended as one of several strategies. This, however, made it
difficult to evaluate the impact of aids on warfarin compliance in the study. Future
research should therefore focus on evaluating the impact that a single
compliance aid such as a dosette box actually has on warfarin compliance,
especially in the long term for ‘high risk’ patients.
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7.4.7 Medication reviews
Complex and complicated medication regimens can impact upon
medication compliance, especially in patients over 65 years of age (Col, Fanale
et al. 1990). In this research study, a significant proportion (62.74 percent) of the
patient participants were aged 65 years and over, and although warfarin itself
may not be considered a complex and complicated medication regimen, it has
the potential to be when combined with other medications. Importantly, therefore,
pharmacists in both groups conducted medication reviews on all patient
participants, including the elderly, to ensure that medication regimens were
simplified as much as possible. Home medication reviews became incorporated
into both programs because they were perceived to be best practice and were
highly promoted by the local division of general practice (Australian Government
Department of Health and Ageing 2001). Once again, common practices in both
programs made it difficult to compare the effect that the medication reviews had
on the patients’ warfarin compliance for the new and customary warfarin
education programs.
Both programs achieved higher than the ‘norm’ warfarin compliance
scores over the three-month period - above 70 percent as compared with the 5060 percent reported in the literature (Haynes, McDonald et al. 2002a; Haynes,
McKibbon et al. 1996). It could be argued that these results were in part due to
the benefits of the medication reviews, which ensured that warfarin was taken
appropriately without any potential drug-to-drug interactions. A recommendation
for all home-based warfarin education programs, therefore, is to incorporate
home medication reviews as part of overall strategies to improve warfarin
compliance.

7.4.8 Summary of the effectiveness of the interventions used to improve
warfarin compliance

Several interventions were incorporated into both the new and the
customary warfarin education programs, based on ‘best evidence’ to improve
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medication compliance (Haynes, McDonald et al. 2002a; McDonald, Garg et al.
2002). These interventions included: educating the patients, carers and/or family
members; offering reinforcement, reassurance and follow-up; recommending
compliance aids; and undertaking medication reviews.
The high mean scores achieved for the ‘Self-Management’ and
‘Medication-Taking-Measures’ questionnaires (APPENDIX 17-18), as well as the
high proportion of therapeutic International Normalised Ratio (INR) scores,
suggest that these interventions contributed to improving the participating
patients’ confidence to manage and comply with their warfarin therapy at home,
resulting in good warfarin therapeutic control. Unfortunately, because several
interventions were incorporated simultaneously, it was not possible to identify
which ones were the most effective with regard to improving warfarin compliance
in both programs.
Several recommendations arose from the study results. Firstly, there is a
clear need to develop best practice guidelines for the number of INR blood tests
required by patients to ensure good therapeutic control. Secondly, given the
trend towards self-monitoring (often referred to as self-management), there is a
need to develop a good practice model for a structured warfarin selfmanagement program, based on the new warfarin education program. Finally,
medication reviews should be incorporated into all home-based warfarin
education programs to reduce the risk of drug-to-drug interactions.

7.5 SIMPLE, EASY-TO-READ WARFARIN INFORMATION

7.5.1 Introduction
The amount of information presented to patients beginning anticoagulant
medication can be overwhelming (Ansell, Buttaro et al. 1997). It has been found
that on average 40 percent of patients forget the information given to them
(Prochaska and DeClementi 1986). Based on this knowledge, during the initial
new warfarin education session the decision was made to verbally communicate
only the important points as per the ‘Warfarin Counselling Checklist ’ (APPENDIX
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13) and to provide each patient with the new written warfarin information booklet
(APPENDIX 12) for written and visual reinforcement. The contents of both the
checklist and the warfarin information booklet were based on ‘best evidence’
about what patients taking warfarin need to know in order to help optimise
warfarin therapeutic outcomes (Ansell, Buttaro et al. 1997; Gallus, Baker et al.
2000; Haines 1998; Witte, Gurwich et al. 1980)
Health professionals have a duty of care to provide information which is
easy-to-read and understand (Wilson, Racine et al. 2003). A number of
strategies were used to ensure that the new warfarin information booklet
(APPENDIX 12) was easily read and understood by most patients, including
those with low literacy skills. These strategies included using readability
instruments such as SMOG (McLauglin 1969), the Fry readability formula (Fry
1968) and the Microsoft Word 2000 computerised Flesch-Kincaid test to ensure
that the booklet was written at a suitable level. Other strategies included adhering
to guidelines such as those in the ‘Toolkit for producing patient information’ (The
United Kingdom Department of Health 2002) (APPENDIX 2) and the ‘Guidelines
for writing patient information’ (Doak, Doak et al. 1996b) (APPENDIX 3) to
ensure that the booklet was written in a simple, easy-to-read format with
culturally-sensitive illustrations. Prior to the commencement of the research
study, changes were also made to the new booklet, as discussed in chapter 5,
based on the comments and recommendations made by literacy experts,
pharmacists, TACT staff, Illawarra Health interpreters and the 10 pilot study
participants.
To assess the readability, quality and the patients’ satisfaction with the
new warfarin information booklet (APPENDIX 12), it was compared and
contrasted to the Boots warfarin information booklet (2003) used in the
customary warfarin education program. The results of these analyses will now be
discussed.
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7.5.2 The overall effectiveness of the new warfarin education program
compared to the customary program for patients with low literacy
The literature reports that patients with low literacy skills generally
experience poor anticoagulation control because they cannot read or understand
the information given to them (Estrada, Martin-Hryniewicz et al. 2004). The
participating patients with low literacy skills in this study (educated at or above a
grade 6 level) achieved a high proportion of therapeutic INR scores (69.5 percent
intervention group and 69.2 percent control group), as well as high mean scores
in the ‘Self-Management’ questionnaire (19.9 intervention group and 19.9 control
group) and the ‘Medication-Taking-Measures’ questionnaire (3.8 intervention
group and 3.8 control group). These results suggest that both programs equally
promoted good therapeutic control and instilled confidence in patients with low
literacy skills to manage and comply with their warfarin therapy at home.
However, intervention group patients with low literacy skills achieved higher
mean scores than the control group patients with low literacy skills in the
‘Warfarin Knowledge’ questionnaire s, both initially (76.2 percent versus 68.1
percent) and after three months (63.9 percent versus 57.8 percent). As already
discussed, these results suggest that the new warfarin education program was
more effective than the customary warfarin education program, as well as other
programs reported in the literature (Cheah and Martens 2003; Nadar, Begum et
al. 2003; Tang, Lai et al. 2003) at improving warfarin knowledge in patients with
low literacy skills.
Overall therefore, although the new warfarin education program was more
effective at improving warfarin knowledge in patients with low literacy skills, both
the new and customary programs equally promoted good therapeutic control and
encouraged patients with low literacy skills to manage and comply well with their
warfarin therapy. Interestingly, the high proportion of therapeutic INR scores
(69.5 percent intervention group and 69.2 percent control group) achieved by the
patient participants with low literacy skills in this study, were higher than the 30
percent to 60 percent average reported for the general population in the literature
(Gray, Garabedian-Ruffalo et al. 1985; Khan, Kamali et al. 2004). A
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recommendation for future research would be to compare the new warfarin
education program, inclusive of the new warfarin information booklet (APPENDIX
12), with other available warfarin education programs and written information, on
a much larger sample size of patients with low literacy skills.

7.5.3 The effectiveness and readability of the new warfarin information
booklet (APPENDIX 12) compared to the Boots warfarin information booklet
(2003)
Unlike other currently available written warfarin information leaflets and
booklets (Estrada, Hryniewicz et al. 2000; Tang, Lai et al. 2003), the new
warfarin information booklet tried to address the needs of ‘high risk’ patient
population. The ‘Toolkit for producing patient information’ (The United Kingdom
Department of Health 2002) (APPENDIX 2) and the ‘Guidelines for writing patient
information’ (Doak, Doak et al. 1996b) (APPENDIX 3) were used to help ensure
that most patients, including those with low literacy skills, could read and
understand the information.
The combined results of the SMOG test (McLauglin 1969)(APPENDIX 4),
the Fry test (1968) (APPENDIX 5) and the Microsoft Word 2000 computerised
Flesch-Kincaid test found that the new booklet was written between grade 6 - 8
reading levels which complied with the recommendations for reading grade
levels necessary for patients with low literacy skills (Buchbinder, Hall et al. 2001).
This new booklet was found to be written at least 2 - 3 grades below the Boots
warfarin information booklet (2003), as well as several reading grade levels
below other available written warfarin information (Estrada, Hryniewicz et al.
2000). It could be argued that because these readability tests are not healthcare
specific they may not be entirely accurate. In the absence of healthcare specific
readability tools apart from RAIN (Singh 2002), which is time consuming and
difficult to use, there were no other tools available for use in the study. The
development of a healthcare-specific readability instrument would therefore be
extremely valuable for all health professionals developing written patient
healthcare information.
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The patient demographic data collected in the research study indicated
that 32 percent (16) of the intervention group patients and 19.2 percent (10) of
the control group patients were educated at or below a grade 6 level. These
patients with low literacy skills would have been able to read and understand the
new warfarin information booklet (APPENDIX 12), but would not have been able
to read and understand the Boots warfarin booklet (2003) or other available
written warfarin information (Estrada, Hryniewicz et al. 2000; Estrada, MartinHryniewicz et al. 2004).
These results confirm the need to provide simple, easy-to-read warfarin
information, which can be read and understood by a wider patient population,
inclusive of those with low literacy skills. The new warfarin information booklet
(APPENDIX 12) used in this research study was developed and written with
these patients in mind. Based on the high evaluation scores for the intervention
group patients with low literacy skills, the new booklet appears to have
contributed to the effectiveness of the new program in empowering all patients,
including those with low literacy skills, to make confident educated decisions
about their warfarin therapy and management.

7.5.4 The quality and suitability of the new warfarin information booklet
(APPENDIX 12) compared to the Boots warfarin information booklet (2003).
A patient’s understanding and satisfaction with written information is
influenced by factors such as format, colour, text, print size and the use of
illustrations (Clark, AbuSabha et al. 1999). In this study the quality and the
suitability of the two warfarin information booklets were assessed using the
‘Suitability Assessment Materials’ (SAM) (Doak, Doak et al. 1985), the ‘Bernier
Instructional Design Scale’ (BIDS) (Bernier 1996) and the ‘Checklist for print
materials’ (Bidford Maine Area Health Education Center 1996)(see Appendices
6-8).
The SAM instrument (Doak, Doak et al. 1985) found the new warfarin
information booklet (APPENDIX 12) to be superior to the Boots booklet (2003) in
terms of content, literacy, demand, illustrations, layout, learning stimulation and
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motivation. The BIDS instrument (Bernier 1996) identified that the new booklet
contained more instructional design and learning principles than did the Boots
booklet (2003). Also, the ‘Checklist for print materials’ (Bidford Maine Area Health
Education Center 1996) identified several potential deficiencies within the Boots
booklet, but none in the new warfarin information booklet. Based on these tests,
therefore, the new warfarin information booklet could be considered superior in
terms of quality and suitability to the commonly used Boots warfarin information
booklet (2003).
Even though the SAM instrument identified the superiority of the new
booklet, it also identified some areas in which it could be improved to better meet
the needs of patients with low literacy skills. The SAM instrument suggested that
the booklet should limit its scope to essential warfarin information only and to
develop a subsequent booklet to record blood test results and warfarin doses.
The SAM instrument also suggested: changing some of the vocabulary (for
example replace ‘binge eat’ with ‘over eat’); modifying the cover page to
incorporate people from different cultures; and labelling the illustrations/lists more
clearly. Unfortunately, the new booklet had already been printed when these
results were identified which is why they were not incorporated into the booklet.
These changes, however, have been incorporated in the revised edition of the
new warfarin information booklet, which will be available in 2005.

7.5.5 The readability, quality and suitability of other written warfarin
information sought by the patient participants
The small percentage of intervention group patients (16 percent) who
sought more warfarin information achieved significantly lower mean scores for
their ‘Warfarin Knowledge’ questionnaire after three months, than did the
intervention group patients who did not. On the other hand, the small percentage
of control group patients (7.7 percent) who sought more information achieved
slightly higher mean ‘Warfarin Knowledge’ questionnaire scores, than did the
control patients who did not. Even though these results were based on very small
numbers of patients within both groups, they suggest that seeking more warfarin
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information does not always improve warfarin knowledge and understanding.
One of the reasons for this may be that the information available from these other
sources is pitched at a level above the comprehension of many patients, as
identified in the literature (Estrada, Hryniewicz et al. 2000; Estrada, MartinHryniewicz et al. 2004; Wilson, Racine et al. 2003), adding to their warfarin
knowledge deficits and confusion. An interesting future study would be to
investigate from where patients, especially those with low literacy skills, seek
more warfarin information and what impact this information-seeking behaviour
has on their warfarin knowledge, management and compliance in the long-term.

7.5.6 Non-English speaking background patients and written warfarin
information
Diverse cultural groups interpret written material based on the values,
rules of behaviour and healthcare practices consistent with their culture
(Davidhizar and Brownson 1999; Guidry and Fagan 1999). For the purposes of
this study, both the intervention and control group non-English speaking
background (NESB) patients were offered a warfarin information booklet written
in English and an accredited Illawarra Health interpreter to translate the relevant
warfarin information to them.
As would be expected (Nadar, Begum et al. 2003), the non-English
speaking background (NESB) patients achieved lower mean scores for each of
the evaluation questionnaires, than did the English speaking background patients
in both groups. Tthe NESB intervention group patients, as compared to the
NESB control group patients, achieved higher mean scores for the ‘SelfManagement’ and ‘Warfarin Knowledge’ questionnaires. These results suggest
that compared to the customary warfarin education program, the new warfarin
education program improved the NESB patients’ knowledge and understanding
of warfarin and their confidence to manage their therapy. However, the small
number of NESB patients (9 intervention and 6 control), make it impossible to
draw meaningful conclusions from these results. A recommendation for future
research, therefore, would be to compare and contrast the new and customary
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warfarin education programs on a much larger sample size of NESB patients.
Also, in the absence of information in the literature, further research needs to be
done regarding the language and cultural issues pertaining to written warfarin
information available to patients from non-English speaking backgrounds.
One obvious limitation of the study was that the written warfarin
information was only available in English. Unfortunately, restrictions in finances
and time made it impossible for the information to be translated into the
appropriate languages during this study. Future studies could evaluate the value
of translating the new warfarin information booklet into different languages.
Additionally, the written information needs to be culturally sensitive
(Wilson, Racine et al. 2003), as does the behaviour of health professionals
educating patients from non-English speaking backgrounds (Lambert and Minas
1998; Minas, Lambert et al. 1996; Wilson, Racine et al. 2003). Prior to the study,
the new warfarin booklet was circulated to Illawarra health service interpreters to
ensure that it contained culturally sensitive graphics. In future, when the booklet
is translated into different languages it would be appropriate to include graphics
and photographs of patients who actually come from the different cultural
backgrounds. Adherence to culturally-appropriate behaviours should become
part of the everyday practice of all health professionals dealing with patients from
diverse cultural communities (Wilson, Racine et al. 2003).
The researcher/TACT pharmacist providing the new warfarin education
program had an advantage over the pharmacist providing the customary warfarin
education program because she comes from a non-English speaking
background. Even though this could be seen as a limitation of the study it must
be taken into account that the study area is home to over 100 different
nationalities, only 10 of which were represented in this research study. Notably,
the study population did not include either Muslim or indigenous Australian
patients. These cultures are especially important because Muslim patients often
change their medication doses and intake time during Ramadan without seeking
medical advice (Aadil, Houti and Moussamih 2004), and indigenous Australians
often experience poor therapeutic outcomes based on communication, social and
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cultural barriers (Morgan, Slade and Morgan 1997; Shannon 1994). In both
cases, future research could focus on identifying cultural strategies, which could
be adopted by all health professionals when trying to educate these patients
about warfarin.

7.5.7 Summary
The issues of readability, quality and the suitability of written warfarin
information were addressed in several ways throughout the research study.
Several readability tests found the new warfarin information booklet (APPENDIX
12) to be written in a much simpler, easier-to-read format than the Boots warfarin
information booklet (2003). Following evaluations with validated instruments, the
new booklet was also found to be superior to the Boots booklet (2003) in terms of
quality and suitability for a wider patient population, inclusive of those with low
literacy skills.
The high proportion of therapeutic INR scores and the high ‘Warfarin
Knowledge’ questionnaire scores achieved by the intervention patients with low
literacy skills, suggests that the new program, including the new warfarin
education booklet (APPENDIX 12), impacts favourably on warfarin knowledge
and therapeutic control in patients with low literacy skills. Even though further
research is needed to confirm this, these promising results imply that all patients
should receive good quality, simple, easy-to-understand warfarin education
programs and simple, easy-to-read written warfarin information.
Other recommendations borne out of the study are that readability tools
such as SMOG (McLauglin 1969) and Fry Test (Fry 1968)), as well as guidelines
such as ‘The toolkit for producing patient information’ (The United Kingdom
Department of Health 2002) and the ‘Guidelines for writing patient information’
(Doak, Doak et al. 1996b), should be used when preparing written patient
information. In doing so, health professionals can ensure that information is
available in a simple, easy-to-read format, which will appeal to a wider patient
population. Prior to the distribution of the written patient information its quality
and suitability should also be assessed by using instruments such as the
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‘Suitability Assessment Materials’ (SAM) (Doak, Doak et al. 1985), the ‘Bernier
Instructional Design Scale’ (BIDS) (Bernier 1996) and the ‘Checklist for print
materials’ (Bidford Maine Area Health Education Center 1996) (Appendices 6-8).

7.6 THE CONTINUITY OF CARE BETWEEN HOSPITAL AND COMMUNITY
SETTINGS
Poor continuity of care between hospital and community settings has been
reported to negatively impact upon poor therapeutic outcomes and adverse drug
events (Australian Council for Safety and Quality in Health Care 2002; Balla and
Jamieson 1994). To improve the continuity of care between hospital (ambulatory
care in this instance) and community settings, the new warfarin education
program followed the Australian Pharmaceutical Advisory Council (APAC)
‘National guidelines to achieve the continuum of quality use of medicines
between hospital and community’ (1998). The strategies used to incorporate
these guidelines have already been described in the methodology chapter of this
thesis and will not be discussed here. It is important to note, however, that these
guidelines, which can be seen to reflect best practice were also included into the
customary warfarin education program during the course of the study. This may
have impacted upon some of the results and made them less significantly
different than expected.
The patient participants in the research study were referred to The
Ambulatory Care Team (TACT) from the following three sources: emergency
departments, hospital wards and general practitioners. The emergency
department and hospital ward referrals outnumbered the general practitioner
referrals at a ratio of 4:1. This highlights the need to prioritise the continuity of
care between hospital and community settings to ensure that general
practitioners know how to optimally continue monitoring their patients’ warfarin
once discharged from the care of TACT.
Many of the interventions incorporated to improve the continuity of care
were similar to those used to improve warfarin compliance. These interventions
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included: encouraging carers and/or family members to be present during the
initial education sessions; ensuring that an interpreter was available for patients
from non-English speaking backgrounds; undertaking medication reviews; and
encouraging the patients to be active participants in their warfarin management.
It is difficult, therefore, to accurately assess the impact that the continuity
of care guidelines had on the therapeutic outcomes of the patient participants in
this study. However, the high average warfarin knowledge scores (≥73 percent
initially and ≥65.5 percent after three months), the high proportion of therapeutic
INR scores (69 percent) and the low incidence of minor potential warfarin-related
adverse drug events (4.9 percent) achieved by all patient participants in this
study leaves little doubt about the benefits of adhering to the APAC guidelines.
These results support the need to always incorporate APAC guidelines into
ambulatory care services such as TACT because the timely transfer of
information to patients, carers and/or their health professionals working in the
community (Thornton, Simon and Mathew 1999) ultimately contributes toward
optimising therapeutic outcomes and minimising adverse drug events.
A recommendation for future research would be to evaluate the direct
impact of the APAC guidelines on ambulatory care services, assessing whether
or not similar benefits and/or disadvantages are achieved. Some interesting
aspects to focus on in these future studies would include: assessing the general
practitioners preferred method of receiving patient information (email, fax, letter);
their perceptions about the timeliness of the information; as well as the quality of
the information that they received about their patient.
In summary, both programs appear to have successfully incorporated the
APAC guidelines to improve the continuity of care between hospital (ambulatory
care) and community settings. Even though further research is needed,
preliminary data from this study indicate that when ambulatory care services like
TACT adhere to these guidelines there is an improvement in patients achieving
good therapeutic control with fewer warfarin-related adverse events.
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7.7 PATIENT FOLLOW-UP

7.7.1 Introduction
Patient follow-up was used in the new warfarin education program
because it has been identified as a key element of an effective patient education
program (Dudas, Bookwalter et al. 2001; Haynes, McDonald et al. 2002a). The
intervention patients received a follow-up telephone call one week after the initial
warfarin education session. During this initial telephone follow-up they had their
warfarin information reinforced and they were also encouraged to ask questions
and make comments about their warfarin therapy. All the participating patients
(intervention and control) then received telephone follow-up calls after three
months, and, as initially informed, were asked to complete the evaluation
questionnaires. During the three-month follow-up telephone calls, all the patient
participants were also encouraged to ask questions and make any comments
about their warfarin therapy and education programs.

7.7.2 Impact of patient follow-up on warfarin management and compliance
As already discussed, patients were possibly more diligent with their
warfarin management and compliance because they were being monitored in the
study. Evidence in the literature also supports the positive impact of patient
follow-up on medication management, compliance and therapeutic control
(Dudas, Bookwalter et al. 2001; Jackson, Peterson et al. 2004). It would be
reasonable to conclude, therefore, that the telephone follow-up contributed to all
patient participants achieving high mean scores for their ‘Self-Management’ and
‘Medication-Taking-Measures’ questionnaires, as well as the high proportion of
therapeutic INR scores during the three-month study period. An interesting
investigation in the future would be to examine the impact that long-term followup (at least 12-24 months) has on patients’ warfarin knowledge and
understanding, their compliance, management and therapeutic outcomes.
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7.7.3 Impact of patient follow-up on warfarin-related adverse drug events
Reports in the literature identify that follow-up after hospital discharge
significantly reduces the incidence of adverse drug events requiring
hospitalisation (Dudas, Bookwalter et al. 2001; Jackson, Peterson et al. 2004).
Therefore, telephone follow-up in this study has almost certainly contributed to
the very low incidence of minor warfarin-related adverse drug events, none of
which required hospitalisation. Only 4.9 percent (5) of the patient participants in
the study experienced minor possible warfarin-related bleeds, as compared with
the 13.7 percent reported in the literature for other outpatient anticoagulation
clinics (Wilt, Gums, Amhed and Moore 1995). These results promote the benefits
of incorporating patient follow-up into a warfarin education program. To identify
the benefits of patient follow-up alone, future studies would need to identify the
long-term effects on warfarin-related adverse drug events in patients receiving
regular follow-up, compared to those receiving no follow-up.

7.7.4 Impact of patient follow-up on warfarin knowledge
It is notable that even though the intervention group patients received
follow-up telephone calls one week after their initial warfarin education session,
their warfarin knowledge deteriorated at a similar rate as that of the control group
patients during the study. This deterioration in warfarin knowledge could have
serious implications for patients diagnosed with medical conditions requiring
potentially lifelong warfarin therapy. Such diagnoses include: atrial fibrillation;
transient ischaemic attacks; cerebrovascular accidents; and mechanical cardiac
valves, which were found to exist in 41.2 percent (42) of the patient participants.
More of a concern is that many of these patients were elderly, aged 65 years and
over (62.8 percent), and therefore at a potentially greater risk of experiencing
poor therapeutic outcomes and warfarin-related adverse events (Cheah and
Martens 2003; Tang, Lai et al. 2003; Taylor, Ramsay et al. 1994; Wilson, Racine
et al. 2003). A recommendation based on these results is to have regular patient
follow-up, especially for elderly patients, reassuring them and reinforcing warfarin
information on a three monthly basis.
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Based on the three-month follow-up period of this study, it is difficult to
predict the long-term effects of the warfarin knowledge deficits. Further studies,
especially on elderly patients, need to investigate whether or not three monthly
follow-up, reinforcement and reassurance improves warfarin knowledge,
management, compliance and therapeutic outcomes over time.

7.7.5 Summary of the impact of patient follow-up
Patient follow-up was believed to contribute to the patient participants’
improved warfarin knowledge, management and compliance, as well as their
good overall therapeutic control and low incidence of warfarin-related bleeds. No
significant differences were found between the new and the customary warfarin
education programs, probably because they both incorporated many similar
strategies and interventions to target follow-up as a key element.
Based on the significant deterioration of all patients’ warfarin knowledge
after three months, a quarterly follow-up scheme is recommended. The long-term
consequences of patient follow-up on warfarin-related therapeutic outcomes and
adverse drug events, are difficult to predict from the results of this short-term
study, so further research is needed.

7.8 OTHER INTERESTING RESULTS FOUND IN THE RESEARCH STUDY

7.8.1 Introduction
Other interesting results identified in this study will now be discussed.
Firstly, discussions will focus on the impact of prior warfarin knowledge and
general practice visits. Secondly, the effects of the new and customary warfarin
education programs on adverse drug events, hospitalisation and emergency
department visits will be compared. Lastly, discussion will turn to the impact of
written information pertaining to drug-to-drug interactions with warfarin, especially
with regard to complementary medicines.
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7.8.2 Prior warfarin knowledge
The research data indicated that the 39.2 percent (40) of participating
patients (30 percent intervention and 48.1 percent control) who claimed to have
prior warfarin knowledge, did not achieve higher mean scores for their ‘SelfManagement’, ‘Medication-Taking-Measures’ or ‘Warfarin Knowledge’
questionnaires, than the participating patients with no prior knowledge. In other
words, patients in both groups who claimed to have prior warfarin knowledge did
not appear to be more confident with their warfarin management and compliance,
nor did they have a better warfarin knowledge and understanding, than did the
patients with no prior warfarin knowledge.
These results have important implications for warfarin education because
many health professionals perform a quick overview of warfarin information for
patients whom they believe to have prior warfarin knowledge (Haines 1998). It is
therefore important for health professionals not to take for granted information
which has been previously communicated to patients because, despite their best
efforts, they can and do forget (Ansell, Buttaro et al. 1997). The results of this
study imply that all patients receiving warfarin therapy - for the first time or not should ideally receive a complete and thorough warfarin education program with
continuous follow-up, reinforcement and reassurance to help promote good
warfarin knowledge, management and compliance.

7.8.3 General practitioner visits
Following discharge from The Ambulatory Care Team (TACT), patient
participants were cared for by their general practitioners. The data reveal that on
average the patients in both groups visited their general practitioners
approximately seven times each, during the three-month follow-up period. The
intervention group patients who visited their general practitioners more frequently
were more confident about their warfarin management and had a better warfarin
knowledge, than did intervention group patients who visited their general
practitioners less frequently. Conversely, control group patients who visited their
general practitioners more frequently were less confident about their warfarin
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management and had poorer warfarin knowledge, than did control group patients
who visited their general practitioners less frequently. A possible explanation for
these results given that both groups achieved similar overall therapeutic INR
scores, is that the control group patients as opposed to the intervention group
patients were more inclined to let their general practitioners manage their
warfarin therapy for them. Similar to the results found by Dantas et al (2004), it
appears that even though the control group patients were satisfied with the
warfarin information they received and experienced few adverse drug events,
they were more inclined to accept directives rather than be collaborative with
their general practitioners. More research is needed to investigate this further.

7.8.4 Warfarin-related adverse drug events, hospitalisation and emergency
department visits
Eighteen percent (9) of the intervention group patients and 21.2 percent
(11) of the control group patients were hospitalised during the three-month
follow-up period. Importantly, none of these hospitalisations were due to possible
warfarin-related adverse drug events. Instead, 5.9 percent (6) in total for both
groups were due to exacerbations of the disease for which the warfarin was
initially prescribed.
Sixteen percent (8) of the intervention group patients and 11.5 percent (6)
of the control group patients visited the emergency departments during the threemonth follow-up period. In total, only 3.92 percent (4) of these emergency
department visits were associated with minor bleeds potentially caused by
warfarin therapy. These results compare well with reports in the literature
claiming that in anticoagulation clinics, 2.8 percent of patients experience major
bleeds and 18.3 percent of patients experience minor bleeds, and that in general
practice settings, 10.9 percent of patients experience major bleeds and 17.6
percent of patients experience minor bleeds (Ansell, Buttaro et al. 1997). It could
be argued that as this study was only conducted over a short period of time these
results are not a true reflection of what may occur in the long-term. Given that
most warfarin-related adverse events occur within the first few months of therapy
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(Jackson, Peterson et al. 2004; Levine, Raskob, Landefeld and Kearon 2001;
White, Beyth, Zhou and Romano 1999), initial indications of this study show that
both the new and customary education programs are helping to reduce the
number of such occurrences.
These results have important implications because not only have both
programs reduced the incidence of possible warfarin-related adverse events,
they have also reduced hospitalisation costs. With recent increases in warfarinrelated hospitalisations (AIHW 2002; AIHW 2003), it would be fair to assume that
current hospitalisation costs are well in excess of the 1992 estimation of $100
million per annum (Rigby, Clark et al. 1999). Further studies are therefore
required to analyse the potential reductions in warfarin-related adverse drug
events and healthcare costs associated with using the new warfarin education
program.
The 4.9 percent (5) incidence of minor warfarin-related bleeds in this study
is much lower than the 18.3 percent average reported in the literature for
anticoagulation clinics (Ansell, Buttaro et al. 1997). These results and the
absence of any major bleeds associated with warfarin therapy in this study may
be a reflection of the small sample size, however they are noteworthy because
they suggest that both programs potentially reduce the incidence of warfarin
related adverse drug events.

7.8.5 Warfarin information on possible drug-to-drug interactions (including
complementary medicines)
The increasing use of complementary medicines (Harris and Rees 2000;
Shenfield, Atkin and Kristoffersen 1997; Welch 2001) potentially increases
possible drug-to-complementary medicine interactions with warfarin (Myers
2002). This is why participating patients were educated and given the ‘Patient
information on potential drug-to-drug warfarin interactions sheet’ (APPENDIX
27). This information sheet also contains information about interactions between
warfarin and complementary medicines.
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Upon receipt of the drug-to-drug interaction sheet (APPENDIX 27), 10
percent (10) of participating patients who had taken complementary medicines
without their general practitioners’ knowledge either ceased to do so or continued
after consultation with their general practitioners. Without this information,
patients would have taken their complementary medicines without their general
practitioners’ knowledge and potentially caused serious warfarin-tocomplementary medicines interactions.
An important recommendation for future practice would be to ensure that
all patients prescribed warfarin, as well as their health professionals, should be
familiarised with the potential interactions between complementary medicines
and warfarin. This could be done by ensuring that all patients and their health
professionals were given relevant education and information such as the ‘Patient
information on potential drug-to-drug warfarin interactions sheet’ (APPENDIX
27).
Current research is identifying an increasing number of potential
interactions between warfarin and complementary medicines (Myers 2002).
Future research needs to identify how much health professionals and patients
need to know about these interactions to achieve optimal warfarin-related
therapeutic outcomes and minimal adverse drug events.

7.8.6 Summary
The research study identified that patients who had prior warfarin
knowledge did not necessarily have better warfarin knowledge, management,
compliance and therapeutic outcomes than did those with no prior warfarin
knowledge. Increased general practitioner visits did not always lead to improved
warfarin knowledge and management, which confirms the need for regular
patient follow-up, reinforcement and reassurance.
Many of the strategies and interventions incorporated in both warfarin
education programs in this study have successfully contributed to the reduction in
the incidence of warfarin-related adverse events, as well as in the number of
emergency department and hospital visits. With the current increase in the use of
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complementary medicines (Harris and Rees 2000; Shenfield, Atkin et al. 1997;
Welch 2001), health professionals and patients need to be made fully aware of
the potential warfarin-to-complementary medicines interactions to prevent further
possible warfarin-related adverse drug events. The information sheet used in this
study, ‘Patient information on potential drug-to-drug warfarin interactions sheet’
(APPENDIX 27) would be a good starting point. Importantly, each of these
findings provides valuable information to help reduce the large and unresolved
problem of warfarin-related adverse drug events (Halstead, Roughead et al.
1999).

7.9 RECOMMENDATIONS OF THE STUDY

Several recommendations to improve current practice in warfarin education
arose from the research study. These recommendations include the provision of
the following to all patients prescribed warfarin:


the new warfarin education program should be considered suitable as
a possible best practice model for effective home-based warfarin
education program.’



a good quality, simple, easy-to-read warfarin information booklet
(APPENDIX 12).



a warfarin counselling checklist to achieve specific objectives
(APPENDIX 13).



a validated ‘Warfarin Knowledge’ questionnaire to evaluate patients’
warfarin knowledge and understanding based on APPENDIX 19.



a written information sheet about potential drug-to-drug interactions
(including warfarin-to-complementary medicines interactions) such as
the ‘Patient information on potential drug-to-drug warfarin interactions’
(APPENDIX 27).



regular three-monthly follow-up sessions to reinforce and reassure
patients about their warfarin information
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best practice guidelines for the number of INR blood tests which are
required to achieve optimal therapeutic control.



a best practice model for home-based warfarin self-management
programs which incorporates the new warfarin education program and
a structured self-management (self-monitoring) program.

The following are recommendations for all health professionals developing and
producing patient medication education programs:


the regular use of readability tests such as SMOG (McLauglin 1969)
and the Fry Test (Fry 1968) to ensure that patient information is written
below a grade 8 level or preferably a grade 6 level.



the need to develop an easy-to-use healthcare-specific readability
instrument.



the regular use of the ‘Toolkit for producing patient information’ (The
United Kingdom Department of Health 2002) and the ‘Guidelines for
writing patient information’ (Doak, Doak et al. 1996b) when developing
new patient information to ensure that it is written in a simple, easy-toread format.



evaluation of the quality and suitability of written patient medication
information by using instruments such as the ‘Suitability Assessment
Materials’ (SAM) (Doak, Doak et al. 1985), the ‘Bernier Instructional
Design Scale’ (BIDS) (Bernier 1996) and the ‘Checklist for print
materials’ (Bidford Maine Area Health Education Center 1996)
(Appendices 6-8).



target the needs of the ‘high risk’ patient population.

These recommendations, in combination with the interventions and strategies
used in the study to target the five key elements of an effective medication
education program, should be used to improve current medication education
practices, including warfarin education programs. The five key elements which
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need to be improved include: patients/health professional communication and
partnerships; warfarin compliance; simple, easy-to-read warfarin information;
continuity of care between hospital and community settings; and patient followup.

7.10 LIMITATIONS OF THE STUDY

There were a number of limitations in the study, many of which have
already been discussed. The following is a brief overview of these limitations.
One of the major limitations of the study was that the researcher/TACT
pharmacist developed both the new and customary warfarin education programs,
delivered to Illawarra Health’s The Ambulatory Care Team (TACT) patients. This,
together with the fact that many of the strategies and interventions developed for
the new warfarin education program were also absorbed into the customary
warfarin education program during the course of the study, may have affected
the results and made them less significantly different than expected. In hindsight,
it would have been better to compare and contrast the new program with another
home-based warfarin education program available within Australia, because the
results of this study may have been a better indication of the benefits and/or
deficits of the new program.
Another limitation of the study was that it was conducted over a threemonth period and many long-term benefits could not be analysed. Regardless,
long-term analysis would not have been possible in this study because many of
the patient participants were diagnosed with a deep venous thrombosis (41.2
percent). These patients would only have been prescribed warfarin therapy for
three months, making them ineligible for studies conducted over a longer period
of time. Future, longer studies would need to be conducted on patients
diagnosed with an illness such as atrial fibrillation, potentially requiring lifelong
warfarin therapy.
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The inclusion of patient participants from the general population could also
be described as a limitation of this study. As a result, many of the benefits of the
new warfarin program could not be assessed for their direct impact on the ‘high
risk’ group – that is, on patients who were elderly, had low literacy skills and/or
came from non-English speaking backgrounds. It would therefore be useful to
conduct further studies exclusively on ‘high risk’ patients.
The use of readability tools such as the SMOG formula (McLauglin 1969),
the Fry readability formula (Fry 1968) and the Microsoft Word 2000 computerised
Flesch-Kincaid test, which are not healthcare specific, may also be viewed as a
limitation of the study. However, in the absence of a simple, easy-to-use
healthcare specific readability tool there was no alternative in this instance. The
development of such a tool is highly recommended.
For non-English speaking background patients, a limitation in the study
was that the written warfarin information was only available in English. A
recommendation for future studies is to supply each non-English speaking
background patient with a booklet translated into their own native language.
A final imitation of the study was requiring all patient participants to
answer follow-up questionnaires when, in some cases, carers and family
members managed their warfarin therapy for them. Future studies should
therefore ensure that the person responsible for managing the warfarin therapy
answer all the evaluation questionnaires.

7.11 CONCLUSIONS
If current educational practices continue, recent increases in warfarin
prescribing will almost certainly result in an increased incidence of poor warfarinrelated therapeutic outcomes and adverse drug events (Gurwitz, Field et al.
2003; Halstead, Roughead et al. 1999). The patients at ‘high risk’ of experiencing
these poor therapeutic outcomes and adverse events include the elderly and
those with low literacy skills (Estrada, Martin-Hryniewicz et al. 2004; Tang, Lai et
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al. 2003), as well as non-English speaking background patients (Lambert and
Wynne 2003; Nadar, Begum et al. 2003).
The basis of this thesis is good patient warfarin education, which is the key to
improving warfarin knowledge, management and compliance (Haines 1998;
Kagansky, Knobler et al. 2004). These in turn will help to optimise warfarinrelated therapeutic outcomes and minimise adverse drug events by empowering
patients to make educated decisions, as reported in the literature (Australian
Council for Safety and Quality in Health Care 2002; Bhasale, Miller et al. 1998).
The research study focused on developing and evaluating a new warfarin
education program to improve warfarin knowledge, management and compliance
in a wider patient population, inclusive of the ‘high risk’ group.
The new warfarin education program was founded on a conceptual
framework which targeted five key elements of an effective patient education
program. These elements were: health professional/patient communication and
partnerships; warfarin compliance; simple, easy-to-read written warfarin
information; improved continuity of care between hospital and community
settings; and patient follow-up. Many similar strategies and interventions
targeting these key elements were incorporated into both the new and the
customary warfarin education programs during the course of the study and
almost certainly affected the results by making them less significantly different
than expected.
Overall, however, the trend in the results suggested that the new warfarin
education program was more effective than the customary warfarin education
program in educating patients, including ‘high risk’ patients, about their warfarin
therapy. In other words, patients receiving the new warfarin education program
had a better warfarin knowledge and understanding, and were more confident
about their warfarin management and compliance at home.
Both the new and the customary warfarin education programs used in this
study appeared to be more effective than other available warfarin education
programs, achieving better warfarin knowledge scores and therapeutic
outcomes, with fewer warfarin-related adverse drug events and healthcare visits.
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It could be argued, therefore, that the interventions and strategies incorporated in
both programs, which targeted the five key elements in the conceptual
framework, successfully produced a new more effective warfarin education
program.
Throughout the research study, interventions and strategies targeting the five
key elements of an effective education program were applied to the home-based
ambulatory care service TACT. There is no reason why this new home-based
warfarin education program could not be applied to other hospital and
community-based warfarin education programs, especially since the key to
effective anticoagulant management is good patient warfarin education (Haines
1998).
Based on the success of the results in this study, the researcher contends
that by targeting the five key elements of an effective warfarin education
program, a wider patient population, inclusive of those from the ‘high risk’ group,
will be effectively educated about their warfarin therapy. This in turn will help
them to achieve optimum warfarin-related therapeutic outcomes and minimum
adverse drug events.
One of the major benefits of this study is that the conceptual framework, with
its five key elements, provides a blueprint for the development of other effective
patient medication education programs in both hospital and community settings.
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APPENDIX 1
FLESCH Reading Ease Scale (Flesch 1948)
Step 1. Count the words.
Count the words in your piece of writing. Count as single words contractions,
hyphenated words, abbreviations, figures, symbols and their combinations.
Step 2. Count the syllables.
Count the syllables in your piece of writing. Count the syllables in words as they
are pronounced. Count abbreviations, figures, symbols and their combinations as
one-syllable words. If a word has two accepted pronunciations, use the one with
fewer syllables. If in doubt, check a dictionary.
Step 3. Count the sentences.
Count the sentences in your piece of writing. Count as a sentence each full unit
of speech marked off by a period, colon, semicolon, dash, question mark or
exclamation point. Disregard paragraph breaks, colons, semicolons, dashes or
initial capitals within a sentence.
Step 4. Figure the average number of syllables per word.
Divide the number of syllables by the number of words.
Step 5. Figure the average number of words per sentence.
Divide the number of words by the number of sentences.
Step 6. Find your readability score.
Find the average sentence length and word length of your piece of writing on the
chart (below). Take a straightedge or ruler and connect the two figures. The
intersection of the straightedge or ruler with the centre column shows your
readability score.

1

2

You can also use this formula:
Multiply the average sentence length by 1.015. Multiply the average word length
by 84.6. Add the two numbers. Subtract this sum from 206.835. The balance is
your readability score.
The scale shows scores from 0 to 100. Zero means practically unreadable and
100 means extremely easy. The minimum score for Plain English is 60, or about
20 words per sentence and 11/2 syllables per word. Conversational English for
consumers should score at least 80, or about 15 words per sentence and 1 1/2
syllables per word.
Score
90 to 100
80 to 90
70 to 80
60 to 70
50 to 60
30 to 50
0 to 30

School Level
5th grade
6th grade
7th grade
8th and 9th grade
10th to 12th grade (high school)
college
college graduate
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APPENDIX 2

Toolkit for Producing Patient Information(The United Kingdom
Department of Health 2002)
To make the text more inviting to read use the following;












Short sentences-in general no more than 15 to 20 words long
Lower case letters where possible as they are easier to read. Exceptions
to this are proper names and the first letter in a sentence.
Present and active tenses where possible.
A question and answer format is helpful to divide up the test.
Bulleted or numbered points to divide up complicated information.
Small blocks of text. Do not use long paragraphs divide them using
headings and new paragraphs.
White space makes the information easier to read.
Large bold font emphasises text. Avoid upper letters, italics and
underlining as they make the text more difficult to read.
Numbers from one to nine are easy to read if they are written in words,
and numbers from 10 can be represented as numbers.
A font size of no less than 12 point.
Diagrams and pictures are very effective and should be in line with
communication principles. Where appropriate, use them to illustrate the
text, remember to label them and do not print over them. You should not
use clipart as it does not add to the reputation of the professional
organisation.

You should apply these principles to all documents, not just those for people with
sight difficulties. A large number of patients using the NHS will be over 40, and
clear, legible print with the lines not too close together will make documents
easier to read.
 Font size: 12 point (minimum) to 14 point but if you are writing information
for the elderly or people with sight difficulties always use 14 point or larger.
 Use a medium weight typeface for example Frutiger Roman.
 Contrast: use a light background with dark print.
 It is acceptable to use a dark background with white print (reversed out)
for headings but not for large sections of the text.
 Use a sans serif font-Frutiger.
 Justify the text to the left only.
 Use one or two colours.
 Do not write text over background pictures or a design.
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APPENDIX 3
Guidelines for writing patient information (Doak, Doak and Root 1996)
1. Write the way you talk; use active voice.
2. Use common words, and, on average, use short sentences.
3. Give examples to explain hard words.
4. Include interaction and reviews.

Guidelines for typography and layout
a) Type style and size


Use serif type and lowercase lettering, except where grammatically
necessary to use capital letters.



Use 12-point type or larger.



Do not use large or stylised initial letters.



In general, do not use reverse print, that is, white on black.

b) Line length


Try to limit line length to 30 to 50 characters and spaces.



Make the left edge of lines rectified.



Leave right ends of lines ragged.

c) Layout of text on the page


Leave some white spaces on the page to avoid a look of solid text.



Use headers (“road signs”) underlined or in bold print to introduce each
new topic and to break up the appearance of a page of solid text.



Use an eye-catcher, a box or larger font or an indent, to draw readers’
eyes to the most important information.
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APPENDIX 4

SMOG Formula (McLauglin 1969)
1. Count 10 consecutive sentences near the beginning of the text to be
assessed, 10 in the middle and 10 near the end. Count as a sentence any string
of words ending with a period, question mark or exclamation point.
2. In the 30 selected sentences count every word of three or more
syllables. Any string of letters or numerals beginning and ending with a space or
punctuation mark should be counted if you can distinguish at least three syllables
when you read it aloud in context. If a polysyllabic word is repeated, count each
repetition.
3. Estimate the square root of the number of polysyllabic words counted.
This is done by taking the square root of the nearest perfect square for example
95 is 100 which yields a square root of 10. If the count lies roughly between two
perfect squares, choose the lower number. For instance, if the count is 110, take
the square root of 100 rather than of 121.
4. Add 3 to the approximate square root. This gives the SMOG GRADE,
which is the reading grade that a person must have reached if he is to
understand fully the text assessed.
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APPENDIX 5
Fry Readability Formula (Fry 1968)
1. Select three one-hundred-word passages from near the beginning, middle
and end of the book. Skip all proper nouns.
2. Count the total number of sentences in each hundred-word passage
(estimating to the nearest tenth of a sentence). Average these three
numbers.
3. Count the total number of syllables in each hundred-word sample. There
is a syllable for each vowel sound; for example car (1), blackbird (2),
continental (4). Don’t be fooled by word size; for example polio (3),
through (1). Endings such as –y, -ed, -el, or –le usually make a syllable,
for example: ready (2), bottle (2). I find it convenient to count every
syllable over one in each word and add 100. Average the total number of
syllables for the three samples.
4. Plot on the graph the average number of sentences per hundred words
and the average number of syllables per hundred words. Most plot points
fall near the heavy curved line. Perpendicular lines mark off approximate
grade level areas.

Graph from ( Klug Redman 2001 The Practice of Patient Education 9th Edition page 57 )
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APPENDIX 6
SAM (The Suitability Assessment Materials) (Doak, Doak and Root 1985)
SAM Scoring Sheet
2 points for superior rating
1 point for adequate rating
0 points for non-suitable rating
N/A if the factor does not apply to this material.
FACTOR TO BE RATED
SCORE

COMMENTS

1.CONTENT
(a) Purpose is evident
(b) Content about behaviours
(c) Scope is limited
(d) Summary or review included
2. LITERACY DEMAND
(a) Reading grade level
(b) Writing style, active voice
(c) Vocabulary uses common words
(d) Context is given first
(e) Learning aids via “road signs”
3.GRAPHICS
(a) Cover graphic shows purpose
(b) Type of graphics
(c) Relevance of illustrations
(d) Lists, tables, etc, explained
(e) Captions used for graphics
4.LAYOUT AND TYPOGRAPHY
(a) Layout factors
(b) Typography
(b) Subheads (“chunking”) used
5. LEARNING, STIMULATION, MOTIVATION
(a) Interaction used
(b) Behaviour are modelled and specific
(c) Motivation and self-efficacy
6. CULTURAL APPROPRIATENESS
(a) Match in logic, language, experience
(b) Cultural image and examples
.
Total SAM Score____________
Total possible score: ________
Percent score: _____________%
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APPENDIX 7
Bernier Instructional Design Scale (BIDS) (Bernier 1996)
The rating scale:
0= Not met
1= Partially met
2= Met
NA= Not applicable
Principle Scale

0

1

2

NA

1.There is sufficient contrast between the ink and
paper to make reading easy.
2.The font or print size can be read easily by the
target audience.
3.The type style is easy to read.
4.Drawings/illustrations are recognizable to the target
group with or without explanatory text.
5.Drawings/illustrations are labeled clearly.
6.Drawings/illustrations represent racial and ethnic
groups appropriate to the target audience.
7.Titles and subtitles are clear and informative
8.The vocabulary of the PEM is one that reflects
words commonly used by the target group.
9.Necessary health terms are defined.
10.Terms are used in a consistent manner throughout
the PEM.
11.The writing style is one that will actively engage
the reader and stimulate active participation.
12.The active voice is used (e.g. “Many persons with
colostomies find it beneficial to be a member of an
ostomy support group” is better than the passive voice
“Many persons with colostomies have found that they
benefited from an ostomy support group”).
13.The use of double (or multiple negatives) is
avoided (e.g. This sentence is confusing: There is no
reason why a person with diabetes should not
exercise when they are not ill).
14.The purpose of the PEM is made clear to the
target group.
15.The relevance of the educational content to the
target group is clearly stated.
16.The learning objectives that are stated or implied
and the educational content of the PEM relate to one
another.
17.The learning objectives that are stated or implied
relate to the intended learning outcome that is stated
or implied in the PEM.
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18.Only the most essential information about the topic
is presented, using not more than 3-4 main points.
19.The content is accurate.
20.The content is presented in concrete terms rather
than abstract ideas and concepts.
21.The content is written in a style that is ‘patientcentered’ that is, in the perspective of the patient
foremost.
22.The content is presented in a way that relates and
integrates the new information to what is already
known and understood by the target group.
23.Examples are used to bridge the gap between
what the target group already knows and the content
that is to be taught and learned.
24.The examples that are used contain the central
characteristics of the ideas and concepts under
discussion.
25.The content is presented in a manner, which is
respectful of the customs and traditions of the target
group.
26.The information load of the educational material is
appropriate to the target group (The more unfamiliar
the information, the smaller the amount to be
presented at the time).
27.The content focuses on what the target group
should do as well as know.
28.The main ideas of the PEM are divided into
meaningful units of content.
29.The educational material moves from simple to
more complex content in a manner that is organised
and logical.
30. The educational content is current.
31.Specific, precise instructions are given if the target
group is expected to carry out some health or selfcare activity.
32.Important ideas and points of content are repeated
as reinforcement throughout the PEM.
33.Sentences are kept in logical order and present a
coherent structure for the information being conveyed
in the PEM.
34.Summaries/synopses of the educational content
being delivered are included throughout the PEM.
35.The PEM is written at a readability level that is
appropriate to the target group (Materials intended for
the general public should be written at the 6th – 8th
grade level).
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APPENDIX 8

Checklist For Print Materials (Bidford Maine Area Health Education
Center 1996)
Title of Material:_____________________________________________
Directions: Place a check next to each item that meets the described attribute.
ORGANISATION
1 ٱ. The cover is attractive. It indicates the core content and intended audience.
2 ٱ. Desired behaviour changes are stressed. ‘Need to know’ information is
stressed.
3 ٱ. Not more than three or four main points are presented.
4 ٱ. Headers and summaries are used to show organization and provide
message repetition.
5 ٱ. A summary that stresses what to do is included.
WRITING STYLE
6 ٱ. The writing is in conversational style, active voice.
7 ٱ. There is little or no technical jargon.
8 ٱ. Text is vivid and interesting. Tone is friendly.
APPEARANCE
9 ٱ. Pages or sections appear uncluttered. Ample white spaces.
10 ٱ. Lowercase letters used (capitals used only when grammatically needed).
11 ٱ. There is a high degree of contrast between the print and the paper.
12 ٱ. Print size is at least 12 point, serif type, and no stylized letters.
13 ٱ. Illustrations are simple - preferably line drawings.
14 ٱ. Illustrations serve to amplify the text.
APPEAL
15 ٱ. The material is culturally, gender and age appropriate.
16 ٱ. The material closely matches the logic, language, and experience of the
intended audience.
17 ٱ. Interaction is invited via questions, response, suggested action, etc.

1

APPENDIX 9
Guidelines on the continuum of care of quality use of medicines between
hospital and community (Australian Pharmaceutical Advisory Council
1998)
Principle 1:

It is the responsibility of the admitting institution to ensure

the development and coordination of a medication discharge plan for each
patient. The person responsible for coordinating the development,
implementation, and monitoring of the medication discharge plan, including
medication supply and medication information, should be identified as soon as
practicable after admission.
Principle 2:

Hospital staff should obtain an accurate medication history,

including prescription and over-the-counter medicines and other therapies such
as herbal products, at the time of admission.
Principle 3:

Hospital staff should evaluate the current medication at the

time of admission, in consultation with the patient’s general practitioner, with a
view to;
-identifying the appropriateness and effectiveness of current medication
and rationalising current medications if appropriate,
-paying particular attention to any problems associated with current drug
therapy, including any possible relationship with the current medical
condition, and
-documenting allergies and any previous adverse drug reactions.
Principle 4:

During the hospital stay, treatment plans relating to the

probable medication management during the stay and where applicable at
discharge should be developed in consultation with the patient and/or carer.
Hospital staff should negotiate with the patient issues relating to treatment and
the development of a discharge plan, and these discussions should be
documented in the patient’s notes. This plan should form part of the overall care
plan or critical pathway.
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-The use of interpreters may be required to ensure good communication
with people from non-English speaking backgrounds.
-To enable the discharge process to be successful, there needs to be
effective communication and coordination between all relevant
parties in the hospital environment.
-Where appropriate, community health providers, especially the patient’s
general practitioner, should be consulted.
-Carers should also be consulted where appropriate.
Principle 5:

Prior to discharge, pre-discharge medication review and

dispensing of adequate medication should take place in a planned and timely
fashion. Adequate medication means sufficient medication to carry the patient
through to the next arranged review (by their general practitioner, outpatient
clinic, or some other arrangement), or to complete the course of treatment.
If patients are discharged with inadequate supplies of medication, this can
compromise quality of care for the patient. Supply of the medication from the
hospital facility must be adequate to ensure continuity of medication is not
interrupted by the inability to obtain further ongoing supplies if required, within a
reasonable timeframe.
Principle 6:

At the time of discharge, each patient should be provided

with a discharge folio containing relevant information such as Consumer
Medicine Information, a medication record, patient/carer plan, and information on
the availability and future supply of medication.
Principle 7:

No patient should be discharged from hospital until the

details of the admission, medication changes (including additions/deletions) and
arrangements for follow-up have been communicated to the healthcare
provider(s) nominated by the patient as being responsible for his or her ongoing
care.
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APPENDIX 10
Information Required for the Initial New Warfarin Education
Session
1.

New warfarin information booklet (APPENDIX 12)

2.

Warfarin counselling checklist (APPENDIX 13)

3.

Warfarin pretest questionnaire (APPENDIX 15)

4.

Patient demographic data sheet (APPENDIX 16)

5.

‘Self-Management’ questionnaire (APPENDIX 17)

6.

‘Medication-Taking-Measures’ questionnaire
(APPENDIX 18)

7.

‘Warfarin Knowledge’ questionnaire (APPENDIX 19)

8.

‘Satisfaction with Information about Medicines Scale’
(SIMS)(APPENDIX 20)

9.

NPS medicine information line fridge magnet

10. Patient information on potential drug-to-drug warfarin
interactions (APPENDIX 27)
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APPENDIX 11
Typical transcript of the initial new warfarin education session
Good morning/afternoon, my name is Judy Mullan and I am the pharmacist
who has come to speak to you about your warfarin medication and to help you
understand:
 What warfarin is, how it works and how to take it properly.
 What to do if you miss a dose.
 Why regular blood tests are important and what the results mean.
 What the possible side effects are and when to look for medical help.
 Why you need to tell other healthcare providers about your warfarin.
 What other factors such as medicine, food and alcohol can affect your
warfarin dose.

Remember that we are working in a partnership and if you have any concerns
or questions please ask me at anytime. Also, remember that if you follow our
instructions, take your warfarin properly and refer to this booklet, you will help
stop any problems developing from your warfarin therapy.
After the education session you will be expected to manage your own
warfarin therapy at home. It is important for us to know whether you intend to
take your warfarin tablets regularly and follow the recommendations you are
about to learn?
 If Yes – continue with the education session
 If No - explain potential problems and make an appointment for them to
speak to the medical practitioners

Before we begin the session, I would like to ask you a few questions about
what you know about warfarin, so that I can get an idea about how much you
may or may not already know.

Complete Warfarin pre-test questionnaire (Appendix 15).
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The purpose of this questionnaire is also to evaluate the patients’ perceptions
about warfarin and whether or not they have any fears associated with taking
warfarin medication. If they do, attempts should be made to reduce their negative
perceptions and/or fears by using encouragement, reassurance and
reinforcement, as well as providing positive feedback. Giving examples of many
similar cases to theirs, which have been successfully treated with warfarin
therapy also often helps relieve anxieties and fears.
Once the patient is comfortable and confident with the idea of continuing with
warfarin therapy, the education session resumes with the key points underlined
in the new warfarin booklet, also provided as a visual guide.

Warfarin and how it works
Warfarin is an anticoagulant and is sometimes called a ‘blood thinner.’ It
can save your life because it slows down the clotting process and stops harmful
clots forming. Blood clots can be harmful because they can travel through blood
vessels to other parts of the body, such as the lungs and brain. If a blood clot
reaches the blood supply to the brain, it may cause a stroke.
Warfarin starts to work 24 hours after taking a dose, but its full effect may
take between 72 and 96 hours. On the other hand, the effects of a single
Warfarin dose can last between 2-5 days.

Patients are then informed about why their warfarin has been prescribed for them
e.g. preventing harmful clots for atrial fibrillation, helping the body to dissolve a
deep venous thrombosis etc. They are also reminded that although good warfarin
compliance reduces the development of harmful clots, poor compliance can lead
to the development of clots.

Warfarin Brands
Your doctor has ordered your warfarin dose in milligrams (mg).
In Australia, there are two different brands of warfarin, known as ‘Coumadin’ and
‘Marevan.’ TACT has given you the ‘Coumadin’ brand (Tick the Coumadin box).
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However, you need to know that the ‘Marevan’ brand is also available. Unless
your doctor tells you to changes brands in the future, you are to keep taking the
‘Coumadin’ brand of warfarin after you are discharged from our service. To make
sure you are taking the right tablets always check the brand, colour and strength.

Patients are then advised which dose of warfarin to take that night and reminded
that the dose may vary, depending on the INR blood test results. To ensure that
patients know how to manage their doses appropriately, they are asked to make
up possible doses of 9mg, 8mg, 4mg and 3mg, using the warfarin 1mg, 2mg and
5mg tablets given to them.

How to take warfarin
You should always take the exact warfarin dose ordered by your doctor at
the same time every day. We recommend that you take your warfarin tables in
the evening, swallowed whole with a glass of water, either before or after food,
whichever you prefer. Don’t stop taking the tablets or change the dose unless
your doctor tells you to.
The most important thing to remember is to take your warfarin every day.
If you think you will have trouble remembering to take your warfarin, we
recommend that you use a reminder such as a calendar, an alarm clock, a
mobile phone alarm or special tablet boxes.

Patients will be asked what time of day they intend to take their warfarin therapy.
If the patient is unsure or chooses an inappropriate time, then they will be
encouraged to have an evening dose at approximately 6pm.

What to do if you miss a dose?
If you forget to take a dose at the normal time but then remember within about
three hours, you should still take the tablets. However, if you forget for a longer
time do not take a dose, just take your next normal dose when it is due. Never
take a double dose because this could thin the blood too much and cause
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serious bleeding side effects. If this ever happens write down the date and time
you missed your dose in this booklet and tell your doctor that you missed a dose
at your next visit or when you have your blood test. Otherwise, contact your
doctor or pharmacist if you are not sure what to do.

Why are regular blood tests important?
Different people need different warfarin doses to control their blood’s
clotting power and the only way we can work out this dose is from your blood test
results. The blood test is called an INR test or International Normalised Ratio test
and it shows how long it takes your blood to clot. You will need to have regular
INR blood tests so that your doctor can prescribe you the correct warfarin dose.
Generally your INR results should be between 2 and 3. A low INR (below
2) means that your blood may not be thin enough and clots can continue to grow,
whereas an INR above 3 (and in some situations above 3.5) may mean that your
blood is a little too thin and the dose of warfarin needs to be lowered before any
bleeding side effects occur.
You must always follow your doctor’s orders for regular INR blood tests,
as well as writing down your INR blood test results on pages 18-21 of this booklet
within 24 hours of the test.

Patients are reminded that their dose may need to be adjusted according to their
INR blood results. Therefore, blood results outside of this therapeutic range
(generally 2-3) need to be addressed immediately so that dosage adjustments
can be made and optimal therapeutic outcomes achieved. Also, patients are
reassured that regular blood tests, visits to the doctor and complying with the
recommendations in the booklet will help to stop any of these problems
developing.
The researcher/pharmacist takes the time to fill in the patient’s first few warfarin
doses, on pages 18-21 of the new warfarin booklet. She also shows them where
to fill in their own INR results, warfarin dosage and appointment times in the
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future. Patients are encouraged to keep these records as valuable information for
themselves, their medical practitioner and specialists.

Possible side effects and when to look for medical help
Warfarin does thin the blood and therefore can increase the incidence of
bleeding and bruising which you will notice straight away. There are, however,
some very important signs of serious bleeding, which you need to know about.

The early warning signs of serious bleeding include:
 nosebleeds
 bleeding gums
 dark red or dark brown urine
 red or black faeces (dark stools)
 cuts that bleed for a much longer time
 unexplained bruising or other bleeding

If you notice any of these, contact your doctor or local emergency
department immediately because the earlier a problem is found, the easier it is to
solve. You will also need to tell your doctor about any of the following symptoms;
vomiting, diarrhoea, pain, swelling and shortness of breath, because these can
also affect, or be the effects of, inadequate warfarin therapy.

Patients are reminded that even though the likelihood of serious bleeding
complications are rare when the recommendations are followed and regular
blood tests are performed, in the event that they should occur, immediate
medical attention needs to be sought.

Inform other healthcare providers
Your will need to inform all your healthcare providers, including:
specialists; doctors; dentists; pharmacists; nurses; physiotherapists; massage
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therapists; other healthcare workers; friends and relatives who look after you,
that you are taking warfarin tablets.

Explain to patients that this is important because these healthcare providers may
want to undertake a procedure or give medications which could result in an
adverse event (e.g. bleeding) when used in combination with the warfarin
therapy.

You might like to consider wearing Medic Alert jewellery (e.g. bracelets or
pendants) available from your pharmacy, to let others know that you take
warfarin tablets.

This should especially be encouraged when patients are elderly, live alone
and/or have any cognitive and physical limitations.

What else can affect your warfarin dose?
Other medicine(s), food and alcohol can affect how warfarin works. Tell
your doctor if there are any big changes in the medicine, alcohol or food that you
normally take because these can affect your warfarin dose.
Patients are then given the ‘Patient information on potential drug-to-drug warfarin
interactions’ (Appendix 27), which is used as a visual guide while talking about
the following possible interactions.

Some examples of medicines which can affect the way warfarin works
include:
 Prescription medicines - old and new medicines, in particular antibiotics and
heart medication such as Amiodarone.
 Non-prescription medicines – medicines bought in the chemist, supermarket
or health food store.
 pain relievers (e.g. aspirin and NSAID such as ibuprofen)
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 cough and cold medicines
 stomach remedies (e.g. antacids)
 laxatives
 some creams for tinea
 rubs and liniments
 vitamins

To ensure that patients have understood, the researcher/pharmacist asks them
which medications they could take and which medications they should definitely
avoid taking, if they develop a headache or pain while on warfarin therapy.
 Natural and Herbal Preparations
Many natural or herbal products can affect the way warfarin works. You
should therefore talk to your doctor or avoid taking: garlic supplements; gingko
biloba; herbal teas, especially ‘Green Tea’; Chinese herbs, especially “Dong
Quai”; St. John’s Wort and many other herbal preparations referred to in the
“Patient information on potential drug-to-drug warfarin interactions” (APPENDIX
27).
 Vitamin Supplements
Also talk to your doctor before taking vitamin supplements, because
vitamins C, E, and K (especially high doses) can affect the way your warfarin
works. Eating a well-balanced diet will provide you with enough vitamin
supplements.

Ask the patient whether or not they are taking any of these or any other
complementary medicines. If the answer is yes, highlight the potential
interactions on their copy of the ‘Patient information on potential drug-to-drug
warfarin interactions’ (Appendix 27) and suggest that they either cease taking
them or talk to their general practitioner about taking them.
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The researcher/pharmacist should now perform a medication review on all the
patients’ medications including their complementary medicines, to ensure that
there are no drug-to-drug interactions with their warfarin therapy. Advice about
the timing of their doses should subsequently be given to patients to minimise the
chances of any interactions. Any recommendations for changes in medications
should be done in collaboration with the patient’s medical practitioners and/or
other members of The Ambulatory Care Team.
 Alcohol
Since alcohol can affect the warfarin dose you can drink alcohol in
moderation (no more than 2 units per day) and avoid binge drinking.
 Your Diet
Do not crash diet or binge-eat because your warfarin dose will be
balanced with your eating habits. Most importantly Vitamin K has the opposite
effect to warfarin, which is why you should eat no more than normal amounts of
vitamin K rich foods. These foods include: green leafy vegetables (spinach,
broccoli, lettuce, cabbage, brussels sprouts, alfalfa), canola, soybean and olive
oils. We highly recommend that you have a well balanced diet and take in
consistently small amounts of vitamin k rich foods.

Other things to consider
As already mentioned, warfarin can cause increased bleeding and bruising
which is why you should avoid contact sports such as basketball, football and
kick boxing.
Ask patients if they play any contact sport and advise them accordingly.

Pregnancy must be avoided (Only discuss this when and if appropriate).
If you decide to go away on a holiday while you are still on your warfarin
therapy, you will need to check with you doctor. You should always take enough
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warfarin tablets with you and if you intend to stay for more than two weeks, you
will need to organise INR blood tests while you are away.

Handy Hints
These are some handy hints for you while you are on your warfarin therapy:
 Since warfarin causes increased bleeding and bruising, try to avoid cutting
yourself or bumping yourself
 Use a non-slip bath mat when bathing
 Use a soft bristle toothbrush
 Use gloves when gardening
 Use an electric shaver when shaving
We’ve now come to the end of the education session and I was wondering
whether or not you had any questions or concerns you would like to discuss with
me.
If “yes”, the patient’s questions are to be answered using positive
encouragement, reinforcement and reassurance.
If “no”, remind the patient that they can contact the TACT office, seven days a
week between 8.30am and 9.30pm, if they have any concerns or queries
regarding their warfarin therapy. The TACT telephone number on the back of the
TACT information leaflet should be underlined.
Alternatively, recommend that patients contact the National Prescribing Service
(NPS) medicines information line on 1300 888 763, Monday to Friday between
9am to 6pm (The fridge magnets containing these details should now be issued
to the patients). Also inform patients of the relevant internet sites listed at the
back of the warfarin information booklets; http://www.nps.org.au;
http://www.coumadin.com and http://www.warfarininfo.com
The researcher/pharmacist once again reinforces the key points of the education
session as per the ‘Warfarin Counselling Checklist’ (APPENDIX 13) offering the
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reassurance that if the warfarin therapy is taken properly, it will be safe and
effective.

To make sure that you have understood what you have been taught, I would like
to ask you a few questions.
 Why is it important not to miss a dose of warfarin and what should you do
if you miss a dose?
 What brand of warfarin have you been given?
 What dosage of warfarin will you be taking today?
 Why is it important to have regular INR blood tests and what is your
expected INR range?

Upon completion of these questions by the patients they are reminded about
having to complete their questionnaires, both immediately and in three months
time over the telephone.
Finally the patients are informed that the new warfarin booklets have been
especially designed and printed for use in Judy Mullan’s Ph.D. project ‘To
develop and trial a new warfarin education program to help improve warfarin
knowledge, management and compliance in a wider warfarin prescribed
population’ and if they would like further information regarding the project, to
please contact:

Ms Judy Mullan
Graduate School of Public Health
Faculty of Health and Behavioural Science
University of Wollongong NSW 2500
Phone 02 4221 4274
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APPENDIX 13
Warfarin Counselling Checklist (adapted from Witte, Gurwich et al 1980)
 Reason for anticoagulation (e.g. PE, DVT, AF, others)
 Explanation about what warfarin is and how it works
 Patient’s regimen
Identification of warfarin brand, colour and strength
Dosage, route and frequency of warfarin tablets
Importance of compliance
What to do if a dose is missed
 Emphasise the importance of regular INR blood tests
 Alert patients to warfarin-related side effects
Bleeding/bruising
Possible signs of warfarin toxicity
Proper action to take in case of an emergency
 Tell all their healthcare practitioners about their warfarin regimen
Encourage medical bracelets
 Inform patients about factors which can affect warfarin dosage
Other medications -prescribed
-non-prescribed
-complementary
Alcohol
Diet
Exercise
Avoid Pregnancy - when and if applicable
 Note that patients should use:
Non-slip mats in the bath/shower
Soft bristle toothbrush
Garden gloves
Electric razor instead of blades
 Reassurance
Warfarin therapy, when taken properly, is safe and effective
Careful monitoring is essential: regular INR blood tests; visits to the GP;
and documentation of all INR results
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APPENDIX 14
New Warfarin Education Program Objectives (Witte, Gurwich, Anzalone and
Campagna 1980; Wyness 1990; Haines 1998)
Overall Goal: The patient takes warfarin effectively and safely.
1. Understands what the warfarin does
1.1 explains the action of the warfarin
1.2 explains the reason for taking the warfarin
1.3 explains how quickly the drugs works
2. Understands how to take the warfarin safely
2.1 explains how to take the warfarin
2.2 explains the frequency of taking the warfarin
2.3 predicts the optimum time of day for taking the warfarin
2.4 explains use of an aid (e.g. calendar, alarm device) to remember to take warfarin and
to record INR results
2.5 identifies the action to take if a dose is missed or may have been missed
2.6 explains that warfarin may be prescribed using generic and trade names
2.7 explains the reason the same brand of the drug should be used consistently
2.8 explains who will prescribe the warfarin and when
2.9 explains the importance of identifying the correct tablet by checking the brand, colour
and strength in milligrams
3. Understands facts about the INR test
3.1 describes the term INR (International Normalised Ratio)
3.2 states the need to go to a laboratory for regular INR tests
3.3 explains the reason INR is measured
3.4 explains the relationship of INR to amount of drug prescribed
3.4 describes the procedure for obtaining INR results and recording them appropriately
3.5 explains the goal international normalised ratio
3.6 explains the reasons accurate drug-taking is essential
3.7 explains potential consequences associated with a low INR
3.8 explains potential consequences associated with a high INR
4. Understands possible side effects and what should be done if they occur
4.1 identifies signs of bleeding to report
4.2 explains bruises may occur easily and indications for reporting
4.3 identifies any symptoms or illness to report
4.4 identifies all health care workers e.g. dentist, pharmacist and podiatrist as
individuals to notify
4.5 identifies the need to inform all health professionals prior to surgery

1

4.6 identifies the benefits for carrying identification card and wearing Medic Alert tag
5. Understands factors affecting anticoagulant dosage
5.1 Other medications
5.1.1 identifies prescription medicines new and old can alter the effects of warfarin
5.1.2 identifies nonprescription medicines (including complementary medicines) can alter
the effects of warfarin
5.1.3 explains that prior to taking any medication (prescribed or non-prescribed) the
patient should check with their doctor or pharmacist
5.1.4. explains that many natural and herbal preparations can alter the effects of warfarin
5.1.5 explains that vitamin supplements, especially vitamins C; E and K, can alter the
effects of warfarin
5.1.6 explains the effect of alcohol
5.2 Diet
5.2.1 explains the reason for maintaining a similar day-to-day dietary intake
5.2.2 explains the effect of vitamin K on action of warfarin
5.2.3 gives examples of foods high in vitamin K
5.3 Lifestyle
5.3.1 explains hazards of physical injury when taking oral anticoagulants
5.3.2 identifies activities such as sewing, gardening, kitchen activities, sports, use of
power tools, as areas for caution
5.3.3 identifies activities of daily living that may need to be modified to prevent injury
5.3.4 explains action to take if travel is planned
5.3.5 identifies the dangers of pregnancy whilst prescribed warfarin
6. Demonstrates commitment to ongoing knowledge and safety.
6.1 proposes adaptations to be made in lifestyle as necessary
6.2 suggests other possible sites for gathering warfarin information
6.3 states expected duration of the warfarin regimen
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APPENDIX 15
Pretest Questionnaire
(Circle one response Answered by patient

carer

patient and carer)

Question 1
Have you ever taken warfarin before?
Question 2
Do you know anything about warfarin?

Yes or No.

If No. Go directly to education session
If Yes.
a. How does warfarin work?

b. Does warfarin have any side effects?

c. How and when should warfarin be taken?

d. What else do you know about warfarin?
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APPENDIX 16
Patients Demographic Data Sheet
Date…………………………………
Client ID……………………………Intervention/Control .
Family Name…………………………….……Given Name …………………………...
Address…………………………………………………………………………………….
Suburb…………………………………Telephone………………………………………
DOB……………………

Sex

M/F

Weight…………………………..

Occupation………………………………………Educational Level……………………
Allergies……………………………………
Other Medications
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………..……
Referral source……………………………………GP Name…………………………
Date of Commencement…………………………………………………………………
Referral Diagnosis…………………………………………………………………….
Past Medical Surgical History…………………………………………………………...
………………………………………………………………………………………………
Relevant Investigation and results (e.g. Doppler) …………………………………..
Next of Kin/Carer……………………Present at Educational Session Yes/No
Language spoken at home………………………Country of Birth…………………..
Interpreter needed Yes/ No
Aboriginal or Torres Strait Islander Yes / No
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APPENDIX 17
‘Self-Management’ Questionnaire ( adapted from Lorig, Stewart, Ritter,
Gonzales, Laurent and Lynch 1996)

(Circle one response Answered by patient

carer

patient and carer)

1. How confident are you that you can take warfarin tablets correctly?
Not at all confident

1

2

3

4

5 Totally confident

2. How confident are you that you can recognise serious bleeding side
effects which need medical help?
Not at all confident

1

2

3

4

5 Totally confident

3. How confident are you that you can self-manage your warfarin at
home? (hint: especially with regard to your diet, alcohol and/or other
medications)
Not at all confident

1

2

3

4

5 Totally confident

4. How confident are you that you know and understand the information
given to you about warfarin?
Not at all confident

1

2

3

4

5 Totally confident

5. Are you worried about taking warfarin tablets?
( ) No

( ) Yes

If yes
I. What is it about taking warfarin tablets that worries you?

II. Has the warfarin education program affected your worries
about taking warfarin tablets?

III. Other comments

6. Ask the carer (if present) for any comments about the education
program or their concerns about the warfarin tablets.
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Appendix 18
‘Medication-Taking-Measures’ Questionnaire (Morisky, Green and
Levine 1986)

(Circle One response Answered by patient

carer

patient and carer)

Please circle “Yes” or “No” for each question:
1. Do you ever forget to take your medicine?

Yes

No

2. Are you careless at times about taking medicine?

Yes

No

3. When you feel better do you sometimes stop taking your medicine?
Yes

No

4. Sometimes if you feel worse when you take the medicine, do you stop taking
it?
Yes
No

Comments
___________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
_______________________________________________

Scoring: This scale is designed to test medication compliance. To score,
code “Yes”=0, “No”=1. The sum of the answers is the score. A score of 4 is
considered high compliance, 3 is moderate compliance, and 2 or less is low
compliance.
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APPENDIX 19
‘Warfarin Knowledge’ Questionnaire (adapted from Scalley, Kearney and
Jacobs 1979; Witte, Gurwich et al. 1980; Wyness 1990; Horne, Hankins and Jenkins 2001)

(Circle one response Answered by patient

carer

patient and carer)

Question 1
Which brand of warfarin is prescribed for you?
Question 2
Why is the warfarin prescribed for you?
Question 3
How does the warfarin work?
Question 4
What are the different strengths and colours of your warfarin tablets?
Question 5
How will you know what dose of warfarin to take?
Question 6
How and when should you take your dose of warfarin?
Question 7
What should you do if you forget to take your dose of warfarin?
Question 8
Can you suggest two things which you could use to remind you about taking your
warfarin tablets if necessary?
Question 9
Why should you have regular INR (International Normalised Ratio) blood tests?
Question 10
What is your target INR blood test range?
Question 11
1. What are FOUR signs of bleeding from too much warfarin?
2. What should you do if you notice any of these side effects?
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Question 12
Why is it necessary to tell your doctor about starting or stopping any other
medicines, including prescribed medicines (e.g. antibiotics), non-prescribed
medicines (e.g. cold and flu tablets) and herbal or vitamin preparations?
Question 13
1. Do you need to tell your dentist that you are taking warfarin?
2. Should you tell any of your other healthcare providers that you are taking
warfarin?
Question 14
Which medicine could you take for pain relief (e.g. a headache) while taking
warfarin?
Question 15
Are there any foods that can affect how warfarin works?
Question 16
Is it safe to drink alcohol while taking warfarin?
Question 17
Name TWO activities or things you need to be careful doing while taking
warfarin?
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APPENDIX 20
Satisfaction with Information About Medicines Scale (SIMS)
(Horne, Hankins et al. 2001)
We would like to ask you about the information you have received about your medicines. Please
rate the information you have received about each of the following aspects of your medicines. If
you use more than one medicine, please give your overall feeling about information you have
received about all your medicines.
(Rated: too much, about right, too little, none received, none needed).
1. What your medicine is called.
2. What your medicine is for.
3. What it does.
4. How it works.
5. How long it will take to act.
6. How you can tell if it is working.
7. How long you will need to be on your medicine.
8. How to use your medicine.
9. How to get a further supply.
10. Whether the medicine has any unwanted effects (side effects).
11. What are the risks of you getting side effects?
12. What you should do if you experience unwanted side effects.
13. Whether you can drink alcohol whilst taking this medicine.
14. Whether the medicine interferes with other medicines.
15. Whether the medication will make you feel drowsy.
16. Whether the medication will affect your sex life.
17. What you should do if you forget to take a dose.
Other information (please specify below)
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APPENDIX 21
Outcome Measures Of The Warfarin Education Program Questionnaire
(adapted from Lorig, Stewart et al. 1996 page 53-55)
1.In the past three months have you tried to find out more information
about your warfarin therapy?
( )No ( )Yes
If yes:
i. Where did you go for this information ? e,g. general practitioner, NPS
medicines number, internet, etc
ii. How many hours did you spend looking for this information?
1= None
2=1 - 5 hours
3=6 - 10 hours
4= 11 or more hours
2.In the past three months how many times did you visit your doctor?
How many visits________________
3. In the past 3 months how many times did you stay in a hospital overnight
or longer?
( ) None

_____times

How many nights in total did you stay in a hospital?
( ) None
_____nights
Reason for hospitalisation____________________________________
4. In the past three months did you visit the emergency department?
( ) None

How many visits__________

Reason for emergency department visit (s)_______________________
5. In the past three months have you had any warfarin related side effects
(e.g. nose bleeds, blood in
urine)?______________________________________
_______________________________________________________________
6. Record your INR values over the three-month period.
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APPENDIX 22
DISCERN
(Charnock, Sheppard et al 1999; Shepperd and Charnock 2002)
SECTION 1: Is the publication reliable?
1. Are the aims clear?
No
1

2

Partially
3

4

Yes
5

Hint: Look for a clear indication at the beginning of the publication:


What it is about



What it is meant to cover (and what topics are meant to be excluded)



Who might find it useful

If the answer to Question 1 is “No”, go directly to Question 3
2. Does it achieve its aims?
No
1

2

Partially
3

4

Yes
5

Hint: Consider whether the publication provides the information it aimed to as
outlined in Question 1
3. Is it relevant?
No
1

2

Partially
3

4

Yes
5

Hint: Consider whether:


The publication addresses the questions that readers might ask



Recommendations and suggestions concerning treatment choices are realistic or
appropriate

4. Is it clear what sources of information were used to compile the publication
(other than the author or producer)?
No
Partially
Yes
1
2
3
4
5
Hint:


Check whether the main claims or statements made about treatment choices are
accompanied by a reference to the sources used as evidence e.g. a research
study or expert opinion



Look for a means of checking the sources used such as a bibliography/reference
list of the addresses of the experts or organisations quoted, or external links to
the online sources
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Rating Note: In order to score a full ‘5’ the publication should fulfill both hints. Lists of
additional sources of support and information (Question 7) are not necessarily sources
of evidence for the current publication
5. Is it clear where the information used or reported in the publication was
produced?
No
1

2

Partially
3

4

Yes
5

Hint Look for:


Dates of the main sources of information used to compile the publication



Dates of any revisions of the publication (but not dates of reprinting in the case of
print publications)



Date of publication (copyright date)

Rating note: The hints are placed in order of importance - in order to score a full ‘5’ the
date relating to the first hint should be found
6. Is it balanced and unbiased?
No
1

2

Partially
3

4

Yes
5

Hint: look for:


A clear indication of whether the publication is written from a personal or
objective point of view



Evidence that a range of sources of information were used to compile the
publication e.g. more than one research study or expert



Evidence of an external assessment of the publication

Be wary if:


The publication focuses on the advantages or disadvantages of one particular
treatment choice without reference to other possible choices



The publication relies primarily on evidence from single cases (which may not be
typical of people with this condition or of responses to a particular treatment)



The information is presented in a sensational, emotive or alarmist way

7. Does it provide details of additional sources of support and information?
No
1

2

Partially
3

4

Yes
5

Hint: look for suggestions for further reading or for details of other organisations
providing advice and information about the condition and treatment
choices
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8. Does it refer to areas of uncertainty?
No
1

2

Partially
3

Yes
5

4

Hint:


Look for discussion of the gaps in knowledge or differences in expert opinion
concerning treatment choices



Be wary if the publication implies that treatment choice affects everyone in the
same way, e.g. 100% success rate with a particular treatment

SECTION 2: How good is the quality of information on treatment choices?
N.B. The questions apply to the treatment (or treatments) described in the publication.
Self-care is considered a form of treatment throughout this section.
9. Does it describe how each treatment works?
No
1

2

Partially
3

Yes
5

4

Hint: Look for a description of how a treatment acts on the body to achieve its effect
10. Does it describe the benefits of each treatment?
No
1

2

Partially
3

Yes
5

4

Hint: Benefits can include controlling or getting rid of symptoms, preventing recurrence
of the condition and eliminating the condition, both short-term and long-term
11. Does it describe the risks of each treatment?
No
1

2

Partially
3

4

Yes
5

Hint: Risks can include side effects, complications and adverse reactions to treatment,
both short-term and long-term
12. Does it describe what would happen if no treatment is used?
No
1

2

Partially
3

4

Yes
5

Hint: Look for a description of the risks and benefits if postponing treatment, of watchful
waiting (i.e. monitoring how the condition progresses without treatment) or of
permanently forgoing treatment
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13. Does it describe how the treatment choices affect overall quality of life?
No
1

2

Partially
3

Yes
5

4

Hint: Look for


Description of the effects of the treatment choices on day-to-day activity



Description of the effects of the treatment choices on relationships with family,
friends and carers

14. Is it clear that there may be more than one possible treatment choice?
No
1

2

Partially
3

Yes
5

4

Hint: Look for:


A description of who is most likely to benefit from each treatment choice
mentioned, and under what circumstances



Suggestions of alternatives to consider or investigate further (including choices
not fully described in the publication) before deciding whether to select or reject a
particular treatment

15. Does it provide support for shared decision-making?
No
1

2

Partially
3

Yes
5

4

Hint: Look for suggestions of things to discuss with family, friends, doctors or other
health professionals concerning treatment choices
SECTION 3: Overall rating of the publication
16. Based on the answers to all of the above questions, rate the overall quality of the
publication as a source of information about treatment choices
LOW

MODERATE

HIGH

Serious or
extensive
shortcomings

Potentially
important but
not serious
shortcomings

Minimal
shortcomings

1

2

3

4

5

Copyright British Library and the University of Oxford 1997
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APPENDIX 23
UNIVERSITY OF WOLLONGONG
Research Information Sheet For Illawarra Health Staff
RESEARCHER:

Judy Mullan (Ph.D. student)

SUPERVISORS:

Assoc Professor Heather Yeatman
Professor Patrick Crookes

DEPARTMENT:

Graduate School of Public Health

My name is Judy Mullan and I am undertaking research toward my Ph.D.
in the Graduate School of Public Health at the University of Wollongong. I am
employed by Illawarra Health as a part-time pharmacist with The Ambulatory
Care Team (TACT). My background in pharmacy has led to a special interest in
patient education, especially with regard to warfarin, which is the focus of this
research.
The purpose of this research study is to develop and trial a new patient
warfarin education program based on a conceptual framework, which reflects
‘best evidence’ with regard to patient medication education programs. The new
program will be compared and contrasted against the customary warfarin
education program delivered to TACT patients who are prescribed the oral
anticoagulant warfarin.
This comparative analysis will assist with the evaluation of the new
program and its impact on warfarin knowledge, management and compliance for
the wider warfarin prescribed population. This population includes the ‘high risk’
patient populations such as the elderly, those with low literacy skills and those
from non-English speaking backgrounds.
Overview of the Research Study


Eligible Participants: Patients admitted to TACT, who are newly prescribed
warfarin, or who have recommenced on warfarin after at least 15 years,
will be considered eligible participants. They will be made aware of the fact
that their participation in the research study is voluntary and that they are
free to withdraw from the study at any time. They will also be notified that
their refusal to participate in the study or their withdrawal from the study
will not detrimentally affect their Illawarra Health TACT service in any way.



Participant Demographic Data: Routinely collected by the TACT
pharmacists from the patients, their notes and the Dracis database will
provide important patient medical information which can be used to ensure
optimal therapeutic management and outcome evaluation. An analysis of
the demographic patient information will also help establish whether or not
demographic variables have impacted on the outcomes of the different
patient warfarin education programs.
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Throughout the research process the patients’ names will be coded and all
the demographic data will remain confidential and locked in a secured
cabinet at the University of Wollongong.


Warfarin Education Sessions: These will take place in the patients’ homes,
or at an alternative place specified by the patient. The 50 intervention
patients will receive the new warfarin education program and the 50
control patients will receive the customary warfarin education program,
each of these education sessions will take approximately 30 minutes.

Evaluation of the Patient Participants


Immediately and three months after the initial warfarin education session,
all consenting patient participants will be asked to complete four
questionnaires which will take approximately 20 minutes. The initial
questionnaires will be answered immediately after the education session
and the three-month follow-up questionnaires will be answered over the
telephone. These questionnaires relate to warfarin self-management,
warfarin compliance, warfarin knowledge and understanding, as well as
satisfaction with the warfarin information provided.



During the three-month telephone follow-up, patients will be asked to
complete their evaluation questionnaires, as well as their outcome
measures questionnaire. The latter asks questions about INR results and
health care visits (e.g. general practitioner, hospital and emergency
department visits.)

If you have any enquiries about the research, please contact myself or my
supervisors and we will gladly help with any questions or concerns pertaining to
this research.
Researcher: Judy Mullan (e-mail jmullan@uow.edu.au, mobile 0412175029)
Supervisors: Associate Professor Heather Yeatman (02) 4221 3555
Professor Patrick Crookes (02) 4221 3123

Looking forward to your cooperation with this research,
Judy Mullan
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APPENDIX 24
Suggested Dialogue for Patient Recruitment and Obtaining Consent
“ Judy Mullan, one of the TACT pharmacists, is currently researching ways in which to improve
the warfarin education delivered by TACT. This involves obtaining information from our patients
that will assist with improving the educational services we deliver. If you are interested in
participating in the research study I will provide you with an information sheet and explain the
process to you. Would you like me to give you more information?”

If the answer is No –thank them for their kind consideration and inform them that their care will
not be compromised in any way.
If the answer is YES- give the patient a ‘Patient Participant Information Sheet’ and proceed.

“This is the information sheet that has all the details of the research study. You can keep this for
your own reference, however I will now read through the details with you” (read through and
explain the information on the sheet).

On completion of reading the ‘Patient Participant Information Sheet’ continue with:

“Because this is a research study, your written consent is required for you to be an active
participant and so the information you provide can be used. This is the consent form which is
written in the standard format for Illawarra Health and the University of Wollongong ” (show
patients the ‘Patient Participant Consent Form’ and then read through and explain the information
on the consent form).
If the patient gives verbal consent, ask them to sign in the space provided, also enter the date.
Ensure that the patient receives and keeps the ‘Patient Participant Information Sheet’.

“A TACT pharmacist will contact you by telephone to make an appointment for the warfarin
education session which will take place in your own home, or an alternative place which you
prefer, at a time that suits you.”
“Do you have any questions about the research study?” (Answer if possible, if not assure them
that the pharmacists will address any of their concerns).
“Thank you for your support and cooperation.”
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APPENDIX 25

UNIVERSITY OF WOLLONGONG
Patient Participant Information Sheet
RESEARCHER:

Judy Mullan

SUPERVISORS:

Associate Professor Heather Yeatman
Professor Patrick Crookes

DEPARTMENT:

Graduate School of Public Health,
The University of Wollongong

Judy Mullan is a pharmacist working for Illawarra Health’s The Ambulatory
Care Team (TACT), doing research toward her Ph.D. in the Graduate School of
Public Health at the University of Wollongong. Her background in pharmacy has
led to a special interest in patient information, especially with regard to warfarin,
which is the focus of this research.

The research study aims to provide a new warfarin education program,
which will help to improve warfarin knowledge, management and compliance for
a wider warfarin prescribed population. To gain this information, she is inviting
you to take part in the study where you will be given either the customary or the
new warfarin education program. The education session will be given at a time
and place you choose, preferably your own home, and throughout the study your
name and everything you say and write will remain confidential.

At the completion of the education session you will be asked to complete
four questionnaires on two separate occasions, immediately and three months
after the education session. The initial education session and the questionnaires
will take approximately 30 minutes each and the answers will be recorded and
evaluated with your approval. You will be contacted by telephone to complete the
three-month follow-up questionnaires and you will also be asked a few questions
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relating to your health outcomes. The health outcome questions will be about
your INR results, general practitioner visits, hospital visits and possible warfarinrelated adverse drug events.

Your participation in this research study is voluntary and you are free to
withdraw at any time. If you choose to participate in the research study you will
be asked to give your permission for the researcher to view your medical
records, including the information available on the Dracis database, as well as
your blood test results from your pathology service if you do not have your own
records available. Also, if you choose to withdraw from the research study at any
time, you will be allowed to withdraw all your personal data if you so wish. Upon
withdrawal from the research study your refusal to participate or withdrawal of
consent will not in any way affect the service provided to you by The Ambulatory
Care Team (TACT).

If you have any enquiries about the study, please contact Judy Mullan or
her supervisors and they will gladly help you with any queries or concerns you
may have in relation to this research study.

Researcher/ Pharmacist Judy Mullan

0412175029 (mobile)
e-mail jmullan@uow.edu.au

Supervisors: Associate Professor Heather Yeatman 02 4221 3555
Professor Patrick Crookes 02 4221 3123.

If you have any concerns or complaints regarding the way the research study is
or has been conducted, you can contact the Complaints Officer, Human
Research Ethics Committee, University of Wollongong on (02) 4221 4457.

Looking forward to your involvement in this research,
Judy Mullan
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APPENDIX 26
UNIVERSITY OF WOLLONGONG
Patient Participant Consent Form
RESEARCHER:

Judy Mullan (0412175029; e-mail: jmullan@uow.edu.au)

SUPERVISORS:

Associate Professor Heather Yeatman (02 4221 3555)
Professor Patrick Crookes (02 4221 3123)

DEPARTMENT: The Graduate School of Public Health
TITLE: To develop and trial a new warfarin education program which will help to
improve warfarin knowledge, management and compliance for a wider warfarin
prescribed population.

I have been given information about the proposed study and have discussed the
research project ‘To develop and trial a new warfarin education program which
will help to improve warfarin knowledge, management and compliance for a
wider warfarin prescribed population’ with a TACT staff member. I understand
that this research is being conducted as part of a Ph.D. study in the Graduate
School at the University of Wollongong.

I understand that if I consent to participate in the project, I will be expected to
participate in a warfarin education program, complete evaluation questionnaires
and a telephone questionnaire within a 3-month period. I have been informed
that my responses will be recorded and evaluated. I have also been informed
that anything I say will be kept confidential and my name will not be revealed to
anyone. I have been advised of the potential risks and burdens associated with
this research and have had an opportunity to ask the TACT staff member about
any questions I may have with regard to the research and my participation.
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I understand that my participation in this research is voluntary, which means that
I am free to refuse to participate and I am free to withdraw from the research at
any time. My refusal to participate or my withdrawal of consent will not affect my
treatment or health care in any way.

I am aware that if I have any enquiries about the research study, I can contact
Judy Mullan, Associate Professor Heather Yeatman and Professor Patrick
Crookes (4221 3555) for further information. Alternatively, if I have any concerns
or complaints regarding the way the research is or has been conducted, I can
contact the Complaints Office, Human Research Ethics Committee, University of
Wollongong on 02 4221 4457.

By signing below I am indicating my consent to participate in the research
entitled ‘To develop and trial a new warfarin education program which will help to
improve warfarin knowledge, management and compliance in a wider warfarin
prescribed population’ conducted by Judy Mullan, as it has been described to me
in the information sheet and in discussion with me. I understand that the data
collected from my participation will be used for the purpose of a thesis,
conference presentations and journal publications, and I consent for it to be used
in this manner.

Signed………………………………………………Date………………………
Name (please print)……………………………………………………………....
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APPENDIX 27
Patient Information on drug-to-drug warfarin interactions
MEDICINES WHICH CAN AFFECT WARFARIN


Antibiotics



Antifungals



Antiplatelet Agents
Aspirin (Solprin, Disprin, Astrix)
Clopidogrel (Iscover, Plavix)
Dipyridamole (Persantin)
Ticlopidine (Ticlid)



Non-Steroidal Antiinflammatory Drugs (NSAIDs)
including Cox 2 inhibitors
Celecoxib (Celebrex)
Diflunisal (Dolobid)





Ibuprofen (Brufen, Nurofen)
Indomethacin (Indocid)
Piroxicam (Feldene)
Rofecoxib (Vioxx)
Tenoxicam (Tilcotil)
Tiaprofenic Acid (Surgam)
Salicylate Creams,Ointments and Liniments
Deep Heat
Dencorub
Methylsalicylate liniment
Please Note: This is not a
Metsal
comprehensive or exhaustive
Tramadol (Tramal)

list. Contact your pharmacist for
further information
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COMPLEMENTARY MEDICINES WHICH CAN AFFECT WARFARIN

↑ Effect of warfarin
(↑ INR)


Danshen

(salvia miltiorrhiza)


Dong Quai

(angelica sinesis)


Garlic

(allium sativum)




Coenzyme Q10



Ginseng



Green Tea



St John's Wort

Devil’s claw

(harpagophytum)


↓ Effect of warfarin
(↓ INR )

Ginkgo

(hypericum perforatum)


Vitamin C



Vitamin

(ginko biloba)


K

↑ Bleeding risk
 Feverfew
(tanecetum parthenium)
 Ginko
(ginkgo biloba)
 Ginger
(zingiber officinale)
 Korean ginseng
(panax ginseng)
 Liquorice
(glycyrrhiza glabra)

Papain

(papaya extract)



Vitamin E

Many herbs contain coumarins that may increase the activity of warfarin
 Alfalfa (medicago sativa)
 Angelica (angelica archangelica)
 Aniseed (pimpinella anisum)
 Arnica (arnica Montana)
 Asafoetida (ferula spp.)
Please Note: This is not a comprehensive or
 Bedstraw (galium Odoratum)
exhaustive list.
 Celery (apium graveolens)
Contact your pharmacist for further
 Fenugreek (trigonella foenum-graecum)
information
 German chamomile (matricaria recutita)
 Horse chestnut (aesculus hippocastanum)
 Prickly ash (zanthoxylum americana,z.clava-herculis)
 Quassia (picrasma excelsa)
Red clover (trifolium pratense)
 Roman chamomile (anthemis nobilis)
Sweet clover (melilotus spp)
References:
http://www.clinical.caregroup.org/altmed/interactions/Drugs/Warfarin.html;
http://www.nlm.nih.gov/medlineplus/druginfo/anticoagulantssystemic202050.html
http://altmedicine.about.com/library/bl092400warfrain.html
AMH (2002). Australian Medicines Handbook. Adelaide, Finsbury Press, Thebarton, SA.
Ansell, J., Hirsch, J. and Wenger, N. (2002). Management of Oral Anticoagulant Therapy: Warfarin Drug Interactions,
Stroke Center. 2002.
Campbell, P., Roberts, G., Eaton, V., Coghlan, D. and Gallus, A. S. (2001). "Managing warfarin therapy in the
community." Australian Prescriber 24(4): 86-89.
Lin Ho, L. and Brighton, T. (2002). "Warfarin, antiplatelet drugs and their interactions." Australian Prescriber 25(4): 81-85.
Myers, S. P. (2002). "Interactions between complementary medicines and warfarin." Australian Prescriber 25(3): 54-56.
Wells, P. S., Holbrook, A. M., Crowther, N. R. and Hirsh, J. (1994). "Interaction of Warfarin with Drugs and Food."
American College of Physicians 121(9): 676-682.
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APPENDIX 28

Transcript of the Customary Warfarin Education Program
Hello my name is Marion Townsend and I am one of the TACT
pharmacists. I have come to talk to you about your warfarin medication. Firstly, I
would like to assure you that warfarin has been proven to be effective in
conditions such as yours, (add in patients diagnosis). These and many other
people take warfarin and get benefit from it without any problems.
Warfarin does, however, have some disadvantages in that:
 it takes a while to have its full effect.
 blood tests called the INR are necessary to see if it is working
properly and the dose adjusted accordingly. The tests are done
daily to start with, after the third dose of warfarin has been taken.
As the INR stabilises, to between two and three, the frequency of
blood tests reduces. However, as long as you are on warfarin, the
INR must be tested at regular times.
There are two brands of warfarin ‘Coumadin’ and ‘Marevan’ and you have been
started on the ‘Coumadin’ brand, so we recommend that you do not take the
‘Marevan’ brand, unless it is recommended by your doctor (put a cross on the
Marevan page).
The dose of Coumadin that will be prescribed for you is in milligrams (mg)
and as you can see, tablets come in three different strengths and three different
colours; 5mg is green, 2 mg is lavender and 1 mg light tan. The label on the
bottle and its lid also match the colour of the tablets to help with identification.
You have been given warfarin to take because it stops harmful blood clots
from forming. Warfarin is an anticoagulant and for warfarin to work properly you
have to follow our and your doctor’s instructions, and tell us or your doctor about
any changes in your condition.
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What is an Anticoagulant
Anticoagulant drugs like warfarin help to prevent or treat thrombosis by
decreasing the clotting power of the blood. The objective of your treatment is only
to slow down the clotting process; if the blood was prevented from clotting
altogether this would cause bleeding.
In order to do this safely and effectively, a careful check must be kept on
the effect of the anticoagulant on your blood so that your doctor can prescribe the
dosage that will keep the clotting process at the correct level.
Different people require different amounts of warfarin. Therefore, the
dosage is tailored to you according to your blood test results and your blood tests
are very important.
While on warfarin your doctor will ask you to have an INR blood test
regularly. An INR test indicates how long blood takes to clot. A ‘normal’ INR i.e.
the INR of a person not taking an anticoagulant, is approximately 1. When you
take anticoagulants, the higher your INR, the longer your blood takes to clot. The
lower your INR is toward 1, the closer it is to ‘normal’ blood. Changes in your
warfarin dose will change your INR; however, these changes may not happen
immediately. It can take four to five days before you have the full impact of a
dose change on your INR. Your INR levels are very important as they help
your doctor maintain the dose that suits you.
The three things to remember about INR testings are:


have the INR test done every time it is ordered by your doctor.



call your doctor or laboratory as instructed or within 24 hours of the test in
case the warfarin dose needs adjusting.



record the test results in the record section provided in this book.

Taking Warfarin
You must take your tablets at approximately the same time everyday as
specified by your doctor. Warfarin can be taken before, during or after meals. By
getting into the daily routine of marking a calendar after you have taken warfarin
and not relying on your memory, you will be unlikely to miss a dose.
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Missing a dose
If you forget to take a dose and then remember within two to three hours,
you can still take your tablets. If you forget for a longer time, do not take the
tablets to catch up, but take your next dose when it is due and tell your doctor or
laboratory. Do not take a double dose.
Changes to your INR
Different things in your life affect how warfarin works on your blood. These
things include; whether you are eating properly, other medicines you take, the
amount of alcohol you drink and a new illness.
The most important thing to remember is that when there is a big change to any
of these things you must tell your doctor. The times these big changes usually
occur is when you leave hospital and go home (make sure you arrange for a
blood test soon after leaving hospital) and when you go away on holidays.
Other Medicines
The use of other medicines may interfere with the way warfarin works,
therefore, keep in mind the following:


Before taking any medicines, even prescribed by a doctor (or
dentist), be certain to check with the doctor who is monitoring your
warfarin dose.



When we talk about medicines, we mean not only prescription
medicines but anything you might buy (in a chemist or food store)
for common colds, aches, pains and so on.



It is especially important to check with your doctor or pharmacist
before taking common medicines such as: aspirin; paracetamol or
other pain medications; rubs and liniments; cold or cough.
preparations; certain stomach remedies (eg. antacids); laxatives;
multivitamins containing vitamin K; and herbal medicines.



Check with you pharmacist before buying any of these as they may
affect your INR.



If in the past you have been taking any drugs, even prescription
medications such as the “Pill”, be sure to check with your doctor
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before taking them now because they might affect your response to
warfarin.
Diet Principles
A well-balanced and varied diet is essential to everyone to maintain health
and vitality, whether they are taking warfarin or not. This means that your diet
should include: breads, cereals, fruit, vegetables, milk, cheese, yoghurt, lean
meat, poultry, fish, legumes, nuts and eggs. Your diet should consist of only
small amounts of sugar, butter, margarine and oil.
While taking warfarin you should maintain a well-balanced and consistent
diet. You should avoid crash dieting and binge eating. As your dosage of warfarin
has been adjusted to match your current eating pattern and lifestyle, it is
important that any major changes be talked over with your doctor. You should
also stabilise your intake of vitamin K because warfarin is affected by vitamin K.
A high vitamin K intake in your diet can affect your response to warfarin and
lower your INR significantly. You should therefore keep your intake of vitamin Kcontaining food relatively constant. This does not mean cutting these foods out of
your diet but eating them in small to moderate quantities regularly (about half a
cup or two to four tablespoons a serve).
The foods that are highest in vitamin K include the leafy green vegetables
(not peas or green beans), soya beans, canola and olive oil.
Vitamin and Herbal Supplements
If you are taking dietary supplements check to see that they do not contain
vitamin K. Large amounts of vitamin C (more than 5gms per day) and vitamin E
greater than 400IU per day can also affect your response to warfarin. Herbal
supplements and remedies often contain substances which may upset your INR
balance by increasing your bleeding or increasing your risk of clotting while you
are taking warfarin. You must discuss taking any supplements or herbal
remedies with your doctor before starting them. Once you and your doctor decide
the supplement is suitable for you, it is important that you take it regularly every
day to maintain a stable INR. It is also important to let your doctor know if you
stop taking any supplements as this may also affect your INR.
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Alcohol
Use in moderation and avoid binge drinking. Discuss with your doctor a safe
amount to suit you.
Other important things for you to remember
There are several additional things for you to keep in mind while working
with your doctor to maintain the INR which is best for you.


Take the exact number of anticoagulant tablets prescribed by your doctor.



Don’t stop taking warfarin or change the dose unless your doctor tells you.



Take the prescribed dose at approximately the same time each day. Try to
connect taking it with something you do regularly e.g. meal time, bed time
and use your calendar to keep track of the doses you take.



If you forget to take a dose, call your doctor for advice.



Tell your doctor right away if you develop any illness (for example
diarrhoea, vomiting, infection or fever) as this may affect your dosage
requirements. Also tell your doctor if you develop any unusual symptoms
such as pain, swelling or discomfort.



Well before undergoing any treatment, surgery or dental work be certain to
inform the doctor or dentist performing the procedure that you are taking
warfarin. This includes emergency treatment following any injury. Also, tell
the doctor who is supervising your anticoagulation therapy.



Remember that because you are taking an anticoagulant you may have
an increased tendency towards bleeding. Therefore, you should check
with your doctor before beginning any sport activities. Avoid situations with
a high risk of injury.



Warfarin can seriously affect an unborn baby. All women who may
become pregnant should discuss with their doctor the possible risks and
available means of reducing those risks. If a woman becomes pregnant
she must discuss this with her doctor at the earliest opportunity. However,
there have been no reports of the sperm from a man taking warfarin
affecting an unborn child.
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Contact your doctor before you start on any extended trips and while
travelling try to keep your diet and level of activity as close to normal as
possible. You may need a laboratory test while you are away which is not
hard to arrange. Ensure the information written on page 20 is up to date
and take this book with you. Advise the doctor you see while you are away
of this information. Make sure you take enough tablets with you to last the
entire trip.

Handy Hints
You may need to change some of your activities to minimise the possibility of
problems occurring. Some changes to consider are:


Using a non-slip bath mat when bathing



Using a soft bristle toothbrush



Using gloves when gardening and having a clean bandage with you in
case you scratch yourself and begin to bleed.



Using an electric shaver when shaving

Reducing the Chances of Problems
In prescribing your warfarin dosage the doctor aims for the level of
anticoagulation which prevents abnormal clot formation and does not permit
excessive bleeding. Although people who are not taking anticoagulants can
ignore occasional slight bleeding (e.g. a nosebleed) in your case this could be
the result of excessive anticoagulation. Therefore, it’s important for you to be
extra careful in looking for certain signs. You should therefore look for obvious
signs of bleeding. These obvious signs of bleeding include:


Cuts may bleed for a longer time.



Occasional nosebleeds may occur.



Heavier bleeding during periods or other vaginal bleeding.



Bleeding gums.

The less obvious signs of bleeding include:


Dark red or brown urine.



Dark or black bowel movements



Bruising
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A bruise occurs when you bleed under the skin. If you notice you are bruising
for unknown reasons or more than normal, tell your doctor right away.
As you continue to take warfarin, it’s very important that you be constantly on the
lookout for the signs we’ve been talking about and if any of these signs should
appear, call your doctor immediately.

Remember that the purpose of this booklet and the warfarin therapy is to
help you lead a normal life. By following your warfarin directions and the
guidelines given in this booklet, you will reduce the risk of complications.
If you do experience any problems, tell your doctor immediately so the problems
can be handled promptly and effectively.
Finally, use good judgment throughout your therapy program and if you have any
questions be sure to ask your doctor or pharmacist.
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